0001558370-24-01425910-Q TACTILE SYSTEMS TECHNOLOGY INC 20241104202411041608131608141608140 0001558370-24-014259 10-Q 79 20240930 20241104 20241104 TACTILE SYSTEMS TECHNOLOGY INC 0001027838 3841 000000000 DE 1231 10-Q 34 001-37799 241423544 1331 TYLER STREET NE STE 200 MINNEAPOLIS MN 55413 866-435-3948 1331 TYLER STREET NE STE 200 MINNEAPOLIS MN 55413 10-Q 1 tcmd-20240930x10q.htm 10-Q 23997089P1YP3YP7Y2360058400http://fasb.org/us-gaap/2024#OperatingLeaseRightOfUseAssethttp://fasb.org/us-gaap/2024#OperatingLeaseRightOfUseAssethttp://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrenthttp://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrenthttp://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent0001027838--12-312024Q3falseP3M0.33330.3333P1Y0.33330.33330.3333P1Y10M24D0001027838us-gaap:CommonStockMember2024-07-012024-09-300001027838us-gaap:CommonStockMember2023-07-012023-09-300001027838us-gaap:CommonStockMember2024-01-012024-09-300001027838us-gaap:CommonStockMember2023-01-012023-09-300001027838us-gaap:RetainedEarningsMember2024-09-300001027838us-gaap:AdditionalPaidInCapitalMember2024-09-300001027838us-gaap:RetainedEarningsMember2024-06-300001027838us-gaap:AdditionalPaidInCapitalMember2024-06-300001027838us-gaap:RetainedEarningsMember2023-12-310001027838us-gaap:AdditionalPaidInCapitalMember2023-12-310001027838us-gaap:RetainedEarningsMember2023-09-300001027838us-gaap:AdditionalPaidInCapitalMember2023-09-300001027838us-gaap:RetainedEarningsMember2023-06-300001027838us-gaap:AdditionalPaidInCapitalMember2023-06-300001027838us-gaap:RetainedEarningsMember2022-12-310001027838us-gaap:AdditionalPaidInCapitalMember2022-12-3100010278382024-06-300001027838us-gaap:CommonStockMember2024-09-300001027838us-gaap:CommonStockMember2024-06-300001027838us-gaap:CommonStockMember2023-12-310001027838us-gaap:CommonStockMember2023-09-300001027838us-gaap:CommonStockMember2023-06-300001027838us-gaap:CommonStockMember2022-12-310001027838us-gaap:IPOMember2016-08-020001027838tcmd:FollowOnPublicOfferingMember2023-02-270001027838us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001027838us-gaap:EmployeeStockOptionMember2023-12-310001027838us-gaap:EmployeeStockOptionMember2023-09-300001027838tcmd:EquityIncentivePlan2016Member2024-01-012024-01-010001027838tcmd:TimeBasedRestrictedStockUnitsRsusMembertcmd:EquityIncentivePlan2016Member2023-12-310001027838tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMembertcmd:EquityIncentivePlan2016Member2023-12-310001027838tcmd:TwoThousandTwentyThreePsuMembertcmd:EquityIncentivePlan2016Memberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-09-300001027838tcmd:TwoThousandTwentySixPsuMembertcmd:EquityIncentivePlan2016Memberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-01-012024-09-300001027838tcmd:TwoThousandTwentyFourPsuMembertcmd:EquityIncentivePlan2016Memberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-09-300001027838tcmd:TwoThousandTwentyFivePsuMembertcmd:EquityIncentivePlan2016Memberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-01-012024-09-300001027838srt:MinimumMembertcmd:TimeBasedRestrictedStockUnitsRsusMembertcmd:EquityIncentivePlan2016Member2024-01-012024-09-300001027838srt:MaximumMembertcmd:TimeBasedRestrictedStockUnitsRsusMembertcmd:EquityIncentivePlan2016Member2024-01-012024-09-300001027838srt:MinimumMemberus-gaap:EmployeeStockOptionMember2024-01-012024-09-300001027838srt:MaximumMemberus-gaap:EmployeeStockOptionMember2024-01-012024-09-300001027838tcmd:TimeBasedRestrictedStockUnitsRsusMember2024-01-012024-09-300001027838tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember2024-01-012024-09-300001027838tcmd:VeteransAdministrationMember2024-07-012024-09-300001027838tcmd:PrivateInsurersMember2024-07-012024-09-300001027838tcmd:MedicareMember2024-07-012024-09-300001027838tcmd:DurableMedicalEquipmentDistributorsMember2024-07-012024-09-300001027838tcmd:VeteransAdministrationMember2024-01-012024-09-300001027838tcmd:PrivateInsurersMember2024-01-012024-09-300001027838tcmd:MedicareMember2024-01-012024-09-300001027838tcmd:DurableMedicalEquipmentDistributorsMember2024-01-012024-09-300001027838tcmd:VeteransAdministrationMember2023-07-012023-09-300001027838tcmd:PrivateInsurersMember2023-07-012023-09-300001027838tcmd:MedicareMember2023-07-012023-09-300001027838tcmd:DurableMedicalEquipmentDistributorsMember2023-07-012023-09-300001027838tcmd:VeteransAdministrationMember2023-01-012023-09-300001027838tcmd:PrivateInsurersMember2023-01-012023-09-300001027838tcmd:MedicareMember2023-01-012023-09-300001027838tcmd:DurableMedicalEquipmentDistributorsMember2023-01-012023-09-300001027838tcmd:TermLoanMember2023-08-012023-08-010001027838tcmd:FollowOnPublicOfferingMember2023-02-272023-02-270001027838tcmd:2023-11-282023-11-280001027838us-gaap:RetainedEarningsMember2024-07-012024-09-300001027838us-gaap:RetainedEarningsMember2024-01-012024-09-300001027838us-gaap:RetainedEarningsMember2023-07-012023-09-300001027838us-gaap:RetainedEarningsMember2023-01-012023-09-300001027838tcmd:2023-08-042024-09-040001027838srt:MinimumMemberus-gaap:RevolvingCreditFacilityMember2023-08-012023-08-010001027838srt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2023-08-012023-08-010001027838us-gaap:RevolvingCreditFacilityMember2021-09-080001027838srt:MinimumMemberus-gaap:EquipmentMember2024-09-300001027838srt:MinimumMemberus-gaap:BuildingMember2024-09-300001027838srt:MaximumMemberus-gaap:EquipmentMember2024-09-300001027838srt:MaximumMemberus-gaap:BuildingMember2024-09-300001027838srt:MinimumMember2024-09-300001027838us-gaap:EquipmentMember2024-01-012024-09-300001027838us-gaap:TradeNamesMember2024-09-300001027838us-gaap:PatentsMember2024-09-300001027838us-gaap:TradeNamesMember2023-12-310001027838us-gaap:PatentsMember2023-12-310001027838tcmd:AfflovestPMember2021-09-300001027838us-gaap:PatentsMember2024-09-300001027838us-gaap:DevelopedTechnologyRightsMember2024-09-300001027838us-gaap:CustomerRelationshipsMember2024-09-300001027838us-gaap:CustomerContractsMember2024-09-300001027838tcmd:DefensiveIntangibleAssetsMember2024-09-300001027838us-gaap:PatentsMember2023-12-310001027838us-gaap:DevelopedTechnologyRightsMember2023-12-310001027838us-gaap:CustomerRelationshipsMember2023-12-310001027838us-gaap:CustomerContractsMember2023-12-310001027838tcmd:DefensiveIntangibleAssetsMember2023-12-310001027838us-gaap:EmployeeStockOptionMember2024-09-300001027838tcmd:TimeBasedRestrictedStockUnitsRsusMembertcmd:EquityIncentivePlan2016Member2024-09-300001027838tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMembertcmd:EquityIncentivePlan2016Member2024-09-300001027838tcmd:DefinedContribution401kRetirementPlanMember2024-07-012024-09-300001027838tcmd:DefinedContribution401kRetirementPlanMember2024-01-012024-09-300001027838tcmd:DefinedContribution401kRetirementPlanMember2023-07-012023-09-300001027838tcmd:DefinedContribution401kRetirementPlanMember2023-01-012023-09-300001027838us-gaap:RevolvingCreditFacilityMember2023-12-212023-12-210001027838tcmd:TermLoanMember2024-01-012024-09-300001027838tcmd:TermLoanMember2021-09-080001027838tcmd:TermLoanMember2024-09-300001027838us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-01-012024-09-300001027838us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMember2023-08-012023-08-010001027838srt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMember2023-06-212023-06-210001027838srt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2023-06-212023-06-210001027838srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMember2023-06-212023-06-210001027838srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2023-06-212023-06-210001027838us-gaap:RevolvingCreditFacilityMemberus-gaap:FederalFundsEffectiveSwapRateMember2023-06-212023-06-210001027838us-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2023-06-212023-06-210001027838us-gaap:SecuredOvernightFinancingRateSofrMember2023-06-212023-06-210001027838tcmd:2023-06-212023-06-210001027838us-gaap:ProductMember2024-07-012024-09-300001027838tcmd:RentalProductServiceMember2024-07-012024-09-300001027838us-gaap:ProductMember2024-01-012024-09-300001027838tcmd:RentalProductServiceMember2024-01-012024-09-300001027838us-gaap:ProductMember2023-07-012023-09-300001027838tcmd:RentalProductServiceMember2023-07-012023-09-300001027838us-gaap:ProductMember2023-01-012023-09-300001027838tcmd:RentalProductServiceMember2023-01-012023-09-300001027838us-gaap:CostOfGoodsTotalMemberus-gaap:SupplierConcentrationRiskMembertcmd:VendorOneMember2024-07-012024-09-300001027838us-gaap:CostOfGoodsTotalMemberus-gaap:SupplierConcentrationRiskMembertcmd:VendorOneMember2024-01-012024-09-300001027838us-gaap:CostOfGoodsTotalMemberus-gaap:SupplierConcentrationRiskMembertcmd:VendorOneMember2023-07-012023-09-300001027838us-gaap:CostOfGoodsTotalMemberus-gaap:SupplierConcentrationRiskMembertcmd:VendorOneMember2023-01-012023-09-300001027838us-gaap:EmployeeStockMember2024-09-300001027838us-gaap:EmployeeStockMember2024-01-010001027838us-gaap:EmployeeStockMember2016-04-2700010278382023-09-3000010278382022-12-310001027838us-gaap:FairValueInputsLevel3Member2023-09-300001027838us-gaap:FairValueInputsLevel3Member2022-12-310001027838us-gaap:FairValueInputsLevel3Member2023-01-012023-09-300001027838tcmd:CorporateHeadQuarterSecondLeaseMember2018-12-310001027838tcmd:CorporateHeadQuarterInitialLeaseMember2018-10-310001027838us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001027838us-gaap:PerformanceSharesMember2024-07-012024-09-300001027838us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001027838tcmd:EmployeeStockPurchasePlanMember2024-07-012024-09-300001027838us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001027838us-gaap:PerformanceSharesMember2024-01-012024-09-300001027838us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001027838us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001027838us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001027838us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001027838us-gaap:PerformanceSharesMember2023-01-012023-09-300001027838us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001027838tcmd:TimeBasedRestrictedStockUnitsRsusMembertcmd:EquityIncentivePlan2016Member2024-07-012024-09-300001027838tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMembertcmd:EquityIncentivePlan2016Member2024-07-012024-09-300001027838us-gaap:SellingAndMarketingExpenseMember2024-07-012024-09-300001027838us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001027838us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001027838us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001027838us-gaap:EmployeeStockMember2024-07-012024-09-300001027838us-gaap:CostOfSalesMember2024-07-012024-09-300001027838us-gaap:SellingAndMarketingExpenseMember2024-01-012024-09-300001027838us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001027838us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001027838us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001027838us-gaap:CostOfSalesMember2024-01-012024-09-300001027838tcmd:TimeBasedRestrictedStockUnitsRsusMembertcmd:EquityIncentivePlan2016Member2023-07-012023-09-300001027838tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMembertcmd:EquityIncentivePlan2016Member2023-07-012023-09-300001027838us-gaap:SellingAndMarketingExpenseMember2023-07-012023-09-300001027838us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001027838us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001027838us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001027838us-gaap:EmployeeStockMember2023-07-012023-09-300001027838us-gaap:CostOfSalesMember2023-07-012023-09-300001027838tcmd:TimeBasedRestrictedStockUnitsRsusMembertcmd:EquityIncentivePlan2016Member2023-01-012023-09-300001027838tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMembertcmd:EquityIncentivePlan2016Member2023-01-012023-09-300001027838us-gaap:SellingAndMarketingExpenseMember2023-01-012023-09-300001027838us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001027838us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001027838us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001027838us-gaap:EmployeeStockMember2023-01-012023-09-300001027838us-gaap:CostOfSalesMember2023-01-012023-09-300001027838us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001027838us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001027838us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001027838us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001027838srt:MinimumMembertcmd:TwoThousandTwentyFourPsuMembertcmd:EquityIncentivePlan2016Member2024-01-012024-09-300001027838srt:MinimumMembertcmd:TwoThousandTwentyFivePsuMembertcmd:EquityIncentivePlan2016Member2024-01-012024-09-300001027838srt:MinimumMembertcmd:PerformanceBasedStockSettledRestrictedStockUnitsMembertcmd:EquityIncentivePlan2016Member2024-01-012024-09-300001027838srt:MaximumMembertcmd:TwoThousandTwentyFourPsuMembertcmd:EquityIncentivePlan2016Member2024-01-012024-09-300001027838srt:MaximumMembertcmd:TwoThousandTwentyFivePsuMembertcmd:EquityIncentivePlan2016Member2024-01-012024-09-300001027838srt:MaximumMembertcmd:PerformanceBasedStockSettledRestrictedStockUnitsMembertcmd:EquityIncentivePlan2016Member2024-01-012024-09-300001027838tcmd:TwoThousandTwentyThreePsuMembertcmd:EquityIncentivePlan2016Member2024-01-012024-09-300001027838tcmd:TimeBasedRestrictedStockUnitsRsusMembertcmd:EquityIncentivePlan2016Member2024-01-012024-09-300001027838tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMembertcmd:EquityIncentivePlan2016Member2024-01-012024-09-300001027838tcmd:EquityIncentivePlan2016Member2024-09-300001027838srt:MinimumMember2024-01-012024-09-300001027838srt:MaximumMember2024-01-012024-09-300001027838tcmd:LymphedemaProductsMember2024-07-012024-09-300001027838tcmd:AirwayClearanceProductsMember2024-07-012024-09-300001027838tcmd:LymphedemaProductsMember2024-01-012024-09-300001027838tcmd:AirwayClearanceProductsMember2024-01-012024-09-300001027838tcmd:LymphedemaProductsMember2023-07-012023-09-300001027838tcmd:AirwayClearanceProductsMember2023-07-012023-09-300001027838tcmd:LymphedemaProductsMember2023-01-012023-09-300001027838tcmd:AirwayClearanceProductsMember2023-01-012023-09-300001027838tcmd:VendorOneMember2024-09-300001027838tcmd:VendorOneMember2023-09-300001027838tcmd:WeaverLawsuitMember2024-05-2400010278382021-09-082021-09-080001027838us-gaap:IPOMember2016-08-022016-08-020001027838us-gaap:EmployeeStockMember2024-01-012024-09-300001027838tcmd:TermLoanMember2022-02-222022-02-2200010278382021-09-0800010278382023-05-252023-05-2500010278382023-07-012023-09-3000010278382023-01-012023-09-300001027838tcmd:CorporateHeadQuarterThirdLeaseMember2019-12-310001027838tcmd:CorporateHeadQuarterSecondLeaseMember2019-12-3100010278382024-09-3000010278382023-12-310001027838us-gaap:RevolvingCreditFacilityMemberus-gaap:SubsequentEventMember2024-11-010001027838us-gaap:SubsequentEventMember2024-10-3000010278382024-07-012024-09-3000010278382024-10-3100010278382024-01-012024-09-30xbrli:sharesiso4217:USDutr:sqftxbrli:puretcmd:itemiso4217:USDxbrli:sharesTable of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORMÂ 10-Qâ˜‘ QUARTERLY REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OFÂ 1934For the quarterly period ended: September 30, 2024orâ˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from to Commission File Number: 001-37799Tactile Systems Technology, Inc.(Exact name of registrant as specified in its charter)Â Delaware3701 Wayzata Blvd, Suite 300 41-1801204(State or other jurisdiction ofincorporation or organization)Minneapolis, Minnesota 55416(I.R.S. EmployerIdentification No.)â€‹(Address and zip code of principal executive offices)â€‹(612) 355-5100â€‹(Registrantâ€™s telephone number, including area code)â€‹Securities registered pursuant to Section 12(b) of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock, Par Value $0.001 Per ShareTCMDThe Nasdaq Stock MarketIndicate by check mark whether the registrant (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934 during the preceding 12Â months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90Â days. Â Yes â˜‘ Â No â—»Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to RuleÂ 405 of RegulationÂ S-T (Â§232.405 of this chapter) during the preceding 12Â months (or for such shorter period that the registrant was required to submit such files). Â Yes â˜‘ Â No â—»Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging

growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in RuleÂ 12b-2 of the Exchange Act.Â â€‹â€‹â€‹â€‹LargeÂ acceleratedÂ filerâ˜Â AcceleratedÂ filerâ˜Â Non-acceleratedÂ filerÂ â˜Â SmallerÂ reportingÂ companyÂ â˜Â Emerging growth companyâ˜If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜Indicate by check mark whether the registrant is a shell company (as defined in RuleÂ 12b-2 of the Exchange Act). Â Yes â˜ Â No â˜’23,997,089 shares of common stock, par value $0.001 per share, were outstanding as of October 31, 2024.â€‹ Table of ContentsTABLE OF CONTENTSâ€‹â€‹ â€‹PARTÂ Iâ€”FINANCIALÂ INFORMATION â€‹â€‹â€‹â€‹â€‹â€‹ItemÂ 1.â€‹Financial Statementsâ€‹4ItemÂ 2.â€‹Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€‹24ItemÂ 3.â€‹Quantitative and Qualitative Disclosures About Market Riskâ€‹34ItemÂ 4.â€‹Controls and Proceduresâ€‹34Â â€‹â€‹â€‹â€‹PARTÂ IIâ€”OTHER INFORMATIONâ€‹â€‹Â â€‹â€‹â€‹ItemÂ 1.â€‹Legal Proceedingsâ€‹34ItemÂ 1A.â€‹Risk Factorsâ€‹34ItemÂ 2.â€‹Unregistered Sales of Equity Securities and Use of Proceedsâ€‹34ItemÂ 3.â€‹Defaults Upon Senior Securitiesâ€‹34ItemÂ 4.â€‹Mine Safety Disclosuresâ€‹35Item 5.â€‹Other Informationâ€‹35ItemÂ 6.â€‹Exhibitsâ€‹35â€‹â€‹2 Table of Contents Forward-Looking InformationAll statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "ongoing," "plan," "potential," "predict," "project," "should," "target," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this Quarterly Report on Form 10-Q. These risks, uncertainties and other factors include, but are not limited to:â—our ability to obtain reimbursement from third-party payers for our products; â—the impact of inflation, rising interest rates or recession;â—the adequacy of our liquidity to pursue our business objectives; â—adverse economic conditions or intense competition; â—price increases for supplies and components;â—wage and component price inflation; â—loss of a key supplier; â—entry of new competitors and products; â—compliance with and changes in federal, state and local government regulation;â—loss or retirement of key executives, including transition matters related to our recent Chief Executive Officer change;â—technological obsolescence of our products; â—technical problems with our research and products; â—our ability to expand our business through strategic acquisitions; â—our ability to integrate acquisitions and related businesses; â—the effects of current and future U.S. and foreign trade policy and tariff actions; andâ—the inability to carry out research, development and commercialization plans.You should read the matters described in "Risk Factors" and the other cautionary statements made in our Annual Report on Form 10-K for the year ended December 31, 2023, and in subsequent Quarterly Reports on Form 10-Q. We cannot assure you that the forward-looking statements in this report will prove to be accurate and therefore you are encouraged not to place undue reliance on forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. You are urged to carefully review and consider the various disclosures made by us in this report and in other filings with the Securities and Exchange Commission (the â€œSECâ€) that advise of the risks and factors that may affect our business. Other than as required by law, we undertake no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make.â€‹3 Table of Contents PARTÂ Iâ€”FINANCIAL INFORMATIONItem 1. Financial Statementsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Tactile Systems Technology, Inc.Condensed Consolidated Balance Sheets(Unaudited)â€‹Â Â Â Â Â September 30,Â Â Â Â Â December 31,(InÂ thousands,Â except share and per share data)Â Â Â Â 2024Â Â Â Â 2023Assetsâ€‹â€‹â€‹â€‹â€‹â€‹Current assetsâ€‹â€‹â€‹â€‹â€‹â€‹Cash and cash equivalentsâ€‹â€‹$ 82,146â€‹â€‹$ 61,033Accounts receivableâ€‹Â 39,970â€‹Â 43,173Net investment in leasesâ€‹Â 13,953â€‹Â 14,195Inventoriesâ€‹Â 21,176â€‹Â 22,527Prepaid expenses and other current assetsâ€‹Â 5,127â€‹Â 4,366Total current assetsâ€‹Â 162,372â€‹Â 145,294Non-current assetsâ€‹â€‹â€‹â€‹â€‹â€‹Property and equipment, netâ€‹Â 5,878â€‹Â 6,195Right of use operating lease assetsâ€‹Â 17,553â€‹Â 19,128Intangible assets, netâ€‹Â 43,708â€‹Â 46,724Goodwillâ€‹â€‹ 31,063â€‹â€‹ 31,063Accounts receivable, non-currentâ€‹Â 3,628â€‹Â 10,936Deferred income taxesâ€‹Â 19,719â€‹Â 19,378Other non-current assetsâ€‹Â 3,803â€‹Â 2,720Total non-current assetsâ€‹Â 125,352â€‹Â 136,144Total assetsâ€‹$ 287,724â€‹$ 281,438Liabilities and Stockholders' Equityâ€‹â€‹â€‹â€‹â€‹â€‹Current liabilitiesâ€‹â€‹â€‹â€‹â€‹â€‹Accounts payableâ€‹$ 7,290â€‹$ 6,559Note payableâ€‹â€‹ 2,956â€‹â€‹ 2,956Accrued payroll and related taxesâ€‹Â 13,086â€‹Â 16,789Accrued expensesâ€‹Â 7,088â€‹Â 5,904Income taxes payableâ€‹Â 611â€‹Â 1,467Operating lease liabilitiesâ€‹Â 2,883â€‹Â 2,807Other current liabilitiesâ€‹Â 3,240â€‹Â 4,475Total current liabilitiesâ€‹Â 37,154â€‹Â 41,057Non-current liabilitiesâ€‹â€‹â€‹â€‹â€‹â€‹Note payable, non-currentâ€‹â€‹ 23,959â€‹â€‹ 26,176Accrued warranty reserve, non-currentâ€‹Â 1,448â€‹Â 1,681Income taxes payable, non-currentâ€‹Â 495â€‹Â 446Operating lease liabilities, non-currentâ€‹â€‹ 16,767â€‹Â 18,436Total non-current liabilitiesâ€‹Â 42,669â€‹Â 46,739Total liabilitiesâ€‹Â 79,823â€‹Â 87,796â€‹â€‹â€‹â€‹â€‹â€‹Stockholdersâ€™ equity:â€‹â€‹â€‹â€‹â€‹â€‹Preferred stock, $0.001 par value, 50,000,000 shares authorized; none issued and outstanding as of September 30, 2024 and December 31, 2023â€‹Â â€”â€‹Â â€”Common stock, $0.001 par value, 300,000,000 shares authorized; 23,997,089 shares issued and outstanding as of September 30, 2024; 23,600,584 shares issued and outstanding as of December 31, 2023â€‹Â 24â€‹Â 24Additional paid-in capitalâ€‹Â 181,739â€‹Â 174,724Retained earningsâ€‹Â 26,138â€‹Â 18,894Total stockholdersâ€™ equityâ€‹Â 207,901â€‹Â 193,642Total liabilities and stockholdersâ€™ equityâ€‹$ 287,724â€‹$ 281,438â€‹â€‹The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.â€‹â€‹4 Table of Contents â€‹â€‹â€‹â€‹â€‹â€‹â€‹

Company is currently evaluating the effect this standard will have on its consolidated financial statements and related disclosures.In December 2023, the FASB issued ASU No. 2023-09, â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€ which requires entities to enhance disclosures around income taxes. The guidance is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its consolidated financial statements and related disclosures.Note 4. InventoriesInventories consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹(InÂ thousands)Â Â Â Â At SeptemberÂ 30,Â 2024Â Â Â Â At DecemberÂ 31,Â 2023Finished goodsâ€‹ $ 7,022â€‹ $ 7,979Component parts and work-in-processâ€‹Â 14,154â€‹Â 14,548Total inventoriesâ€‹ $ 21,176â€‹ $ 22,527â€‹â€‹â€‹â€‹Note 5. Goodwill and Intangible AssetsGoodwillIn the third quarter of fiscal 2021, we completed the AffloVest Acquisition. The purchase price of the AffloVest product line exceeded the net acquisition-date estimated fair value amounts of the identifiable assets acquired and the liabilities assumed by $31.1 million, which was assigned to goodwill.Â â€‹9 Table of Contents Intangible Assetsâ€‹Our patents and other intangible assets are summarized as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

defendants were unjustly enriched. The Weaver Lawsuit seeks unspecified damages. In August 2022, the matter was transferred to the United States District Court for the District of Delaware by order granting the Parties Stipulation to Transfer. On February 10, 2023, we filed a motion to dismiss the action. The plaintiff filed an Amended Complaint on March 3, 2023. On March 31, 2023, we filed a motion to dismiss the Amended Complaint. On July 31, 2023, the plaintiff filed a Joint Notice of Preliminary Settlement indicating that the parties had reached a non-binding settlement-in-principal on most of the material terms that would resolve all claims between the parties and requested that the Court temporarily stay all deadlines, hearings, and conferences while the parties continued to finalize settlement. On June 6, 2024, the parties entered into a Stipulation of Settlement in the Weaver Lawsuit. On June 7, 2024, the plaintiff filed an unopposed motion for preliminary approval of the settlement. Â On June 27, 2024, the Court entered an order granting the motion for preliminary approval of the settlement. Â The final settlement hearing occurred on August 28, 2024, and on September 4, 2024, the Court entered its order approving the settlement, including the agreed upon attorneysâ€™ fees and expense awards to plaintiffsâ€™ counsel and service awards to the shareholder plaintiffs. Pursuant to the settlement, we are adopting, implementing, and maintaining certain corporate governance reforms. The attorneysâ€™ fees and expense award of approximately $0.5 million was covered by insurance and has been paid. The settlement does not constitute an admission of liability or wrongdoing by us or any of our current or former directors or officers. This matter is now concluded.On October 25, 2024, the United States District Court, District of Massachusetts (Boston) unsealed two qui tam complaints against us. The first complaint is captioned United States ex. rel. Benjaman Scarborough vs. Tactile Systems Technology, Inc., Case No. 1:21-cv-10813-IT, and was filed under seal on May 17, 2021, on behalf of the United States by a former employee (the â€œScarborough Complaintâ€). The Scarborough Complaint alleges that we submitted false claims and made false statements in connection with the Medicare 16 Table of Contents programs, in violation of the Federal False Claims Act. The second complaint is captioned United States ex. rel. Jackie Gorham, an individual, and Dustin Gast, an individual, vs. Tactile Systems Technology, Inc. Case No. 1:21-cv-11809-IT, and was filed under seal on September 1, 2021, on behalf of the United States by two former employees (the â€œGorham Complaintâ€). The Gorham Complaint alleges that we submitted false claims and made false statements in connection with the Medicare, Medicare Advantage plans, Medicaid and other government payers, in violation of the Federal False Claims Act and submitted false claims resulting from kickbacks in violation of the Federal False Claims Act and the Federal Anti-Kickback Statute. Â Both complaints seek damages, statutory penalties, attorneysâ€™ fees, and costs.NoteÂ 10. Stockholders' EquityStock-Based CompensationOur 2016 Equity Incentive Plan (the â€œ2016 Planâ€) authorizes us to grant stock options, stock appreciation rights, restricted stock, stock units and other stock-based awards to employees, non-employee directors and certain consultants and advisors. There were up to 4,800,000 shares of our common stock initially reserved for issuance pursuant to the 2016 Plan. The 2016 Plan provides that the number of shares reserved and available for issuance under the 2016 Plan will automatically increase annually on January 1 of each calendar year, commencing in 2017 and ending on and including January 1, 2026, by an amount equal to the lesser of: (a) 5% of the number of common shares of stock outstanding as of December 31 of the immediately preceding calendar year, or (b) 2,500,000 shares; provided, however, that our Board of Directors may determine that any annual increase be a lesser number. In addition, all awards granted under our 2007 Omnibus Stock Plan and our 2003 Stock Option Plan that were outstanding when the 2016 Plan became effective and that are forfeited, expired, cancelled, settled for cash or otherwise not issued, will become available for issuance under the 2016 Plan. Pursuant to the automatic increase feature of the 2016 Plan, 1,180,019 shares were added as available for issuance thereunder on January 1, 2024. Our Board of Directors exercised its prerogative to forego the automatic increase on January 1, 2023. As of September 30, 2024, 6,462,956 shares were available for future grant pursuant to the 2016 Plan.Upon adoption and approval of the 2016 Plan, all of our previous equity incentive compensation plans were terminated. However, existing awards under those plans continue to vest in accordance with the original vesting schedules and will expire at the end of their original terms.We recorded stock-based compensation expense of $2.1 million and $1.8 million for the three months ended September 30, 2024 and 2023, respectively, and $6.0 million and $5.6 million for the nine months ended September 30, 2024 and 2023, respectively. This expense was allocated as follows:â€‹Three Months Endedâ€‹Nine Months Ended â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â (InÂ thousands)Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Cost of revenueâ€‹$ 100â€‹$ 116â€‹$ 286â€‹$ 340Sales and marketing expensesâ€‹â€‹ 595â€‹â€‹ 634â€‹â€‹ 1,939â€‹â€‹ 2,196Research and development expensesâ€‹â€‹ 42â€‹â€‹ 5â€‹â€‹ 123â€‹â€‹ 98Reimbursement, general and administrative expensesâ€‹â€‹ 1,333â€‹â€‹ 1,011â€‹â€‹ 3,621â€‹â€‹ 2,963Total stock-based compensation expenseâ€‹$ 2,070â€‹$ 1,766â€‹$ 5,969â€‹$ 5,597â€‹Stock OptionsStock options issued to participants other than non-employees typically vest over three or four years and typically have a contractual term of seven or ten years. Stock-based compensation expense included in the Condensed Consolidated Statements of Operations for stock options was $0.0 million and $0.2 million for the three months ended September 30, 2024 and 2023, respectively, and $0.2 million and $0.8 million for the nine months ended September 30, 2024 and 2023, respectively. At September 30, 2024, there was approximately $42,100 of total unrecognized pre-tax stock option expense under our equity compensation plans, which is expected to be recognized on a straight-line basis over a weighted-average period of 1.0 years.17 Table of Contents Our stock option activity for the nine months ended September 30, 2024, was as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹â€‹Weighted-â€‹Weighted-â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

430,521Performance stock unitsâ€‹ 63,103â€‹ â€”â€‹ 142,351â€‹ 17,392Employee stock purchase planâ€‹ 79,295â€‹ â€”â€‹ â€”â€‹ â€”Totalâ€‹ 873,568â€‹ 505,493â€‹ 1,032,562â€‹ 637,984â€‹â€‹Note 14. Fair Value MeasurementsWe determine the fair value of our assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We use a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1). The next highest priority is based on quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in non-active markets or other observable inputs (Level 2). The lowest priority is given to unobservable inputs (Level 3).As of September 30, 2024, our obligations under the AffloVest Acquisition earn-out arrangements had been paid in full. Prior to the determination of the actual amount of the earn-out, the earn-out liability was valued by employing a Monte Carlo Simulation model in a risk-neutral framework, which is a Level 3 input. The underlying simulated variable included recognized revenue. The recognized revenue volatility estimate was based on a study of historical asset volatility for a set of comparable public companies. The model included other assumptions including the market price of risk, which was calculated as the weighted average cost of capital less the long-term risk-free rate. The earn-out liability was adjusted to fair value at each reporting date until the end of the earn-out period, which was September 30, 2023. Changes in fair value were included in intangible asset amortization and earn-out expenses in our Condensed Consolidated Statements of Operations.â€‹â€‹â€‹â€‹â€‹â€‹22 Table of Contents â€‹Changes in the earn-out liability measured at fair value using Level 3 inputs were as follows:â€‹â€‹â€‹â€‹â€‹(InÂ thousands)â€‹â€‹Earn-out liability at December 31, 2022â€‹$ 13,050Payment on earn-outâ€‹â€‹ (5,000)Fair value adjustmentsâ€‹â€‹ (2,475)Earn-out liability at September 30, 2023â€‹$ 5,575â€‹On May 25, 2023, the Company paid $5.0 million, plus an imputed interest payment of $250,000, relating to the initial earn-out. Subsequent to September 30, 2023, it was determined that the calculated amount of the second earn-out payment was $5.6 million, which was paid by the Company on November 28, 2023. â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹The carrying amounts of financial instruments such as cash equivalents, accounts receivable, other assets, accounts payable, accrued expenses and other liabilities approximate their related fair values due to the short-term maturities of these items. Non-financial assets, such as equipment and leasehold improvements, and intangible assets are subject to non-recurring fair value measurements if they are deemed impaired.Note 15. Subsequent EventOn October 30, 2024, our Board of Directors authorized a program to repurchase up to $30.0 million of common stock. Under the program, purchases may be made from time to time in the open market, in privately negotiated purchases, or both. The timing and number of shares to be purchased will be based on the price of the Company's common stock, general business and market conditions and other investment considerations and factors. The share repurchase program expires on October 31, 2026. The program does not obligate the Company to repurchase any specific number of shares and may be suspended or discontinued at any time without prior notice.â€‹â€‹â€‹â€‹23 Table of Contents Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations.The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and the accompanying notes thereto included elsewhere in this report.Overview We are a medical technology company that develops and provides innovative medical devices for the treatment of underserved chronic diseases. Our mission is to help people suffering from chronic diseases live better and care for themselves at home. We focus our efforts on advancing the standard of care in treating underserved chronic diseases in the home setting to improve patient outcomes and quality of life and help control rising healthcare expenditures. Our areas of therapeutic focus are (1) vascular disease, with a goal of advancing the standard of care in treating lymphedema and chronic venous insufficiency, (2) oncology, where lymphedema is a common consequence among cancer survivors and (3) providing airway clearance therapy for those suffering from chronic respiratory conditions. We possess a unique, scalable platform to deliver at-home healthcare solutions throughout the United States. This evolving home care delivery model is recognized by policymakers and insurance payers as a key for controlling rising healthcare costs. Our solutions deliver cost-effective, clinically proven, long-term treatment for people with these chronic diseases.Our current lymphedema products are the Flexitouch Plus, Entre Plus and Nimbl systems and our airway clearance product is the AffloVest. A predecessor to our Flexitouch system received 510(k) clearance from the U.S. Food and Drug Administration (the â€œFDAâ€) in July 2002, and we introduced the system to address the many limitations of self-administered home-based manual lymphatic drainage therapy. We began selling our more advanced Flexitouch system after receiving 510(k) clearance from the FDA in October 2006. In September 2016, we received 510(k) clearance from the FDA for the Flexitouch system in treating lymphedema of the head and neck. In June 2017, we announced that we received 510(k) clearance from the FDA for the Flexitouch Plus, the third-generation version of our Flexitouch system. In December 2020, we received 510(k) clearance for two new indications for our Flexitouch Plus system: phlebolymphedema and lipedema. We introduced our Entre system in the United States in February 2013 and the second generation, Entre Plus, in March 2023. The Entre Plus system is sold or rented to patients who need a simple pump or who do not yet qualify for insurance reimbursement for an advanced compression device such as our Flexitouch Plus system. Nimbl, our next-generation pneumatic compression platform, received 510(k) clearance in June 2024 and, beginning in October 2024, is commercially available throughout the United States for the treatment of upper extremity lymphedema. Sales and rentals of our lymphedema products represented 88% of our revenue in each of the nine months ended September 30, 2024 and 2023.On September 8, 2021, we acquired the assets of the AffloVest airway clearance product line. AffloVest is a portable, wearable vest that provides airway clearance toÂ treat patients with chronic respiratory conditions such as bronchiectasis or conditions resulting from neuromuscular disorders. For each of the nine months ended September 30, 2024 and 2023, sales of AffloVest represented 12% of our revenue.To support the growth of our business, we continue to invest in our commercial infrastructure, consisting of our direct sales force, training resources, reimbursement capabilities and clinical expertise. We market our lymphedema products in the United States using a direct-to-patient and -provider model. The AffloVest device is sold through respiratory durable medical equipment providers throughout the United States that service patients and bill third-party payers for the product. We also employ a small group of respiratory specialists, who educate DME representatives, provide product demonstrations for targeted clinicians and support technical questions related to the AffloVest. As of September 30, 2024, we employed 270 field sales representatives for our lymphedema products and a team of 19 supporting our airway clearance products. This compares to 246 field sales representatives for our lymphedema products and a team of 13 specialists supporting our airway clearance products as of September 30, 2023.We invest in our reimbursement function to improve operational efficiencies and enhance individual payer expertise, while continuing our strategic focus of payer development. Our payer relations function focuses on payer policy development, education, contract negotiations, and data analysis. Our reimbursement 24 Table of Contents operations function is responsible for verifying patient insurance benefits, individual patient case development, prior authorization submissions, case follow-up, and appeals when necessary. We also have a clinical team, consisting of a scientific advisory board, in-house therapists and nurses, and a Chief Medical Officer, that serves as a resource to clinicians and patients and guides the development of clinical evidence in support of our products. Most clinical studies require observation and interaction with clinicians and patients to monitor results and progress. We rely on third-party contract manufacturers for the sourcing of parts, the assembly of our controllers and the manufacturing of the garments used with our systems. We conduct final assembly of the garments used with our products, perform quality assurance and ship our products from our facility in Minnesota. We also manufacture and ship the AffloVest device from our Minnesota-based facility.In July 2022, we launched Kyleeâ„¢ a free mobile app that makes it easier for patients to manage their conditions by tracking treatments and symptoms, as well as having direct access to educational resources. Flexitouch Plus and Nimbl devices include Bluetooth technology, which is viewable using Kylee.â€‹For the three months ended September 30, 2024, we generated revenue of $73.1 million and had net income of $5.2 million, compared to revenue of $69.6 million and net income of $22.3 million for the three months ended September 30, 2023. For the nine months ended September 30, 2024, we generated revenue of $207.4 million and had net income of $7.2 million, compared to revenue of $196.8 million and net income of $20.3 million for the nine months ended September 30, 2023. Our primary sources of capital since our initial public offering in 2016 have been from operating income, bank financing and our public offering in February 2023.We operate in one segment for financial reporting purposes.Current Economic ConditionsGeneral global economic downturns and macroeconomic trends, including heightened inflation, capital market volatility, interest rate fluctuations, increased unemployment and economic slowdown or recession, may result in unfavorable conditions that could negatively affect demand for our products and exacerbate some of the other risks that affect our business, financial condition and results of operations.â€‹â€‹25 Table of Contents Results of OperationsComparison of the Three and Nine Months Ended September 30, 2024 and 2023The following table presents our results of operations for the periods indicated:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

was primarily attributable to a $0.4 million increase in professional fees and a $0.2 million increase in personnel-related compensation expenses, partially offset by a $0.1 million decrease in clinical study related expenses.R&D expenses increased $0.8 million, or 13%, to $6.8 million in the nine months ended September 30, 2024, compared to $6.0 million in the nine months ended September 30, 2023. The increase was primarily attributable to a $0.5 million increase in professional fees, a $0.2 million increase in personnel-related compensation expenses, and a $0.1 million increase in clinical study related expenses.Reimbursement, General and Administrative ExpensesReimbursement, general and administrative expenses increased $1.7 million, or 10%, to $18.1 million in the three months ended September 30, 2024, compared to $16.5 million in the three months ended September 30, 2023. This increase was primarily attributable to a $1.2 million increase in personnel-related compensation expenses and a $0.9 million increase in IT related expenses, partially offset by a $0.4 million decrease in occupancy costs, depreciation expense and professional fees.Reimbursement, general and administrative expenses increased $4.3 million, or 9%, to $51.2 million in the nine months ended September 30, 2024, compared to $46.9 million in the nine months ended September 30, 2023. This increase was primarily attributable to a $2.3 million increase in personnel-related compensation expenses, and a $2.0 million increase in IT related expenses.Intangible Asset Amortization and Earn-out ExpenseIntangible asset amortization and earn-out expense increased $3.7 million to an expense of $0.6 million in the three months ended September 30, 2024, compared to a benefit of $3.1 million in the three months ended September 30, 2023. The increase in expense was related to there being no earn-out expense in the three months ended September 30, 2024, as final payment under the AffloVest Acquisition earn-out arrangement was made on November 28, 2023, and therefore there was no change in fair value of an earn-out expense recorded in the three months ended September 30, 2024, compared to a decrease in the fair value of the earn-out expense of $3.7 million for the three months ended September 30, 2023, due to the lower than expected airway clearance product revenue. Intangible asset amortization and earn-out expense increased $2.5 million to an expense of $1.9 million in the nine months ended September 30, 2024, compared to a benefit of $0.6 million in the nine months ended September 30, 2023. The increase was related to there being no earn-out expense in the nine months ended September 30, 2024, as final payment under the AffloVest Acquisition earn-out arrangement was made on November 28, 2023, and therefore there was no change in fair value of an earn-out expense recorded in the nine months ended September 30, 2024, compared to a decrease in the fair value of the earn-out expense of $2.5 million for the nine months ended September 30, 2023, due to the lower than expected airway clearance product revenue.29 Table of Contents â€‹â€‹Other Income (Expense), NetWe recorded other income, net of $0.5 million and other expense, net of $0.4 million for the three months ended September 30, 2024 and 2023, respectively. The primary drivers of the change were a decrease in interest expense of $0.4 million and an increase in interest income of $0.4 million. We recorded other income, net of $0.8 million and other expense, net of $2.2 million for the nine months ended September 30, 2024 and 2023, respectively. The primary drivers of the change were a decrease in interest expense of $1.6 million and an increase in interest income of $1.4 million.Income TaxesWe recorded income tax expense of $2.1 million and an income tax benefit $14.7 million for the three months ended September 30, 2024 and 2023, respectively. The primary driver of the change was the fact that we did not have a full valuation allowance on our deferred tax assets for the current year period, while in the prior year period there was a release of a valuation allowance to recognize the full value of our deferred tax assets.We recorded an income tax expense of $3.3 million and an income tax benefit of $16.3 million for the nine months ended September 30, 2024 and 2023, respectively. The primary driver of the change was the fact that we did not have a full valuation allowance on our deferred tax assets for the current year period, while in the prior year period there was a release of a valuation allowance to recognize the full value of our deferred tax assets. Liquidity and Capital ResourcesCash FlowsOn September 30, 2024, our principal sources of liquidity were cash and cash equivalents of $82.1 million and net accounts receivable of $43.2Â million. This compares to cash and cash equivalents of $66.0 million and net accounts receivable of $58.5 million at September 30, 2023. Â The following table summarizes our cash flows for the periods indicated:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Endedâ€‹â€‹September 30,(InÂ thousands)Â Â Â Â 2024Â Â Â Â 2023Net cash provided by (used in):â€‹â€‹â€‹â€‹â€‹â€‹â€‹Operating activitiesÂ $ 24,322â€‹$ 17,503Investing activitiesâ€‹â€‹ (2,005)â€‹â€‹ (1,541)Financing activitiesâ€‹â€‹ (1,204)â€‹â€‹ 28,145Net increase in cash and cash equivalentsÂ $ 21,113â€‹$ 44,107â€‹â€‹Operating ActivitiesNet cash provided by operating activities during the nine months ended September 30, 2024 was $24.3 million, resulting from non-cash net income adjustments of $11.0 million, net income of $7.2 million and a net increase in operating assets and liabilities of $6.1 million. The positive non-cash net income adjustments consisted primarily of $6.0 million of stock-based compensation expense and $5.1 million of depreciation. Cash provided relating to the change in operating assets and liabilities primarily consisted of a decrease in accounts receivable of $10.5 million, a decrease in inventories of $1.4 million and a $0.6 million increase in accounts payable, partially offset by a decrease in accrued payroll and related taxes of $3.7 million, an increase in prepaid 30 Table of Contents expenses and other assets of $1.8 million, a decrease in income taxes payable of $0.8 million and a decrease in accrued expenses and other liabilities of $0.3 million.Net cash provided by operating activities during the nine months ended September 30, 2023 was $17.5 million, resulting from net income of $20.3 million and a net increase in operating assets and liabilities of $9.9 million, which were partially offset by non-cash net income adjustments of $12.7 million. Cash provided relating to the change in operating assets and liabilities primarily consisted of a decrease in accounts receivable of $19.3 million and a decrease in net investment in leases of $2.5 million, partially offset by a decrease in accrued expenses of $5.5 million, a decrease in accounts payable of $3.6 million, a decrease in accrued payroll and related taxes of $2.3 million, and an increase in prepaid expenses and inventories of $0.7 million. The negative non-cash net loss adjustments consisted primarily of $20.7 million of deferred income taxes and a $2.5 million change in the fair value of earn-out liability, offset by $5.6 million of stock-based compensation expense and $4.9 million of depreciation and amortization expense.Investing ActivitiesNet cash used in investing activities during the nine months ended September 30, 2024, was $2.0 million, consisting of purchases of property and equipment primarily related to tenant improvements, and patent costs.Net cash used in investing activities during the nine months ended September 30, 2023, was $1.5 million, consisting of purchases of property and equipment, and patent costs.Financing ActivitiesNet cash used in financing activities during the nine months ended September 30, 2024, was $1.2 million, primarily consisting of a $2.3 million payment made on our term loan, partially offset by $1.0 million in proceeds from the issuance of common stock under the ESPP.Net cash provided by financing activities during the nine months ended September 30, 2023, was $28.1 million, primarily consisting of net proceeds from the offering of our common stock of $34.6 million and $1.0 million in proceeds from the issuance of common stock under the ESPP, partially offset by a payment of $5.0 million on the AffloVest earn-out and a $2.3 million payment made on our term loan.â€‹Credit Agreement On April 30, 2021, we entered into an Amended and Restated Credit Agreement (the â€œRestated Credit Agreementâ€) with the lenders from time to time party thereto, and Wells Fargo Bank, National Association, as Administrative Agent. The Restated Credit Agreement amended and restated in its entirety our prior credit agreement. On September 8, 2021, we entered into a First Amendment Agreement (the â€œAmendmentâ€), which amended the Restated Credit Agreement (as amended by the Amendment, the â€œCredit Agreementâ€) with the lenders from time to time party thereto and Wells Fargo Bank, National Association, as administrative agent. The Amendment, among other things, added a $30.0 million incremental term loan to the $25.0 million revolving credit facility provided by the Restated Credit Agreement. The term loan is reflected on our condensed consolidated financial statements as a note payable. The Credit Agreement provides that, subject to satisfaction of certain conditions, we may increase the amount of the revolving loans available under the Credit Agreement and/or add one or more term loan facilities in an amount not to exceed $25.0 million in the aggregate, such that the total aggregate principal amount of loans available under the Credit Agreement (including under the revolving credit facility) does not exceed $80.0 million.Â On September 8, 2021, in connection with the closing of the acquisition of the AffloVest business, we borrowed the $30.0 million term loan and utilized that borrowing, together with a draw of $25.0 million under the revolving credit facility and cash on hand, to fund the purchase price. â€‹31 Table of Contents On February 22, 2022, we entered into a Second Amendment Agreement (the â€œSecond Amendmentâ€), which further amends the Credit Agreement. The Second Amendment modified the maximum leverage ratio, the minimum fixed charge coverage ratio and the minimum consolidated EBITDA covenants under the Credit Agreement, and added a minimum liquidity covenant, through the quarter ended June 30, 2023. The Second Amendment also increased the applicable margin for LIBOR rate loans under the Credit Agreement during the period commencing on the date of the Second Amendment and ending on the last day of the fiscal quarter ending June 30, 2023. Pursuant to the Second Amendment, we made a mandatory principal prepayment of the term loan of $3.0 million on February 22, 2022.â€‹On June 21, 2023, we entered into a Third Amendment Agreement (the â€œThird Amendmentâ€) that replaced the interest rate benchmark under the Credit Agreement from LIBOR to the term Secured Overnight Financing Rate (â€œSOFRâ€). All tenors of term SOFR are subject to a credit spread adjustment of 0.10% (â€œAdjusted Term SOFRâ€). â€‹On August 1, 2023, we entered into a Fourth Amendment Agreement (the â€œFourth Amendmentâ€), which further amended the Credit Agreement. The Fourth Amendment, among other things, decreased the commitment fees payable under the revolving credit facility and eliminated the temporary increase in the applicable margin for Adjusted Term SOFR loans. The Fourth Amendment also eliminated the liquidity financial covenant and modified the remaining financial covenants to reflect the termination of the temporary covenant relief period that was in place until June 30, 2023 pursuant to the Second Amendment. In addition, the Fourth Amendment provided for an additional term loan in the amount of $8.25 million, which we used for a paydown of the revolving credit facility. The Fourth Amendment also extended the maturity date of the term loans and revolving credit facility under the Credit Agreement from September 8, 2024 to August 1, 2026.â€‹On November 1, 2024, we entered into a Fifth Amendment Agreement (the â€œFifth Amendmentâ€), which further amended the Credit Agreement. The Fifth Amendment permits the Company to make payments to repurchase shares of its common stock, as long as the Company is not in default before and after giving effect to such repurchases, and as long as such repurchases do not exceed $30.0 million.â€‹On December 21, 2023, we made a payment of $16.8 million to repay in full the outstanding balance on the revolving credit facility.â€‹As of September 30, 2024, we had outstanding borrowings of $27.0 million under the Credit Agreement, comprised entirely of the term loan. The principal of the term loan is required to be repaid in quarterly installments of $750,000.â€‹For additional information regarding the Credit Agreement, including interest rates, fees and maturities, see Note 8 â€“ â€œCredit Agreementâ€ of the condensed consolidated financial statements contained in this report.â€‹Share Repurchase Programâ€‹On October 30, 2024, our Board of Directors authorized a program to repurchase up to $30.0 million of common stock. Under the program, purchases may be made from time to time in the open market, in privately negotiated purchases, or both. The timing and number of shares to be purchased will be based on the price of our common stock, general business and market conditions and other investment considerations and factors. The share repurchase program expires on October 31, 2026. The program does not obligate us to repurchase any specific number of shares and may be suspended or discontinued at any time without prior notice. We intend to finance the share repurchase program with cash on hand.â€‹Future Cash RequirementsFor a discussion of our material estimated future cash requirements under our contractual obligations and commercial commitments, in total and disaggregated into current and long-term, see â€œFuture Cash Requirementsâ€ included in Item 7, Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes since December 31, 2023.32 Table of Contents Adequacy of ResourcesOur future cash requirements may vary significantly from those now planned and will depend on many factors, including:â—the impacts of inflation, rising interest rates or a recession on our business;â—sales and marketing resources needed to further penetrate our market;â—expansion of our operations;â—response of competitors to our solutions and applications; â—costs associated with clinical research activities;â—increases in interest rates;â—labor shortages and wage inflation;â—component price inflation;â—costs to develop and implement new products; and â—use of capital for acquisitions or licenses, if any.Historically, we have experienced increases in our expenditures consistent with the growth in our revenue, operations and personnel, and we anticipate that our expenditures will continue to increase as we expand our business.We believe our cash, cash equivalents and cash flows from operations will be sufficient to meet our working capital, capital expenditure, debt repayment and related interest, and other cash requirements for at least the next twelve months.Inflation and changing prices did not have a material effect on our business during the quarter ended September 30, 2024, and we do not expect that inflation or changing prices will materially affect our business for at least the next twelve months.Recent Accounting PronouncementsRefer to Note 3 â€“ â€œSummary of Significant Accounting Policiesâ€ of the condensed consolidated financial statements contained in this report for a description of recently issued accounting pronouncements that are applicable to our business.Critical Accounting EstimatesCritical accounting estimates are those that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition and results of operations. For additional information, please see the discussion of our most critical accounting estimates under â€œCritical Accounting Estimatesâ€ in Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2023.33 Table of Contents Item 3. Quantitative and Qualitative Disclosures About Market RiskFor a discussion on our market risks, see Item 7A, â€œQuantitative and Qualitative Disclosures About Market Risk,â€ included in our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes since December 31, 2023. Item 4. Controls and Procedures.Evaluation of Disclosure Controls and ProceduresOur management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2024. The term â€œdisclosure controls and procedures,â€ as defined in RulesÂ 13a-15(e)Â and 15d-15(e)Â under the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rulesÂ and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the companyâ€™s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2024, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.Changes in Internal Control over Financial ReportingThere was no change in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, that occurred during the quarter ended September 30, 2024, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.PARTÂ IIâ€”OTHER INFORMATIONItem 1. Legal Proceedings.Information pertaining to certain legal proceedings in which we are involved can be found in Note 9 â€“ â€œCommitments and Contingenciesâ€ to our condensed consolidated financial statements included in Part I, Item 1 of this report and is incorporated herein by reference. ItemÂ 1A.Â Risk Factors.In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in â€œRisk Factorsâ€ in our Annual Report on Form 10-K for the year ended December 31, 2023, which could materially affect our business, financial condition or future results. There have been no material changes in our risk factors from those disclosed in that report.ItemÂ 2.Â Unregistered Sales of Equity Securities and Use of Proceeds.None.Item 3. Defaults Upon Senior Securities.Not applicable.34 Table of Contents Item 4. Mine Safety Disclosures.Not applicable.Item 5. Other Information.Fifth Amendment to Credit AgreementBecause we are filing this Quarterly Report on Form 10-Q within four business days after the triggering event, we are making the following disclosure under this Item 5 instead of filing a Current Report on Form 8-K under Item 1.01, Entry into a Material Definitive Agreement and Item 2.03, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant:On November 1, 2024, we entered into a Fifth Amendment Agreement (the â€œFifth Amendmentâ€), which amends the Amended and Restated Credit Agreement, dated as of April 30, 2021, as amended by the First Amendment Agreement dated as of September 8, 2021, the Second Amendment Agreement dated as of Â February 22, 2022, the Third Amendment Agreement dated as of June 21, 2023, and the Fourth Amendment Agreement dated as of August 1, 2023 (as further amended by the Fifth Amendment, the â€œCredit Agreementâ€), by and among us, the lenders from time to time party thereto, and Wells Fargo Bank, National Association, as administrative agent.The Credit Agreement restricts the Company from making certain payments, including any payments to repurchase shares of its common stock. The Fifth Amendment provides for an exception to this restriction by permitting the Company to make payments to repurchase shares of its common stock, as long as the Company is not in default before and after giving effect to such repurchases, and as long as such repurchases do not exceed $30.0 million.The foregoing description of the Fifth Amendment is a summary, does not purport to be complete, and is qualified in its entirety by reference to the Fifth Amendment, a copy of which is attached to this Quarterly Report on Form 10-Q as Exhibit 10.2 and is incorporated herein by reference.Trading ArrangementsDuring the quarter ended September 30, 2024, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K). ItemÂ 6.Â Exhibits.The exhibits filed as part of this Quarterly Report on FormÂ 10-Q

are set forth on the ExhibitÂ Index below.â€‹35 Table of Contents EXHIBIT
INDEXâ€‹â€‹â€‹â

benefits pursuant to this Plan shall be exempt from the requirements of Code Section 409A to the maximum extent possible as â€œshort-term deferralsâ€ pursuant to Treasury Regulation Section 1.409A-1(b)(4), as involuntary separation pay pursuant to Treasury Regulation Section 1.409A-1(b)(9)(iii), and/or under any other exemption that may be applicable, and this Plan shall be construed accordingly. To the extent that any amounts payable under this Plan are required to be delayed under Code Section 409A, such amounts are intended to be and should be considered for purposes of Code Section 409A as separate payments from the amounts that are not required to be delayed. Notwithstanding anything herein to the contrary, if any Participant is considered a â€œspecified employeeâ€ (as defined in Treasury Regulation Section 1.409A-1(i)) as of the Termination Date, then no payments of deferred compensation subject to Code Section 409A and payable due to such Participantâ€™s separation from service shall be made under this Plan before the first business day that is six months after the Termination Date (or upon the Participantâ€™s death, if earlier) (the â€œSpecified Periodâ€). Any deferred compensation payments that would otherwise be required to be made to a Participant during the Specified Period will be accumulated by the Company and paid to the Participant on the first day after the end of the Specified Period. The foregoing restriction on the payment of amounts to a Participant during the Specified Period will not apply to the payment of employment taxes. Section 280GIf any payment or benefit to be paid or provided to a Participant under this Plan, taken together with any payments or benefits otherwise paid or provided to such Participant by the Company or any corporation that is a member of an â€œaffiliated groupâ€ (as defined in Section 1504 of the Code without regard to Section 1504(b) of the Code) of which the Company is a member (the â€œother arrangementsâ€), would collectively constitute a â€œparachute paymentâ€ (as defined in Section 280G(b)(2) of the Code), and if the net after-tax amount of such parachute payment to such Participant is less than what the net after-tax amount to such Participant would be if the aggregate payments and benefits otherwise constituting the parachute payment were limited to three times such Participantâ€™s â€œbase amountâ€ (as defined in Section 280G(b)(3) of the Code) less $1.00, then the aggregate payments and benefits otherwise constituting the parachute payment shall be reduced to an amount that shall equal three times such Participantâ€™s base amount, less $1.00. Should such a reduction in payments and benefits be required, such Participant shall be entitled, subject to the following sentence, to designate those payments and benefits under this Plan or the other arrangements that will be reduced or eliminated so as to achieve the specified reduction in aggregate payments and benefits to such Participant and avoid characterization of such aggregate payments and benefits as a parachute payment. The Company will provide such Participant with all information reasonably requested by such Participant to permit the Participant to make such designation. To the extent that such Participantâ€™s ability to make such a designation would cause any of the payments and benefits to become subject to any additional tax under Code Section 409A, or if such Participant fails to make such a designation within ten business days of receiving the requested information from the Company, then the Company shall achieve the necessary reduction in such payments and benefits by first reducing or eliminating the portion of the payments and benefits that are payable in cash and then by reducing or eliminating the non-cash portion of the payments and benefits, in each case in reverse order beginning with payments and benefits which are to be paid or provided the furthest in time from the date of the Companyâ€™s determination. A net after-tax amount shall be determined by taking into account all applicable income, excise and employment taxes, whether imposed at the federal, state or local level, including the excise tax imposed under Section 4999 of the Code. 6â€‹â€‹Reductions of Severance Benefits Except as otherwise provided in this Plan, all severance benefits payable under this Plan will be reduced, as and when it is otherwise payable, by the amount of any severance or similar payment required to be paid to you by the Company under applicable federal, state, and local laws. Cash severance payments are also subject to all applicable withholding due on any severance benefits, including state and federal income tax withholding and FICA and Medicare tax withholding.Coordination/Offsets for Employment AgreementsIf you are party to an individual written employment contract or agreement with the Company (or a subsidiary) that provides for the payment of any benefits upon termination of your employment, then your cash severance benefits under this Plan will be reduced as follows. Any cash severance pay under this Plan will be reduced (offset), as and when it is otherwise payable, by the amount of any cash payment made or due to be made by the Company to you pursuant to an employment contract, agreement or other severance arrangement, to the extent such payment is called a severance payment or otherwise becomes payable due to a termination of your employment with the Company (but not including any cash severance payments that are specifically due to COBRA premiums or outplacement) . If such an agreement, contract or arrangement provides for cash severance payments in excess of those provided under this Plan, no severance pay will be due under this Plan. However, you may still be eligible for other benefits under the Plan, to the extent benefits are not duplicative of what you are receiving under the agreement, contract or arrangement.Termination of Severance BenefitsAll severance benefits payable under this Plan will be terminated if the Company determines that you have violated your ongoing obligations with respect to non-disclosure of confidential information, assignment of intellectual property, non-competition and non-solicitation, including those obligations under your Confidentiality, Assignment of Intellectual Property and Restrictive Covenants Agreement and any other agreement with the Company that survive the termination of your employment with the Company. Specifically with respect to Equity Awards, and notwithstanding anything to the contrary in any agreement evidencing an Equity Award, if you violate any of your ongoing obligations described above, then (i) you will immediately forfeit all outstanding Equity Awards and any right to receive shares thereunder, and (ii) with respect to shares that have been issued pursuant to an Equity Award within two (2) years prior to such violation, you shall either (A) return such shares to the Company or (B) pay to the Company in cash an amount equal to the fair market value of the shares as of the date their receipt became taxable to you.V.AMENDMENT AND TERMINATION OF THE PLANExcept as provided below, the Company reserves the right in its discretion to amend or terminate this Plan, or to alter, reduce, or eliminate any severance benefit, practice or policy hereunder, in whole or in part, at any time and for any reason without the consent of or notice to any employee or any other person having any beneficial interest in this Plan. Such action may be taken by the Board of the Company, the Compensation Committee of the Board, or by any other individual or committee to whom such authority has been delegated by the Board.However, during the 12-month period following a Change in Control, the Plan may not be amended, terminated or otherwise altered to reduce the amount (or negatively change the terms) of any severance benefit that becomes payable to a Participant who was a Participant in the Plan on the day prior to the Change in Control. In addition, if a Change in Control occurs within the 6-month period following the effective date of an amendment to terminate the Plan or otherwise reduce the amount (or negatively alter the terms) of any severance benefit under the Plan, such amendment (or portion of such amendment) will become null and void upon the Change in Control. Upon the Change in Control, the Plan will automatically revert to the terms in effect prior to the adoption of said amendment.7â€‹â€‹Notwithstanding the above limitations, the Plan may be amended at any time (and such amendment will be given affect) if such amendment is required to bring the Plan into compliance with applicable law, including but not limited to Section 409A of the Internal Revenue Code of 1986, as amended (and the regulations or other applicable guidance thereunder). VI.SUBMITTING CLAIMS FOR BENEFITSNormally, the Company will determine an employeeâ€™s eligibility and benefit amount on its own and without any action on the part of the terminating employee, other than returning the release form. The severance payments will begin as soon as administratively feasible after the date the release becomes irrevocable. Formal Claims for Benefits. If you think you are entitled to benefits but have not been so notified by the Company, if you disagree with a decision made by the Company, or if you have any other complaint regarding the Plan that is not resolved to your satisfaction, you or your authorized representative may submit a written claim for benefits. The claim must be submitted to the Companyâ€™s Human Resources Department within six months after the date you terminated employment. Claims received after that time will not be considered.The Company will ordinarily respond to the claim within 90 days of the date on which it is received. However, if special circumstances require an extension of the period of time for processing a claim, the 90-day period can be extended for an additional 90 days by giving you written notice of the extension, the reason why the extension is necessary, and the date a decision is expected.The Company will give you a written notice of its decision if it denies your claim for benefits in whole or in part. The notice will explain the specific reasons for the decision, including references to the relevant plan provision upon which the decision is based, with a description of any additional material or information necessary for you to perfect your claim, and the procedures for appealing the decision. Appeals. If you disagree with the initial claim determination, in whole or in part, you or your authorized representative can request that the decision be reviewed by filing a written request for review with the Companyâ€™s Human Resources Department within 60 days after receiving notice that the claim has been denied. You or your representative may present written statements describing reasons why you believe the claim denial was in error, and should include copies of any documents you want us to consider in support of your appeal. Your claim will be decided based on the information submitted, so you should make sure that your submission is complete. Upon request to the Company, you may review all documents we considered or relied on in deciding your claim. (You may also receive copies of these documents free of charge.)Any appeal will be reviewed and decided by person(s) other than the person(s) who made the determination on your original claim. Generally, the decision will be reviewed within 60 days after the Company receives a request for review. However, if special circumstances require a delay, the review may take up to 120 days. (If a decision cannot be made within the 60-day period, you will be notified of this fact in writing.) You will receive a written notice of the decision on the appeal, which will explain the reasons for the decision by making specific reference to the Plan provisions on which the decision is based.Limitations Period. The claims procedure above is mandatory. If an employee has completed the entire claims procedure and still disagrees with the outcome of the employeeâ€™s claim, the employee may commence a civil action under Â§ 502(a) of the Employee Retirement Income Security Act of 1974, as amended (â€œERISAâ€). The employee must commence such civil action within one year of the date of the final denial, or the employee will waive all rights to relief under ERISA.8â€‹â€‹VII.PLAN ADMINISTRATIONThe following information relates to the administration of the Plan and the determination of Plan benefits. Type of Plan: The Plan is a severance benefit plan. Plan Administrator/Plan Sponsor: The Company is the â€œPlan Sponsorâ€ and â€œPlan Administratorâ€ of this Plan. Communications to the Company regarding the Plan should be addressed to:Tactile Systems Technology, Inc. 3701 Wayzata Blvd., Suite 300Minneapolis, MN 55416Attention: Chief Financial OfficerTelephone: +1 (612) 355-5100As Plan Administrator, the Company has complete discretionary authority to interpret the provisions of the Plan and to determine which employees are eligible to participate and eligible for Plan benefits, the requirements to receive severance benefits, and the amount of those benefits. The Company also has authority to correct any errors that may occur in the administration of the Plan, including recovering any overpayment of benefits from the person who received it.Employer Identification Number: 41-1801204Plan Year: The calendar year. The first Plan Year is a short Plan Year, starting on the date the Plan was initially adopted and ending on December 31, 2018.Agent for Service of Legal Process: Legal process regarding the Plan may be served on the Company at the address listed above.Assignment of Benefits: You cannot assign your benefits under this Plan to anyone else, and your benefits are not subject to attachment by your creditors. The Company will not pay Plan benefits to anyone other than you (or your estate, if you die after having a qualifying severance event but before receiving the complete severance amount payable to you up to the date of your death).Governing Law: This Plan, to the extent not preempted by ERISA or any other federal law shall be governed by and construed in accordance with, the laws of the State of Minnesota.Employment Rights: Establishment of the Plan shall not be construed to in any way modify the partiesâ€™ at-will employment relationship, or to give any employee the right to be retained in the Companyâ€™s service or to any benefits not specifically provided by the Plan. The right of an employer to terminate the employment relationship of an employee (or to accelerate the termination date) will not in any way be affected by the terms of this Plan or any release.Successor/Purchasing Entity: For the avoidance of doubt, references in this Plan to the â€œCompanyâ€ include, after a Change in Control or other corporate transaction, the successor to the Company or purchasing entity. 9â€‹ EX-10.2 3 tcmd-20240930xex10d2.htm EX-10.2 â€‹Exhibit 10.2â€‹Execution Copyâ€‹FIFTH AMENDMENT AGREEMENTâ€‹This FIFTH AMENDMENT AGREEMENT (this â€œAmendmentâ€), dated as of November 1, 2024, is entered into among Tactile Systems Technology, Inc., a Delaware corporation (dba Tactile Medical) (the â€œBorrowerâ€), the Lenders (as defined below) signatory hereto, and Wells Fargo Bank, National Association, a national banking association, as administrative agent for the Lenders (in such capacity, the â€œAdministrative Agentâ€).RECITALSWHEREAS, the Borrower, the financial institutions from time to time party thereto (the â€œLendersâ€) and the Administrative Agent are parties to that certain Amended and Restated Credit Agreement, dated as of April 30, 2021, as amended by that certain First Amendment Agreement dated as of September 8, 2021, that certain Second Amendment Agreement dated as of February 22, 2022, that certain Third Amendment Agreement dated as of June 21, 2023, and that certain Fourth Amendment Agreement dated as of August 1, 2023 (as further amended, restated, supplemented or otherwise modified from time to time prior to the date hereof, the â€œExisting Credit Agreementâ€, and as amended by this Amendment, the â€œCredit Agreementâ€);WHEREAS, the Borrower has requested that the Administrative Agent and the Lenders agree to certain amendments to the Existing Credit Agreement, and, subject to the terms and conditions set forth in this Amendment, the Administrative Agent and the Lenders have agreed to provide certain amendments.AGREEMENTNOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto covenant and agree to be bound as follows:Section 1.Capitalized Terms. Capitalized terms used and not otherwise defined herein shall have the meanings assigned to them in the Credit Agreement, unless the context otherwise requires.Section 2.Amendments to Existing Credit Agreement. The Existing Credit Agreement is hereby amended as follows:2.1.Section 9.6 is amended by adding a new Section 9.6(f) to the end thereof:(i)beginning on the Fifth Amendment Date, the Borrower shall be permitted to make one or more Restricted Payments solely for the purpose of repurchasing issued and publicly held common voting Equity Interests of the Borrower (the â€œPermitted Equity Interest Repurchasesâ€); provided that (w) in no event shall such repurchases exceed $30,000,000 individually or in the aggregate, (x) at the time of the making such Restricted Payment, (A) no Default or Event of Default has occurred, or is continuing or would result from the making such Restricted Payment in connection with such repurchase, and (B) the Borrower is in in compliance on a Pro Forma Basis (after giving effect to the making of any Restricted Payment in connection with such repurchase) withâ€‹1â€‹each covenant contained in Section 9.15, (y) the Board of Directors of Borrower has duly authorized each such Restricted Payment and related repurchase of common voting Equity Interests, including analysis of the Solvency of the Borrower after giving effect to such repurchases and the incurrence of any Indebtedness in connection therewith, and (z) Borrower shall cancel, retire or otherwise return all such shares of common voting Equity Interests to treasury stock.Section 3.Effectiveness of Amendment. The amendments set forth in Section 2 hereof shall become effective on the Fifth Amendment Date upon delivery of, or compliance with, the following:3.1.This Amendment, duly executed by the Credit Parties, the Administrative Agent, and each of the Lenders (whether the same or different copies) and delivered (including by way of facsimile or other electronic transmission (including by e-mail in .pdf format)) in each case with original signatures to follow promptly thereafter, to the Administrative Agent.3.2.Certificates of current status or good standing for each Credit Party in the state of its organization, in each case as of a recent date.3.3.The Administrative Agent shall have received for itself and for the account of the Lenders all reasonable and documented fees and expenses of counsel to the Administrative Agent payable pursuant to SectionÂ 12.3 of the Credit Agreement to the extent requested in advance by the Administrative Agent.Section 4.Release, No Waiver, Representations, Warranties, Authority, No Adverse Claim.4.1.Release of Claims. Each Credit Party, for itself and on behalf of its legal representatives, successors, and assigns, hereby (a)Â expressly waives, releases, and relinquishes the Administrative Agent and each of the Lenders from any and all claims, offsets, defenses, affirmative defenses, and counterclaims of any kind or nature whatsoever that such Credit Party has asserted, or might assert, against the Administrative Agent or the Lenders with respect to the Obligations, the Credit Agreement (including as affected by this Amendment), and any other Loan Document, other than any such claim arising from the bad faith, gross negligence or willful misconduct of the Administrative Agent or a Lender as determined by a final non-appealable order by a court of competent jurisdiction, in each case arising on or before the date hereof, such waiver and release being with full knowledge and understanding of the circumstances and effect thereof, and (b)Â expressly covenants and agrees never to institute, cause to be instituted, or continue prosecution of any suit or other form of action or proceeding of any kind or nature whatsoever against the Administrative Agent or the Lenders by reason of or in connection with any of the foregoing matters, claims, or causes of action.4.2.No Waiver. The execution of this Amendment and acceptance of any documents related hereto shall not be deemed to be a waiver of any Default or Event ofâ€‹2â€‹Default under the Credit Agreement or breach, default, or event of default under any Security Document or other document held by the Administrative Agent or the Lenders, whether or not known to the Administrative Agent or the Lenders and whether or not existing on the date of this Amendment.4.3.Representations and Warranties, No Default. Each Credit Party hereby represents that after giving effect to this Amendment:(a)It is a corporation or limited liability company, as applicable, duly incorporated or organized, as the case may be, validly existing and (to the extent such concept applies to such entity) in good standing under the laws of its jurisdiction of incorporation or organization and, is duly qualified and authorized to do business in each jurisdiction in which the character of its Properties or the nature of its business requires such qualification and authorization except where the failure to be so qualified would not reasonably be expected to result a Material Adverse Effect.(b)It has the power and authority and legal right to execute and deliver, and to perform its obligations under, this Amendment, the Credit Agreement, the Notes, and all other Loan Documents, each as amended by this Amendment, to which it is a party and the performance of its obligations thereunder have been duly authorized by proper organizational proceedings, and the Loan Documents to which such Person is a party constitute legal, valid and binding obligations of such Person enforceable against such Person in accordance with their terms, except as enforceability may be

limited by bankruptcy, insolvency, reorganization, moratorium or similar state or federal Debtor Relief Laws from time to time in effect which affect the enforcement of creditorsâ€™ right in general and the availability of equitable remedies.(c)The execution, delivery and performance of this Amendment, the Credit Agreement, and all other Loan Documents, each as amended by this Amendment, the Extensions of Credit thereunder and the transactions contemplated hereby or thereby do not and will not, by the passage of time, the giving of notice or otherwise, (a)Â require any Governmental Approval or violate any Applicable Law relating to any Credit Party or any Subsidiary thereof where the failure to obtain such Governmental Approval or such violation could reasonably be expected to have a Material Adverse Effect, (b)Â conflict with, result in a breach of or constitute a default under the articles of incorporation, bylaws or other organizational documents of any Credit Party or any Subsidiary thereof, (c)Â conflict with, result in a breach of or constitute a default under any indenture, agreement or other instrument evidencing Indebtedness or a payment obligation in excess of the Threshold Amount to which such Person is a party or by which any of its properties may be bound or any Governmental Approval relating to such Person, which could, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, (d)Â result in or require the creation or imposition of any Lien upon or with respect to any property now owned or hereafter acquired by such Person other than Permitted Liens or (e)Â require any consent or authorization of, filing with, or other act in respect of, an arbitrator or Governmental Authority and no consent of any other Person is required in connection with the execution, delivery, performance, validity or enforceability of any Loan Document other than (i)Â consents, authorizations, filings orâ€‹â€‹other acts or consents for which the failure to obtain or make could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, (ii)Â consents or filings under the UCC, (iii)Â filings with the United States Copyright Office and/or the United States Patent and Trademark Office and (iv) filings of any mortgage or deed of trust with the applicable county recording office or register of deeds.(d)The representations and warranties in Article VII of the Credit Agreement, are true and correct in all material respects, without duplication as to any materiality modifiers, qualifications, or limitations set forth in Article VII of the Credit Agreement, with respect to such Credit Party and its Subsidiaries as of the Fifth Amendment Date, except to the extent such representations and warranties specifically relate to an earlier date, in which case they are true and correct in all material respects as of such earlier date.(e)There will exist no Default or Event of Default under the Credit Agreement.(f)To the Borrowerâ€™s knowledge, no events have taken place and no circumstances exist at the date hereof that would give any Credit Party a basis to assert a defense, offset, or counterclaim to any claim of the Administrative Agent or any Lender with respect to the Obligations.Section 5.Affirmation of Loan Documents, Further References, Affirmation of Security Interest and Guarantee. Each of the Administrative Agent, the Lenders, and the Credit Parties acknowledge and affirm that each of the Credit Agreement, any Guarantee, the Security Agreement, and each of the other Loan Documents to which it is a party is hereby ratified and confirmed in all respects except as expressly amended hereby, and all terms, conditions, and provisions of each such Loan Document shall remain unmodified and in full force and effect except as expressly amended hereby. Each Credit Party confirms to the Administrative Agent and the Lenders that the Obligations are and continue to be guaranteed and secured by the security interest granted in favor of the Administrative Agent for the benefit of the Administrative Agent and the Lenders under any Guarantee and any Security Documents, as applicable, and that all of the terms, conditions, provisions, agreements, requirements, promises, obligations, duties, covenants, and representations of such Credit Party under such documents and any and all other documents and agreements entered into with respect to the obligations under the Credit Agreement are hereby ratified, assumed, and affirmed in all respects by such Credit Party, except as expressly modified hereby.Section 6.Merger and Integration, Superseding Effect. This Amendment embodies the entire agreement and understanding among any Credit Party, the Administrative Agent, the Issuing Lender and the Lenders and supersedes all prior agreements and understandings among any Credit Party, the Administrative Agent, the Issuing Lender and the Lenders relating to the subject matter hereof or thereof.Section 7.Severability. Any provision in this Amendment that is held to be inoperative, unenforceable or invalid in any jurisdiction shall, as to that jurisdiction, be inoperative, unenforceable or invalid without affecting the remaining provisions in thatâ€‹â€‹jurisdiction or the operation, enforceability or validity of that provision in any other jurisdiction, and to this end the provisions of this Amendment are declared to be severable.Section 8.Successors. This Amendment shall be binding upon the Credit Parties, the Lenders, the Administrative Agent, and their respective successors and assigns, and shall inure to the benefit of the Credit Parties, the Administrative Agent, the Lenders, and the successors and assigns of the Administrative Agent and the Lenders.Section 9.Expenses. The Borrower shall pay the Administrative Agent, upon execution of this Amendment, the fees and expenses as provided in SectionÂ 12.3 of the Credit Agreement to the extent requested in advance by the Administrative Agent.Section 10.Headings. Section headings in this Amendment are for convenience of reference only and shall not govern the interpretation of any of the provisions of this Amendment.Section 11.Counterparts. This Amendment may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract.Section 12.Governing Law. THIS AMENDMENT SHALL BE CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF MINNESOTA, BUT GIVING EFFECT TO FEDERAL LAWS APPLICABLE TO NATIONAL BANKS.[The remainder of this page is intentionally left blank]â€‹â€‹5â€‹IN WITNESS WHEREOF, the parties hereto have caused this Fifth Amendment Agreement to be executed as of the date and year first above written.â€‹â€‹TACTILE SYSTEMS TECHNOLOGY, INC., as Borrowerâ€‹â€‹â€‹By:/s/ Elaine Birkemeyerâ€‹Name:Elaine Birkemeyerâ€‹Title:Chief Financial Officerâ€‹â€‹â€‹â€‹SWELLING SOLUTIONS, INC., as Guarantorâ€‹â€‹â€‹By:/s/ Elaine Birkemeyerâ€‹Name:Elaine Birkemeyerâ€‹Title:Chief Financial Officerâ€‹â€‹[Signature Page to Fifth Amendment Agreement]â€‹â€‹â€‹WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent, Swingline Lender, Issuing Lender and Lenderâ€‹â€‹â€‹By:/s/ Brandon Mossâ€‹Name:Brandon Mossâ€‹Title:Vice Presidentâ€‹[Signature Page to Fifth Amendment Agreement] EX-31.1 4 tcmd-20240930xex31d1.htm EX-31.1 â€‹Exhibit 31.1â€‹CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OFÂ 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACTÂ OF 2002â€‹I, Sheri L. Dodd, certify that:1.I have reviewed this Quarterly Report on Form 10-Q of Tactile Systems Technology, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; andb.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.â€‹â€‹â€‹â€‹/s/ Sheri L. Dodd â€‹Sheri L. Doddâ€‹Chief Executive Officerâ€‹Date: November 4, 2024â€‹ EX-31.2 5 tcmd-20240930xex31d2.htm EX-31.2 â€‹Exhibit 31.2â€‹CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002â€‹I, Elaine M. Birkemeyer, certify that:â€‹1.I have reviewed this Quarterly Report on Form 10-Q of Tactile Systems Technology, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; andb.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.â€‹â€‹â€‹â€‹/s/ Elaine M. Birkemeyerâ€‹Elaine M. Birkemeyerâ€‹Chief Financial Officerâ€‹Date: November 4, 2024â€‹ EX-32.1 6 tcmd-20240930xex32d1.htm EX-32.1 â€‹Exhibit 32.1â€‹CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002â€‹In connection with the Quarterly Report on Form 10-Q of Tactile Systems Technology, Inc. (the â€œCompanyâ€) for the period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), the undersigned, Sheri L. Dodd, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to her knowledge:â€‹(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; andâ€‹(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹/s/ Sheri L. Doddâ€‹Sheri L. Doddâ€‹Chief Executive Officerâ€‹â€‹Date: November 4, 2024â€‹ EX-32.2 7 tcmd-20240930xex32d2.htm EX-32.2 â€‹Exhibit 32.2â€‹CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002â€‹In connection with the Quarterly Report on Form 10-Q of Tactile Systems Technology, Inc. (the â€œCompanyâ€) for the period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), the undersigned, Elaine M. Birkemeyer, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to her knowledge: â€‹(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; andâ€‹(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹/s/ Elaine M. Birkemeyerâ€‹Elaine M. Birkemeyerâ€‹Chief Financial Officerâ€‹Date: November 4, 2024â€‹ EX-101.SCH 8 tcmd-20240930.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 995200100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Goodwill And Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Patent Costs, Net (Details) (Calc 2) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Warranty Reserves (Details) link:presentationLink link:calculationLink link:definitionLink 99940802 - Disclosure - Credit Agreement - Maturities of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 99940902 - Disclosure - Commitments and Contingencies - Lease related assets and liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99940903 - Disclosure - Commitments and Contingencies - Undiscounted cash flows (Details) link:presentationLink link:calculationLink link:definitionLink 41004 - Disclosure - Commitments and Contingencies - Undiscounted cash flows (Details) - Calc2 link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Credit Agreement - Maturities of Debt (Details) - calc 2 link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Nature of Business and Operations link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995211301 - Disclosure - Net Income Per Share link:presentationLink link:calculationLink link:definitionLink 995211401 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 99920302 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 99930903 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 99931003 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 99931303 - Disclosure - Net Income Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 99931403 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - Nature of Business and Operations (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Credit Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Commitments and Contingencies - Lease Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 99940905 - Disclosure - Commitments and Contingencies - Major Vendors (Details) link:presentationLink link:calculationLink link:definitionLink 99940907 - Disclosure - Commitments and Contingencies - Retirement Plan (Details) link:presentationLink link:calculationLink link:definitionLink 99940908 - Disclosure - Commitments and Contingencies - Legal Proceedings (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - Stockholders' Equity - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 99941002 - Disclosure - Stockholders' Equity - Stock Options and Restricted Stock (Details) link:presentationLink link:calculationLink link:definitionLink 99941003 - Disclosure - Stockholders' Equity - Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 99941301 - Disclosure - Net Income Per Share - Basic and Diluted Net income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 99941302 - Disclosure - Net Income Per Share - Antidilutive Securities Excluded From Computation

of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 99941401 - Disclosure - Fair Value Measurements - Earn out liability (Details) link:presentationLink link:calculationLink link:definitionLink 99941402 - Disclosure - Fair Value Measurements - Fair Value Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 99941501 - Disclosure - Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Warranty Reserves link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Credit Agreement link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 995211501 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Warranty Reserves (Tables) link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - Credit Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 99931103 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 99940904 - Disclosure - Commitments and Contingencies - Lease commitments and operating lease cost (Details) link:presentationLink link:calculationLink link:definitionLink 99940906 - Disclosure - Commitments and Contingencies - Purchase Commitments (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 tcmd-20240930_cal.xml EX-101.CAL EX-101.DEF 10 tcmd-20240930_def.xml EX-101.DEF EX-101.LAB 11 tcmd-20240930_lab.xml EX-101.LAB Document and Entity Information Document Information [Table] Document Information [Line Items] Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Condensed Consolidated Balance Sheets Statement [Table] Statement [Line Items] Net Income Per Share Assets [Abstract] Assets Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Accounts Receivable, Net, Current Accounts receivable Net Investment in Lease Net investment in leases Inventory, Net Inventories Total inventories Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Other Assets, Miscellaneous [Abstract] Non-current assets Property, Plant and Equipment, Net Property and equipment, net Operating Lease, Right-of-Use Asset Right of use operating lease assets Intangible Assets, Net (Excluding Goodwill) Total intangible assets (Net) Intangible assets, net Goodwill Goodwill Amount of non-current accounts receivable on account of medicare. Medicare Accounts Receivable Non Current Accounts receivable, non-current Deferred Tax Assets, Net, Noncurrent Deferred income taxes Other Assets, Noncurrent Other non-current assets Assets, Noncurrent Total non-current assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities Accounts Payable, Current Accounts payable Notes Payable, Current Note payable Employee-related Liabilities, Current Accrued payroll and related taxes Accrued Liabilities, Current Accrued expenses Total Accrued Income Taxes, Current Income taxes payable Operating Lease, Liability, Current Less: Current obligations under operating lease liabilities Operating lease liabilities Operating lease liabilities, Current Other Liabilities, Current Other current liabilities Liabilities, Current Total current liabilities Liabilities, Noncurrent [Abstract] Non-current liabilities Notes Payable, Noncurrent Note payable, non-current Product Warranty Accrual, Noncurrent Accrued warranty reserve, non-current Accrued Income Taxes, Noncurrent Income taxes payable, non-current Operating Lease, Liability, Noncurrent Operating lease liabilities, non-current Non-current obligations under operating lease liabilities Total long-term liabilities, net of current portion Total non-current liabilities Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.001 par value, 50,000,000 shares authorized; none issued and outstanding as of September 30, 2024 and December 31, 2023 Common Stock, Value, Issued Common stock, $0.001 par value, 300,000,000 shares authorized; 23,997,089 shares issued and outstanding as of September 30, 2024; 23,600,584 shares issued and outstanding as of December 31, 2023 Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Retained earnings Stockholders' Equity Attributable to Parent Balances at the end Balances at the beginning Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares, issued Common Stock, Shares, Outstanding Common stock, shares, outstanding Condensed Consolidated Statements of Operations Products and Services [Axis] Products and Services [Domain] Sales revenue Information relating to rental product services which generate revenue for the company. Rental revenue Revenue from Contract with Customer, Excluding Assessed Tax Total revenue Revenue Cost of Revenue Total cost of revenue Gross Profit Gross profit Operating Expenses [Abstract] Operating expenses Selling and Marketing Expense Sales and marketing Research and Development Expense Research and development General and Administrative Expense Reimbursement, general and administrative Amount of impairment of intangible asset and earn outs. Amortization of Intangible Assets and Earn outs Intangible asset amortization and earn-out Operating Expenses Total operating expenses Operating Income (Loss) Income from operations Nonoperating Income (Expense) Other income (expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income before income taxes Income Tax Expense (Benefit) Income tax expense (benefit) Net income Net income for the period Net Income Per Share Net income per common share Income (Loss) from Continuing Operations, Per Basic Share Basic Income (Loss) from Continuing Operations, Per Diluted Share Diluted n/a Earnings Per Share Other Disclosure [Abstract] Weighted-average common shares used to compute net income per common share Weighted Average Number of Shares Outstanding, Basic Basic Weighted-average shares outstanding Weighted Average Number of Shares Outstanding, Diluted Diluted Weighted-average shares used to compute diluted net income per share Condensed Consolidated Statements of Stockholders' Equity Equity Components [Axis] Equity Component [Domain] Common Stock Additional Paid-In Capital Retained Earnings (Accumulated Deficit). Increase (Decrease) in Stockholders' Equity Shares, Outstanding Balances at the end (in shares) Balances at the beginning (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Stock-based compensation Stock Issued During Period, Value, Stock Options Exercised Exercise of common stock options and vesting of performance and restricted stock units Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised Exercise of common stock options and vesting of performance and restricted stock units (in shares) Stock Issued During Period, Value, New Issues Sale of common stock from follow-on public offering, net of offering expenses Stock Issued During Period, Shares, New Issues Number of shares of common stock sold Sale of common stock from follow-on public offering, net of offering expenses (in shares) Stock Issued During Period, Value, Employee Stock Purchase Plan Common shares issued for employee stock purchase plan Stock Issued During Period, Shares, Employee Stock Purchase Plans Common shares issued for employee stock purchase plan (in shares) Condensed Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Continuing Operations [Abstract] Cash flows from operating activities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Deferred Income Taxes and Tax Credits Deferred income taxes Share-based Compensation Stock-based compensation expense Gain (Loss) on Disposition of Assets Loss on disposal of property and equipment and intangibles Liabilities, Fair Value Adjustment Change in fair value of earn-out liability Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities, net of acquisition: Increase (Decrease) in Accounts Receivable Accounts receivable Represents the increase (decrease) in net investment in leases. Increase (Decrease) In Net Investment in Lease Net investment in leases Increase (Decrease) in Inventories Inventories Increase (Decrease) in Income Taxes Receivable Income taxes Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Represents the increase (decrease) in right of use operating lease assets. Increase (Decrease) In Operating Lease Right Of Use Asset Right of use operating lease assets Increase (Decrease) in Contract Receivables, Net Accounts receivable, non-current Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Employee Related Liabilities Accrued payroll and related taxes The increase (decrease) during the reporting period in other expenses (excluding accrued payroll and related taxes) and income taxes payable incurred but not yet paid. Increase Decrease In Other Accrued Liabilities And Income Taxes Payable Accrued expenses and other liabilities Net Cash Provided by (Used in) Operating Activities Net cash provided by operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Proceeds from Sale of Property, Plant, and Equipment Proceeds from sale of property and equipment Payments to Acquire Intangible Assets Intangible assets expenditures Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities Proceeds from Notes Payable Proceeds from issuance of note payable Payment for Contingent Consideration Liability, Financing Activities Payments on earn-out Earn-out liability payment Repayments of Notes Payable Payments on note payable Repayments of Lines of Credit Payments on revolving line of credit Payments of Debt Issuance Costs Payments of deferred debt issuance costs Proceeds from Stock Options Exercised Proceeds from exercise of common stock options Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised Proceeds from the issuance of common stock from the employee stock purchase plan Proceeds from Issuance of Common Stock Proceeds from issuance of common stock at market Net Cash Provided by (Used in) Financing Activities Net cash (used in) provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents - end of period Cash and cash equivalents - beginning of period Supplemental Cash Flow Information [Abstract] Supplemental cash flow disclosure Interest Paid, Net Cash paid for interest Income Taxes Paid Cash paid for taxes Noncash or Part Noncash Acquisition, Value of Assets Acquired Capital expenditures incurred but not yet paid n/a Nature of Business and Operations Nature of Operations [Text Block] Nature of Business and Operations Basis of Presentation Basis of Presentation and Significant Accounting Policies [Text Block] Basis of Presentation Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Inventories Inventory Disclosure [Text Block] Inventories Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and Intangible Assets Accrued Expenses The entire disclosure for accrued expenses that are classified as current at the end of the reporting period. Accrued Expenses Disclosure, Current [Text Block] Accrued Expenses Warranty Reserves Product Warranty Disclosure [Text Block] Warranty Reserves Credit Agreement Debt Disclosure [Text Block] Credit Agreement Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Stockholders' Equity Shareholders' Equity and Share-based Payments [Text Block] Stockholders' Equity Revenue Revenue from Contract with Customer [Text Block] Revenue Income Taxes Income Tax Disclosure [Text Block] Income Taxes Earnings Per Share [Text Block] Net Income Per Share Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Subsequent Event Subsequent Events [Text Block] Subsequent Event Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Consolidation, Policy [Policy Text Block] Principles of Consolidation Use of Estimates, Policy [Policy Text Block] Use of Estimates Disclosure of accounting policy pertaining to new accounting pronouncements not yet adopted. New Accounting Pronouncements, Note Yet Adopted Policy [Policy Text Block] Accounting Pronouncement Not Yet Adopted Schedule of Inventory, Current [Table Text Block] Schedule of inventories Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of finite lived intangible assets Finite-lived Intangible Assets Amortization Expense [Table Text Block] Schedule of future amortization expense Tabular disclosure of the carrying value as of the balance sheet date of accrued expenses excluding accounts payable. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Schedule of Accrued Expenses [Table Text Block] Schedule of accrued expenses Schedule of Product Warranty Liability [Table Text Block] Schedule of warranty reserves Schedule of Maturities of Long-term Debt [Table Text Block] Schedule of maturities of the term note payable The tabular disclosure of lease-related assets and liabilities. Assets and Liabilities, Lessee [Table Text Block] Summary of lease-related assets and liabilities Operating Lease, Lease Income [Table Text Block] Summary of undiscounted cash flows Restricted Stock Units (RSUs) [Member] Restricted stock units Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time. Time-Based Restricted Stock Units This member stands for performance-based stock-settled restricted stock units plan. Performance-based stock-settled restricted stock units Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of allocation of total stock-based compensation expense Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of stock option activity Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Schedule of stock-settled restricted stock unit activity Disaggregation of Revenue [Table Text Block] Summary of revenue disaggregated by product Tabular disclosure of disaggregation of revenue revenues from third-party payers. Schedule Of Revenue From Third Party Payers [Table Text Block] Summary of revenue by channel Sales-type Lease, Lease Income [Table Text Block] Sales-type lease revenue and the associated cost of goods sold Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of computation of the basic and diluted net income per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of potentially dilutive securities outstanding Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of changes in the earn-out liability Schedule of Subsidiary or Equity Method Investee [Table] Sale of Stock [Axis] Sale of Stock [Domain] IPO Represents the information pertaining to follow on public offering. Follow On Public Offering [Member] Follow-On Public Offering Subsidiary, Sale of Stock Nature of Business and Operations Shares Issued, Price Per Share IPO price per share (in dollars per share) Share Price Stock price Proceeds from Issuance Initial Public Offering Net proceeds from the initial public offering Amount of expenses relating to the initial public offering during the period. Expense Relating To Initial Public Offering Expense Relating To Initial Public Offering Inventory, Net [Abstract] Inventories Inventory, Finished Goods, Gross Finished goods Inventory, Work in Process, Gross Component parts and work-in-process Schedule of Finite-Lived Intangible Assets [Table] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Represent information pertaining to AffloVest APA. AffloVest APA AffloVest APA Income Statement Location [Axis] Income Statement Location [Domain] Cost of revenue. Cost of revenue. Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Patents Patents pending This member stands for defensive intangible assets. Defensive intangible assets Defensive intangible assets Customer accounts Customer accounts Customer relationships Customer relationships Developed technology Developed technology Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Tradenames Tradenames Finite-Lived Intangible Assets [Line Items] Goodwill and Intangible Assets Asset Impairment Charges Impairment recognized Finite-Lived Intangible Assets, Net [Abstract] Definite-lived intangible assets: Finite-Lived Intangible Assets, Remaining Amortization Period Weighted Average Amortization Period Finite-Lived Intangible Assets, Gross Gross Carrying Amount Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Amortization Finite-Lived Intangible Assets, Net Total Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract] Unamortized intangible assets: Indefinite-lived Intangible Assets (Excluding Goodwill) Gross Carrying Amount, Indefinite Intangible Assets, Gross (Excluding Goodwill) Total intangible assets (Gross) Amortization of Intangible Assets Amortization expense Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Future Amortization Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year 2024 (October 1 - December 31) Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 2025 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2026 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2027 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2028 Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Finite-Lived Intangible Asset, Expected Amortization, after Year Four Thereafter Product Warranty Accrual, Current Warranty Accrued warranty reserve, current Accrued Professional Fees, Current Legal and consulting In-transit inventory accrued expense. In-transit inventory accrued expense In-transit inventory Carrying value as of the balance sheet date of obligations incurred through that date and payable for travel and entertainment expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Travel And Entertainment Current Travel The carrying amount as of the balance sheet date of accrued clinical studies. Accrued Clinical Studies Expenses, Current Clinical studies Carrying value as of the balance sheet date of obligations relating to sales and use tax. Accrued Sales And Use Tax Sales and use tax Other Accrued Liabilities, Current Other Movement in Standard Product Warranty Accrual [Roll Forward] Standard Product Warranty Accrual Ending balance Beginning balance Standard Product Warranty

Accrual, Increase for Warranties Issued Warranty provision Standard Product Warranty Accrual, Decrease for Payments Processed warranty claims Standard and Extended Product Warranty Accrual Total accrued warranty reserve Line of Credit Facility [Table] Credit Facility [Axis] Credit Facility [Domain] Revolving credit facility Represents information pertaining to term loan. Term Loan Range [Axis] Range [Domain] Maximum Maximum Minimum Minimum Variable Rate [Axis] Variable Rate [Domain] Federal Funds Base Rate Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] SOFR Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event Line of Credit Facility [Line Items] Credit Agreement Debt Instrument, Face Amount Debt instrument face amount Line of Credit Facility, Maximum Borrowing Capacity Line of credit Line Of Credit, Threshold Contingent Increase In Borrowing Capacity Line Of Credit, Threshold Contingent Increase In Borrowing Capacity Line of credit, threshold contingent increase in borrowing capacity The total aggregate principal amount under the credit agreement. Credit Agreement, Total Aggregate Principal Amount Credit agreement, total aggregate principal amount Long-term Debt Long-term debt Net Note Payable Long-term Line of Credit Credit facility outstanding amount The amount of mandatory principal prepayment paid Debt Instrument, Payment of Mandatory Principal Prepayment Principal prepayment of term loan Debt Instrument, Basis Spread on Variable Rate Basis spread (as a percent) Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Unused line fee (as a percent) Proceeds from Issuance of Debt Increase in term debt Debt Instrument, Frequency of Periodic Payment Debt instrument frequency of periodic payment Debt Instrument, Periodic Payment Debt instrument periodic payment Share Repurchase Program, Authorized, Amount Amount of authorized shares to repurchase Long-term Debt, Fiscal Year Maturity [Abstract] Maturities of notes payable Long-Term Debt, Maturity, Remainder of Fiscal Year 2024 (October 1 - December 31) Long-Term Debt, Maturity, Year One 2025 Long-Term Debt, Maturity, Year Two 2026 Long-Term Debt, Gross Total Debt Issuance Costs, Net Less: Deferred financing fees Long-Term Debt, Current Maturities Less: Current portion of note payable Long-term Debt, Excluding Current Maturities Non-current portion of note payable Lessee, Lease, Description [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Building Equipment Represents member for initial lease for corporate head quarter. Initial lease Represents member for second lease corporate head quarter. Second lease Represents member for third lease corporate head quarter. Third lease Lessee, Lease, Description [Line Items] Commitments and Contingencies Lessee, Operating Lease, Term of Contract Lease terms Area of Land Area of office space Additional office space added to the lease. Additional office space added Additional office space added to the lease Lessee, Operating Lease, Existence of Option to Extend [true false] Option to renew Assets and Liabilities, Lessee [Abstract] Lease-related assets and liabilities Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease, Liability Present value of future minimum lease payments Operating Lease, Weighted Average Remaining Lease Term Weighted average remaining lease term Operating Lease, Weighted Average Discount Rate, Percent Weighted average discount rate Operating Lease, Payments Cash paid for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Non-cash right of use assets obtained in exchange for new operating lease obligations Operating Lease Liabilities, Payments Due [Abstract] Undiscounted cash flows Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2024 (October 1 - December 31) Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2025 Lessee, Operating Lease, Liability, Payments, Due Year Two 2026 Lessee, Operating Lease, Liability, Payments, Due Year Three 2027 Lessee, Operating Lease, Liability, Payments, Due Year Four 2028 Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Lessee Operating Lease Liability Payments Due after Year Four Thereafter Lessee, Operating Lease, Liability, Payments, Due Total minimum lease payments Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: Amount of lease payments representing interest Operating Lease, Right-of-Use Asset, Amortization Expense Operating lease cost Concentration Risk [Table] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Purchases Concentration Risk Type [Axis] Concentration Risk Type [Domain] Vendor Supplier [Axis] Supplier [Domain] Represents the information pertaining to vendor one. Vendor One Concentration Risk [Line Items] Commitments and Contingencies Represents the number of vendors. Number Of Vendors Number of vendors Concentration Risk, Percentage Total purchases (in percentage) Purchase Obligation, Fiscal Year Maturity [Abstract] Purchase commitments Purchase Obligation, Due in Next Twelve Months Purchase orders issued Defined Contribution Plan [Table] Retirement Plan Name [Axis] Defined Contribution Plan Name [Domain] (Deprecated 2017-01-31) Represent information pertaining to Defined Contribution 401K Retirement Plan 401(k) Defined Contribution Plan Disclosure [Line Items] Retirement Plan Defined Contribution Plan, Employer Discretionary Contribution Amount Discretionary contributions Loss Contingencies [Table] Litigation Case [Axis] Litigation Case [Domain] Information relating to Weaver Lawsuit. Weaver Lawsuit [Member] The "Weaver Lawsuit" Loss Contingencies [Line Items] Number of officers and directors. Number of officer and directors Number of former officers and directors Loss Contingency, Loss in Period Attorneys' fees and expense Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Plan Name [Axis] Plan Name [Domain] Represents information pertaining to the 2016 Equity Incentive Plan (the "2016 Plan"). 2016 Plan Sales and marketing expenses Research and development expenses Reimbursement, general and administrative expenses Reimbursement, general and administrative expenses Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation [Abstract] Stock-based compensation Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of shares authorized Represents information pertaining to the automatic annual increase in shares reserved and available for issuance as a percentage to outstanding number of shares. The automatic increases occur on the first day of the year beginning January 1, 2017. Share Based Compensation Arrangement By Share Based Payment Award, Automatic Annual Increase In Shares Reserved And Available For Issuance, Percentage Automatic annual increase to the number of shares reserved and available for issuance as a percentage of outstanding common stock (as a percent) Represents information pertaining to the automatic annual increase in shares reserved and available for issuance. The automatic increases occur on the first day of the year beginning January 1, 2017. Share Based Compensation Arrangement By Share Based Payment Award, Automatic Annual Increase In Shares Reserved And Available For Issuance, Number Automatic annual increase to the number of shares reserved and available for issuance Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Increase in number of shares reserved and available for issuance Common Stock, Capital Shares Reserved for Future Issuance Shares reserved Shares available for future issuance Allocated Share-based Compensation Expense Compensation expense Stock-based compensation expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Vesting [Axis] Vesting [Domain] Tranche one Tranche two Share-Based Payment Arrangement, Tranche Three [Member] Tranche three Common stock options Represents information pertaining to PSUs granted in year 2026. Two Thousand Twenty Six Psu [Member] 2026 PSUs Represents information pertaining to PSUs granted in year 2025. Two Thousand Twenty Five Psu [Member] 2025 PSUs Represents information pertaining to PSUs granted in year 2024. Two Thousand Twenty Four Psu [Member] 2024 PSUs Represents information pertaining to PSUs granted in year 2023. Two Thousand Twenty Three Psu [Member] 2023 PSUs Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stockholders' Equity Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract] Stock-based compensation, general disclosures. Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Term (in years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Total unrecognized pre-tax compensation expense related to nonvested stock option awards Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Total unrecognized pre-tax compensation expense related to awards Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Weighted-average period over which unrecognized compensation cost is expected to be recognized The number of performance awards under share-based payment arrangement. Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Performance Periods Number of performance awards under share-based payment arrangement Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Award vesting percentage The percent of revenue change and adjusted EBITDA margin to be achieved under performance goals of awards under share based payment arrangement. Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Goals, Revenue Change and Adjusted EBITDA Margin Performance goals revenue change and adjusted EBITDA margin Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Options Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding at end of period Outstanding at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Cancelled/Expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding at end of period Outstanding at beginning of period Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised Cancelled Cancelled/Expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Other information Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Options exercisable number of shares exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Options exercisable, weighted-average exercise price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual life (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Options exercisable, weighted-average remaining contractual life Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Aggregate Intrinsic Value, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, Options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Units Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Restricted stock unit awards outstanding at the end of the period (in shares) Restricted stock unit awards outstanding at the beginning of the period (in shares) Share-based awards granted Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Vested (in shares) The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Cancelled in Period Cancelled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted Average Grant Date Fair Value Per Unit Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Restricted stock unit awards outstanding at the end of the period (in dollars per share) Restricted stock unit awards outstanding at the beginning of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were cancelled during the reporting period. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Cancellations, Weighted Average Grant Date Fair Value Cancelled (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Restricted stock unit awards, Average Intrinsic Value Schedule of Stock by Class [Table] Employee Stock Purchase Plan Class of Stock [Line Items] Stockholders' Equity Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Purchase price of common stock under plan (as a percent) Period which an employee's right to purchase shares of stock at a discount, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Employee Stock Purchase Plan, Offering Periods, Period Offering period (in months) Represents the incremental annual share percentage increase minimum. Incremental Shares To Be Issued Percentage Incremental share increase (as a percent) Represents the minimum increase in shares on an annual basis. Incremental Share Increase Incremental share increase (in shares) Disaggregation of Revenue [Table] Represents information pertaining to Lymphedema products. Lymphedema products Lymphedema products Represents information pertaining to Airway clearance products. Airway clearance products Airway clearance products Customer [Axis] Customer [Domain] Represents information pertaining to private insurers and other payers. Private insurers and other payers Private insurers and other payers Represents information pertaining to veterans administration. Veterans Administration Veterans Administration Represents information pertaining to government payer medicare. Medicare Medicare Represents information pertaining to Durable medical equipment distributors. Durable medical equipment distributors Durable medical equipment distributors Disaggregation of Revenue [Line Items] Revenue Percentage of revenue disaggregated by products. Percentage Of Revenue Percentage of total revenue (in percent) Sales-type Lease, Lease Income [Abstract] Revenue from sale type lease Sales-type Lease, Revenue Sales-type lease revenue Cost of Goods Sold, Sales-type Lease Cost of sales-type lease revenue Sales-type Lease, Selling Profit (Loss) Gross profit Rental period of rent-to-purchase arrangements. Rent-to-purchase arrangements, Rental Period Rental period of rent-to-purchase arrangements Effective Income Tax Rate Reconciliation, Percent [Abstract] Effective Income Tax Rate Reconciliation, Percent Effective Income Tax Rate Reconciliation, Percent Net effective rate Earnings Per Share, Basic Net income per share - Basic Earnings Per Share, Diluted Net income per share - Diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Performance Shares [Member] Performance stock units Represents the information pertaining to Employee stock purchase plan shares. Employee stock purchase plan [Member] Employee stock purchase plan Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net Income Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from computation of earnings per share Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Significant Unobservable Inputs (Level 3) Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements Business Combination, Contingent Consideration, Liability Earn-out liability, ending balance Earn-out liability, beginning balance Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Fair value adjustments Amount of cash outflow for imputed interest payment on business combination contingent consideration liability. Business Combination Contingent Consideration Liability imputed interest payment Imputed interest payment Subsequent Event [Table] Subsequent Event [Line Items] Subsequent Event EX-101.PRE 12 tcmd-20240930_pre.xml EX-101.PRE XML 14 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Oct. 31, 2024 Document and Entity Information Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 001-37799 Â Entity Registrant Name Tactile Systems Technology, Inc. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 41-1801204 Â Entity Address, Address Line One 3701 Wayzata Blvd, Suite 300 Â Entity Address, City or Town Minneapolis Â Entity Address, State or Province MN Â Entity Address, Postal Zip Code 55416 Â City Area Code 612 Â Local Phone Number 355-5100 Â Title of 12(b) Security Common Stock, Par Value $0.001 Per Share Â Trading Symbol TCMD Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 23,997,089 Entity Central Index Key 0001027838 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Amendment Flag false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name:

dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 15 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets Â Â Cash and cash equivalents $ 82,146 $ 61,033 Accounts receivable 39,970 43,173 Net investment in leases 13,953 14,195 Inventories 21,176 22,527 Prepaid expenses and other current assets 5,127 4,366 Total current assets 162,372 145,294 Non-current assets Â Â Property and equipment, net 5,878 6,195 Right of use operating lease assets 17,553 19,128 Intangible assets, net 43,708 46,724 Goodwill 31,063 31,063 Accounts receivable, non-current 3,628 10,936 Deferred income taxes 19,719 19,378 Other non-current assets 3,803 2,720 Total non-current assets 125,352 136,144 Total assets 287,724 281,438 Current liabilities Â Â Accounts payable 7,290 6,659 Note payable 2,956 2,956 Accrued payroll and related taxes 13,086 16,789 Accrued expenses 7,088 5,904 Income taxes payable 611 1,467 Operating lease liabilities 2,883 2,807 Other current liabilities 3,240 4,475 Total current liabilities 37,154 41,057 Non-current liabilities Â Â Note payable, non-current 23,959 26,176 Accrued warranty reserve, non-current 1,448 1,681 Income taxes payable, non-current 495 446 Operating lease liabilities, non-current 16,767 18,436 Total non-current liabilities 42,669 46,739 Total liabilities 79,823 87,796 Stockholders' equity: Â Â Preferred stock, $0.001 par value, 50,000,000 shares authorized; none issued and outstanding as of September 30, 2024 and December 31, 2023 Common stock, $0.001 par value, 300,000,000 shares authorized; 23,997,089 shares issued and outstanding as of September 30, 2024; 23,600,584 shares issued and outstanding as of December 31, 2023 24 24 Additional paid-in capital 181,739 174,724 Retained earnings 26,138 18,894 Total stockholders' equity 207,901 193,642 Total liabilities and stockholders' equity $ 287,724 $ 281,438 X - DefinitionAmount of non-current accounts receivable on account of medicare. + ReferencesNo definition available. + Details Name: tcmd_MedicareAccountsReceivableNonCurrent Namespace Prefix: tcmd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedIncomeTaxesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedIncomeTaxesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -

Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -

SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before allowance for credit loss, of net investment in sales-type and direct financing leases. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-7AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479016/842-30-45-1 + Details Name: us-gaap_NetInvestmentInLease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OtherAssetsMiscellaneousAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for estimated claims under standard and extended warranty protection rights granted to customers. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_ProductWarrantyAccrualNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Condensed Consolidated Balance Sheets Â Â Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001 Preferred stock, shares authorized 50,000,000 50,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value (in dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized 300,000,000 300,000,000 Common stock, shares, issued 23,997,089 23,600,584 Common stock, shares, outstanding 23,997,089 23,600,584 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946

-SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Total revenue $ 73,093 $ 69,586 $ 207,399 $ 196,771 Total cost of revenue 18,306 20,227 55,080 57,645 Gross profit 54,787 49,359 152,319 139,126 Operating expenses Â Â Â Â Sales and marketing 26,838 26,030 82,803 80,538 Research and development 2,417 1,964 6,794 6,030 Reimbursement, general and administrative 18,118 16,449 51,158 46,874 Intangible asset amortization and earn-out 633 (3,073) 1,898 (557) Total operating expenses 48,006 41,370 142,653 132,885 Income from operations 6,781 7,989 9,666 6,241 Other income (expense) 452 (404) 832 (2,235) Income before income taxes 7,233 7,585 10,498 4,006 Income tax expense (benefit) 2,078 (14,714) 3,254 (16,307) Net income $ 5,155 $ 22,299 $ 7,244 $ 20,313 Net income per common share Â Â Â Â Basic $ 0.21 $ 0.95 $ 0.30 $ 0.89 Diluted $ 0.21 $ 0.94 $ 0.30 $ 0.88 Weighted-average common shares used to compute net income per common share Â Â Â Â Basic 23,985,364 23,483,269 23,842,049 22,714,574 Diluted 24,254,176 23,848,729 24,070,084 22,987,667 Sales revenue Â Â Â Â Total revenue $ 63,168 $ 58,866 $ 180,742 $ 171,459 Total cost of revenue 15,603 17,016 46,810 48,523 Gross profit 47,565 41,850 133,932 122,936 Rental revenue Â Â Â Â Total revenue 9,925 10,720 26,657 25,312 Total cost of revenue 2,703 3,211 8,270 9,122 Gross profit $ 7,222 $ 7,509 $ 18,387 $ 16,190 X - DefinitionAmount of impairment of intangible asset and earn outs. + ReferencesNo definition available. + Details Name: tcmd_AmortizationOfIntangibleAssetsAndEarnOuts Namespace Prefix: tcmd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definitionn/a + ReferencesNo definition available. + Details Name: tcmd_EarningsPerShareOtherDisclosureAbstract Namespace Prefix: tcmd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section

S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=tcmd_RentalProductServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 18 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands Common Stock Additional Paid-In Capital Retained Earnings (Accumulated Deficit). Total Balances at the beginning at Dec. 31, 2022 $ 20 $ 131,001 $ (9,621) $ 121,400 Balances at the beginning (in shares) at Dec. 31, 2022 20,252,677 Â Â Â Increase (Decrease) in Stockholders' Equity Â Â Â Â Stock-based compensation Â 5,597 Â 5,597 Exercise of common stock options and vesting of performance and restricted stock units Â 13 Â 13 Exercise of common stock options and vesting of performance and restricted stock units (in shares) 249,064 Â Â Â Sale of common stock from follow-on public offering, net of offering expenses $ 3 34,622 Â 34,625 Sale of common stock from follow-on public offering, net of offering expenses (in shares) 2,875,000 Â Â Â Common shares issued for employee stock purchase plan Â 882 Â 882 Common shares issued for employee stock purchase plan (in shares) 120,816 Â Â Â Net income for the period Â Â 20,313 20,313 Balances at the end at Sep. 30, 2023 $ 23 172,115 10,692 182,830 Balances at the end (in shares) at Sep. 30, 2023 23,497,557 Â Â Â Balances at the beginning at Jun. 30, 2023 $ 23 170,347 (11,607) 158,763 Balances at the beginning (in shares) at Jun. 30, 2023 23,458,302 Â Â Â Increase (Decrease) in Stockholders' Equity Â Â Â Â Stock-based compensation Â 1,766 Â 1,766 Exercise of common stock options and vesting of performance and restricted stock units Â 2 Â 2 Exercise of common stock options and vesting of performance and restricted stock units (in shares) 39,255 Â Â Â Net income for the period Â Â 22,299 22,299 Balances at the end at Sep. 30, 2023 $ 23 172,115 10,692 182,830 Balances at the end (in shares) at Sep. 30, 2023 23,497,557 Â Â Â Balances at the beginning at Dec. 31, 2023 $ 24 174,724 18,894 193,642 Balances at the beginning (in shares) at Dec. 31, 2023 23,600,584 Â Â Â Increase (Decrease) in Stockholders' Equity Â Â Â Â Stock-based compensation Â 5,969 Â 5,969 Exercise of common stock options and vesting of performance and restricted stock units Â 2 Â 2 Exercise of common stock options and vesting of performance and restricted stock units (in shares) 288,598 Â Â Â Common shares issued for employee stock purchase plan Â 1,044 Â 1,044 Common shares issued for employee stock purchase plan (in shares) 107,907 Â Â Â Net income for the period Â Â 7,244 7,244 Balances at the end at Sep. 30, 2024 $ 24 181,739 26,138 207,901 Balances at the end (in shares) at Sep. 30, 2024 23,997,089 Â Â Â Balances at the beginning at Jun. 30, 2024 $ 24 179,669 20,983 200,676 Balances at the beginning (in shares) at Jun. 30, 2024 23,966,748 Â Â Â Increase (Decrease) in Stockholders' Equity Â Â Â Â Stock-based compensation Â 2,070 Â 2,070 Exercise of common stock options and vesting of performance and restricted stock units (in shares) 30,341 Â Â Â Net income for the period Â Â 5,155 5,155 Balances at the end at Sep. 30, 2024 $ 24 $ 181,739 $ 26,138 $ 207,901 Balances at the end (in shares) at Sep. 30, 2024 23,997,089 Â Â Â X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 19 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities Â Â Net income $ 7,244 $ 20,313 Adjustments to reconcile net income to net cash provided by operating activities: Â Â Depreciation and amortization 5,079 4,916 Deferred income taxes (341) (20,717) Stock-based compensation expense 5,969 5,597 Loss on disposal of property and equipment and intangibles 308 3 Change in fair value of earn-out liability Â (2,475) Changes in assets and liabilities, net of acquisition: Â Â Accounts receivable 3,203 10,947 Net investment in leases 242 2,527 Inventories 1,351 (374) Income taxes (807) (99) Prepaid expenses and other assets (1,844) (369) Right of use operating lease assets (18) 292 Accounts receivable, non-current 7,308 8,425 Accounts payable 582 (3,622) Accrued payroll and related taxes (3,703) (2,316) Accrued expenses and other liabilities (251) (5,545) Net cash provided by operating activities 24,322 17,503 Cash flows from investing activities Â Â Purchases of property and equipment (1,932) (1,424) Proceeds from sale of property and equipment 12 Â Intangible assets expenditures (85) (117) Net cash used in investing activities (2,005) (1,541) Cash flows from financing activities Â Â Proceeds from issuance of note payable Â 8,250 Payments on earn-out Â (5,000) Payments on note payable (2,250) (2,250) Payments on revolving line of credit Â (8,250) Payments of deferred debt issuance costs Â (125) Proceeds from exercise of common stock options 2 13 Proceeds from the issuance of common stock from the employee stock purchase plan 1,044 882 Proceeds from issuance of common stock at market Â 34,625 Net cash (used in) provided by financing activities (1,204) 28,145 Net increase in cash and cash equivalents 21,113 44,107 Cash and cash equivalents - beginning of period 61,033 21,929 Cash and cash equivalents - end of period 82,146 66,036 Supplemental cash flow disclosure Â Â Cash paid for interest 1,612 2,810 Cash paid for taxes 4,428 3,006 Capital expenditures incurred but not yet paid $ 49 $ 40 X - DefinitionRepresents the increase (decrease) in net investment in leases. + ReferencesNo definition available. + Details Name: tcmd_IncreaseDecreaseInNetInvestmentInLease Namespace Prefix: tcmd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the increase (decrease) in right of use operating lease assets. + ReferencesNo definition available. + Details Name: tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset Namespace Prefix: tcmd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in other expenses (excluding accrued payroll and related taxes) and income taxes payable incurred but not yet paid. + ReferencesNo definition available. + Details Name: tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable Namespace Prefix: tcmd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) and income tax credits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_DeferredIncomeTaxesAndTaxCredits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInIncomeTaxesReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties. + ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesFairValueAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (f) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the

sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_RepaymentsOfLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Nature of Business and Operations 9 Months Ended Sep. 30, 2024 Nature of Business and Operations Â Nature of Business and Operations Note 1. Nature of Business and OperationsTactile Systems Technology, Inc. (â€œwe,â€ â€œus,â€ â€œour,â€ and the â€œCompanyâ€) manufactures and distributes medical devices for the treatment of patients with underserved chronic diseases at home. We provide our FlexitouchÂ® Plus and Entreâ„¢ Plus systems, which help control symptoms of lymphedema, a chronic progressive medical condition, through our direct sales force for use in the home following receipt of prescriptions from vascular, wound and lymphedema clinics throughout the United States. On September 8, 2021, we acquired the assets of the AffloVest airway clearance business (â€œAffloVest Acquisitionâ€). AffloVest is a portable, wearable vest that treats patients with chronic respiratory conditions. We sell this device through home medical equipment and durable medical equipment (â€œDMEâ€) providers throughout the United States.Â We were originally incorporated in Minnesota under the name Tactile Systems Technology, Inc. on January 30, 1995. During 2006, we established a merger corporation and subsequently, on July 21, 2006, merged with and into this merger corporation, resulting in our reincorporation as a Delaware corporation. The resulting corporation assumed the name Tactile Systems Technology, Inc. In September 2013, we began doing business as â€œTactile Medicalâ€.On August 2, 2016, we closed the initial public offering of our common stock, which resulted in the sale of 4,120,000 shares of our common stock at a public offering price of $10.00 per share. We received net proceeds from the initial public offering of approximately $35.4 million, after deducting underwriting discounts and approximately $2.9 million of transaction expenses.On February 27, 2023, we closed on a public offering of 2,875,000 shares of our common stock at a public offering price of $13.00 per share. We received net proceeds from this offering of $34.6 million after deducting underwriting discounts, commissions, and offering expenses.Our business is affected by seasonality. In the first quarter of each year, when most patients have started a new insurance year and have not yet met their annual out-of-pocket payment obligations, we experience substantially reduced demand for our products. We typically experience higher revenue in the third and fourth quarters of the year when patients have met their annual insurance deductibles, thereby reducing their out-of-pocket costs for our products, and because patients desire to exhaust their flexible spending accounts at year end. This seasonality applies only to purchases and rentals of our products by patients covered by commercial insurance and is not relevant to Medicare, Medicaid or the Veterans Administration, as those payers either do not have plans that have declining deductibles over the course of the plan year and/or do not have plans that include patient deductibles for purchases or rentals of our products. X - Definitionn/a + ReferencesNo definition available. + Details Name: tcmd_NatureOfBusinessAndOperationAbstract Namespace Prefix: tcmd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of Presentation 9 Months Ended Sep. 30, 2024 Basis of Presentation Â Basis of Presentation Note 2. Basis of PresentationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (â€œGAAPâ€) for interim financial reporting and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included.The results for the nine months ended September 30, 2024, are not necessarily indicative of results to be expected for the year ending December 31, 2024, or for any other interim period or for any future year. The condensed consolidated interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023.Principles of ConsolidationThe accompanying unaudited condensed consolidated financial statements include the accounts of Tactile Systems Technology, Inc. and its wholly owned subsidiary, Swelling Solutions, Inc. All intercompany balances and transactions have been eliminated in consolidation.Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and to disclose contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. â€‹ X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies Â Summary of Significant Accounting Policies Note 3. Summary of Significant Accounting PoliciesSignificant Accounting Policies Â There were no material changes in our significant accounting policies during the nine months ended September 30, 2024. See Note 3 â€“ â€œSummary of Significant Accounting Policiesâ€ to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023, for information regarding our significant accounting policies. Accounting Pronouncement Not Yet AdoptedIn November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update (â€œASUâ€) No. 2023-07, â€œSegment Reporting (Topic 280): Improvements to Reportable Segment Disclosuresâ€ which requires entities to enhance disclosures around segment reporting. The guidance is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its consolidated financial statements and related disclosures.In December 2023, the FASB issued ASU No. 2023-09, â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€ which requires entities to enhance disclosures around income taxes. The guidance is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the effect this

standard will have on its consolidated financial statements and related disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories 9 Months Ended Sep. 30, 2024 Inventories Â Inventories Note 4. InventoriesInventories consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹(InÂ thousands)Â Â Â Â At SeptemberÂ 30,Â 2024Â Â Â Â At DecemberÂ 31,Â 2023Finished goodsâ€‹$ 7,022â€‹$ 7,979Component parts and work-in-processâ€‹Â 14,154â€‹Â 14,548Total inventoriesâ€‹$ 21,176â€‹$ 22,527â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details Name: us-gaap_InventoryDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Â Goodwill and Intangible Assets Note 5. Goodwill and Intangible AssetsGoodwillIn the third quarter of fiscal 2021, we completed the AffloVest Acquisition. The purchase price of the AffloVest product line exceeded the net acquisition-date estimated fair value amounts of the identifiable assets acquired and the liabilities assumed by $31.1 million, which was assigned to goodwill.Â â€‹Intangible Assetsâ€‹Our patents and other intangible assets are summarized as follows:â€‹Weighted-â€‹At SeptemberÂ 30,Â 2024â€‹â€‹Averageâ€‹Grossâ€‹â€‹â€‹â€‹â€‹â€‹Amortizationâ€‹Carryingâ€‹Accumulatedâ€‹Net(InÂ thousands)Â Â Â Â Periodâ€‹Amountâ€‹Amortizationâ€‹AmountDefinite-lived intangible assets:â€‹Patentsâ€‹12 yearsâ€‹$ 1,148â€‹$ 310â€‹$ 838Defensive intangible assetsâ€‹1 yearâ€‹â€‹ 1,125â€‹â€‹ 1,029â€‹â€‹ 96Customer accountsâ€‹ â€”â€‹â€‹ 125â€‹â€‹ 125â€‹â€‹ â€”Customer relationshipsâ€‹10 yearsâ€‹â€‹ 31,000â€‹â€‹ 7,299â€‹â€‹ 23,701Developed technologyâ€‹8 yearsâ€‹â€‹ 13,000â€‹â€‹ 3,618â€‹â€‹ 9,382Subtotalâ€‹â€‹â€‹â€‹ 46,398â€‹â€‹ 12,381â€‹â€‹ 34,017Unamortized intangible assets:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Tradenamesâ€‹â€‹â€‹â€‹ 9,500â€‹â€‹ â€”â€‹â€‹ 9,500Patents pendingâ€‹â€‹â€‹â€‹ 191â€‹â€‹ â€”â€‹â€‹ 191Total intangible assetsâ€‹â€‹â€‹$ 56,089â€‹$ 12,381â€‹$ 43,708â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

-Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Â Commitments and Contingencies NoteÂ 9. Commitments and ContingenciesLease ObligationsWe lease property and equipment under operating leases, typically with terms greater than 12 months, and determine if an arrangement contains a lease at inception. In general, an arrangement contains a lease if there is an identified asset and we have the right to direct the use of and obtain substantially all of the economic benefit from the use of the identified asset. We record an operating lease liability at the present value of lease payments over the lease term on the commencement date. The related right of use (â€œROUâ€) operating lease asset reflects rental escalation clauses, as well as renewal options and/or termination options. The exercise of lease renewal and/or termination options are at our discretion and are included in the determination of the lease term and lease payment obligations when it is deemed reasonably certain that the option will be exercised. When available, we use the rate implicit in the lease to discount lease payments to present value; however, certain leases do not provide a readily determinable implicit rate. Therefore, we must estimate our incremental borrowing rate to discount the lease payments based on information available at lease commencement.We classify our leases as buildings, vehicles or computer and office equipment and do not separate lease and non-lease components of contracts for any of the aforementioned classifications. In accordance with applicable guidance, we do not record leases with terms that are less than one year on the Condensed Consolidated Balance Sheets.None of our lease agreements contain material restrictive covenants or residual value guarantees.BuildingsWe lease certain office and warehouse space at various locations in the United States where we provide services. These leases are typically greater than one year with fixed, escalating rents over the noncancelable terms and, therefore, ROU operating lease assets and operating lease liabilities are recorded on the Condensed Consolidated Balance Sheets, with rent expense recognized on a straight-line basis over the term of the lease. The remaining lease terms vary from approximately one to seven years as of September 30, 2024.We entered into a lease (â€œinitial leaseâ€) in October 2018, for approximately 80,000 square feet of office space for our new corporate headquarters in Minneapolis, Minnesota. In December 2018, we amended the initial lease to add approximately 29,000 square feet of additional office space, which is accounted for as a separate lease (â€œsecond leaseâ€) in accordance with ASU No. 2016-02, â€œLeasesâ€ (Topic 842) (â€œASC 842â€). In December 2019, we further amended the lease which extended the expiration date of the initial lease, extended the expiration date of and added approximately 4,000 square feet to the second lease, as well as added approximately 37,000 square feet of additional office space, accounted for as a separate lease (â€œthird leaseâ€) in accordance with ASC 842. The portion of the space covered under the initial lease was placed in service in September 2019. The portion of the space covered under the second lease commenced in September 2020. Finally, the portion of the space covered under the third lease commenced in September 2021. The three portions were recognized as an operating lease and included in the ROU operating lease assets and operating lease liabilities on the Condensed Consolidated Balance Sheets.Computer and Office EquipmentWe also have operating lease agreements for certain computer and office equipment. The remaining lease terms as of September 30, 2024, ranged from less than one year to approximately four years with fixed monthly payments that are included in the ROU operating lease assets and operating lease liabilities. The leases provide an option to purchase the related equipment at fair market value at the end of the lease. The leases will automatically renew as a month-to-month rental at the end of the lease if the equipment is not purchased or returned.â€‹Lease Position, Undiscounted Cash Flow and Supplemental InformationThe table below presents information related to our ROU operating lease assets and operating lease liabilities that we have recorded:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹(InÂ thousands)Â Â Â Â At SeptemberÂ 30,Â 2024Â Â Â Â At DecemberÂ 31,Â 2023Right of use operating lease assetsâ€‹$ 17,553â€‹$ 19,128â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Operating lease liabilities:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Currentâ€‹$ 2,883â€‹$ 2,807Non-currentâ€‹Â 16,767â€‹Â 18,436Totalâ€‹$ 19,650â€‹$ 21,243â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Operating leases: â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted average remaining lease termâ€‹Â 6.0 yearsâ€‹â€‹6.7 yearsWeighted average discount rateâ€‹â€‹4.4%â€‹â€‹4.3%â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended September 30,â€‹â€‹2024â€‹2023Supplemental cash flow information for our operating leases:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Cash paid for operating lease liabilitiesâ€‹$ 2,642â€‹$ 2,579Non-cash right of use assets obtained in exchange for new operating lease obligationsâ€‹$ 386â€‹$ 132â€‹The table below reconciles the undiscounted cash flows for the periods presented to the operating lease liabilities recorded on the Condensed Consolidated Balance Sheet for the periods presented:â€‹â€‹â€‹â€‹â€‹â€‹(InÂ thousands)â€‹â€‹â€‹2024 (October 1 - December 31) â€‹$ 9242025â€‹â€‹ 3,7342026â€‹Â 3,8072027â€‹Â 3,3092028â€‹Â 3,275Thereafterâ€‹Â 7,008Total minimum lease paymentsâ€‹â€‹ 22,057Less: Amount of lease payments representing interestâ€‹â€‹ (2,407)Present value of future minimum lease paymentsâ€‹â€‹ 19,650Less: Current obligations under operating lease liabilitiesâ€‹â€‹ (2,883)Non-current obligations under operating lease liabilitiesâ€‹$ 16,767â€‹Operating lease costs were $0.9 million for each of the three months ended September 30, 2024 and 2023. Operating lease costs were $2.6 million and $2.7 million for the nine months ended September 30, 2024 and 2023, respectively. Â Major VendorsWe had purchases from one vendor that accounted for 22% of our total purchases for the three months ended September 30, 2024, and purchases from one vendor that accounted for 20% of our total purchases for the nine months ended September 30, 2024. We had purchases from one vendor that accounted for 29% of our total purchases for the three months ended September 30, 2023, and purchases from one vendor that accounted for 26% of our total purchases for the nine months ended September 30, 2023. Purchase CommitmentsWe issued purchase orders prior to September 30, 2024, totaling $24.8 million for goods that we expect to receive within the next year.Retirement PlanWe maintain a 401(k) retirement plan for our employees in which eligible employees can contribute a percentage of their pre-tax compensation. We recorded an expense related to our discretionary contributions to the 401(k) plan of $0.6 million and $0.4 million for the three months ended September 30, 2024 and 2023, respectively, and $1.7 million and $1.1 million for the nine months ended September 30, 2024 and 2023, respectively.Legal ProceedingsFrom time to time, we are subject to various claims and legal proceedings arising in the ordinary course of business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.On May 24, 2022, a stockholder derivative lawsuit was filed in the United States District Court for the District of Minnesota, purportedly on behalf of the Company against certain of our present and former officers and directors and the Company (as a nominal defendant), captioned Jack Weaver v. Moen, et al., File No. 0:22-cv-01403-NEB-BRT (the â€œWeaver Lawsuitâ€). The Weaver Lawsuit generally arises out of the same subject matter as a previously settled securities class action captioned Brian Mart v. Tactile Sys. Tech., Inc., et al., File No. 0:20-cv-02074-NEB-BRT (D. Minn.) (the â€œMart Lawsuitâ€), which alleged, inter alia, that we and eight of our former officers and directors made materially false or misleading statements about our business, operational and compliance policies. The Weaver Lawsuit alleges the following claims under the Exchange Act and common law: (1) that the director defendants made materially false or misleading public statements in proxy statements in violation of Section 14(a) of the Exchange Act; (2) that the director defendantsâ€™ stock and option awards should be rescinded under Section 29(b) of the Exchange Act; (3) that the officer defendantsâ€™ employment contract compensation should be rescinded under Section 29(b) of the Exchange Act; (4) that certain officer defendants are liable for contribution arising out of any liability incurred in the Mart Lawsuit, under Sections 10(b) and 21D of the Exchange Act; (5) that the individual defendants breached their fiduciary duties; and (6) that the individual defendants were unjustly enriched. The Weaver Lawsuit seeks unspecified damages. In August 2022, the matter was transferred to the United States District Court for the District of Delaware by order granting the Parties Stipulation to Transfer. On February 10, 2023, we filed a motion to dismiss the action. The plaintiff filed an Amended Complaint on March 3, 2023. On March 31, 2023, we filed a motion to dismiss the Amended Complaint. On July 31, 2023, the plaintiff filed a Joint Notice of Preliminary Settlement indicating that the parties had reached a non-binding settlement-in-principal on most of the material terms that would resolve all claims between the parties and requested that the Court temporarily stay all deadlines, hearings, and conferences while the parties continued to finalize settlement. On June 6, 2024, the parties entered into a Stipulation of Settlement in the Weaver Lawsuit. On June 7, 2024, the plaintiff filed an unopposed motion for preliminary approval of the settlement. Â On June 27, 2024, the Court entered an order granting the motion for preliminary approval of the settlement. Â The final settlement hearing occurred on August 28, 2024, and on September 4, 2024, the Court entered its order approving the settlement, including the agreed upon attorneysâ€™ fees and expense awards to plaintiffsâ€™ counsel and service awards to the shareholder plaintiffs. Pursuant to the settlement, we are adopting, implementing, and maintaining certain corporate governance reforms. The attorneysâ€™ fees and expense award of approximately $0.5 million was covered by insurance and has been paid. The settlement does not constitute an admission of liability or wrongdoing by us or any of our current or former directors or officers. This matter is now concluded.On October 25, 2024, the United States District Court, District of Massachusetts (Boston) unsealed two qui tam complaints against us. The first complaint is captioned United States ex. rel. Benjaman Scarborough vs. Tactile Systems Technology, Inc., Case No. 1:21-cv-10813-IT, and was filed under seal on May 17, 2021, on behalf of the United States by a former employee (the â€œScarborough Complaintâ€). The Scarborough Complaint alleges that we submitted false claims and made false statements in connection with the Medicare programs, in violation of the Federal False Claims Act. The second complaint is captioned United States ex. rel. Jackie Gorham, an individual, and Dustin Gast, an individual, vs. Tactile Systems Technology, Inc. Case No. 1:21-cv-11809-IT, and was filed under seal on September 1, 2021, on behalf of the United States by two former employees (the â€œGorham Complaintâ€). The Gorham Complaint alleges that we submitted false claims and made false statements in connection with the Medicare, Medicare Advantage plans, Medicaid and other government payers, in violation of the Federal False Claims Act and submitted false claims resulting from kickbacks in violation of the Federal False Claims Act and the Federal Anti-Kickback Statute. Â Both complaints seek damages, statutory penalties, attorneysâ€™ fees, and costs. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity 9 Months Ended Sep. 30, 2024 Stockholders' Equity Â Stockholders' Equity NoteÂ 10. Stockholders' EquityStock-Based CompensationOur 2016 Equity Incentive Plan (the â€œ2016 Planâ€) authorizes us to grant stock options, stock appreciation rights, restricted stock, stock units and other stock-based awards to employees, non-employee directors and certain consultants and advisors. There were up to 4,800,000 shares of our common stock initially reserved for issuance pursuant to the 2016 Plan. The 2016 Plan provides that the number of shares reserved and available for issuance under the 2016 Plan will automatically increase annually on January 1 of each calendar year, commencing in 2017 and ending on and including January 1, 2026, by an amount equal to the lesser of: (a) 5% of the number of common shares of stock outstanding as of December 31 of the immediately preceding calendar year, or (b) 2,500,000 shares; provided, however, that our Board of Directors may determine that any annual increase be a lesser number. In addition, all awards granted under our 2007 Omnibus Stock Plan and our 2003 Stock Option Plan that were outstanding when the 2016 Plan became effective and that are forfeited, expired, cancelled, settled for cash or otherwise not issued, will become available for issuance under the 2016 Plan. Pursuant to the automatic increase feature of the 2016 Plan, 1,180,019 shares were added as available for issuance thereunder on January 1, 2024. Our Board of Directors exercised its prerogative to forego the automatic increase on January 1, 2023. As of September 30, 2024, 6,462,956 shares were available for future grant pursuant to the 2016 Plan.Upon adoption and approval of the 2016 Plan, all of our previous equity incentive compensation plans were terminated. However, existing awards under those plans continue to vest in accordance with the original vesting schedules and will expire at the end of their original terms.We recorded stock-based compensation expense of $2.1 million and $1.8 million for the three months ended September 30, 2024 and 2023, respectively, and $6.0 million and $5.6 million for the nine months ended September 30, 2024 and 2023, respectively. This expense was allocated as follows:â€‹Three Months Endedâ€‹Nine Months Ended â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â (InÂ thousands)Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Cost of revenueâ€‹$ 100â€‹$ 116â€‹$ 286â€‹$ 340Sales and marketing expensesâ€‹â€‹ 595â€‹â€‹ 634â€‹â€‹ 1,939â€‹â€‹ 2,196Research and development expensesâ€‹â€‹ 42â€‹â€‹ 5â€‹â€‹ 123â€‹â€‹ 98Reimbursement, general and administrative expensesâ€‹â€‹ 1,333â€‹â€‹ 1,011â€‹â€‹ 3,621â€‹â€‹ 2,963Total stock-based compensation expenseâ€‹$ 2,070â€‹$ 1,766â€‹$ 5,969â€‹$ 5,597â€‹Stock OptionsStock options issued to participants other than non-employees typically vest over three or four years and typically have a contractual term of seven or ten years. Stock-based compensation expense included in the Condensed Consolidated Statements of Operations for stock options was $0.0 million and $0.2 million for the three months ended September 30, 2024 and 2023, respectively, and $0.2 million and $0.8 million for the nine months ended September 30, 2024 and 2023, respectively. At September 30, 2024, there was approximately $42,100 of total unrecognized pre-tax stock option expense under our equity compensation plans, which is expected to be recognized on a straight-line basis over a weighted-average period of 1.0 years.Our stock option activity for the nine months ended September 30, 2024, was as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

weighted-average period of 1.9 years.Our time-based restricted stock unit activity for the nine months ended September 30, 2024, was as follows:â€‹â€‹â€‹

Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements 9 Months Ended Sep. 30, 2024 Fair Value Measurements Â Fair Value Measurements Note 14. Fair Value MeasurementsWe determine the fair value of our assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We use a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1). The next highest priority is based on quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in non-active markets or other observable inputs (Level 2). The lowest priority is given to unobservable inputs (Level 3).As of September 30, 2024, our obligations under the AffloVest Acquisition earn-out arrangements had been paid in full. Prior to the determination of the actual amount of the earn-out, the earn-out liability was valued by employing a Monte Carlo Simulation model in a risk-neutral framework, which is a Level 3 input. The underlying simulated variable included recognized revenue. The recognized revenue volatility estimate was based on a study of historical asset volatility for a set of comparable public companies. The model included other assumptions including the market price of risk, which was calculated as the weighted average cost of capital less the long-term risk-free rate. The earn-out liability was adjusted to fair value at each reporting date until the end of the earn-out period, which was September 30, 2023. Changes in fair value were included in intangible asset amortization and earn-out expenses in our Condensed Consolidated Statements of Operations.â€‹â€‹â€‹â€‹â€‹â€‹â€‹Changes in the earn-out liability measured at fair value using Level 3 inputs were as follows:â€‹â€‹â€‹â€‹â€‹(InÂ thousands)â€‹â€‹Earn-out liability at December 31, 2022â€‹$ 13,050Payment on earn-outâ€‹â€‹ (5,000)Fair value adjustmentsâ€‹â€‹ (2,475)Earn-out liability at September 30, 2023â€‹$ 5,575â€‹On May 25, 2023, the Company paid $5.0 million, plus an imputed interest payment of $250,000, relating to the initial earn-out. Subsequent to September 30, 2023, it was determined that the calculated amount of the second earn-out payment was $5.6 million, which was paid by the Company on November 28, 2023. â€‹â€‹â€‹â€‹â€‹â€‹â€‹

Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 37 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies Â Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (â€œGAAPâ€) for interim financial reporting and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included.The results for the nine months ended September 30, 2024, are not necessarily indicative of results to be expected for the year ending December 31, 2024, or for any other interim period or for any future year. The condensed consolidated interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023. Principles of Consolidation Principles of ConsolidationThe accompanying unaudited condensed consolidated financial statements include the accounts of Tactile Systems Technology, Inc. and its wholly owned subsidiary, Swelling Solutions, Inc. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and to disclose contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Accounting Pronouncement Not Yet Adopted Accounting Pronouncement Not Yet AdoptedIn November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update (â€œASUâ€) No. 2023-07, â€œSegment Reporting (Topic 280): Improvements to Reportable Segment Disclosuresâ€ which requires entities to enhance disclosures around segment reporting. The guidance is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its consolidated financial statements and related disclosures.In December 2023, the FASB issued ASU No. 2023-09, â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€ which requires entities to enhance disclosures around income taxes. The guidance is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its consolidated financial statements and related disclosures. X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements not yet adopted. + ReferencesNo definition available. + Details Name: tcmd_NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock Namespace Prefix: tcmd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories (Tables) 9 Months Ended Sep. 30, 2024 Inventories Â Schedule of inventories â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹(InÂ thousands)Â Â Â Â At SeptemberÂ 30,Â 2024Â Â Â Â At DecemberÂ 31,Â 2023Finished goodsâ€‹$ 7,022â€‹$ 7,979Component parts and work-in-processâ€‹Â 14,154â€‹Â 14,548Total inventoriesâ€‹$ 21,176â€‹$ 22,527â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets (Tables) 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Â Schedule of finite lived intangible assets â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

https://asc.fasb.org/1943274/2147479773/842-30-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6A + Details Name: us-gaap_OperatingLeaseLeaseIncomeTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity (Tables) 9 Months Ended Sep. 30, 2024 Schedule of allocation of total stock-based compensation expense â€‹Three Months Endedâ€‹Nine Months Endedâ€‹â€‹September 30,Â â€‹September 30,Â (InÂ thousands)Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Cost of revenueâ€‹$ 100â€‹$ 116â€‹$ 286â€‹$ 340Sales and marketing expensesâ€‹â€‹ 595â€‹â€‹ 634â€‹â€‹ 1,939â€‹â€‹ 2,196Research and development expensesâ€‹â€‹ 42â€‹â€‹ 5â€‹â€‹ 123â€‹â€‹ 98Reimbursement, general and administrative expensesâ€‹â€‹ 1,333â€‹â€‹ 1,011â€‹â€‹ 3,621â€‹â€‹ 2,963Total stock-based compensation expenseâ€‹$ 2,070â€‹$ 1,766â€‹$ 5,969â€‹$ 5,597 Schedule of stock option activity â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹â€‹Weighted-â€‹Weighted-â€‹â€‹â€‹â€‹â€‹â€‹â€‹Averageâ€‹Averageâ€‹Aggregateâ€‹â€‹Optionsâ€‹ExerciseÂ Priceâ€‹Remainingâ€‹Intrinsic(InÂ thousands except options and per share data)â€‹Outstandingâ€‹Per Share (1)â€‹Contractual Lifeâ€‹Value (2)Balance at December 31, 2023â€‹ 429,960â€‹$ 40.74â€‹3.8 yearsâ€‹$ 223Exercisedâ€‹ (1,153)â€‹$ 1.35â€‹â€‹â€‹$ 14Cancelled/Expiredâ€‹ (24,142)â€‹$ 43.45â€‹â€‹â€‹â€‹â€‹Balance at September 30, 2024â€‹ 404,665â€‹$ 40.69â€‹3.1 yearsâ€‹$ 218â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Options exercisable at SeptemberÂ 30,Â 2024â€‹ 385,514â€‹$ 42.11â€‹3.0 yearsâ€‹$ 116â€‹(1)The exercise price of each option granted during the period shown was equal to the market price of the underlying stock on the date of grant. (2)The aggregate intrinsic value of options exercised represents the difference between the exercise price of the option and the closing stock price of our common stock on the date of exercise. The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period. Time-Based Restricted Stock Units Â Schedule of stock-settled restricted stock unit activity â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_InventoryNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcess Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 50 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill And Intangible Assets (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Sep. 30, 2021 Goodwill and Intangible Assets Â Â Â Â Â Â Goodwill $ 31,063 Â $ 31,063 Â $ 31,063 Â Impairment recognized 0 Â Â Â Â Â Definite-lived intangible assets: Â Â Â Â Â Â Gross Carrying Amount 46,398 Â 46,398 Â 46,268 Â Accumulated Amortization 12,381 Â 12,381 Â 9,535 Â Total 34,017 Â 34,017 Â 36,733 Â Unamortized intangible assets: Â Â Â Â Â Â Total intangible assets (Gross) 56,089 Â 56,089 Â 56,259 Â Total intangible assets (Net) 43,708 Â 43,708 Â 46,724 Â Amortization expense 900 $ 900 2,800 $ 2,900 Â Â Future Amortization Â Â Â Â Â Â 2024 (October 1 - December 31) 951 Â 951 Â Â Â 2025 3,714 Â 3,714 Â Â Â 2026 3,650 Â 3,650 Â Â Â 2027 3,641 Â 3,641 Â Â Â 2028 3,638 Â 3,638 Â Â Â Thereafter 18,423 Â 18,423 Â Â Â Total 34,017 Â 34,017 Â 36,733 Â Tradenames Â Â Â Â Â Â Unamortized intangible assets: Â Â Â Â Â Â Gross Carrying Amount, Indefinite 9,500 Â 9,500 Â 9,500 Â Patents pending Â Â Â Â Â Â Unamortized intangible assets: Â Â Â Â Â Â Gross Carrying Amount, Indefinite $ 191 Â $ 191 Â $ 491 Â Patents pending Â Â Â Â Â Â Definite-lived intangible assets: Â Â Â Â Â Â Weighted Average Amortization Period 12 years Â 12 years Â 12 years Â Gross Carrying Amount $ 1,148 Â $ 1,148 Â $ 1,018 Â Accumulated Amortization 310 Â 310 Â 248 Â Total 838 Â 838 Â 770 Â Future Amortization Â Â Â Â Â Â Total $ 838 Â $ 838 Â $ 770 Â Defensive intangible assets Â Â Â Â Â Â Definite-lived intangible assets: Â Â Â Â Â Â Weighted Average Amortization Period 1 year Â 1 year Â 1 year Â Gross Carrying Amount $ 1,125 Â $ 1,125 Â $ 1,125 Â Accumulated Amortization 1,029 Â 1,029 Â 920 Â Total 96 Â 96 Â 205 Â Future Amortization Â Â Â Â Â Â Total 96 Â 96 Â 205 Â Customer accounts Â Â Â Â Â Â Definite-lived intangible assets: Â Â Â Â Â Â Gross Carrying Amount 125 Â 125 Â 125 Â Accumulated Amortization $ 125 Â $ 125 Â $ 125 Â Customer relationships Â Â Â Â Â Â Definite-lived intangible assets: Â Â Â Â Â Â Weighted Average Amortization Period 10 years Â 10 years Â 11 years Â Gross Carrying Amount $ 31,000 Â $ 31,000 Â $ 31,000 Â Accumulated Amortization 7,299 Â 7,299 Â 5,511 Â Total 23,701 Â 23,701 Â 25,489 Â Future Amortization Â Â Â Â Â Â Total $ 23,701 Â $ 23,701 Â $ 25,489 Â Developed technology Â Â Â Â Â Â Definite-lived intangible assets: Â Â Â Â Â Â Weighted Average Amortization Period 8 years Â 8 years Â 9 years Â Gross Carrying Amount $ 13,000 Â $ 13,000 Â $ 13,000 Â Accumulated Amortization 3,618 Â 3,618 Â 2,731 Â Total 9,382 Â 9,382 Â 10,269 Â Future Amortization Â Â Â Â Â Â Total 9,382 Â 9,382 Â $ 10,269 Â Cost of revenue. Â Â Â Â Â Â Unamortized intangible assets: Â Â Â Â Â Â Amortization expense $ 300 $ 300 $ 900 $ 900 Â Â AffloVest APA Â Â Â Â Â Â Goodwill and Intangible Assets Â Â Â Â Â Â Goodwill Â Â Â Â Â Â $ 31,100 X - DefinitionAmount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: tcmd_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour Namespace Prefix: tcmd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRemaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99

-Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before accumulated amortization of intangible assets, excluding goodwill. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_IntangibleAssetsGrossExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tcmd_DefensiveIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Accrued Expenses Â Â Â Warranty $ 1,991 $ 2,357 $ 1,872 Legal and consulting 921 611 Â In-transit inventory 1,565 401 Â Travel 1,000 1,038 Â Clinical studies 339 363 Â Sales and use tax 168 183 Â Other 1,104 951 Â Total $ 7,088 $ 5,904 Â X - DefinitionThe carrying amount as of the balance sheet date of accrued clinical studies. + ReferencesNo definition available. + Details Name: tcmd_AccruedClinicalStudiesExpensesCurrent Namespace Prefix: tcmd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations relating to sales and use tax. + ReferencesNo definition available. + Details Name: tcmd_AccruedSalesAndUseTax Namespace Prefix: tcmd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for travel and entertainment expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: tcmd_AccruedTravelAndEntertainmentCurrent Namespace Prefix: tcmd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIn-transit inventory accrued expense. + ReferencesNo definition available. + Details Name: tcmd_InTransitInventoryAccruedExpense Namespace Prefix: tcmd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_ProductWarrantyAccrualClassifiedCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 52 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Warranty Reserves (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Movement in Standard Product Warranty Accrual [Roll Forward] Â Â Â Â Â Beginning balance $ 3,692 $ 3,828 $ 4,038 $ 4,212 Â Warranty provision 629 1,228 2,371 3,128 Â Processed warranty claims (882) (1,403) (2,970) (3,687) Â Ending balance 3,439 3,653 3,439 3,653 Â Accrued warranty reserve, current 1,991 1,872 1,991 1,872 $ 2,357 Accrued warranty reserve, non-current 1,448 1,781 1,448 1,781 $ 1,681 Total accrued warranty reserve $ 3,439 $ 3,653 $ 3,439 $ 3,653 Â X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_MovementInStandardProductWarrantyAccrualRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_ProductWarrantyAccrual Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_ProductWarrantyAccrualClassifiedCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for estimated claims under standard and extended warranty protection rights granted to customers. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_ProductWarrantyAccrualNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_StandardProductWarrantyAccrual Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_StandardProductWarrantyAccrualPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_StandardProductWarrantyAccrualWarrantiesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 53 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Credit Agreement (Details) - USD ($) 9 Months Ended Dec. 21, 2023 Aug. 01, 2023 Jun. 21, 2023 Feb. 22, 2022 Sep. 08, 2021 Sep. 30, 2024 Nov. 01, 2024 Oct. 30, 2024 Credit Agreement Â Â Â Â Â Â Â Â Line of credit, threshold contingent increase in borrowing capacity Â Â Â Â $ 25,000,000.0 Â Â Â Credit agreement, total aggregate principal amount Â Â Â Â 80,000,000.0 Â Â Â Long-term debt Â Â Â Â Â $ 27,000,000.0 Â Â Credit facility outstanding amount Â Â Â Â 25,000,000.0 Â Â Â Basis spread (as a percent) Â Â 0.10% Â Â Â Â Â Subsequent Event Â Â Â Â Â Â Â Credit Agreement Â Â Â Â Â Â Â Â Amount of authorized shares to repurchase Â Â Â Â Â Â Â $ 30,000,000.0 SOFR Â Â Â Â Â Â Â Â Credit Agreement Â Â Â Â Â Â Â Basis spread (as a percent) Â Â 3.50% Â Â Â Â Â Revolving credit facility Â Â Â Â Â Â Â Credit Agreement Â Â Â Â Â Â Â Line of credit Â Â Â 25,000,000.0 Â Â Â Debt instrument periodic payment $ 16,800,000 Â Â Â Â Â Â Â Revolving credit facility | Subsequent Event Â Â Â Â Â Â Â Credit Agreement Â Â Â Â Â Â Â Amount of authorized shares to repurchase Â Â Â Â Â Â $ 30,000,000.0 Â Revolving credit facility | Federal Funds Â Â Â Â Â Â Â Credit Agreement Â Â Â Â Â Â Â Basis spread (as a percent) Â Â 0.50% Â Â Â Â Â Revolving credit facility | Base Rate Â Â Â Â Â Â Â Credit Agreement Â Â Â Â Â Â Â Basis spread (as a percent) Â Â 1.00% Â Â Â Â Â Revolving credit facility | SOFR Â Â Â Â Â Â Â Credit Agreement Â Â Â Â Â Â Â Basis spread (as a percent) Â 3.50% Â Â Â 7.10% Â Â Revolving credit facility | Maximum Â Â Â Â Â Â Â Credit Agreement Â Â Â Â Â Â Â Unused line fee (as a percent) Â 0.20% Â Â Â Â Â Revolving credit facility | Maximum | Base Rate Â Â Â Â Â Â Â Credit Agreement Â Â Â Â Â Â Â Basis spread (as a percent) Â Â 2.25% Â Â Â Â Â Revolving credit facility | Maximum | SOFR Â Â Â Â Â Â Â Credit Agreement Â Â Â Â Â Â Â Basis spread (as a percent) Â Â 3.25% Â Â Â Â Â Revolving credit facility | Minimum Â Â Â Â Â Â Â Credit Agreement Â Â Â Â Â Â Â Unused line fee (as a percent) Â 0.125% Â Â Â Â Â Revolving credit facility | Minimum | Base Rate Â Â Â Â Â Â Â Credit Agreement Â Â Â Â Â Â Â Basis spread (as a percent) Â Â 0.75% Â Â Â Â Â Revolving credit facility | Minimum | SOFR Â Â Â Â Â Â Â Credit Agreement Â Â Â Â Â Â Â Basis spread (as a percent) Â Â 1.75% Â Â Â Â Â Term Loan Â Â Â Â Â Â Â Credit Agreement Â Â Â Â Â Â Â Debt instrument face amount Â Â Â Â 30,000,000.0 Â Â Â Long-term debt Â Â Â Â $ 30,000,000.0 $ 26,915,000 Â Â Principal prepayment of term loan Â Â Â $ 3,000,000.0 Â Â Â Increase in term debt Â $ 8,250,000 Â Â Â Â Â Â Debt instrument frequency of periodic payment Â Â Â Â Â quarterly Â Â Debt instrument periodic payment Â Â Â Â Â $ 750,000 Â Â X - DefinitionAmount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4 + Details Name: srt_StockRepurchaseProgramAuthorizedAmount1 Namespace Prefix: srt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe total aggregate principal amount under the credit agreement. + ReferencesNo definition available. + Details Name: tcmd_CreditAgreementTotalAggregatePrincipalAmount Namespace Prefix: tcmd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of

mandatory principal prepayment paid + ReferencesNo definition available. + Details Name: tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment Namespace Prefix: tcmd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine Of Credit, Threshold Contingent Increase In Borrowing Capacity + ReferencesNo definition available. + Details Name: tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity Namespace Prefix: tcmd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDescription of the frequency of periodic payments (monthly, quarterly, annual). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentFrequencyOfPeriodicPayment Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of the required periodic payments including both interest and principal payments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentPeriodicPayment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility. + ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_BaseRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=tcmd_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Credit Agreement - Maturities of Debt (Details) - USD ($) $ in Thousands Sep. 30, 2024 Sep. 08, 2021 Maturities of notes payable Â Â Net Note Payable $ 27,000 Â Term Loan Â Â Maturities of notes payable Â Â 2024 (October 1 - December 31) 750 Â 2025 3,000 Â 2026 23,250 Â Total 27,000 Â Less: Deferred financing fees (85) Â Net Note Payable 26,915 $ 30,000 Less: Current portion of note payable (2,956) Â Non-current portion of note payable $ 23,959 Â X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LongTermDebtByMaturityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_CreditFacilityAxis=tcmd_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Lease Obligations (Details) - ftÂ² 9 Months Ended Sep. 30, 2024 Dec. 31, 2019 Dec. 31, 2018 Oct. 31, 2018 Minimum Â Â Â Â Commitments and Contingencies Â Â Â Â Lease terms 12 months Â Â Â Building | Minimum Â Â Â Â Commitments and Contingencies Â Â Â Â Lease terms 1 year Â Â Â Building | Maximum Â Â Â Â Commitments and Contingencies Â Â Â Â Lease terms 7 years Â Â Â Equipment Â Â Â Â Commitments and Contingencies Â Â Â Â Option to renew true Â Â Â Equipment | Minimum Â Â Â Â Commitments and Contingencies Â Â Â Â Lease terms 1 year Â Â Â Equipment | Maximum Â Â Â Â Commitments and Contingencies Â Â Â Â Lease terms 4 years Â Â Â Initial lease Â Â Â Â Commitments and Contingencies Â Â Â Â Area of office space Â Â Â 80,000 Second lease Â Â Â Â Commitments and Contingencies Â Â Â Â Area of office space Â Â 29,000 Â Additional office space added to the lease Â 4,000 Â Â Third lease Â Â Â Â Commitments and Contingencies Â Â Â Â Additional office space added to the lease Â 37,000 Â Â X - DefinitionAdditional office space added to the lease. + ReferencesNo definition available. + Details Name: tcmd_AdditionalOfficeSpaceAdded Namespace Prefix: tcmd_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionArea of land held. + ReferencesNo definition available. + Details Name: us-gaap_AreaOfLand Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicates (true false) whether lessee has option to extend operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcmd_CorporateHeadQuarterInitialLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcmd_CorporateHeadQuarterSecondLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcmd_CorporateHeadQuarterThirdLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Lease related assets and liabilities (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Lease-related assets and liabilities Â Â Â Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Right of use operating lease assets Â Right of use operating lease assets Right of use operating lease assets $ 17,553 Â $ 19,128 Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating lease liabilities, Current Â Operating lease liabilities, Current Operating lease liabilities, Current $ 2,883 Â $ 2,807 Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating lease liabilities, non-current Â Operating lease liabilities, non-current Operating lease liabilities, non-current $ 16,767 Â $ 18,436 Present value of future minimum lease payments $ 19,650 Â $ 21,243 Weighted average remaining lease term 6 years Â 6 years 8 months 12 days Weighted average discount rate 4.40% Â 4.30% Cash paid for operating lease liabilities $ 2,642 $ 2,579 Â Non-cash right of use assets obtained in exchange for new operating lease obligations $ 386 $ 132 Â X - ReferencesNo definition available. + Details Name: us-gaap_AssetsAndLiabilitiesLesseeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes current operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2 + Details Name: us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes noncurrent operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes operating lease right-of-use asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 57 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Undiscounted cash flows (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Undiscounted cash flows Â Â 2024 (October 1 - December 31) $ 924 Â 2025 3,734 Â 2026 3,807 Â 2027 3,309 Â 2028 3,275 Â Thereafter 7,008 Â Total minimum lease payments 22,057 Â Less: Amount of lease payments representing interest (2,407) Â Present value of future minimum lease payments 19,650 $ 21,243 Less: Current obligations under operating lease liabilities (2,883) (2,807) Non-current obligations under operating lease liabilities $ 16,767 $ 18,436 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: tcmd_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour Namespace Prefix: tcmd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 58 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Lease commitments and operating lease cost (Details) - USD ($) $ in

Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Commitments and Contingencies Â Â Â Â Operating lease cost $ 0.9 $ 0.9 $ 2.6 $ 2.7 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 59 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Major Vendors (Details) - Vendor One - item 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Commitments and Contingencies Â Â Â Â Number of vendors 1 1 1 1 Purchases | Vendor Â Â Â Â Commitments and Contingencies Â Â Â Â Total purchases (in percentage) 22.00% 29.00% 20.00% 26.00% X - DefinitionRepresents the number of vendors. + ReferencesNo definition available. + Details Name: tcmd_NumberOfVendors Namespace Prefix: tcmd_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2 + Details Name: us-gaap_ConcentrationRiskLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=tcmd_VendorOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Purchase Commitments (Details) $ in Millions Sep. 30, 2024 USD ($) Purchase commitments Â Purchase orders issued $ 24.8 X - DefinitionAmount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligationDueInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligationFiscalYearMaturityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 61 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Retirement Plan (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 401(k) Â Â Â Â Retirement Plan Â Â Â Â Discretionary contributions $ 0.6 $ 0.4 $ 1.7 $ 1.1 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 70 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1 + Details Name: us-gaap_DefinedContributionPlanDisclosureLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of discretionary contributions made by an employer to a defined contribution plan. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_RetirementPlanNameAxis=tcmd_DefinedContribution401kRetirementPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Legal Proceedings (Details) $ in Millions Sep. 04, 2024 USD ($) May 24, 2024 item Loss Contingencies [Line Items] Â Â Attorneys' fees and expense | $ $ 0.5 Â The "Weaver Lawsuit" Â Â Loss Contingencies [Line Items] Â Â Number of former officers and directors | item Â 8 X - DefinitionNumber of officers and directors. + ReferencesNo definition available. + Details Name: tcmd_NumberOfOfficerAndDirectors Namespace Prefix: tcmd_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingencyLossInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_LitigationCaseAxis=tcmd_WeaverLawsuitMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Stock-Based Compensation (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Jan. 01, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Stock-based compensation Â Â Â Â Â Compensation expense Â $ 2,070 $ 1,766 $ 5,969 $ 5,597 Cost of revenue. Â Â Â Â Â Stock-based compensation Â Â Â Â Â Compensation expense Â 100 116 286 340 Sales and marketing expenses Â Â Â Â Â Stock-based compensation Â Â Â Â Â Compensation expense Â 595 634 1,939 2,196 Research and development expenses Â Â Â Â Â Stock-based compensation Â Â Â Â Â Compensation expense Â 42 5 123 98 Reimbursement, general and administrative expenses Â Â Â Â Â Stock-based compensation Â Â Â Â Â Compensation expense Â $ 1,333 $ 1,011 $ 3,621 $ 2,963 2016 Plan Â Â Â Â Â Stock-based compensation Â Â Â Â Â Number of shares authorized Â 4,800,000 Â 4,800,000 Â Automatic annual increase to the number of shares reserved and available for issuance as a percentage of outstanding common stock (as a percent) Â 5.00% Â 5.00% Â Automatic annual increase to the number of shares reserved and available for issuance Â 2,500,000 Â 2,500,000 Â Increase in number of shares reserved and available for issuance 1,180,019 Â Â Â Â Â Shares available for future issuance Â 6,462,956 Â 6,462,956 Â X - DefinitionRepresents information pertaining to the automatic annual increase in shares reserved and available for issuance. The automatic increases occur on the first day of the year beginning January 1, 2017. + ReferencesNo definition available. + Details Name: tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber Namespace Prefix: tcmd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionRepresents information pertaining to the automatic annual increase in shares reserved and available for issuance as a percentage to outstanding number of shares. The automatic increases occur on the first day of the year beginning January 1, 2017. + ReferencesNo definition available. + Details Name: tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage Namespace Prefix: tcmd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=tcmd_EquityIncentivePlan2016Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Stock Options and Restricted Stock (Details) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 USD ($) $ / shares shares Sep. 30, 2023 USD ($) $ / shares shares Sep. 30, 2024 USD ($) item $ / shares shares Sep. 30, 2023 USD ($) $ / shares shares Dec. 31, 2023 USD ($) $ / shares shares Stock-based compensation, general disclosures. Â Â Â Â Â Stock-based compensation expense | $ $ 2,070 $ 1,766 $ 5,969 $ 5,597 Â Employee Stock Option Â Â Â Â Â Stock-based compensation, general disclosures. Â Â Â Â Â Stock-based compensation expense | $ 0 $ 200 200 $ 800 Â Total unrecognized pre-tax compensation expense related to nonvested stock option awards | $ $ 42,100 Â $ 42,100 Â Weighted-average period over which unrecognized compensation cost is expected to be recognized Â Â 1 year Â Â Options Outstanding Â Â Â Â Â Outstanding at beginning of period | shares Â Â 429,960 Â Â Exercised | shares Â Â (1,153) Â Â Cancelled/Expired | shares Â Â (24,142) Â Â Outstanding at end of period | shares 404,665 Â 404,665 Â 429,960 Weighted Average Exercise Price Per Share Â Â Â Â Â Outstanding at beginning of period | $ / shares Â Â Â $ 40.74 Â Â Exercised | $ / shares Â Â Â 1.35 Â Â Cancelled/Expired | $ / shares Â Â Â 43.45 Â Â Outstanding at end of period | $ / shares $ 40.69 Â $ 40.69 Â $ 40.74 Other information Â Â Â Â Â Options exercisable number of shares exercisable | shares 385,514 400,484 385,514 400,484 Â Options exercisable, weighted-average exercise price | $ / shares $ 42.11 $ 43.45 $ 42.11 $ 43.45 Â Weighted average remaining contractual life (in years) Â Â 3 years 1 month 6 days Â 3 years 9 months 18 days Options exercisable, weighted-average remaining contractual life Â Â 3 years Â Â Aggregate Intrinsic Value, Options outstanding | $ $ 218 Â $ 218 Â $ 223 Aggregate Intrinsic Value, Exercised | $ Â Â 14 Â Â Aggregate Intrinsic Value, Options exercisable | $ 116 Â $ 116 Â Â Employee Stock Option | Minimum Â Â Â Â Â Stock-based compensation, general disclosures. Â Â Â Â Â Vesting period (in years) Â Â 3 years Â Â Term (in years) Â Â 7 years Â Â Employee Stock Option | Maximum Â Â Â Â Â Stock-based compensation, general disclosures. Â Â Â Â Â Vesting period (in years) Â Â 4 years Â Â Term (in years) Â Â 10 years Â Â 2016 Plan | Time-Based Restricted Stock Units Â Â Â Â Â Stock-based compensation, general disclosures. Â Â Â Â Â Stock-based compensation expense | $ 1,500 $ 1,200 $ 4,400 $ 3,800 Â Total unrecognized pre-tax compensation expense related to awards | $ $ 7,700 Â $ 7,700 Â Â Weighted-average period over which unrecognized compensation cost is expected to be recognized Â Â 1 year 10 months 24 days Â Â Units Outstanding Â Â Â Â Â Restricted stock unit awards outstanding at the beginning of the period (in shares) | shares Â Â 589,142 Â Â Granted (in shares) | shares Â Â 539,496 Â Â Vested (in shares) | shares Â Â (254,490) Â Â Cancelled (in shares) | shares Â Â (113,724) Â Â Restricted stock unit awards outstanding at the end of the period (in shares) | shares 760,424 Â 760,424 Â 589,142 Weighted Average Grant Date Fair Value Per Unit Â Â Â Â Â Restricted stock unit awards outstanding at the beginning of the period (in dollars per share) | $ / shares Â Â Â $ 16.35 Â Â Granted (in dollars per share) | $ / shares Â Â 13.82 Â Â Vested (in dollars per share) | $ / shares Â Â 17.44 Â Â Cancelled (in dollars per share) | $ / shares Â Â 14.70 Â Â Restricted stock unit awards outstanding at the end of the period (in dollars per share) | $ / shares $ 14.44 Â $ 14.44 Â $ 16.35 Aggregate Intrinsic Value Â Â Â Â Â Restricted stock unit awards, Average Intrinsic Value | $ $ 11,110 Â $ 11,110 Â $ 8,425 2016 Plan | Time-Based Restricted Stock Units | Minimum Â Â Â Â Â Stock-based compensation, general disclosures. Â Â Â Â Â Vesting period (in years) Â Â 1 year Â Â 2016 Plan | Time-Based Restricted Stock Units | Maximum Â Â Â Â Â Stock-based compensation, general disclosures. Â Â Â Â Â Vesting period (in years) Â Â 3 years Â Â 2016 Plan | Performance-based stock-settled restricted stock units Â Â Â Â Â Stock-based compensation, general disclosures. Â Â Â Â Â Stock-based compensation expense | $ 400 $ 300 $ 1,000 $ 600 Â Total unrecognized pre-tax compensation expense related to awards | $ $ 2,000 Â $ 2,000 Â Â Weighted-average period over which unrecognized compensation cost is expected to be recognized Â Â 2 years 2 months 12 days Â Â Number of performance awards under share-based payment arrangement | item Â Â 3 Â Â Units Outstanding Â Â Â Â Â Restricted stock unit awards outstanding at the beginning of the period (in shares) | shares Â Â 198,232 Â Â Granted (in shares) | shares Â Â 223,762 Â Â Vested (in shares) | shares Â Â (44,162) Â Â Cancelled (in shares) | shares Â Â (104,913) Â Â Restricted stock unit awards outstanding at the end of the period (in shares) | shares 272,919 Â 272,919 Â 198,232 Weighted Average Grant Date Fair Value Per Unit Â Â Â Â Â Restricted stock unit awards outstanding at the beginning of the period (in dollars per share) | $ / shares Â Â Â $ 18.93 Â Â Granted (in dollars per share) | $ / shares Â Â 13.76 Â Â Vested (in dollars per share) | $ / shares Â Â 27.31 Â Â Cancelled (in dollars per share) | $ / shares Â Â 14.14 Â Â Restricted stock unit awards outstanding at the end of the period (in dollars per share) | $ / shares $ 15.19 Â $ 15.19 Â $ 18.93 Aggregate Intrinsic Value Â Â Â Â Â Restricted stock unit awards, Average Intrinsic Value | $ $ 3,987 Â $ 3,987 Â $ 2,785 2016 Plan | Performance-based stock-settled restricted stock units | Minimum Â Â Â Â Â Stock-based compensation, general

disclosures. Â Â Â Â Â Performance goals revenue change and adjusted EBITDA margin Â Â 25.00% Â Â 2016 Plan | Performance-based stock-settled restricted stock units | Maximum Â Â Â Â Â Stock-based compensation, general disclosures. Â Â Â Â Â Performance goals revenue change and adjusted EBITDA margin Â Â 175.00% Â Â 2016 Plan | 2025 PSUs | Minimum Â Â Â Â Â Stock-based compensation, general disclosures. Â Â Â Â Â Performance goals revenue change and adjusted EBITDA margin Â Â 25.00% Â Â 2016 Plan | 2025 PSUs | Maximum Â Â Â Â Â Stock-based compensation, general disclosures. Â Â Â Â Â Performance goals revenue change and adjusted EBITDA margin Â Â 175.00% Â Â 2016 Plan | 2024 PSUs | Minimum Â Â Â Â Â Stock-based compensation, general disclosures. Â Â Â Â Â Performance goals revenue change and adjusted EBITDA margin Â Â 25.00% Â Â 2016 Plan | 2024 PSUs | Maximum Â Â Â Â Â Stock-based compensation, general disclosures. Â Â Â Â Â Performance goals revenue change and adjusted EBITDA margin Â Â 175.00% Â Â 2016 Plan | 2023 PSUs Â Â Â Â Â Stock-based compensation, general disclosures. Â Â Â Â Â Number of performance awards under share-based payment arrangement | item Â Â 3 Â Â 2016 Plan | Tranche one | 2024 PSUs Â Â Â Â Â Stock-based compensation, general disclosures. Â Â Â Â Â Award vesting percentage Â Â 33.33% Â Â 2016 Plan | Tranche one | 2023 PSUs Â Â Â Â Â Stock-based compensation, general disclosures. Â Â Â Â Â Award vesting percentage Â Â 33.33% Â Â 2016 Plan | Tranche two | 2025 PSUs Â Â Â Â Â Stock-based compensation, general disclosures. Â Â Â Â Â Award vesting percentage Â Â 33.33% Â Â 2016 Plan | Tranche three | 2026 PSUs Â Â Â Â Â Stock-based compensation, general disclosures. Â Â Â Â Â Award vesting percentage Â Â 33.33% Â Â X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were cancelled during the reporting period. + ReferencesNo definition available. + Details Name: tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue Namespace Prefix: tcmd_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period. + ReferencesNo definition available. + Details Name: tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod Namespace Prefix: tcmd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of performance awards under share-based payment arrangement. + ReferencesNo definition available. + Details Name: tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods Namespace Prefix: tcmd_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThe percent of revenue change and adjusted EBITDA margin to be achieved under performance goals of awards under share based payment arrangement. + ReferencesNo definition available. + Details Name: tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceGoalsRevenueChangeAndAdjustedEbitdaMargin Namespace Prefix: tcmd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIntrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=tcmd_EquityIncentivePlan2016Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=tcmd_TimeBasedRestrictedStockUnitsRsusMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=tcmd_TwoThousandTwentyFivePsuMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=tcmd_TwoThousandTwentyFourPsuMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=tcmd_TwoThousandTwentyThreePsuMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=tcmd_TwoThousandTwentySixPsuMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Employee Stock Purchase Plan (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Jan. 01, 2024 Apr. 27, 2016 Stockholders' Equity Â Â Â Â Â Â Stock-based compensation expense $ 2,070 $ 1,766 $ 5,969 $ 5,597 Â Â 2016 Plan Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Shares reserved 6,462,956 Â 6,462,956 Â Â Â Employee Stock Purchase Plan Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Purchase price of common stock under plan (as a percent) Â Â 85.00% Â Â Â Offering period (in months) Â Â 6 months Â Â Â Shares reserved 1,497,964 Â 1,497,964 Â 236,003 1,600,000 Incremental share increase (as a percent) Â Â 1.00% Â Â Â Incremental share increase (in shares) Â Â 500,000 Â Â Â Stock-based compensation expense $ 200 $ 100 $ 400 $ 400 Â Â X - DefinitionPeriod which an employee's right to purchase shares of stock at a discount, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod Namespace Prefix: tcmd_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents the minimum increase in shares on an annual basis. + ReferencesNo definition available. + Details Name: tcmd_IncrementalShareIncrease Namespace Prefix: tcmd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresents the incremental annual share percentage increase minimum. + ReferencesNo definition available. + Details Name: tcmd_IncrementalSharesToBeIssuedPercentage Namespace Prefix: tcmd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPurchase price of common stock expressed as a percentage of its fair value. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=tcmd_EquityIncentivePlan2016Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue Â Â Â Â Revenue $ 73,093 $ 69,586 $ 207,399 $ 196,771 Percentage of total revenue (in percent) 100.00% 100.00% 100.00% 100.00% Revenue from sale type lease Â Â Â Â Sales-type lease revenue $ 9,925 $ 10,720 $ 26,657 $ 25,312 Cost of sales-type lease revenue 2,703 3,211 8,270 9,122 Gross profit 7,222 7,509 $ 18,387 16,190 Minimum Â Â Â Â Revenue from sale type lease Â Â Â Â Rental period of rent-to-purchase arrangements Â Â 3 months Â Maximum Â Â Â Â Revenue from sale type lease Â Â Â Â Rental period of rent-to-purchase arrangements Â Â 10 months Â Private insurers and other payers Â Â Â Â Revenue Â Â Â Â Revenue 47,564 39,376 $ 122,907 101,300 Veterans Administration Â Â Â Â Revenue Â Â Â Â Revenue 8,442 7,259 23,339 20,203 Medicare Â Â Â Â Revenue Â Â Â Â Revenue 9,276 15,871 36,032 50,754 Durable medical equipment distributors Â Â Â Â Revenue Â Â Â Â Revenue 7,811 7,080 25,121 24,514 Lymphedema products Â Â Â Â Revenue Â Â Â Â Revenue $ 65,282 $ 62,506 $ 182,278 $ 172,257 Percentage of total revenue (in percent) 89.00% 90.00% 88.00% 88.00% Airway clearance products Â Â Â Â Revenue Â Â Â Â Revenue $ 7,811 $ 7,080 $ 25,121 $ 24,514 Percentage of total revenue (in percent) 11.00% 10.00% 12.00% 12.00% X - DefinitionPercentage of revenue disaggregated by products. + ReferencesNo definition available. + Details Name: tcmd_PercentageOfRevenue Namespace Prefix: tcmd_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRental period of rent-to-purchase arrangements. + ReferencesNo definition available. + Details Name: tcmd_RentToPurchaseArrangementsRentalPeriod Namespace Prefix: tcmd_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionCost of goods sold for sales-type financing lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5 + Details Name: us-gaap_CostOfGoodsSoldSalesTypeLease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to

customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SalesTypeLeaseLeaseIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of sales-type lease revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5 + Details Name: us-gaap_SalesTypeLeaseRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of profit (loss) recognized at commencement from sales-type lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5 + Details Name: us-gaap_SalesTypeLeaseSellingProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=tcmd_PrivateInsurersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=tcmd_VeteransAdministrationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=tcmd_MedicareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=tcmd_DurableMedicalEquipmentDistributorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=tcmd_LymphedemaProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=tcmd_AirwayClearanceProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Taxes Â Â Â Â Income tax expense (benefit) $ 2,078 $ (14,714) $ 3,254 $ (16,307) Effective Income Tax Rate Reconciliation, Percent Â Â Â Â Net effective rate 28.70% (194.00%) 31.00% (407.10%) X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 68 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Net Income Per Share - Basic and Diluted Net income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Net Income Per Share Â Â Â Â Net Income (Loss) $ 5,155 $ 22,299 $ 7,244 $ 20,313 Weighted-average shares outstanding 23,985,364 23,483,269 23,842,049 22,714,574 Weighted-average shares used to compute diluted net income per share 24,254,176 23,848,729 24,070,084 22,987,667 Net income per share - Basic $ 0.21 $ 0.95 $ 0.30 $ 0.89 Net income per share - Diluted $ 0.21 $ 0.94 $ 0.30 $ 0.88 X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-

220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 69 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Net Income Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Net Income Per Share Â Â Â Â Antidilutive securities excluded from computation of earnings per share 873,568 505,493 1,032,562 637,984 Restricted stock units Â Â Â Â Net Income Per Share Â Â Â Â Antidilutive securities excluded from computation of earnings per share 361,130 74,972 520,171 190,071 Common stock options Â Â Â Â Net Income Per Share Â Â Â Â Antidilutive securities excluded from computation of earnings per share 370,040 430,521 370,040 430,521 Performance stock units Â Â Â Â Net Income Per Share Â Â Â Â Antidilutive securities excluded from computation of earnings per share 63,103 Â 142,351 17,392 Employee stock purchase plan Â Â Â Â Net Income Per Share Â Â Â Â Antidilutive securities excluded from computation of earnings per share 79,295 Â Â Â X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tcmd_EmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Earn out liability (Details) - USD ($) $ in Thousands 9 Months Ended Nov. 28, 2023 May 25, 2023 Sep. 30, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Payments on earn-out $ (5,600) $ (5,000) $ (5,000) Significant Unobservable Inputs (Level 3) Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Earn-out liability, beginning balance Â Â 13,050 Payments on earn-out Â Â (5,000) Fair value adjustments Â Â (2,475) Earn-out liability, ending balance Â Â $ 5,575 X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (f) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Fair Value Hierarchy (Details) - USD ($) 9 Months Ended Nov. 28, 2023 May 25, 2023 Sep. 30, 2023 Fair Value Measurements Â Â Â Earn-out liability payment $ 5,600,000 $ 5,000,000.0 $ 5,000,000 Imputed interest payment Â $ 250,000 Â X - DefinitionAmount of cash outflow for imputed interest payment on business combination contingent consideration liability. + ReferencesNo definition available. + Details Name: tcmd_BusinessCombinationContingentConsiderationLiabilityImputedInterestPayment Namespace Prefix: tcmd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration

X - DefinitionAmount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (f) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 72 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Event (Details) $ in Millions Oct. 30, 2024 USD ($) Subsequent Event Â Subsequent Event Â Amount of authorized shares to repurchase $ 30.0 X - DefinitionAmount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4 + Details Name: srt_StockRepurchaseProgramAuthorizedAmount1 Namespace Prefix: srt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant/duration X - DefinitionDetail information that is required to be disclosed in addition to the information that is required to be disclosed in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 (.!9%D'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #@619?:Y;MN\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M3L,P#(=?!>7>NND*2%'7"XC3)B$Q"<0M2KPMHOFCQ*C=VY.6K1."!^ 8^Y?/ MGR6W*@CE(SY''S"2P70SVMXEH<*:'8F" $CJB%:F,B=<;NYJM)+R,QX@2/4A M#PAU5=V!19):DH0)6(2%R+I6*Z$B2O+QC-=]P8?/V,\!5D[M.@H 2\YL&Z: M&$YCW\(5,,$(HTW?!=0+<:[^B9T[P,{),9DE-0Q#..:SF7-Z!P]MV\S*O6QB7 M2#J%^55$UNYJ+ZE[<-N^3ZP^_J[#UVNS- M/S:^"'8M_+J+[@M02P,$% @ X%D69E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14? GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?
\YOI^1.6HCA5,+$P&IG/U9K MQJ"22("'R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?
IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^'!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/]<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL! _]':-*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?
EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\[JA[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7+&SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%[JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?
-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #@6190[/T-=D% #'P &
'AL+W=OYL[Q1;@&=M8TTR"/WU M/;+!3E)9II[U#?CKO-:K(TN/I/&6BV]RS9A"+W&4R/.6JG-!\>1_IK%5)[R M#4O@SI*+F"HX%2M';@2C01841PYQW3,GIF'2F8RS:W,Q&?-416'"Y@+)-(ZI
MV%VPB& /.[ASN/ 0KM9*7W FXPU=L053?V[F LZ<0B4(8Y;(D"=(L.5Y9XH_ MS#RB [(G/H=L*U\=(VWEB?-O^N0F..^XND0L8K[2$A3^GMF,19%6@G+\O1?M
M%_4@:^/#^K7F7DP\T0EF_'H2QBHJ7EGV$$!6](T4@]\^SO;&^IK/9]',OM% MV_S97J^#_%0J'N^#H01QF.3_]&5?$:\#<$4 V0>0=P&XZ@W>/L#+C.8ERVQ= M4D4G8\&W2.BG04T?9'6318.;,-
%I7"@!=T.(4Y-+[]5>0%85H$J"K1(5JAVZ2 MO'GH:NXBN::"R;&CX&TZQO'WRA>Y,]E0'J%;GJBU!-6 !6_C'2AE451R*.H% ML0HNV.84>>X)(B[I&V9! .<%^ MD!OJL_,:?)&2B6?6F?ST SYS?S6Y_4YB;
[SW"N\]FWKI_7&W82:G]G#L=C^9 M+%FC&EKJ%Y;ZQUGZE%*AF(AVZ(%MN% F>W8I5)3I6]TSJ6B$?HKW%1W5W;%?K^'SXQ.VT H7#(4MJ-/UEZG M,%NN-F87.,/$:*L-
8LE(R,F$[YWSD/N1KON:)#2EJ1+Q^OJO'%=U.&\"$2V+" M=MQY#!6P %\B3'Y^^@4MF)*R*31I%UIQN,8QJ>%XOXW:.A4H,\T2AGZT3T% MIM)LC19ZNFRLA#; "I=DA6N02- @3%:
1/$3CXS>:P1FMY=&7VV $RG!B=C1 MYI!-=/7BKVFR8I7(6"-T-UU<3HW34GM@4XC!M]VA6K?+9!0:2D/'(4 M!>D9'( ]0,&*"V-G5*,S]7T&$B 0Y&)&KVU
$"DAB!P%08N81A&Z2"7IG(K;XYKZ*]F'\,4^5S$3*_U)_@8*:@UX$&]H8DZJ7;#::!OH0TKT(79R M.21RS2"1-GMVF6I[;2 0*1&(V.GET,>^&=^SH5RB^U0!T"9Z]#0Z_DYPLZ^' M7*V?J>D]F.
<)\4:C@3L-AIM WV\$GV\ MFE6=PUKG:Z?7<-'8P]:(52WFVL.:>BSAQ[.CRGN/^^7K:I=VN4^>T6,:X..5 MX./9,64*!H/<9$2-?4R-0&6O:H_[O\:<5]N,>L#++=E\E\O7:9+[C6%PM=GBG
MV;ZF4SZ>;P_?4CU>2A2Q)82ZIP/H\$2^XYJ?*+[)-BV?N%(\S@[7C 9,Z ?@ M_I)S=3C1+RCVO2?_ E!+ P04 " #@619T*C# _4& #1(& 'AL M+W=O'1LS23V MM,U%$T^>"BH4I_%
(]3N1",EMV@IIYB")-I M0ZMV,KOLOKL5LTN^5'75LEL!Y+)IJ'C^P&J^OIJ@R?:++]7C7)DOIK/+!7UD M=TQ]6]P*_6FZ\U)6#6MEQ5L@V,/5Y#VZN(ZZ 9W%WQ5;R[UK8$*YY_R[^?"Q MO)I
HXC5K%#&!=7_K-@UJVOC2>OXT3N=[.YI!NY?;[W_W@6O@[FGDEWS^I^] M5/.K238!)7N@RUI]X>L_61]0;/P5O);==WV#=V\()*)92\:8?K!4T5;OYES[U MB=@;@"+/ -P/P*<.(/T
T@6Z4=:%=4,5G5T*O@;"6&MOYJ++33=:1U.UYC'> M*:%_K?0X-;OF;:D?"BN!OI*\KDJJ(3I768#Q-B_Y^'S;WPY[[W;'%.2#P&^((\?PZ_#P&UHX:@;
M3@Z'3W7DN_#Q+GS<^2.^\)="L%8!*J6.TQ7.9GSD'F\6V85]?* M5(+5+,,H2BZGJ_UP;*L$04)V5@_9[" D4+;*B(H]2B,=PKCH,)/NKI6[8I)U9BYHQ=$S70E<28RM@0@DL=D M)--
A%:$\=LM,=C*3H,R/6F*KN*CT3;]\>EYB_9E%[6)6<'X2(X\ L>F4NZ MI1'JN9M#IJHMS*(\ RU33C!!>_ID:39Z-@ZKQ+L>T1YK45!KUR0!_@"6D@$C MFZJ?
=Q4C\#3ZKT>3)4TMHJ(RRQ'./.H'A")@EC2=431]K'2=;C7Z$\N=BR[M%%K9=9@E*?;,?#0 #H4)]P?GY;JJ:ZZPT9Y4]I!-,Y)!:PXXF)=BZ!$Z, ^%H;?!QXE";7XA')-X MS!"7'4E0Y%M* ^K0*:P+"+3IA;-
T?PWW EUV*"*^QSY@#H4YMVW5W6E M/$T.>E72O9:WPZW*@#H<1MVNB"SHLZ\MQC:Y4IR/VV*'59+$N?NAX(%O.,RW M3URQH#B;4#B/QRWG,:M#<7L[O3#&=/;$4MED\X R?@K-
3E=J<(BF*Q[1PF$4(QKZL#C3#V'VTW>U\',YKD\;B/50/Q"-AXKGJWW'%-N"BO3;D)"]X\LP"^W^^FF=X3!N'F>ZVTPZ@&R) S96[!=VTH3_QEX \\A1'K]"K"B]5*O MX!B>0=C]
7).A3FB7*HY%)6_K'QG)B$#E92F7G5'ETLEE;XPZXI*<\!SQQ:* M-?>;Y=MW'9WAC=[];[YUOL+HB \3W4"Q.;]^>:#XHON%?0]5XHWW>6<42W;&.C?'[CN5/L/YJWV[G\O MS/X#4$L#!!0 (
.!9%EJ;PF>W (!8* 8 >&PO=V]R:W-H965T M&ULK99OYLP$,:_BL6FJ9.Z8"!_NP1I335M+R9%C;:]=N$2 MK!J;V4[2[=/O#)2%EB9IN[Q(;+CG\>^.(_9TI_2MR0 LN*HV5G)"TW,
M)L^9_GT)0NUF7N#=7[CFZ\RZ"WX\+=@:EF" %PN-,[]Q27D.TG EB8;5S/L4 M7,P#Z@1EQ \..[,W)BZ85&5NW>1K.O.H(P(!B7F64#'^V, DY"&_0[Y
M_+#\"A*4!Z4\:LM]S+XI0=B4("S]HM>4H"O+RK;?;>O>OPM3L 1F'KY@!O06 MO/C=FV!(/W;E_)_,6A6(F@I$A]SC!;XZH#4FC?V6W)Z3@FFR96(#Y(Q+DBHA MF#:D
%T]_==U:B6&)5+N#^/;4Q[E 93?[N?YK&H%G^_X>_C[_J3,(V-E.: M_X&T"[CR'.RA#&CU>]!@#UZ$S8W9="./'I$\9#T4T8(<-I##%'T'B MEF LDRF7ZR[2X5'20Q$MTE%#.CI(.E=YCAO#*UIX=%
(+'XMJP8\;^/SX_J MW_&C D:TNX%/B6Q13QKJR;.ISP_T[^0121!A>]B,ZGCP@[@H<4CH8]N! _IO MOZ,O0#[2S;7G">"=D9WD_MZF[4Y,WYA>&PO=V]R:W-H965T&ULK5IMK3FV&6/ZJ-
$,I[RK.BNIILE-I>3*?5 M/-^X2=<;5=^8SBZWR5K<"O5M^Z745].#EU6:BZ)*9>&5XOYJ\@%?Q!35!@WB MSU0\5D>?O9K*G90_ZHN/JZL)JI](9&*I:A>)_O,@YB++:D_Z.?YJG4X.8]:& MQY^?O?_:D-
=D[I)*S&7V/5VIS=6$3[R5N$]VF;J1C[^+EA"K_2UE5C7_>X][M;,@FWG)7*9FWQOH)\K38_TV>VHDX,L!#!J0U(*:!/V! 6P-ZZ@A^:^"?.@)K M#1KJTSWW9N(6B4IFEZ5\],H:K;W5'YK9;ZSU?
5%O5!N5:F_3;6=FLUEL=)A M%RM/?ZIDEJX2I2]NE?ZCUX.J('Q?=Z,JGC6GEGWK?;A??VS3OOC9<6WM>- MW%5)L:HNITH_3>USNFQ'OMZ/3 9&IMXG6:A-Y<7Z"5: _<)M'SGLIWH6#E-!
MGJ?BFC@=WHKMN4?1>X\@X@//,S_=G$)T_M_H\7\>O3<9]+ N:.//"_#W5:HD MTY7@010[05W;QXTYG4U>IB%%$5ZZ(?C*;-10<1XT$>MG6- XM4X)LX=IN^J+;)4EQ-]#Y*NTTR47EZE]
;5_E#U"&!(A\:F1-P MRHV&!Z$0-3)G8:,XXHL? !+:@245(S-D .HP/?-6F.C&,;,\!7;*# _@H0 /.4:= MBD+.6?^A8J*18IW>9)*JTOH^R66ITG^2O1K6DZ'71'&FE3HHE) =&&INI0#H MC.IMTI@&
(9Y9$X#Y(RQ<& :CL0D/F$OE2<5WM95+Q0<6?LI!,,T-!,>@&&? M!,Q,>0A"'><#FRHF'77RP@I8REQX]Z7,GR= ZV60. %RE6.3MXT*(VXN>@ 5 M!4%@D@9&U(5F@'(G$;%;
(WY6&U'J4T!#_&TZW<@96H'D1&3L0TZ\Y%9Z 4 M\\0D#+@BA X%N9.*V*T5VR#?"7U"%_,5?(TL,)M_182.Z\!%#M:CRUM0'TB MW\YK&^8?YU2?=R<9L5LS?CPP?
4YI[^V=KO1:0L+QMA6=5O1F70=09]@/L15R M&T<),S%J-ZB\?R MUH]+)RBQ6U%>)U6Z!".PM^-'"P&=$VLG@5"156 @E+5[0]"C3:E/L).0V*TA M%VFV4V /Z+]U?(DBA(IHU/MG$H9L+,(0B
^<$$@G%PER9MKWIG\I5F?)@U8* M:]'+NM[6STQ7O&ZQ"1.K?K:Q!S5VV)4;_%8WOIA[.0N6Q: ##,4>B;IPT(M5Z?;P+Y(.ME-W++[Y-8T@1JM@=GOFD.P$&&+-]#<#3@VN],0C#,R(Q-)I[>)
M6V^_U*!NS7OCABPP)3<$PYR9C0, ABF-K",EA-,5A@ZU1OBU&]Q6-YZX>B$]K$+;1?KB]V!S6*B+7R@(XM"HFU\H#N;Q"PT%QX M (Q13
;672>ZB5MTGUY<[)X1">W:8J,HP=CD;*,X,9MY,8"*=++!C&FGNJF[M2?M286G-^Z=O8K:I(!1#IG(!4)A3\V>T&((%.#)\M.C' AS4:Z;-RL]';Q= MH?:_Z1[N'M[>^-"\LV#/]N1N=^_ZK(IZ1)>#X7.
MZW0]?A?:!!G06OR=L/QX[0WEW)3%%^;DX_+RXG5>,12%M<- M1,3_W;$Y2],&B?OQK0.=[.=L!AX>/Z+_UEX\OYB;J&+S(OTG6=;KRXD_04NV MBK9I :FX_YUU%^0T>'&15NU?=-
_96A,4;ZNZR+K!W(,LR7?_HX>.B(,!F!X9 M0+H!1!! O",#:#> 2@-L?&2 W0VPG^J2TPUH+WVZN_:6N$541[.+LKA'96/- MT9J#EOUV-.9$O>=C9$O&CJDB3953SD^N:_^/Y4%>H
M6/&S(OZZ+M(E*ZM?4/AMF]3?T1GZ-% M]O$B+8Y]!-#E$9YS"H4U:A>,W3#;I.\<;7Y8,'BVB"*;8L+)HMAF9G@4LDJU !1K!M]7,*'-]!_0'.3CAB5BM
MHY)5IT_B8S>/(_!!'.)ZGL2*UJ%F,7]7;:*874[X:EVQ\HY-9C_A%WK5U4. M0H*%0&!*(.Q](.P6G1X)Q,<\YIM3Q=)9[H].FV6 M5RH6+?!N1A#@FV@ 0+ M@<"$"#G["#G:6Z4-
Q5FSDRY17&2\O*BB9K%4A4.+9!H.9W!G.4X@W54+R!G# MD1D%^MP]?:Z6OO"!E7'"$YQO@O%NEZH:1E&Q:5CD*U"^1'>LJIO%A]ML6-G6 M;GQU:K_B;M=E$C=[QV[<-D]JY0ZI]<.4?'=
!:82]9#SA=KY!.*]/?'>*0!_ MN#^H@N -MP,[L%Q;V@RTKILN-9!@(1"8$#)_'S)?OJ1$ZJ#FB6**6\1?U!,2$D]]P?QHL;;/Q" MZFLOPY1Q]92...ON#/97!RU$YEO3!,.E]S[$LN3#4NFR:]9!@(1"8$"IL]0+*
MT@:K4R\[AE%255N^Z/#%"+%LDQ;?&>OBM]F6\;HIEC:\>E6*).T\IGM AW88 M5]^7;P70*<.1*45^#P0JAN=W+.F[.84MBU@^=J6DU_MFFO6@:"$4FAB77HAB MO1+]BZ\W2]CL1:$:3D0-
+RXWS8P_A0._ <1Q;S>F>,TP=4+$*AB8'HY2+6ZT7MXZ4_ MMOE(")PGI.10IV'/HK:L#15V9YA?IR?GI +/\3WWV'W92S^LUWY/?LHT3LM0 M'_',=/A]0V1R(&79
A0MA$(3P]$+0NP]Y[,F#*FSYJ!H"U"T$ I-C%.O O&(M##1XXJ2',@[*4(MASW7E=054_HW-*9+8ZS^L%X O]]Q)[XAQ"!1B4N8?5/II M)Q0);++V@(WI!]SK/GLA0/& .%*E-M?
[;KKR@**%4&ABW'JA2/1"T4B0Z+%, M\QX4;&&XI00$@1RYB2\M-\ M,M2-V+,]V6ZALO/]P)934F$64-<^MBWUTHS\]#33=+W5K PE$ZZ&N93G^@!O(M#MT"%"V$0A/#TD>,0S"49[(>
9TPU$XHDM^+0?(:8G!4 MCZCZ@KX3^/(6 =H7!$4+H=#*$7ZGU0I*^4&=0/X_I34&'2A-;MESN@,X9CLTI M,MQ+/OH*O4&JZ U:7B _>9[K?3/^42!H;Q *38Q++R$I8&]0CV6LP)?
[]4HSR_6./)RGO?*CS] 85+.B:@SR*_9LN@U)X1J#>BCCH"A$F>59\K("*@3' MYA1)[+4@_3]]03K4@M2B-I87*5 M(H60J&)[\GT4M#62T&C@EB/9?QB#&C' MT!X*.0?+7_9_\"4$L#!!0 M (
.!9%G"PL81Y@< *HD 8 >&PO=V]R:W-H965T&ULM5IM^,V$OXKA*\H6]!>2Z3DEUQB8-=[11>X%D%S;3_3$AVS*XDJ23E) M?WU)2I$L\24QX/NRL;3#T3-# M
]&4)>8OGTC!GNYF\>SUQJ_T\2CUC<7VML:/Y'(W^I[KJX6O9>\:^ZHLO^=TLTHA(03*I76#UYT1VI"BT M)X7CK\[IK'^F'GC^^]7[CR9X%"[)CQ1\TE\>[V7H&\O9$^#:6GG3/TQNS&@5#:WT-
#Y(KOZ7JG%RNV-5KB:%Y$#] M$JR@.9;JXD&J/VJVI #L '98', &/:L8%F(/?'CZ#[[[Y'GP#: 7^=V2-P%4N M;A=2H=$^%UGWY$_MDZ'GR1OP,ZOD48#_* 3Y>/Q"1=&' E]#^02##A](_0&@ MZ <
(Y@X\.S>/QP%X* ^L\CX0[[,ZJ0=3-(.G)5 [3R.):T>VZ5+)27.K+5> M$[=7O:MO1(TSN\-)KSN*5G(VRM>RSM0S.XF>B MG&84MT6WR@$N&9?
T;W/#%7GK+CV;LS1;283:QLEFWCIGM=5CW3U!M(#X5S- MT^L:='"B0BHQ%FUGR MK'\[=\K:3NAF.4VHPRC=>,!N>K';(-C_J'*?P5R*MFF+*&I0&T%MD7DBUD*
MY*^&UGHCF2M:25P]TGWASOK&0HBB]20*AXT[A#@:^"T*!K$[*E!$<]4!4PY. MN&B(#H1@7LV5K@$%Q7M:4/GBI+"@\TOW<>=MO*B25>J)\$S#XS#5F!B%#A(+
M051=T_/Q&I@J43^8;J:BQIF:,D'UDG.6K>Y!UXKW2M[&:8%#6F!PZC]F&6MT ME5<%C- 35BO3&3.T5YVBFW MH$(6!IC *5"'40I]. 6_+(98:6/L@#C\9A(C6]G*X6C2!GBL>LRQ!H!V7&TPKO,
((;Z$$\L&H< MIE7'3E-U!* GHS"@39AF#850-HP<5849M5R4ICFT+O/H(/?T,HJI2XSB'SR M#PXT"(-\TF-V;+4S+G0"CQV(K.KELDK3Q+,8X,!3,,Q3O[RWTW!"MWD))@A.
MUXG#+%ZED4=>P8&^X&5=;DME[X!]U3;W6M[&21BX$8:Y\;[AV5&3MEA\W/@ M8,-X@ZRI\XR0O)NXI2^)Q?"M_DRMK#_/UI7.) O#)/O
ME[XE>17&ICD5#;,>V!>N+ZH!!UKA*GL'["'I7UP#KN1MG(2!T6&8T<>[B0K1]!R8 M'54Q24(\'W9\<1IL0;"&:>2>8S3H 136 _?XI3L.KOK6V7EZ>=6&&3F40AI% MOF@&I8#"2N$\FK>F!
[FTP7E&.ZAOF8VA#N(A<7!.51.3JPX&2VNK/3:RCA1 MQ\0W4&_?&G/[W*RE\,.RAIP]QMAUQ=':+?- M\]@G]-$@#= ;TF!4%L@SX1D5[=2QLE1S*O2)H%)[^DC&':9- U.6=9CX#LG1 M(_0)?)
J>A141NA[RU(61?LA9#N?MWI(E 7V'E6C!P2(K+:7(?5>NWI<-"@ M#=!;C;F0[]BPQ*4F'\E[DT6?,3%2]"6%2A9>M?@H"O0.W7%=YVP^'[4:;R7 MKI%+/LH(FBU'A[^.?5T2&E0&"O?
XW>LD;DXAE#@R$6F1:GYHI7I2$K;RU J[MC8=Q'$\[4X=9DL211]FA01R@L#C8^;"".=B31UI5.OU:?1-.6>Z,P.;U91PA M*P+;#,8;Z#D32@;^3]XX1@]$0'2'<*>V#2^AG&RG&!WF"V7$?*
<"R0#VR?A MX_&'IJX+\S8;%RU^+5;U:XVL8$)U D[.5ST)OY0W<08&$9&$1829/7,>6!< MOZ@AZBG.BI8XS@F65EOGL%)[W*,â.....$-)&$U,(;I/69*;*I.$C@]N7-8H2CR M+::SEJIA0M_AFNIU=-
Y(ZKK4&.FR;Z06E.!%%2L=B!.^_58[F;[.<]E,T[LX M^^JC)/S1? PC@#E8;+^:Z. V']Q\-)^93.Y_BF]V[6;GD>"<<&V@_O_E+KN+O0#^L^3MO\ M4$L#!!0 (.!9%E:Q-E4W@8 '80 8 >&PO=V]R:W-
H965T&ULK5AIQLW$/TKA!H4+:#H6,F)D]@&[!QH"K@-ZC3]3'%'6B)< MO?]PVYNY+C)$Z/+];RFN/-FQG29SOG/X:*(K;VMAP/JIB;)Y/IT%5 M5,LP<0U9K*R=KV7$T&^FH?$DRW2H-M-B-
GLRK:6VHXNS-/?.7YRY-AIMZ9T7 MH:UKZ?=79-SN?#0?]1-_Z$T5>6)Z<=;(#=U0_+-YYS&:#E)*79,-VEGA:7T^ MNIP_OUKL_K3AG29=./H6[,G*N8\)>%N>CV9L$!E2D25(_&SI)1G#@F#&IT[F
M:%#)!X^_>^EODN_P924#O73F+UW&ZGQT.A(EK65KXA]N]PMU_IRP/.5,2'_%_M+N]=+$=*M2&ZNCL,"VIM\Z^\[7 X.G Z^\]!HCM0)+NSHF3E*QGEQ9EW.^%Y M-
Z3Q1W(UG89QVG)0;J+'JL:Y>/&;C*TGX=;BJ@U8"T%(6XK?&_*280MGTP@U MO'FJ.I%7663Q%9'/Q+6SL0KBM2VIO'M^"O,&&XO>QJOBFP)OJ)F(Q6PLBEFQ
M_(:\Q>#S(LE;_)\^9Y++XODU'D>&JGH?(3<".2W-+KX\8?YPF!+QB\' Q> M?DOZOS/X 9$NDIA/Q(.BQ7M.'$/B9A\BU1B3]JPS;K,?B[=63<!// YP6A2S M%SL:IZ_Y"]'-M.'S&=?
Z88KUQ(KZI9>N;J3==ZL_@^2V74,WS,LVE3I$KU=M MQ+BF4BMID']:K3!&=4JR(I31,V([%$## _9D%*Q$BW8Z%-D2J$][ZQ6+)*0 MTI ?1>5JFHB_2#3>;74)3%HOWABZU=&UJD(PGRY?
B'>FS=:\MM %8Y>G13<, M,D!CL:NTJD1%IA$*F>"1U&%?-TCEP&89?%=4HKB.A1Q,@=8-/ VH48-W.%UJ MCL(8SGG7;JID5*D]:IH(TF3/%27_VT!"VP0#^X(Y@Y*K[0;%4Y%N,B;0H3P&
M*;9K[VJQE4&U1GH8[@!2\NY@HU"@CE:AMP"%/:GXT^H()&^B1#PFXGG*94G4,@H>Q^:F%O#K4,@6("@4>7Z[5Q'RA$(;7?R3U4D?32PI]53\:> M7(>]ERPP)%AZKDR.1&F$1S3.1[DRQ!9
(K[$EA=CA4 GCH3/V-&' ? T&M1W M?G^ /R1>H)482("'S+HA)@GM/F8ZYKP,39-FN_O]H[]NKZ]4#YCGG^(;!A MS(XX:[W>:"N-V2/PRGFX+7D?6'"M+?!S46;>)RE6PLX'TQFM\E>D'CITJKGS
M9\].)N)5ZYE(W.I35 $F_-+H.^ +O/,;Z.@M2-T6SH=V%> PO#40SG);6,J\ MR'+2L3+CS_NUC2X#?%_@F".#3LM6P#U. T\'IY-*COPK,G(G@' M\W9!UW$4]I5$P*O.,KC(N=#8A]Z(&
<9H6<"MDSII2))1 M7"=C(%R=0TO<$U0'_O"DQW--& 1 M7"=X_W(\+V;CV6PF0B6YJ'Y!!A="'>4]9XYGNV/YH/IO@/]I#EI&HF*H+5U6+ M.R0HK(C*KK0\X(%LL/U6XVY%(,:CQ(5J6H)]OO$X#
M%&Z%8A5S+?Y,3C%YUHM)I08E)T,HGGA=/4\%:'(//W/B2 MS<7XJ.G)?T5Q\0]1U.&.#8\6R\F3P<7O VJ<+-2!;],8,&R#R"-4X,E 7RZE MV**82ZN]X%;I4&UTW*/J6Y87-
JU#6VN^7PJV95V616N888%+(.BZ')):\2%'=1N.?7 8@RM.@;@1L *OVJ MLYN#E0_=14$!Y7#/EQSE%2G5X-!?4D!#5F@UM)M)=O0V['FNPXWJP VE*Q*
MJC[)8O8#\UQ,08PC,G#Z&1+3XOIT5LPM5%^\3+"'"&1^%@SZP/Z M,K\E#]OSB_Q:>EPO@C"TQM'9Y.G)2/C\RLV#Z)KTLERYB,MM^JQ(HOKP!JRO M'5X9W8 5#/]JN/@;4$L#!!0 (
.!9%GZ[2^SS00 'P+ 8 >&PO M=V]R:W-H965T&ULK59M]LV$/XK!Q4H6B#SBY)V66(;<-*L M"X8.09QLGVGI;+&A2)4O!*EUC^TW],E'I>>W2DS-*EH(_;Z06NI!" M@2,,I)'T#BKQB+!&U$"%:
(0E.ZDCL"W)&JF/?17?@_8?E\N;^#@]?P\D1&3MT[V]%B(6!E>7%U=CF 9B9_VA_QUSV4!K3Q%*I0 MH:22*=4Y2)W$,*H*86Z,\61*$2Q^'Y)+L=X#DXYDN=0*:4M>]N,(KE/FII&: M 2E&+33I(2\?
Q;"B_$I"D,K^+O'A1'UE')6YD@75V2*Q)5*JS;((ENJ]?1]W M4I;(I#06Z!Q);Z0E8"..DA6;8&WV"WY=WF/+SSK>U*4>QJ0B(I-!%<$;1U)90 M)UE E@58\5[7:[3]9!^US'U/3E)72%W*0K!
<,Z,.E_9RC8!/#0DZ=V4;9H_" M,CZ7Y!.!)/QIAT]6,5N]!T/FS[W3T*\IA^N;X(--@"FC _/P8WD&<^JU3) M3/F,Y+XFWZ]!IT,H#@6S[D;N10S>PM10S!@I\:[2C&>"A:76@7QN8]<# ?,1
M!=/)3[__4!=R^KXLQR.2A'X;J<27?7K_HT)TD^-;N, ?*=@=G\2*YF[OR-3! M'1:5-LIL:?*N=3&*Z4NRW56&-<+L-
(5P84U]+*E[CV^UHU.VR;1TFQEDIZV65NH)2N4"P8Q(IUDN,>\D@Q>&L[13C8IH?(M6'Q$'3#:\,A2SS@H@TW*A0.]3G/(("NQ#%/(T[44\>!&5*/=QGM?!-4^78[ZK_W5CG M#QG8=-=++]XT\7ZU-
IYN:_&QHM%'RP:TSL=#]\(!^@OWXF]02P,$% @ M X%D69P[D&$"! _@H !@ !X;"]W;W)K7NX?/<'>F;;;7Y9FM$!P^-5':>U,ZU9VEJ>8T-LR/=HJ*=
M4IN&.9J:*K6M058$IT:F>99]3!LF5+*8A;5KLYCISDV\-J [9J&F<<52KV= M)^-DMW CJMKYA70Q:UF%:W1W[;6A63J@%*)!98568+*<)OQV6KJ[8/!GP*W M]F ,7LE&ZV]^01&GWN\0"D]$-
'XWF,FPY'>\7"\0 .\5?HG#U/#E-H,"2===+Z.WOV.LY]GA<2QM^81MMIY,$>&>=;GIG8M (M%;_LH8 #@<-I]A.'O'?(^]X4&!YR1Q;S(S>@O'6A.8'06KPJG)"^:2LG:%= M07YNL8[)
%W"6E1*E((SY6#)N>Z4$ZJ":RT%%VAGJ:/SO%?*>^Q5Q,Y_@OT) MOFCE:@N_J0*+'_U3XCF0S7=D5_FS@&ML1S#)CB#/\NDS>)-!_"3@3?X3\1%[M^C2VOTQGMF4B,G[N:4(@S-+&Z MT%
<74&TX#9HA@(A!8@0U<#;-Z?Y>'P>OGEV_GIMP8$U5*HCBQMLM7% #Y%_36"-!X K1U3!9&PL-+T@7=]6#\OUZL^8.]!6-L1[)-N=ZV/X."W M7-\-;E_U*!S_(3LY&M*%5: <@^BAWMWJ5G#
(3[/W9W#5M,8S# &G1$4SMI$(M.\]+8;G4MC/[C&YKP6N*YO=.T"K%WPGGRXP 4%%E4W*-U@)I;P$5M(UV"=\?+Q+. 6)$N[O M2#.X;86KJ:!*(D1@OF!>AIH>!3<@8_D(S*?9UP]!-
L)1QB/S"]VT3#UZXKPS MAK21,=XSV3&WNVY1$0W)R/9))&PIH68DDT %1?[EN^&5&93!X"'"V(U][_N# MVJ-R&LIH?7=0&I^&TKA27#<(M^R!9F\>.\,OS%"H+$@LR34;G1PG
M8&*W%2=.MZ'#V6A' 5(8UM2@HO$&M%]J^A/H) Z H>5= _-02P,$% @ M X%D69_@+>QV @ T04 !D !X;"]W;W)K&UL MG51M3]LP$/XKIS"A32K-:UDI;24*0^,#$X*]?':32V*1^#+;I>S?
SW;2$"3H M)+[$OO,]SSUGVYQC(_FH2D0-SW4EU-(KM6[FOJ_2$FNFQM2@,"/"6RV<[TZN%K35%1=X)T%MZYK)OVNL:+?T0F_ON.=% MJ:W#7RT:5N #ZI_-G326W[-DO$:A.

F0F"^}BW"^3FR\"_C%<:<&>[";(@> MK7&3+;W "L(*4VT9F%F>\!*KRA(9&7\Z3J]/:8'#_9[]VM5N:MDPA9=4_>:9 M+I?>S(,,<[:M]#WMOF%7S\3RI50I]X5=&QO&'J1;I:GNP$9!S46[LN2N'@:
M6? .(.H D=/=)G(JKYAFJX6D'4@;;=CLQI7JT$8<% _91'K0TI]S@].I&/*'0 M)#FJA:\-H77[:0=>M^#H'? 9W)+0I8*O(L/L-=XW0GHUT5[-.CI(^(#-&.)@ M!%$0)0?
XXKZZV/"%'ZNN!2=O@VT[S%7#4EQZYG]7*)_06QT?A:?!^0%I22\M M.<3^/VF'P=])(R1C&)"\VJ=DND9IS(!RT"5"3I5I/RZ*.1P?S:(@/O_P^OE& M&$K:*B8R]04N-
)A7TUAO4/9/9[U7F';.T#ECN.:"FS\U@X(H4SW4)YB.@BAZ M99]-S^`2ZH:$]0D:)K4"D(\^U^ D7)XVD%-4+1YB,PDDR-"?)#'Z09A7PP<6\ MY(C"43@']3JBT22:[AUOO; _:+,:9>&&BWLK=!MQ_7>?
EY=M&WZ$MX.NULF M"RX45)@;:#*>3CR0[0!I#4V-:]H-:3,"W+8T,Q>E#3#G.9E?H#-L@GZ*K_X! M4$L#!!0 (.!9%EM$]5'D@8 !@7 9 >&PO=V]:W-H965T0<9-7^4@\.(V9>D@]/WQ(.-
"]DZ/'>UU!@<.;SHEQE?RU$$90 O;9);[*"QVO,(M8KD4,!'5W0ZY54L26D>(, M;F* I *56*'X!NXPX6@*;A&8FLBRX$*S:YX6P'BF"HE65. B 6G%0G RD)<& M.B"-
V\A^8DKQM4@1&0SQ%!F^N[IE!U'0*8#OTA1%HJ4$: 8FCL>I29DFF++ MZK3Z[/&<]2B?1;H7#-Q(: .5E!#52C%-U+3L(5*L8*: MHP;J=_]^=A4.DL.&,K<,T]-
"=H4VU#G:V3> !HWUO5F_ULJ8!TN?9TI;\8V[M6EX3GW.M;X5<;KCBN,B*U$5$37N'@?/$!;(J#)ZY> MP$)(8>$PQ8])TG7>\RIJZG40LEO@>D,X8(§7#*>M=13XK=4TFI+Z]$&] MABTAUP [W(Y\!
]'6ZA^..M09V/VW'V[,"YX')?IV&8*PJZ!6^&WT.K]C00- MJ?.568F\989_[WSJWPAU]OT.>>*%LZXE8>1-_ #/[1KO+SGE.\0KJ5*UO&UX MICL$!=%609$W#J;=(_.B:<@NBBNK+%;6[T7#
<.Q%LRY*$"),T!4Y]/Q@PCY* M7H;V[XW<2\VQ!/,,OI_U,V^TY<1V14S)72<&WE.3=BW8]1O,N@>T,R:1]](Y M9'>^W\J8*.QYT]G+<(]MQRP(855UWW_BY+^ N*JH@>NHD= *OI_6-']H%W1
MPSOU?3+Q?WU%GX7=! S]T0,*>AOUOH0?*=S!PPKWR!L%W8P.1]X0_FSA#D?MPGW7 M*P?DO$GKBGNGKL -&H*=#;4'!WY_5K<->'/7##@V#E5#8E<:@&5EGPS4)V^[M1E-W0-77:5?V-
ZA\U$ +^<]U M;Q_&/;P':KP&[(LTQ$HG+A6P\<2F$;$,3S%*-6:[+*#/7A6VT*X3[/BG[*UH M$=N?]7MVL3G=G[R/K2)K G;8_K0>I+<2T>)V]23"D5^,6:3SRB3 1 MDX8.8-HFX2T?&VT-?
$&]>E.EIMX0O^27=TK407TQK F[VGVRQ/7Y.6@:!.*Y M*6QDN90%PM7]+Q-9CEUXADF-U1;]4EALJ;]1:E]AG^N@$12[;$XQY]R*:VS. M:T*.[3\%1P(FUN*J=/&K^<49FU]\9.]4WTT<#GV,!%
(Y])]M.FU3E8([HXWW MKKU^0I#_SMV5F9Y3%A7'1) @9EPXX,5MS59*HNIH&D8 M\04SDMY)1W1,A-H:"DDF+W"KWY^,>DR7<]AR857N M9I\8?WCE<(\KP(^:)@9\OU#*U@L2T
S#3 \&4$L#!!0 (.!9%FI/8-- MQ0(-8& 9 >&PO=V]R:W-H965T @4D^C*MTKI595L_F^0@41,[LQV@_W[G)*19H6C:OL2^QW>/ MG_/9E\E6R"
<5(VK892E74RO6.A_;M@ICS)QKRH:R$S)@F4ZYME4MD41F4 MI;;G. ,[8PFW9I,2NY>SB2ATFG"\EZ"*+&/R^1)3L9U:KK4"!)U@SR8Y M6^,"]8_\7I)E-RQ1DB%7B> @<36UYN[XLF?
\2X>?"6Y5:PXFDZ403\:XC::6 M8P1ABJ$V#(RYAFAHBDO&KYK2:+4U@>[YG_U3F3KDLF<(KD3XFD8ZG5F!! MA"M6I/I!;#]CG4_?\(4B5>47MI6O.[0@+)0661U,"K*$5R/;U>?0"@B<-P*\ M.L
K=5<;E2JOF6:SB11;D,:;V,RD3+6,)G$)-T59:$FK"<7IV3P,98$1W.RH MS K5O-;$:M;LL&:XK!B\-QA&<">XCA7<\ BC/^-M4M-(\O:2+KV3A O,N^ [M'?
"SV]2]$L^_S]2K!AZQQG,PQBKG(4XM>CF*Y0;M&;G9^[N3BAK]?H MZYUB_RM]IQF^"HTPZ,)KI@; /1 *>DY*$R16H&.$E4CI729\/8;SL\!$_(M_ M'M_?^2[;!]$B XSC'4#^ *RI4$I)BI8LHH>-_[>;
[HT-LX,_"I>1M\BP4 M@F:[PPT&P2$6^/"-BBI;,ERG]W(P?(8Y?;;O6: M#.6Z[*CF8A5<5VVG09NF/:]ZU8M[U?'OF%PG7$&**PIUNL.^!;+JHI6A15YV MKJ70U ?+:4P_'I3&@=97@BY^;9@-
FE_9[#=02P,$% @ X%D6=&N!](- M P D !D !X;"]W;W)K&ULQ59M],P$/XK M5D!HD.D\,.R'R@^M!:?C+EK;2RHO@PZ9I&^RSFUP;:XD=;'<= _YZSDV8IM&4($%]B(

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}GOF FS9S+<:+9-!L^SA,U%V+\P$#M#+9"YACY6&$&I;U'QXK@T.N#0XFT?B/#KU%$L/1!"IO(XO@0^RGA68*_*FX?"@FR;X^WQ, M8!'5*SGGL;LO920/l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l;5]SFO&2O,3I>W\(N]=E-8%!.8% /E!:S%Z,(BX2W^AXL#PO+;"-(8 M-Z%3):XSKOR ?H_9YJE^V7/K0M=R+X<5%,"RY&8Z2O&*.D:WG'Q5H^3.$3UX&'V.()9 (G@,"E^P0[Y*5"]#WQ M)SB II6[9*=C!Q6\0\8)R+KO-ZKB,8)'#84->^K9TOVB#N38CN%CVS,0-HU MH%P%KK?B.3,,K>+$R3O\^,FRXEXS1B2[="}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|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|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

M2/L Q1[Q>X 34DR#L(\$&O$"=).)'=NC. V%??TH"[$917__(QT$PW.);M2L0,91* M7RXFRE1C@?
@.3C^,7G;]B)SZ87C>__IS=IR70XR,8'0<.S]=A_1$OVXPD1"] M+B%Z_S0AZA08IZPL(1]+@=-T_Z? RREP);)G?<>@K)2U "&1ID!D00'
MW@R]JX5Y+*&BV2M'*G.*OU05>8"5R);UXJ+_T@NGHA;OXM;?SINF7XX_JCV M%2"=J"1TT6N<2OL48E+R.&O>-#&7R@3XEO-$(LGS9"RPI_?[#@-
[/%R'83X9 MP)?#]?+,Q7]_.N@(1]0[BTT<4-+W#1_[7C]ZM?.Y#D5WA[.2?[<'Q0$Y*>EB MVG/S4(?=:;-(>S5%OP@NI;G+-IGJ>S&FE)Z-
/7+FL2%VP[,LXV,GZLC'/-GN M%48%B&U3_DGMA76IVAJI0[L*\Z8MK$[+V_+TGHFM3I?Z%VRT*+D*].TCVI*O M'2A>-676FBM=M#7=5%?)
(,P"/;_A7!T'9H.N[E[^!5!+ P04 " #@619 M]_CGO=0# !U"P &0 'AL+W=O8XH5WQHK96BV[M0:X6HM5E4<.#)*]M*B[?;] 4^Z7E6L>% MQV*7:[-@KQ8-
W\$:]/?F0:)D#RA944&M"E$3"=NE]2; M&$\V0CP;X2Y;6HXA!"6DVB!P?+W +92E 4(:?Q\PK>%(8SC]/J)_[7Q'7S9< MP:TH?Q29SI=6;)$,MKPM]:/8_PD'?
SJ"J2A5]R3[?F_D6"1ME1;5P1@95$7= MO_GK(0X3@_B< 3L8L(YW?U#'\C/7?+608D^DV8UHYJ-SM;-&[SWNSH5%9 'D&2=+VR-1YB-=GJ
N^GAV!FXA'P3M. &[81< U-%?$5E; A%;@DR;5O,N@U'4 M.9@D+%+"ZXQD1=EJR$B-3A6]4PTZI^=$U$L@^\!>0V!?[TQ7!
MCJHT,BKJW4^.,H\F<4"]T)]3^;%'69C,J6*?4<>?43$:N3X-(O\LGU9AQ+4X M9"A<3,:?\7W* I^Z43C/*J81FV'E4R=RJ!//N,DP A$-PVAZ&R.!#^2F*YLQ
MW,X5=$C)-SP)\/CE^"]B]"Q^1"UPB&KA\'ZZ[1" VU+GA9OO7W M@G\^HB!M9:&+TUR:ZQ.7#_K?E_R0,S.E_ A*RR(U]XG_WO29M'6AU6#BA2YU M)]
<7^32)V" &6,-N--Z]FV"VHGPKJ@H;>(\H&M/-)Y@FI?T1TT>.P22!SNGQ M_]4-974*LUQ#C[J.=Q(AEXV1PLB7JBG%&QPAFU:F.4X]I"EY M/;J=8"\+SD*?
DY^$YN6P&D<>#<)X#)X34#\9";O4\1CN8!./(JSRH9;FBL:> MC$(5R%TW\"EL4FVM^ZEH6!UFRD_]*#5N[P?2;USN"KRG$K9HZEQ%6!:R'_)Z
M08NF&ZPV0N.8UGWF.!>#-!M0OQ58A@?!'#!,VJM_ %!+ P04 " #@619 M>9069'D" #%!0 &0 'AL+W=O-#X@571CG]WDVG@X=F8[%/[];"?-.K5TVI?8
M9]\]]YPOSXW74KWH$M' 6\6%G@2E,?5E&,J\Q(KJ4UFCL#=+J2IJK*E6H:X5
MTL('53R,"#D+*\I$D(W]V4QE8]D8S@3.%.BF]JAZGR*7ZTDP"C8'3VQ5&G<0 M9N.:KG".YGL]4]8*>Y2"52@TDP(4+B?!]>ARFCA_[_#,<*VW]N
J64CYXHR' M8A(01P@YYL8A4+N\X@UR[H LC5\=9M"G=(';^PWZO:_=UK*@&F\D_\$*4TZ" MBP *7-
&FR>Y_HI=/:G#RR77_@OKUCDNE%H7]QH./E&%QSU8!P:F\7YAGF'.&T1HP\0O\"C%;4<"<*+/Z.#RV[MGF*TH3B-#@+.L3Z%F PA(E%R
"_N2XX]7OQ_)>^KM 5*]@,YO5SJFN8X":P@ M-*I7#++CH]$9N3I ,^EI)H?0L[G57]%P!+F$O*1BA1J8 %,B(%7BLU48<$87 MC#/SOH_\8?CCHXN(Q%?
PK_7DP>64C::BT(.=Z[L=*D -W&*.U0(5Q"/?MJCW M_P2C>$A2 C/Z[IX=K#+[J M5DQHX+BTH>3T/ U M4.C-8RLO5
7TEC9^VUIYRPJYV#OEU*:C>$2]),[^PU0 M2P,$% @ X%D61RPQ-K[P *A0 !D !X;"]W;W)K&ULM9C;;N,V$(9?A5 710+L6@>?4]M 8FVPN=B-
$6_::UH:6T0D M4B6I.'W[DI(B6['"K@/VQB8IS<^93SP-9WO>0"(-%+EE(Q=Q(I\RO7%5$" M&18]E@-53[:,9UBJ*M^Y(N> X](H2]W \T9NA@EU%K.R;
<47,U;(E%!8<22* M+,/\GQM(V7[N^,YKPP/9)5(WN(M9CG>P!OF8K[BJN8U*3#*@@C"*,&SGSK5_ M%?
I#;5"^\2>!O3@J(QW*AK$G7;F+YXZG/8(4(JDEL/I[AB6DJ592?OQ=BSI- MG]KPN/RJ?EL&KX+98 %+EOY%8IG,G8F#8MCB(I4/;/\-ZH!*!R.6BO(7[>MW
M/0=%A9 LJXV5!QFAU3]^J4$<&?B#=PR"VB#X58-^;=!_:S!\QV!0&PQ*,E4H M)8<02[R8<;9'7+^MU'2AA%E:J_)U=]!+:EZ2I2=7/S LN" V!;=%$(]$P)A
M&J/['#C6'T:@BQ D)JFX1%_0XSI$%Y\NT2?D(I%@#@(1BAXID>*S:E3EGPDK MA%(0,U['O(";>Z/NL(QFZ\A[Z&^U]5[*YI^\Z7ZI5[_HU^J
MP\6;2G+0+:G7E"N1XPCFCEHT!/!G3:F!K\Y3GM=, MJHJ4I4Y;I"8-J_A(?H];9?&RJA:;4VAR# \?
M_E9::]KB:5,MM*76YGE('7SC[P'!I/Q\&0/7)H=.!O7_Y$=^(?T MP#?G!^7QO]I6.Z&5@_WMM3:/ Y9@&]. SZ>+]7";]*2T]%C-0FP MI5;1,>7J]NT;YCOB-
4H!2VRM3K MC96CO+J8JBJ2Y>55S89)R;*RF ".@>L7U/,M8_*UHCMHK@<7_P)02P,$% M @ X%D6;&4R?I= @ , 8 !D
!X;"]W;W)K&ULK5713MLP%/T5*T,32(,D3M("2R.-5F@\3$(4MF>3W#86CF]FNRW[^]E. MB
H+W1[VDOC:]YR<8_O>Y#M43[H&,.2Y$5+/@MJ8]C(,=5E#P_09MB#MR@I5 MPXP-U3K4K0)6>5 C0AI%D[!A7 9%
[N=N59'CQ@@NX581O6D:IGY=@<#=+(B# MEXD[OJZ-FPB+O&5K6()Y:&^5C<*!I>(-2,U1$@6K6? EOIQG+M\G?.>PTWMC MXIP\(CZYX*::!9$3!
)*XQB8?6UA#D(X(BOC9\\9#)]TP/WQ"_NU]VZ]/#(- M&7J67 >D I6;"/,'>Z^0N_'"RQ1:/\DNRXWG0:DW&B#30^V"AHNNS=[
M[IO=A#Q"G[P!H#Z#_"DAZ0.*-=LJ\K04SK,@5[HARV9;-#?S>>+1UPZ4[Q:51
M=I5;G"ENY!:D0<5!D^,%&,:%/B&GY&&Y(,=')^2(<$GN:IQH)BN=A\9^TR'# MLN>_ZOCI._Q+:,](GTB-*+I"'Q^&+Z TL)C#T]>PT/K=+!+!
[O4\R5_MSOF MI0.GXV!74)>Z927, ELQ&M06@N+CAW@2?1YS]I_(7OE,!I_)(?;BFDMN+T5% MUHCCQ];A)Q[O2GU;3"-*\W"
[;V$DZ6)Z,22]DI8.TM*#TN;8M"CM*9"6*:.) MO5>^U$^Y/&T5EJ!']7:DV9Z4.(VS](W@L:PL/1]7G V*LX.*[!$P8>O@X-7) M_M@J&L?3R1M]
(UDTH],W^L*]>G:]]!M3:RXU$;"RN.AL:FE4UY^ZP&#K2_P1 MC6T8?EC;E@[*)=CU%:)Y"5S7&'X2Q6]02P,$% @ X%D6>T_!S2]"P MO88 !D
!X;"]W;W)K&ULM9U=<]I(&H7_BHJ= MVDJ])@%]-> "UJ7)0=V\N9MKO-C$ M5?VP>!R6VT+$R_V@33KT1B,RW,1)-IC=[I]
[*&:W^;Y*DTP\%$ZYVVSBXL<' MD>;/=P-W\/.)WY/'==4\,9S=;N-'\4E47[8/1?UH>*0LDXW(RB3/G$*L[@;W M[@TGTV; _A5_).*Y//G9:3;E:YY_:QY\7-X-
1LV,1"H658.(Z_^>Q%RD:4.J MY_&_ W1PU&P&GO[\D\[V&U]OS->X%/,_3-95NN[P63@+,4JWJ75[_GSO\5A M@*&M\C3P2;)7OZ/OQ_^$"
<#:HY^@'<8X+4' M!*\,\ \#?%N%X# @L%4(#P-"VP'D,(#8#A@?!HSW9KW\=??61'$5SVZ+_-DI MFE?7M.:'O;_[T;4C2=:4X]>JJ'^;U..J&
<_SY7.2ILY]MG0^9E6?/+6^<7)\F$?A);-\[_NA7 MQQMY@68^<_OAOFYS_IXZ_7QJS#P\$HMZN/OJ<&ZO[AJL\(_EZ.]Y_KERC'7E
MJ*NU%UZ@YS4'\IMR&R_$W: ^4I>B>!*#V3__X9+1OW1&(V1D:1,(:$<1!, M*9?@6"Z!B7XL%UUAO(PD^Y'-"?EIYKLC4M?XTZGC1GY?
QZTD*5*264ERD*3B M47CT*#1Z]'&SC9.BOGJIZDN71?Z8)7]IC_H?7C#AR::,6F89A?J:A811)(PA
M81P$4ZPG1^N)\6@>B562)95XE]:7F\OZLN%X/(_WQ_.;71D0Y $="8N0,(J$ M,22,@V!*Q8R/%3,V']"+O"R=>5P4/Y+LT;G?Y+NLTE7)N'.P"(@_G;0.&$:Q
MOO9;25*D)--)>J0ER4&2BF&3HV$3HV'WB\5NLTOCJMZ_:[>**ODK;M:8.L\F MG:UQ/7_BMCPSZO7US$J2(B595W(:^F'+,I"B8MGT:-G4:-
GGO(JU5TS3SLS] M8.2.6_X8X7W]L9*D2$FFD21COWW%!))4#')'+[5F2ET/KF=Z\31NT%[^%%Q/2B2$/R M)NU740W*Z["8>>-Z'PZOD0VY,AQR
^-9E.VJ72'.7I:ZR$!F#J5%4!J%TAB4 MQE$TM59D2.6:4'ZHF?'?>_'=1Y5]%X;C..R<2"[%I'OBN_L#;S:NF87LQ8U;M M70T6DA0JR:
TCJ*I)LLXRC5F%XW)H=9*TET3C-V@[24T3++2I%!-!J5Q%$TU M4R9%KCDJJLTD6C.[H8E/PLZ9%1H-66E2J":#TCB*IIHI4R37'"/59HZU9G;3
M%)\$G:,L-#.RTJ1030:E<11--5/F2ZXY8*K-G&C-U$4O?F>E @V8K#0I5)-! M:1Q%4ULC9!3E&3.+V>>U*$2\JD2AL_0P6 E8)X'7?I?5K-'74SM1"A5E4!I'
MT51395#D601%6C^[(8DN S;C>_MI)4JAHDPGJLF!4:*J43(.\L[$046\%%F\ M$=K>%_/@OBM7*"V"TBB4QJ
TCJ*I)2(#)_<,M7_O0(/VC,%I450&H72&)3& M432U;&0XYIUIG=*]T_ZK\S%;'IHVM)43: *(3FII5NY=$3::%*K)K#0Y2E-U
M4$96GCFR>H@KD56ELQ79LK90ZQ>8NK M. M$- >+"@M@M(HE,:@-(ZBJ64C\S7O@E:LLR>(<>==)G?:CFO,PKT+PD*20B69 M1C)H2W*4I&J?3-
0\W^35]GT^BB!_5-]J=!U$DN;;/ M_PS6]9P?(BYT@V.;92FZIL%7USJMBG:=OO=EWY;GO%;];K[9N% M)(5*,HVDUZX4CI)473NY-=+<6?9J:.]W&\ FG;?
5S/#>%EE(4J@DTTB.Q^U(M!B6I6B1#-1_2<>9#.\Z@M A*HU :@](XBJ;6BHSO?'-\]_KN"'9.(9K=&9K% MV4A2J"332&IVYVLD9[Y,SGQSOUB]-FH^=.-
)=)=%6N.@L1F4%D%I%$IC4!I' MT=2:D;&9/\:OIWUD/#6'TB(HC4)I#$KC*)I:.3*Q\\V)W<7K:3/6W2\>M74" M3>PNG0:%3H-
=.@V.FH;JOLSA?'/3G/U*>JI9U7IA^_H FJE9:5*H)K/2Y"A- M]>-'9 86F*.9/BOI0-.V-O+:=!J9!?L:9Z5)H9I,HSGUVE=V*$G5-YE;!1S4*101:91U.S,5_F0KI-
/Z3+WFLWWGV,H M"B=>+)K+&NWJV:LSGK]%'1OO.PNG\QBO8O 0I)"9)F-)$=)JI;)J"PP=YCU M6CQINKRZKD&#+QM)"I5D-
I(<):FZ)F.JP)R@'$_FA4CW=I7K9*L_HT/[RZ"T M"$JC4!J#TCB*II:+S+6"*_27!=#^,B@M@M(HE,:@-(ZBJ1\;*[.U\#K]96>P
M[NCU_C+ST+Z5ZHC]LT=9GQOFZQs*524Z43#H/WQA!PEJAHE0[40TFL6 M0F,U*"V"TBB4QJ TCJ*IM7+R$?P7]IJ%W2XL[4Z-_>1]*U$*%64Z4=U.?
8T4 M*Y0I5GBNX^Q)I/FV/FE68K'.\C1__*U#=IJ!J5%4!J%TAB4QE$TM5AD?A9> MH=4LA+::06D1E$:A- :E<11-K1R9X877:34[@YT85M;0].[B>5#H/-
B9>4P- MZ^IKI'*A3.5"4+=9J.G"\C7K:FC$9B=*H:+,3I2C1-4OU)&A&,$UG)%N(Y9/ MVO>BSUV-TE2-DTD6N;#CC&CZQ_R)UW8)&EQ9:5*H M)M-
HNB./M"_ 4:*J33*W(I"^,P+M.X/2(BB-0FD,2N,HFEHK,BHC%T9E1-,% MIMFEH4F9E2:%:C+2_4X![2Y]C:",R*',G.D^R\O*R5=.4:^MLYUXKW4,FI)!
M:1&41J$T!J5Q%$TM%)F2$7/S6?\/RB+0SC,H+8+2*)3&H#2.HJEE<_(EE^;, MSO8;7PX8Y8V[SD+*YD61YD6=KW*A-B]BYDWK;<0U\C
B\S!RII]LM4KS/T1] MM+]_N-)3O_Q7C!-K'!J5%4!J%TAB4 MQE$TM6QD8D;.)&:&KQHW#^U=(- L#4JC4!J#TCCI!GB^ZYZ<\EZ<'Y9K(:HH
MKN+9[484CV(NTK1T]C>F-$>-DV?K)<.J^;J+FWMO,.P_\&]F;N:YR/WANZ? M'TK\['8;/XK?XN(QR4HG%:M::O1^7%^X%$T2__-!E6_O!N[_^9I75;[9_[@6
M\5(4S0OJWZ_RO/KYH!%XSHMO^\V9_1]02P,$% @ X%D63S%3,TF P M$0P !D !X;"]W;W)K&ULK9=M;YLP$,>_BL6J
MJ9/6\DQ"ER"U8=.J;5K5M.MKEUR"5<#,=A[Z[6<#92FX*(OZ)K'-_>_N=\;. M9;*E[(FG +M\JS@4R,5HKPP39ZDD&-
^3DLHY),E93D6&6K%*A%LQH4N(5 MS$'\8*%ES0?-&+#/(25%_XUU3B#V![;TA M=?),X<'0:@\ DXY_0&;]?O^CTY!,Z0:1 =RE='QZ](S=EM=]2
M.6W)G,J?>V#)=/6H/7AZ#^HL7_2)S UY&'EP#9@1!_V('U15>=]W06OY.S M5Y5SV\JY0]ZC!\P8+L2SKF*U,JB4ZK+:1'88VA-
SLU^)OI'C^J/71K&TWCD MM$:O,O?:S+W!S'_"F=(OOTHH067=PHI5CJ*VHN_%SMTNA!]F\#NV,2#V1RY
M2W[+Z@^R7A=G0FX3)T(>^PT4@C+MCOD]#ML/_YLW\BSNK"#Z1P)&[2PP2#L M'<,;R'1X01_/LJP.GL[('7?
X!C,XDF_4\HT&^69R@23RW>5BO2#ZRVK4@W#= ML .JL0G<#N=@)D=RCEO.\2#G'&?RQTL=T#4')/!.!SKN[U;0V:R9QF;N;Q3ZW>,X&/]
(,MOZUX]8PP>2"]P|CXUN M_UX?6>/N]FFL_+!;AG@XA_]E-/?:+]4L_\1L10]._EA*]];Y2-:;U?UG/1&T MK#JR1RID?U<-4]FS
U,&\OF24O$R44U>^R\@^@M02P,$% @ X%D6=K$ M#]_: P $1 !D !X;"]W;W)K&ULK5A;CYLX M&/TK%JU6K=09KN&239 F(6CW8:31I-
T^5'WP@).@@DUM)VG__=I F 0\E*;S M,L'FG//Q'7^^S>Q(Z#>V0XB#'T6.V5S;<5Y.=9TE.U1 =DM*A,6;#:$%Y*))
MMSHK*8)I12IRW3(,5R]@AK5P5O4]T'!&]CS/,']@@.V+ M*?"Y23XUPSM5/' M8[;=<=FAA[,2;M$:\4_E Q4MO55)LP)AEA$,*-
K,M3MS&IN&)%2(_S)T9&?/ M0*;R1,@WV?@WG6N&_"*4HX1+"2A^#FB)\EPJB>_XWHAJ;4Q)/'\^J<=5\B*9 M)\C0DN2?LY3OYIJO@11MX#
[GC^3X#VH2FDB]A.2L^@N.-=85$9,]XZ1HR*)= M9+C^A3\:(\X(0D=-L:]"U24X+Q#LAF"/C> T!&=LA$E#F(PEN W!K;ROS:J< MCB"'X8R2(Z
2+=3D0S5<%5L8G&%966M.Q=M,\'CX&5(*,?\)'A%#](8>!O@=O08;!QQW9,XA3-M.YB"SY>M)$6=11K!>BV.">8+YC M8(53E"KXT3
_&.#K(N,V;>N4]L(:%%RC\A;8Q@=@&9:C^)E>+]M2N?/HJ_^ M+'H\3(]0(NBFBG[AI=V6D%WIV2_HW9,#$FL-ES6RY]) ($W! R7I/N&@K:^[M)*%
[F(,OCR3/@5@5C@+V555*=31''4VNM%-6P@3--;&45C6KA7^],5WC;]4X MOJ98])IBJ]<4BU])[&+\G7;\G2'U<(&V&<89WHHE/h>
F4%GM&Q3X&R7=_K^#>8X97^ M>:U_WJ!_8O?\Q33U^B7@V-V*4X#<2=>S,4JK,4KQ8$Y7.N:WCOF#CE6[UGF] M-
2$^B+,9I6+34YGH]V=D$'0FVU(!\KU.>49CE%9CE&*_MR!:]N2Y-B_,"5IS M@BO-P03?#!@4]+_8<3H+S5(!\OQ.[M$8I=48I3CH&62Z9Z
+@TSC^71M#%KT MD7!QYH$O&*4\2!O]3; _!56H_AP=^+.CJ@$B/<;0OBI(0.T_P4(_P=02P,$% @ M X%D60!6W"T!"P 49H !D !X;"]W;W)K&UL
MM=UO<]K(K]|TN]ED M9I9Q]CI9FU7QE;LD7<9Y\6EZW\W6J8FGVT'+13?H]4;=93O?=<;7V!L^IN/K M9),O%ENXV\S@QV:^"YQ@:":O
MO<#_V0MZ0;]A>]Z[A[_=W+_V>L>'A^[A_]BLG+-'[N'"W!;#@^WPH&&X< __M;-;%QE]NA_M-OXL3AO=[V^&#AN'*/?R?
R'C*3/IC.^&]_\4>]OS<%B\1"$HM(_M3)"8)#%%8AK"K.@.=M$=N/3QK\7G7G+G3;81_MG+9\47BP;OXP+M-TF**X@O>)"ZV:IY_;TJ[<]*V:2>QD,0B$A-
/V&B+E3A+LE#9Y*KG7#\8R=<9#G)XT5Q0W'+?9P; M;YT609ZOR]N6R:9Y-^VV" M.W+O@I/5_2^Y29?%Z';QE ZQ[<-)8F%)!:1F" Q.7J^:
[YH2K@B9]409H7R M8A?*BU/VIG?%(_RB>(SWDDV>Y?%]6C[P']][.LVV026QD,0B$A,7S_:>1Q[V MR5D5B6D(LX)ZN0QJI3.H[^)LGGE/!]6\5W'FQ=[:I)-
B_=!TB."=$VN;4!(+ MG["KO1ST7O=ZOAV"B)Q2D)@D,45B&L*L>%[MXGGEC.?GS6UF?M^4SZ*BAR.'
M!IQ"VTR26AB8D)$I,DIDA,0Y@57;]7'X;MG7UIA:@6H9I -8EJ"M5TI>T_-^P?'OVPDQO4R0W<:X??Q*?&4#J'M0XE MJ86H%J&:0#6):@K5-
*79P:WK,/_\/LQ'"S%4"U$M0C6!:A+5%*II2K-#7!=C MOKL9:WE@P:VUSC/:>57:P;&%_O#@\V (ZJ4 UB6H*U32EV4&M>R_?77Q],@_) MXF';R-
H';1MCBA9[EL^,<_NBRX0?_WCUYZS"2 M6H1J M4DJBE4TY1F![8NT7QWBW9TB>O]SSNE87/SK?>V:,>&:A&J"523J*90 M35.:_4:"NFD+SF_:

K1I0[40U2)4$Z@F44VAFJ8T.\1UTQ;\B4V;VVZ=;K1I M0[4(U02J2513P0G=6)5<:%X[N773%KB;-M?Z0IBI2>.%)S:K:=:87+2.0[40
MU2)4$Z@F44VAFJ8T.]UU'1><7\<%:!V':B&J1:@F4$VBFD(U36EVB.LZ+D#K M.+?6.L]H'1 M :/5'*J%]!:AFD UB6H*U32EVU+ND"=TGG
M[#R.O#+83;9.*UKDH5J$:@+5)*HI5-.49H>Z+O*"J_.7$&A9AVHAJD6H)E!- MHII"-4UI]LF>ZK*N[^Q1VBXAW%K;/%?:"Z_E#=%)(U03J";;?R
7O2OKS\%Y M&M!-T)1FY['NW?KNWLVU4O@0?YLO-\O&7**-&ZJ%J!:AFD UB6H*U32EV:FN M6[E^'YBPJTB4.U$-4B5!.H)E%-H9JF M-
#O$=1/7=Y\RLNT1"+240[6PT@[6)T%P^&H(=%:!:A+5%*II2K.36M=M?7?= M=MJ2XEB?X<9;!Q=MWU
M0C6!:A+5%*II2K/C79=T_$)=%:!:A+5%*II2K.36M=R W*+OE4.U"-5$I;U\&E/9<,]@=.4/GU\H'MU"36EV].HJ;>BNTCZF M\]5DOHX77L%7UQ
H3P.\3>/BR K6;;9.(UJ>H5I4:0WYL4,AT&DEJBE4TY1F M![;NQ8;.RF*L5Y/B^7]FBL=VS[W+1,NQ2ML/PN73U4L.7J" 3ANAFD UB6H*
MU32EV2&M>Z^AN_=ZMOA,MY>YF'PO=ZVG7++%[;<.+]J$H5J$:@+5Y N_Y=\W M<5KL@A9-
5^M3Z)9H2K/S7+=C0W<[]D>N.N0F6T<8[<10+4(U@6JRTO8?MRX: M'K84.JNFM*>X=K.9,7D8Y_'X>FG2>_/>+!:9-RF?R|]TRB,"NUN]U-R5UR1Z
M\S;H=(N1]=W'U^OXWGR(T_LBQ|["W!5#>Z\OBO]7Z?Q^MOLD3]8EZ=TF>9XL MMQ_.3#PU:7F'XNMW29+_^*2&PO=V]R:W-
H965TP!3D8S+AJF<6+',2 Q6$4<0A'!K7=G]DNQJ0OO&3P$;LM)&V,F/L27>^ MSX>&I15!!
('4%%C]K6$$4:29E([?.:E1S*F!N^U7]J^I>65FA@6,6/2+S.5R M:'0--(<0KR)YSS;?(#?D:;Z 12+]19OLW8YKH& E)(MSL%(0$YK]X^<\$#L MNW4 X.0 Y[T
-P>DD3,S9:FM,9;8'W"V05R_K=AT(XU-BE9N"-7+.)5AAR58"T[D8F%*IT9QFD,_\)9O9.3#S%)(KY%J?D&,YK1KXZ!UPJYO"[3+< M5#$H N$4@7!2/O<
7]DU95(U$OR"9Q'4>J=TO>)R$J^VX7O M=N/JZAL"G?\())L!1[:ZA,800*P[KGU19SWC\W9V;,?;WZ^-'M.N'=BG#'=2HA;^0^4GFO4-YKOB*8Q%&=
M]%Y5>LWMUDA^I'3;VF9IJU'\#0C15[L^!*X2-@H)Q30@=(%"@/K<:U5<77:] M/4_-DQYK;J?TL/\Y]>04I=5I]^R*$[N2HO3!V2YB6>*V*+ ;]]%*15W5
M1@GC:>V97[Y-=V_.6XJ_T_/:^[K_1^JWM[G??B/Y,WH9'&&NIB!P>UYOW]Q) M*P)SI\C57QBWF"\(%2B"4-
%;5QT5:YX5[5E'LB2M>V=,JBHZ;2[5APYP_8(: M#YFRF7=T*5U\.OE_%!+ P04 " #@61983_PIQ;X\>DZJJ3PJ];G: M^)A<>4%U1"
(5L:X0D7EX$DN1IA7)',>7!NJU8U;"X^+%*R_HOV1_V'8\]$N]*K;)&;(X@D_GA M,7INC#@2&$Z_@#8"^F_!\(1@T @&
[Q4,&\'PO8)1(ZBG[A_F7AO'(ATMYH7: MDZ+:V]"J)[7[M=KX)?/J1'G0A7E7&IU>+%6626TJKTL2Y0E9JES+?"WR6(J2 M_$Q^$Z8*Y.XQE>NHJFQ)?
F!"1S(M?S3OKO3WWX63Z2]S7YMCJ8A^W(Q]XYGZ98S$1MY M6,G#68^!WTU7B)A# GC()CE_K!U?UC3!__EFNJKR1!9$R2,(6$< M!+-
J,FIK,G)>$8<^ID61]5; +0XIR>INU>>W4WJNWT@8!\$LO\>MWV.G93<[MF2;FI"=_$TTX[SZG3-?YE)[?5Q=#KN%-[]IF/I#$HC:-H=A6ZI!P.P#T)FJ"A-
:E<13- MKDR7HD-G(%S<;>NO$K4BAQ+ !JKH32.HMGUZ))U. ,W)VC, MAM(8E,91-/M>6)>TJ3,OOM6B2]:48OL2A:9M*(U!:1Q%LRO3I6WJOC%]78B(
MJ)7Y7HZ0CS*=-F:NN]1O[L902,U ME,8:VG'[H+/C]M$X_7]D9=IE9>I.N]=)(JLO\\RGHV.S290D(JF^X=,;X6A5 MT%O2#>W8L>$KPQAT3(ZBV?
9WN9FZ<_/O&UFX_A5 \S*4QJ TCJ+9=>CR,@7G M90K-RU :@](XBF8OE^SR\L"=>+^M0;GA9R^J#%XUJ,'D=8>"#LI1M(/__M&"
MY$P4ZWHE>$EBM&PO=V]R:W-H965TB1E)_]^ M)*7(;S1G%"!(5[F.68O M8\CH9NCXSNN+;V2Q%.J%.QJL\
(>03RM'IA\@U*8XS(3W^CF,]0)=11>0C.N_Z)-O=9S M4%)R0?/:6$:0DZ+ZCY]K(G8,(O^$05 ;! <&DAFS05@;A.=ZB&H#3;5;I:)Y MF&*!1P-&-XBIU1)-?
=!D:FN9/BE4W1\%D]\2:2=&$YKG1,A""HYPD:()+00I M%E D!#BZ1O<@294%SK" %&'.H5Z8$3PC&1%JV?LI"$PR_D$:/#U.T?MW'] [M1 KTYY*67*[F U?
(8)5+-ZD#&U>!!2<"ZZ,O,I0E1Q^+%-)]>U/3E./ MSAOP,*Y 8PVJ?O#6([;ZI2/NQUV3?^VD]?J5%/3Z^X&W%,9F@?K>MHWUK"P*-
=2>&N=U1GN);J6*@.7@V!6Y4(8+F1!3MNC%X ,V,38K=L3RJLIP0]0 MBE]LO8;N7"ODP!;Z>H8CO16JN;MYVUP!W>F+CX/W
M8_]V4EWD;&&J>Z4OF"U(P25/XX1V MB4EE)]3MNS[XXG&]9(2BJXXT@T98GYS_= V6EKN=;#C4_D4$A]PTXV-3[/<@O M]1U7([M7R4@)E2"L0ASRK?
7.O=FYO@XP,_XA2R6)KQ1;*(,<- ME9_8Z0-TA@*MES(JS""?"Z .^_ M!OA=@-DYNR4SMFZQQ,F&LQ/B>K92TQ=F;TRT*N9\-UR^"VD M*MPUX?
[3<%OM2K\U7K\UGM'SG]%[QOJKWM'J)4?!"'<;%0RX_<@?@R]*GPD>].#!2^#A"@P M!8^=: 2^*'TF>-B#AR^!1W/@X13<=]8C\$7I,\&C'CQZ"3R>
X^FX%X4C, 7 MI<\$CWOP>!'\X2\N<";^NL=?+^,SB:DN;J1L2D1! M5654XY^F*,T96D\,>9X3C(_XIIG.G*=Q[+J+'KZ$X2X0>]*73X0RT>N5 -D
M5C6U5E5-E3D0BN_G_;4P&.I=Q>K:I>N7<.YML'VE!RP;C,%;JI, M%3_5-G-LDM5:H03O"252-4FS;KR9K,6Q/W8S.VV0W*=N'HNXNUS%/[+J*OUE
M7J85W@VCM*KZ/>$OS]$H5'(59QS':G-X&WKW0XDJTWW MNF=2]<+FLE"O*\#U!/4\9TP^#'1#W+\ )?\"4$L#!!0 (.!9%D4&G?W MB (/0' 9
>&PO=V]R:W-H965TM0E@"%/%1=Z[)7&U"/?UWD)%=4#68/ EX54%35X54M?UPIHX4 5 M]\,@N/ KRH27)DYVJ])$K@QG FX5T:NJHNK/!+C/,
[EH)5(#23@BA8C+WKX6@66WVG\)/!1N^_E6C+W M.@0<A!Q43SI4]M'G8 R-,/"%M MN ^(7P!$+2 ZUD+< N)C+9RW !>ZW\3N$I=10]-
$R0U15AO9[,%EWZ$Q7TS8 M/ID;A:\,<2:=RJIB!@MO-*&B(%,I#!-+$#D#33Z2[X!5(/F>%K:IHE:/\/9= M&W*:@:&,ZS.$W<\SD*M^F:A <)YU /2!1\
(&$0QCW^3(^'1WWA_)_U MV:NM/TM&U/5.Y/BBU_1.7[$;NKB?SD[$D:YI#F,/1YX&M08O??]N>!%\[LOT M6Y)E;TDV>R.R9S6)NYK$A]C3'SW_S+Y2-
"S#IE7L,EFGP> J\=>[*3Y&*>M1 M"@<7SY5FO4J7G5(3JK\SQBI02[<_-(:P$J;IRD[:K:AK-YGWY)/A:#KLD6>X MTIH-](^^V8X" #:"P &0 'AL+W=O
M[W'C/Q;U, 11ZH!F3 M$R=5*A^YKHQ3H%AV> Y,GZRYH%CIK=BX,A> $PNBF>M[WL"EF# G'%O94H1C MOE498;
42&XIQ>+7%#*^GSA=YR"X(9M4&8$;CG.\@5M0W_*ET#NW8DD(!28) M9TC >N)<=T?SH=&W"G<$]O)HC8PG*\[OS>93,G$\N_'@A!7_^*&,PQ%
\]0#_!+@GP-ZCP""$A \UT*O M!/2>:Z%? JSK;N&[#5R$%0['@N^1,-J:S2QL]"U:QXLP\TYNE="G1.-4...4 M$J43KR3"+$$SSA1A&V Q 8G>H@7^P06Z
Y9P(=%%! J33%[]DT*&OC#0&Z* MCEVE+V1HW;@/T/BV,^X\8#]!"FTLEFK,$DAI\U(R,:L"[.A!5-/Q#-*9^(^$M
MY!T4>&^0[_F]FOO,G@\/ZMSY/^OS%UL_"490/8W \@4O>1IUR2[H>O5TIN&- M9(YCF#BZHTD0.W#"UZ^Z ^]]7:3;)
(O:))NW1':2DUZ5DUX3>_AY2U<@$%^C M75&2=7DH*/J6PGPG=F%W[.Z.@_ND1O2DQKQ)X\2W?N5;O|&WY5;$J>[Y$OTN MFTN=OD$8!7V^YEP=-
L9 M-(& @ - 0 !D !X;"]W;W)K&UL?51=;YLP%/TKEE=-K;3%Q$F;*@.D)=&T/52*&G5[M=N F6/4'LTWH_GUM0RF3DKZ
KWW/N>>8>TE;;9YM!>#0BQ3*9KARKEX28HL* M)+,378/R)P=M)',^-$=B:P.LC" I"$V2.R(95SA/X][6Y*ENG. *M@;91DIF M_JU Z#;#4_RV\$D"
(!A0L,S+].L 8A I&7\;?GO$/) !ROW]A_ M1._>6I[RYY96&OQAY>NRO]1B4<6"/"%?AH^R< M\:?-QHG7&W","WN#KA1
MZ($+X6_8IL1Y18&7%'WU55>=7JB^@WJ"9LD71!,Z1T^[#;J^NOF?AGA#@RLZ MN**1=W:!=U!=O*L^IZYCF9]G"?.PM#4K(,.^X2V8$^#\\Z?I7?+M
XVS0>/L M(_9WC=]48"SBUC90GE/9\4R[2PQ3=LKI?'*?DM.X/!DU09BG!V:.7%DDX.!A MR61QBY'I>K0+G*YC7^RU\UT6EY4?:S AP9\?
M'9O06BUX4>1OP)02P,$% M @ X%D6=J7[D"N @ 3PD !D !X;"]W;W)K&ULK59M;]HP$/XK5E9-K;215]J-0:1"F+8/E5!1M\\F.<"J8V>V@>[?[^R$ M#*J
JHTOB5_N>>[NN<3GX4ZJ9[T&,.2EY$*/O+4QU<#W=;Z&DNJ>K$#@SE*J MDAJY^P9-/B[7'+MGF37V 8>R3?:R+(!8P0E$_6; MOC0Z' "0IQL0-8#H-2 Y
8@:0/Q6#TD#2-[JH=\ 7.I^G;L3+J,&ID,E=T19 M:V2S Z>^0Z->3-CO9&X4[C+$F70BRY(9++S1A(J"3*0P3*Q Y PT^4@>P3 % M=I_,.!7D.@-#&=/]]T5?
4LSIYO UW1'$8>'F :U!:\]/V[M\#;XTB7I)LPB7)LDN232]$=E2% M?EN%_ME?(&,Z5V#[&G92DN-AH]AB8TZ==C596/^@MD]OTZ!W._2WATIW&B7'
M1EF'4=B[.S::=AJ%K5&=L7_0(4I0*]>:->:R$:8^"]K5MOO?NZ;W:GT<#B9A MQWJ&MX6ZN?^EKZ\:#U2MF-
"$PQ)=!;T[#%C5[;N>&%FY_K20!KN=&Z[QQ@/* M&N#^4DJSGU@'[1TJ_0-02P,$% @ X%D65CDOL.H @ 'P@ !D !X M;"]W;W)K&ULK99K:]LP%
(;_RL$K6PM;[#B7ELXQ MM"ECA72$9ET_C'U0[.-$5!=/4N(6^N,GV8Y)2F+HR)=8M_>1WG-T251(]:27 MB :>.1-ZY"V-
R2]]7R=+Y$1W9([")F12<6)L52U\G2LD:2GBS ^#8.AS0H47 M1V7;5,617!E&!4X5Z!7G1+U<(Y/%R.MZFX9[NE@:U^#'44X6.$/SD$^5K?D- M):4-
M8V3,@>PR_M9,KYG2";?+&_JWTKOU,B<:QY(]TM0L1]Z%!REF9,7,O2R^8^UG MX'B)9+K\A:(:>][W(%EI(WDMMBO@5%1?
\ES'84L0A@<$82T(WPBZ%P<$O5K0 M*XU6*RMMW1!#XDC) I0;;6FN4,:F5%LW5+@LSHRRO=3]3#R6G%-CTV(T$)'" M6
I#Q0)%0E'#%YC@@C"8*ID@IK9#P^D-&D*9/H,3H +N*&,V'SKRC5V.@_I) M/?5U-75X8.H9YAT(^I\A#,(^/,QNX/3D;]FW(ZY(R\0;BC4(-]%^#8@353"
M)BIAR>P=8$ZDUF]"\7MBQ\"MY>L_^[Q6P/Y^H#N+ESHG"8X\>]@TJC5Z\<GQEC%0"7_0GR!"K78'/]M;0"*]PLL][!>Q6&7+W MQCH..H/(7V]
[:IWU/SWU&T_]5D_EPC>(Y(U*IB00]^H\?89::6\-XE'@NT8 M'C2&!\?>P(-C>C\2;,?[L/$^;$WVCQ6?VSS+#-PC5Y8RFJ"JMG)*E7U!I*V]
M[KDMJE"T\M\;B@HVV#H;%\W)J/SY6]>W>SKOB%I0H8%A9C5!Y]R*5?4<514C M_)>M[5GE97-H7')4;8/LS*&ULM9IA]F+C$"0TSJ>"8),+W.7"
<3]]K/,L@V$T ^221W_?65@(#!1+7; M[7VX8+S[K-A7+&*MQ0OC3V)'J43?\]P0-
Y.=E/OKZ53$.YH3<FR\6>;.F*RB_[!ZX^35M*DN:T$"DK$*>;F\DMOHYL1SM4 M%G^D]$4<'"-]*6O&GO2'3\G-Q-(CHAF-I480]>>9WM,LTR0UCJ\-=-
+&U(Z' MQZ_TJ+IX=3%K(N@]R_Y,$[F|FVH$KW'PJMS7R:HR'1!)E@O.7A#7UHJF#RJY*F^5X+30,VLEN?HV57YRN9(L M?MJQ+*%
<_(3"KV4JOZ,+5)V^N%.2)>B>Y6H>"U+-A/D>G.[NC&7COT6/ M_G7T7BZ==H(Y%<\Q3;"+=363XH.9-#*RNYHT&R?I&GLM]B2F-Q-51 7ESW2R
M_/$'[%D_CVD$"0L@82$D+ *"];2=M=K.3/1EKS+0;_J8CNEJ)RK:PWS*IA^ M;CXO;>O*6DR?#_4Z-L)7GMJZD'5N<\2&TA80$D+(2$14"P
MGK97K;97('7.2#E7UQKF'I8P:UCF1FSPL,H=V]CS@4UT;./,K/$:-V]S-C?F M;$4R*I!:$*K5*G^B,BVVKZD;6R+>&6GGY@X2%D#"0DA8!
3KZ>NW^OI@] S4D MJVHB2?*T2(7D1+>5S641M'< 2@M :2$H+8*B]<7O&AS8A2N+H*T.4%H 2@M! M:1$4K2]QU^_ QE?NT\LB:+>CH?4Z>X[C#
OCB)6%\; V'ELYGHV'Q?'8RO8] MYXWRV+44L+FG8%O80P\9&;\E0#L)H+0 E!:"TB(H6E_3KN6!YW!5#[3A 4H+ M0&DA*"V"HO4E[KH>V/CBO?RMS-
>4Z^:]V!&N.UREW#&>_C7ZP^6=F7:VRO[Q MFG!NZ7_#^@?:US@U; 05MO^C;=>TL,U-B]M2LES=<+%:9!:E6FNF1\%4%WAYP:-
H(*6XLT/=A#EE.^K7;["?5X*PM9[_9I MS[8["F^K?72#_?X.L CYT-\'=7[!3M\O7WQ.^';M! HHQL5RKJ\4M?.ZQV! M]0?)]M4.MC63JJA7ASM*$LJU@?
I^PYA_: #M/LREW\#4$L#!!0 (_! M9%D,8FF1OQ$ "O3 9 >&PO=V]R:W-H965T92XFD@S/:?J%0_-R&FZ>DO1+MI(R-[YNUG'V^FJ5Y]M7TVFV6,E-
MF$V2K8R+O]PGZ2;,BZ_IPS3;IC)<[E?:K*?6;.9--V$47]W>['|[E|>)+M\ M'<7R76IDN\TF3+^]E>ODZ?65>77\X7WTL,K+'Z:W-]OP07Z0^:?MN[3X-CU1
MEM%&QEF4Q$8J[U]?O3%?"=.TRS7VB_P>R:>L]MDHM^5SDGPIO_RR?'TU*YLD MUW*1EXRP^.=1WLGUND05#?FSHEZ=@I8KUC\?Z6*_]<76?
XS>9>L_XB6^>KU MU?S*6,K[<+?.WR=/_Y;5%KDE;Y&LL_W_C:=]V=F5L=AE>;*I5BY:L(GBP[_A MUZHG:BLXYU:PJA6LH2O8U0IV .7<&K5O#V?
7_HK'U/ MLS /;V_2Y,E(RZ4+6OEA+]=^[:*#H[CYG1CV[*5AS2S'^/2! M&3__I'7>X9^.IMX-!]NCP.PY+8YRN1E$YY=]MJ#!3"X*L#D.K$EJGXX>>Q_)
MIHZ>ZS*S+8U%LBGR?1:6A\Q+XT'&,@W7QC+*%NLDVQ7Q)ET'P8'O=//+\\JK M;!LNY.NKXL21R?117MW^_6^F-_MGUVZ"A#$DC"-A
@33%'=.BCL4_:SBAOQ: M?I;&7\9/73H?J-Z>6I[N'V^MF3^[F3[6]6LO9/]>IR_$V@NY@1?H"_&.A=S MUQ<2Y)8^LQ_=4S^Z9#_RS7:=?)-2.]-T=1R)&7N
(&$,">-(F #!-&&]D[#> MA5.BAU0<"6-(&$?"! BF*>Z?%/6HYKYT.](FHUE6)O26H:W.?/F M,H+7%<[.)4+I*'./I?T9%%E.L_-
K=H:E[A@>PK397:NY^>M_G LL]DC=V2;QQXZ@T)R9$@!@FF* M!B=% U+1/_97M')Y'3X6.>]!&EN91LG22(JOQM,J6JQTN369%TF6&U&VEWM1_MZ?
RY5/VX>)>F9'O&9DTDC-$]91K?9)AV)4AD(P0(INT,YDQ=9,_(D^+Q0OJW M79[EQ?5P%#]T7A'/D")":0Q*XU":0-%T=6L6BDGNPC55C3 O#M6'*([++\G]
M\;C_Z_S%[%N:/EIU)(U5-%?+VT'@-1,W-*I T70]+:6G15^;?)7I(BJ',Z1L M)&2T;$@;JVAUV:Y-T[6;JB&#"A1-5TU9,29YW7][%\8+N5[+Y91_W49IGWI0
MXP5*8Q5-4\]R3,=JR@=U55 T73[E]YBTL=)(HC)>#DV?3CM%S1S/70]*(KJIZ.]=Y7;HSID@.4XWC5>%.-5X\YT'B71HOB_\6P]4,I0:<" M4(\&2F-0&H?2!
(JF:ZZ,&I-T!88-6Y1KWJD\U*N!TEA%FVM'Z,1WF@32HQS([ZB40])813/MNA$^L5NI%1E4H&BZC9P33HV;0E:V:]W7NZ":, MEFE04 X-*KJ#UO*R?G-
=>2Q6C\>2KXI!2A0?RFW.W$VRH X+E,:@- ZE"11- MUU8Y+%:/PU+Y9_)P?@L_KZ41[S:?"\&+0ZRZJU__(W7!8+4]#7ONNF9C9'#7
ML9PSFSGSQG)L((\/Y FZ+Y[;U\K]L&CWHZ.O7QI/33];']\/MOOK@[[T5L74 M#GIK8IK-+N]8K'W:8,-H?!A-T/WQW/Y6OH5%^Q:G2Z]CUZ:R+ DLSR*+),
[3 M<)'OPK6QCNZE\7,4[^WR[$5G)T,]#2B-]72"?=@LPS0V9=&5X1G+\%MW31'4 M]!C8K.#0K*)]\XZ&Z<(KQ\/J<3P&'70!I-
!Q!::RG.ZJ^[M0<:]*@ M:+KLRFJQZ,J7-P\/]7P(D=1&DF=NX59!M'OC MYKR93J%6RI"0'!I2=(6T[#,C165\6+3Q02B@74!W]CO4\8#26$6K#S#:@Q"H
MW8&BZ4(JN\.B[8X!AY(^*.R6M%U"8II>\U"",AQ6NR*E%9)#0PH439=*^1L6 M[6]TUOL5BOQ:G-LVNTVG+E"# TIC4!J'T@2*IBNM;! K(*_#O[\
T(+6LD!I M#$KC4)I T?12>&7 V*0)._'2 MQ-&J0BM;H#0.I0D435>Z-A?IXI.1L+.1L-.1L/.1L!.2+E$Z8RLCR::=DW$G M7JA#!*6QGNUTB)0-=8A0-
%U/Y1#9M$,TY,0++;F!TEC/UIDS0D:H>X2BZ3(J MF\FF;29K9GK&NW58GFT_1AMY_7:?FM\W)U+O)TQWB@SUFJ T!J5Q*$V@:+KN MRI6R_4N?AZ'%.5
:@](XE"90-%UXY7'9M,?UW(EP%58S(-W6="R[/87*;$^' MZUC*<5KSK#J6LMM3XNC-?6YW*B/)INMIOF-6'#WJK8I;WWK?;_XERF1R3/%ON1S[]$^,DT-
[3[6A[F%V\JX0^YB< M$[U<,E])O02]_*%V17NH+7I!5G;1S1F]FT"-*Z<])/.<$VJX@\KV9T^S>.[K!HU4=%I5#HXJ.J(T3 MLBZ7\G\"W4P>H 02E,2B-
0VD"1=.5 M5P:00QM R/'N,EFOR]+CXJ?# ?NBM\B>;MWHO09:,%71ZK7XIM>>TP<-*E T M?7=0!I9#&UCUT>]SY(2604%IK*+I4S3MR;QU-0,UM%
T_8F%RM!R^PN;I8:NA_[AY>%4N? M06&:S9MX=)-&BSLH*(<&%1U!YXYU[HBK/7^9-H9&5:?0$S7H2*./1^Q#FK%/ M:

<8^IOD2MI*K;"7WTD]J=J$%2E :@](XE"90-%UX95"Y]+2Y4?6B-&NTQE K MJF<[SS]:%MH,@:+IZE MI]RY4*\)2F-0&H?2!(JFOVI!.5(>
<,H=S1JK,93&>K:3F'(';8= T70]E27E MT994/96_D^G^45;Q0E:']OZJZ3J3>5Z:5FG7Y52G/4$''2T\U*>"TCB4)E T M?6=0=I9G73BK>]!Z*"B-
06D<2A,HFBZ\,L,\NFKJN77D7KM"J57Z?5ER9=7I!!+2LHC4%I'$H3*)JNK?*Q MO!]7/36DV)%NSNC=!&IV>1U3 H.Y93?K:Z!1!8JF[P#*QO*&UTL-
$A!J6D%I MK*)I[R6T;-]K"0BUHU T_3V0RH[R!Q=(#=&/IHW5#TIC%4VK-'<GRZ\ DP6<'"ED-!;0Q*XU": M0-%TY94SY3^_',H'3!:@6S=ZKX'Z7!5-JS*
<3X)6WH8:72B:OCLHH\NGO9OO MG"Q TT?+"76M*EISLH#?G#D+C2I0-%U/94GYM"7U?9,%:/AH.:&>4T73Y+3\ MB=U_08TJD#1=#EK[[BG:XF^>[(
S1^M*-24\KM>N.9,6@^/AT85*)JNJ+*; M?*S=!)LMX'=,A7,GI6$SU% :%I1#@XJNH-IY7)=.&44^7>\T:K: #W6)H#0& MI7$H3:!HFL9SY27-
:2^).CQ'SQ:H8FDWO8-Y8S+4'=VBL=H.BLFA,45'3,N? MGYDK,%>^T/S294GT! (Z_-A#%$IC4!J'T@2*IN\6RFJ:7[I :0XM4(+2&)3& MH32!HNG"*]-
J3A&)LP?8@Z7\I)1QN|%T -K(IFSFHI=3:QFL\M@ 85*)HNKW*FYK0SA4GW MYV<9T.%'ZPVUGJ T#J4)%$W?+91#-7ZA)A64QJ T#J4)%$T77EE9<|K*
M0J=[J+<%I;&*IJ5[<^*WTCW4VD+1='F5M36GK:UZNK=FEFN\^_"I;\ .-;.@ M- :E<2A-H&BZTLKRFL\OG<&A-5-
0&H/2.)0F4#1=>&68S>G**G0&AUIJ4!JK M:+T#=JA7AJ)I\@;**PMHK^QL!C_!J>)8R6$TAB4QJ$T@:+I2BLG+J"?EO[] M&3R
>FU0&H/2.)0F4#1=>.6U!719%SB#T]%&[P50XZVB]8W!H4$%BJ;+]QRU M@';4&AG<&3 &IXFC)82Z9E :A](BJ8KKL=@T-- M,A1-EU>99
%MDC4RN+W/X)W"0>TO*(U!:1Q*$RB:IJ\Y4S99^?FRF?L8 :0] M%L>P.([%"1BNH;]9TY^N8[OH8R)Z@H_?-:#6VA%'/2D"&U+ < V]K9K>M&FF
M/1FST'"QDD82R_H(O5M)J#N&Q3$LCF-Q H9KB&[71*=G5"*2/-1:P^(8%L>Q M. '#-?1W:OK3U6MORG1N/*HG8RZ*O!T^=,X-
Z&&-5QIJIAUQ@6:CV,5_K<0- M-&\IN&(9]%7B3M_ M2NIU*=UR0KTP+(YA<1R+$S!<0_2@)OJE'S]_C #3'^JI87$Q. '#-62O.63FI:=P'B/],>:95 1C7?
C52>5]* M_J-=35M_?[6?'5G=OS.S%=__M4X6]OMH7FO^[O5&?&6MX7H6:3\@%*:?ET MNN.7/-
D6>]>5\3G)\V2S_[B2X5*FY0+%W^^3)#]\>F7_>;<_A]02P,$ M% @ X%D6<3(H+:[! !" !D !X;"]W;W)K&ULK9EM<^(V$,>_BL:]:9.9'G[F)
",PE^Z'7FIIE+KWVM& &>V)9/ M$B'Y]I5DQV#BJ-!L7@3;[/Y6\OZ],JOICK)'OB%$H.D MP'Q *U+*;U:4%5C(4[:V><4(7FJG(K<]QPGL F>E-
9_J:W=L/J5;D6*.E(.V^#LC.WYPC-14'BA]5"=?EC/+42,B.4F%0F#Y\406),\528[C M1P.UVIC*\?#XE1[KRX^ =._CO. P;A^&I$?S&
MP3\UPJAQ&)WJ$#0.P:D.X\9AK)-5WUV=FA +/)\RND-,64N:.M#YU=XR(UFI MI'@OF/PVDWYB?B]H^KBA^9(P_@N*?FPS\8(^HZBH@N MQR6Z"(G
6'W^Q!=?+I$GU!6HK\V=,MQN>136\BQ0AVVHSCMAZ'!\XX MAN@K+<6&HZA'[/>!;G MNP_IO.QZ-
"HL=F]S]P.4".^V[TQ.Q^4[$!\L;*W0T,J1BV&AUJWO ,C?8I MK*;X_115TZ]YA5,RLV31YH0]$6O^\T]NX/S6EUY(6 @)BR!A,20L 8)U1.*W M(O%-
]%HDG]6JM$0I+>12S;%>[,BS.B9]@JF)@2:J-?MI[CEC9VH_'0KAK9$[M#H*N4?C6:#0))EVCJ,=H-!EWC6+C+,]-"!"LDY!1FY"1,2'JX=?K1=^=-[J>
M^ZA"PD)(6 0)BR%A"1"LHXR@548 4L\#2)% PD)(6 0)BR%A"1"L(Y)Q*Y*Q MN9YOL(2B!MSW1GA; T8']33P V\R.BK."V.@L-PP<9]B-FO0-3YK)O]:P
MFY)[\\U=HWF7\J4D4+6:YPCKM*#,G5%U?L3RCEH2Q"4%C:THW+NN,?Y!&WW M@=(2*%I7&ON.GVMN^9FD(2N[OO1.98?LLBU
:6%#.WR41MTGJ1$&9-08E)9 MT;K"V'<>77/K\?_T@AMDMQE\W ON,7*/C<(>(_]M]DXPBLW3/#LIH#T_^V#/
ML2!LK;>3N;S=VU+46SOMU7;+^D9OU!Y=OW6O%V[/]="]CNH-Z3V^WA__BMDZ M*SG*R4J&<@9C.3%6;SG7)X)6>L?S@0I!"WVX(5C^#%
&\OL5I>+U1 5H-_[G M_P)02P,$% @ X%D604CI_ZH!@ ;C !D !X;"]W;W)K&ULM5O;;MLX$/T5PELL6F 3BZ0N5C8QD$3:"[!@F;;?68L M.A;J6RDZE[]?
2G(LBZ*9V)V^-+9\YI##(4<\Y/3\J13?ZA7G$CWG65%?3%92 M5F?3:;U8\9S5IV7%"_7+LA0YD^JK>)C6E> L:8WR;$H5&G98$$7UY,+O%93+W&H$5\3?
E3O?,9-:[#,2.@>(Q M&Y"- =$-W#T&=&- W]N"NS%PW]N"MS%H79]VOK<#%S')YN>B?$*B02NVYD,[M^JVU&J^T:";*G13JUU39R?
EG_LB+-4ACQ\^H0\H+="_MJW)=LR*ISZ=2M==831<;[JN.F^SAINBF+.2]1G&1\,1@']GM0XO]5/FY=9:\ M.GM%K(1WO#I%U/D-$8>XAOY>5-8.T/7
M;-BDKK.Z8@M^,5&YJ>;BD4_FO_Z"?>=WTYA"DD609#$0V6#TW>WHNS9VV^AW MAGYKV.3YQWE G5"%_'%W6,H7")92I:I=\LFWZC44G6_?
S(-0L>,G=TN:2/P-B1Z&Q); M(0.W_:W;_GL6%EJ*,D/KLI;-JJL/\+QC]'8[$CAZWAF#*,'ZNAN#9HI*\WL,"C'9XW:X=3NT
MNOVG*.L:5:)HZ7,*!S/@!F=Z;$=4V$?AX[92>ST MFS;'ZN9-6J3Y.C=NR:R6AZ834+8(E"V&8AO&8&?CC$'3_(8,*C"0;!$H6PS% M-@P,Z0-
#WMA:%5*MQ6+5Y$ F!"L>N-*[TBQKK T< M'"I(MN@-YRG*6\UDC M01X9QZ?4&MFZHYS?L>6_2 E4NN$ 5>U$/C+$ U72@;!$H6PS%-HQ.
MK^MP<.PA%K9*PH-C ,D6@;+%4&S#&/1*$]NEIBT&8XWG!I[O:H++ *,A#?3# MK LLH+D("1U==!GHL(.ILT]V]>
(2V]7E5RZY2L(UNDQRI]9[+\F(795$\'NE4+.VW6?(?Y]G5:-_$))\^I/ M[]>R-&__[<0'ST10*0;*%D.Q#4/4BS/RKJLV8PQ)1@H6P3*%D.Q#6/02S!B
MOUNSQ2 8O]9G^F71M0GES/2[- .*>)CHU[DFF.OA?/3*!Y5>H&P1*%L,Q3:L'^JE M%[7?0MHJB)R15/<],M/W_288\1Q=^!M@>$9(,-
,6OPD7$+)SXS[TM!A/A1&F"Z!]I"-!N(MV' <>@E$[1+H,A5/[4M,LX$*Q;< MF@OM7 >7D8%J(E"V&
(IM&)6=0K[C*_E@2_E@-B_E^AB:BO2:B1VLB:BCH M&^^"3*CQ+LB ,NV"3++]NR#:2R+Z\RKZJ*'2SCD=CX,9IH^#&:5+PS=AW3A,
M=^JGVL+U&BW*=2&[@MKMTVUQ_&5;$]X]O\)GU]CP/,)G<5?ZWM-WE?@W M3#RD18TROE1-.:>!ZK'HBMN[+[*LVNKM^U+*,F_KCA+N&@
ZO=E6&PO=V]R:W-H M965TPDI$!3AC9>$E_.]WT^%]EGL&'\120 $FVSE(JAD4B9]TU3 MA ED6+19#E3MQ(QG6*HI7YHBYX"C I2EIF-
973/#A!K^H%B;L'T!SE>PASDO(0#0U+'PA2"*5FP.JWAC&DJ292Q_A5<1JU MI ;NCW?L7PO?E2\++&#,TI\DDLG0N#-0!#%>I7+&-
M^@\J>C^4*6BN*+-J5M MQS)0N!*29158G2 CM/SC;16'/8#B:08X%< Y!GCO -P*X)ZKX%4 [UR%3@4H M7#=+WXO !5AB?
\#9!G%MK=CTH(A^@5;Q(E37R5QRM4L43OH/-&09H">\!8%: M 4A,4G&-;M'S/$"MJVMTA0A%3PE;"4PC,3"E$M50,ZP$1J6 \XZ BQX9E8E M$QI!U(
/3N/O3^!-Y6SML:/S>.2<))Q#WD:N=8,MSTV!O219 M<$FRR87(#E+@U2GP3K'O4B#Q%L%67?\"4&L!%&(BKYM24K)U"S;]"JQ]Q^K= M#ZI?
M!#RKU[;?")1A,??>T SXLFA>! K9BLKR/JU7Z_[H2]$6*V/[/[8;E@/5#]5 MMC^O]&4S]HCYDE"!4HB5E-7NJ7SSLL$I)Y+EQ0N^8%+U
\4P43TA<&V@]F/& MY&ZB!>HNT_\#4$L#!!0 (.!9%D57=^8=0, !P, 9 >&PO=V]R M:W-
H965TM2UH3=2,:RN')1LB::.C*K:L:24G1DNK*Q9X7NS5AW)E-VK$[M.9N(G:X8IW<2J5U=$_GWG%;B,'5\YSCPA6U+;0;S)$4#/>_9(?O0\G!-"Q$W!/P&-
"^ 0AZ G! MT+XW!FBGM"F[G:YM\;E1)/91(H#D@8-J;1NM^RP2_&S3Y9:0E/&?#T M[#-LQ8]\+6J*[JA$JY)(BMZA.5%LC0@O4,ZJG:8%,D
V!E[E5!-6J6N@W*]R M=/7F&KU!+E+FJ0(\NN=,J['GE_G9!;X+E@V^X:-OF!+Y__- MOGSQ[&=F!,,F"EJ]X#]L(ML:=RJA7<6J(6LZ=>#(4U3NJ3/[]1<_]GZS
M&?R:8OEKBBU?2>QL*<)A*<)+ZJ=+@I47*"_Q@0)UE&@V91A ;1X1_94PI5V/'3@ M,E0:3AG&M[;<.]'H-)8@2Z,@'@6]L '#-,#QV (;, VQ%XZ
2PL0)WX8):'= MB7AP(GZ1$SL%Y[86"'9# V,18@SM(DCA.[5-U9[.@4TM/XO!NL#]* MWP;*1J]3;@,%HZQMF#2S9YP.&:,YE+Y=I?I3OJN;
M/Q&Y95RABFY@*N\F@2TJNUJTZVC1M,76@]!0NK7-$LIW*@T GF^$T,>.F6#X M0S#[!U!+ P04 " #@6192UY[+#4$ #H&0 &0 'AL+W=O($5
M9)DBR7G\TT*-+J9R/+\^TC_6BY>+>2(<5C3[.]V(_<*8&6@#6U)EXI$>_H!V M09[B)33C]5]T:&TM R45%5IOG>4,\1H/LEKFX@S!\D9=[!;!WOHX+
[AX+0. MSGLCN*V#^]X(7NM0+]ULUEXG+B*"+.>,'A!3UI*F+NKLU]XR7VFA-LI:./EM M*OW$\HOWL2N(;R!CG6;\BV;'=D/JOW
MNSMCR_E_T>/_'+V7#*?;0$[-H>6G0PO'0[M5AS;I'UHX'MI2JL?? M4J\)[-6!U?^>E^4L<#Q_-C=?SG6Y-/,LSPV=OEET:88MQ_9\NV\77]KY3A#.
MW,ZLER:O2Y,WF:9'X(*EB9)D>4U>495D8K1NC3)N7:/ZH1%.F&Q)EA/#+\3
MP]=2/GR=4NB$13IAL2983XJ@DR+X4>4CN#C(CH^Q8PW*QZ59X(;!H"I$EU:> M;>$
#XK'I1D.+>O,K)>D69>DV622Y$^>7*Z*1RT5&D8+1V3E&OWJTY8I!,6 M:X+UI @[*4(MI2/4*85.6*03%FN"]:3 UJF-L'Y4\6@C]ZI'8%GNL'J,V+F.
MY=F#PA"]DQ=_F]?/U5G+A2=S)7=KW>$7"7SK%\@TZ=K-JY46::7%NFA]3>R3 M)K:68M)B= FBDQ9II<6Z:'U!3FTEGFR5OFM!
<4;Z"MF!#.N)UBYS)"AV;<<; M_FP9LPN& RHP4HTF:O%V]T772(JVT M6!>M+\RI&\6>GLJCM1O52HNTTF)=M+X@IXX43W99W[7R^)
<=3FB'WK#R:&U0 MM=)B7;1&'//LR74.;%>_,N RN54AFF>0W6CW6N*N?A@_&+_'MRL\,AZIUQCU MD_(3OGD'\IFP75IPE,%6AK)N JD*:UXK-
#>"EO5S\R&ULS5=13]LP$/XK5C9-(%)DZ84UD8" MHD MF! =V\.T!S>YMMX<.[.==OS[V4X:6DB#*N5A+VULW_?E[CO?Q1ZMN/@M%P *
M_F5&1<95GHHYJ[.!>#4@C+J^IXW<#-,F!.- M[-R]B$:\4)0PN!=(%EF&Q=,E4+X:.SUG/?% Y@ME)MQHE.,Y3$]YQ="C]R: M)249,$DX0P)F8^>B=Q[W/
,P%M\(K.3&,S*A3#G_;0:?T['C&8^ 0J(.!=9_ M2[@"(2@V3]N-/1>K4[S3 S>56#M0498^8__5D)L 'K]'0"_ O@O <$.0% ! M@I> <
>@7P'Z5IDR%*M#C!6.1H*OD##6FLT\6#$M6H=/F,G[1 F]2C1.13>8 M"/0-TP+0'6!9"-!)51(=HVLL&-([!5&"IX02]80.8E"84'FHEQ\G,3IX?XC>
M(\+0UP4O)&:I'+E*.V6HW:1R("X=\'?D!_N1,?MZ GD)RCPFN!;P01U>@++%[R9 MGB-T(27HS&B9T6V5$@)RG;84Z2IZ@*00@K"YM?
K"F:@G+KDOVXU2] GQ5D M\F=#=)>E-_UF;TP/.IJ5+ /+8AKN,CH.!YXW;*LC19>2^MXK>LM@()`MZT#*UD F9,[(C"28*?3(^-0(A:=4[PB6%SJ^@UM8
D7!85-TK=3[[HTNR>*. MR+8D'=22#OZK"AUTF84NR>*.R+:R<%IGX;1U8U]75?G\L3I"4Y@3QHRR4TPQ M2Z!)SE;:?>7LDBPNR<*-!M +O'!'
QC6.@T[Z62M+/O*TB59/'PE2TM?/*ME M.6N5Q1;QTIZ"SX?>GM7%K#T MC;)]J]U7IT[9XHIM\],;AJ^$%W/UO>?"WOJ=Y_-
MR|O3'1;Z$TE$8::AWLFI3I(H[R/E0/':,/%B|P!%'HM*),3)U>J MO'1=F>908#G@)3!]L^2BP$IOQS><@FCF<* @JI,@Q8_ZSA!B@U1+J,7PVG
MTZ8TP/WUCOW.:M=;%EC"#:<_2:;RB7/AH R6N*+JD6_NH=%C"TPYE?8;;>K8 M\;F#TDHJ7C1@74%!6/V+7QL?]@##T1& WP#_P4$#2#X$Q >
8P:P.@Z4TNQ M/B18X3@2?(.$B=9L9F'-M&@MGS#S[',E]"W1.!7?82+0.Z85H"E@60G0;ZHD M.D-[-_<$!!9IOD4G"2A,J#S5 4_S!)U/HULP;&
[:Y$SJG/Z1G-_0E#.5 M2W3+,L@.\:ZNOQ7A[T1<^[V$/_AZ@/R+K|CW_*"CGIM^^!1OD1|>122]Z#F4 M Q1X7? #,4'[(H'E"][W(AV%7==$HVXBTS
N98E3F#BZ(T@0:W#B+Y^&8^|[METWR+!3O3'0Y1@A>$$K5%)=X:$[L\K+G&ELOTR'4< MCCWSB=SUOCT=<5Y'7/+ON
-182LJ[!7U4)25@@P1ID!;IOHD]3*]]V\1_J7' M#SMD?U#.VAMWKY\5(%9V+DB4\HJINK6UI^WHN:(=U_T=7L^M*18KPB2BL-10
M;W"N"Q7U+*@WBI>V.RZXTKW6+G,]/D&8 'V_Y%SM-B9!.Y#C-U!+ P04 M" #@619!"+H*0H" "\! &0 'AL+W=O^?
LZ<27JE'TT%@.2YEHO):878+ADS>04U-S/50F-72J5K MCC;4>V9:#;SPHEJR, @6K.:BH5GBYS8Z2U2'4C2PT<1T=U[+B!6R5_ MB *KE'Z@I("2=Q+O5?
|%QGJNG5^NI/%/T@^Y<4A)WAE4]2BV!+5HAC=_'L_A M1!"^)@A'0>BYAXT\Y9HCSQ*M>J)=MG5S U^J5ULXT;B/LD5M5X758;;M=@:> M.FB0?
#]XY^4:D MIKL@%$0VY$U+:TS,)0[N;T[!\=%X-SN$KSM]RG)$H>$?" M((S)PW9-+B^N_K1A%G8B#B?BT/O&?TG\$ME9![?G2]/R'%)]&]F /@#-WKZ9
M+X*/9_BBB2_R[M$_|$7_@2^>^.*SYW=3]\ZRJ9+P#BNEQ2|HB*FXW8F@LA>M
M[71>V49_"7RP7GAK=]/610D['"*PTZ:T=WK.Z[WHC%$OFE%P>S]-25ZN"M# M@*KU_:E3:+O=#RO[>P'M$NQZJ10>]?RTP|K^PU02P,$% @ X%D6>!
< M,]A% P T!0 T !X;"]S=!EL97,N>&ULW5A=3]LP%/TKD1D32!-I&TB; MT5;;*B%-VB8D>-@;0XF>.REE^/KYVF'_A6'0^#+A7$]O$Y]_CZIC'T M*[T4[&
[&F X6N9#5@.RT+C^'8369L9Q6%T7)I$&R0N54FZZ:AE6I&$TK(.4B M[+1:<9A3+LFP+^?Y3:ZK8%+,I1Z0:C.4N-NW=$#:|24)G-RH2-F /)Q]_#TQ
M]/6'P-U//IVM%BX,("8>'R:^3QN3[FY+KZ:? M&JV&>XJ1>Q[RFHG2$G_,[: HO=LZ*![M[DF&%P[I8AOVLD.N:B8@;,)%ISH)' M*@9D1 4?*PZLC.9<+-
UP!P8FA2A4H$VQ&BMM&*F>'-QV/:CC6B?GLE VMHO@ M?H_KZ3O J@<&N1"-P0YQ |-^2;5F2MZ8CIUL!U] 0=V^7Y;&X5319;MS1=8$ M>S-
!OH5*F6K"M,EJ:-@7+ ,[BD]G<-=%&0*H=9&;1LKIM)#4>E@QZH:1G3 A M[N A_Y5M:2^RC3VU.RJ;IC%4-YV,ZX@^IIK3WI2]?)5N4/+'0G^=F^5(VX=:
M8;>*97QA^XNL,8"IMW%U6I9B^47PJ.T/_ S?.42::HV#1M:O\]9_G5CJ/N6UFV MWRJ[AKT>ZS?W>S=Y=0PFXV,P>10UV3L&D\D1F.R^V;?
FX2:C]YG(L#X);1RW MM@Y;S6@ A]H!^0G'9[$.&HSG7&@NZ]Z,IRF3+|Y<1E[3L?ES;4O?S$]91N=" MWS?@@*S;/UC*YWG2S+J%1-
2SUNWOL+QVW)RH32PN4[9@Z:CNJNG8-@/3,%'K M"PB[R(V]_ C&<9@? 0R+@SG .(Z%Q?F?UM-#U^,PS%O/B_103@_E.)8/&=D/ M%L?/2XAA^_&J8-
V!@<2#2W^4:WVV\0O7 ;;G M^RH$6RE>B=A*!5P#XL|;,)+$O]M8'&!@NX#5#L3WQX&:\G.B"'85\X8]P3B2
M)!@"M>BOT3A&LA/#Q[_V%,214GB1P#S.X@B#(&G$4-8?20$3;8T.P M6BP^0"X99K>]9!:GQEX),MBJ:?*"'>D-2')V,?'XQY9,^U MTFZ2K+O?
GP^'KER)FKN_S%IH.+,PMN8>#NURZ-96\JMA/"U&J:CT%%Z:304AH)[*9[H M)LDH86YEGOXV5OXRVG,U+ZU1:I*,=R?NA?6R/"B>!\@[_N#:$L\?:CF
3)*3 M$32XD-;YMD;;/@?&C8#*NZ/&F\]2>6&ON!=?K&G64B]#,W 5P^@RVG[8?^XZ M|=S^GVXTBX4LQ94IFUIHO^M'*U0
U&XEURYAFM=BDNRK,*XK-M4>.HG-J*XI MJ!NN%/YZ5NVNV@-NU(?V7,(),ZM:<#K(3T970CM1,?CFC)(5<%3LDBNN2\$B MR!2!3(\(^2.-
(#,$,CL*Y#S@P$\CR!R!S(\(V>G) H$LC@F919 G",0)+>0U M]XT5S"S89>,D%LZC_5[6MA0.8(12!/:2$ON9,N,-Y8X:#JZ\!SAJ"=T:+-
MF[KF=AO@YG*I)?R,0ZR|*$O30*R,(-\CD.I](6=Z Q5 7L+%X7J$Q>L1+=(7 M8ZHGJ53[M,W@ENIE(&
7SH'/8DK4*L1:@=MH&QBST^=U&,D=+DPD8V*3_,.M MA<=LRVYA/-A-%PR3QYC:'E94$A[_I17!%C[FPGPQ)A=&74L?*NWB&T1D#PF5
MT.6K,8'Y8DPLC+DWY>/*J$I8]P>;_FP@U8K9,$V,B3UQ*R"$-"+&P80P)C;" M3)>F%NR./W=O'V:",;$*KJ'=%ZX;8=E\Q6VGOS !C(D-

)E+R^ZY:@3[)K@# MY;=C(Y4R\A)I*4 M6"2ODZA>0,PF*;%-T&R*O8L7,C"K9-16Z,V"X]_NM#Q/R24?OE0( ]A#FFEIQ8 M+0>$ _8M#'+IP^")ETUS3"XY^;8()NI!C(FY)B??&$$P.V,[QVR3DV^-8)CQ M@GZ.[HT<P)S6 M:V6V(EY'*S +%<06^CT3ZTDV"LP[!;%WXL7N?CI,-P7UY*9OHCA@8<^VA#$> M8Z*;|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end XML 74 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 77 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 218 301 1 false 60 0 false 6 false false R1.htm 995200090 - Document - Document and Entity Information Sheet http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995200100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 995200200 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 995200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 995200400 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 995210101 - Disclosure - Nature of Business and Operations Sheet http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperations Nature of Business and Operations Notes 7 false false R8.htm 995210201 - Disclosure - Basis of Presentation Sheet http://www.tactilemedical.com/role/DisclosureBasisOfPresentation Basis of Presentation Notes 8 false false R9.htm 995210301 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 995210401 - Disclosure - Inventories Sheet http://www.tactilemedical.com/role/DisclosureInventories Inventories Notes 10 false false R11.htm 995210501 - Disclosure - Goodwill and Intangible Assets Sheet http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 11 false false R12.htm 995210601 - Disclosure - Accrued Expenses Sheet http://www.tactilemedical.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 12 false false R13.htm 995210701 - Disclosure - Warranty Reserves Sheet http://www.tactilemedical.com/role/DisclosureWarrantyReserves Warranty Reserves Notes 13 false false R14.htm 995210801 - Disclosure - Credit Agreement Sheet http://www.tactilemedical.com/role/DisclosureCreditAgreement Credit Agreement Notes 14 false false R15.htm 995210901 - Disclosure - Commitments and Contingencies Sheet http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 995211001 - Disclosure - Stockholders' Equity Sheet http://www.tactilemedical.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 995211101 - Disclosure - Revenue Sheet http://www.tactilemedical.com/role/DisclosureRevenue Revenue Notes 17 false false R18.htm 995211201 - Disclosure - Income Taxes Sheet http://www.tactilemedical.com/role/DisclosureIncomeTaxes Income Taxes Notes 18 false false R19.htm 995211301 - Disclosure - Net Income Per Share Sheet http://www.tactilemedical.com/role/DisclosureNetIncomePerShare Net Income Per Share Notes 19 false false R20.htm 995211401 - Disclosure - Fair Value Measurements Sheet http://www.tactilemedical.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 20 false false R21.htm 995211501 - Disclosure - Subsequent Event Sheet http://www.tactilemedical.com/role/DisclosureSubsequentEvent Subsequent Event Notes 21 false false R22.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 22 false false R23.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 99920302 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPolicies 24 false false R25.htm 99930403 - Disclosure - Inventories (Tables) Sheet http://www.tactilemedical.com/role/DisclosureInventoriesTables Inventories (Tables) Tables http://www.tactilemedical.com/role/DisclosureInventories 25 false false R26.htm 99930503 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssets 26 false false R27.htm 99930603 - Disclosure - Accrued Expenses (Tables) Sheet http://www.tactilemedical.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://www.tactilemedical.com/role/DisclosureAccruedExpenses 27 false false R28.htm 99930703 - Disclosure - Warranty Reserves (Tables) Sheet http://www.tactilemedical.com/role/DisclosureWarrantyReservesTables Warranty Reserves (Tables) Tables http://www.tactilemedical.com/role/DisclosureWarrantyReserves 28 false false R29.htm 99930803 - Disclosure - Credit Agreement (Tables) Sheet

http://www.tactilemedical.com/role/DisclosureCreditAgreementTables Credit Agreement (Tables) Tables http://www.tactilemedical.com/role/DisclosureCreditAgreement 29 false false R30.htm 99930903 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingencies 30 false false R31.htm 99931003 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.tactilemedical.com/role/DisclosureStockholdersEquity 31 false false R32.htm 99931103 - Disclosure - Revenue (Tables) Sheet http://www.tactilemedical.com/role/DisclosureRevenueTables Revenue (Tables) Tables http://www.tactilemedical.com/role/DisclosureRevenue 32 false false R33.htm 99931303 - Disclosure - Net Income Per Share (Tables) Sheet http://www.tactilemedical.com/role/DisclosureNetIncomePerShareTables Net Income Per Share (Tables) Tables http://www.tactilemedical.com/role/DisclosureNetIncomePerShare 33 false false R34.htm 99931403 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.tactilemedical.com/role/DisclosureFairValueMeasurements 34 false false R35.htm 99940101 - Disclosure - Nature of Business and Operations (Details) Sheet http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails Nature of Business and Operations (Details) Details http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperations 35 false false R36.htm 99940401 - Disclosure - Inventories (Details) Sheet http://www.tactilemedical.com/role/DisclosureInventoriesDetails Inventories (Details) Details http://www.tactilemedical.com/role/DisclosureInventoriesTables 36 false false R37.htm 99940501 - Disclosure - Goodwill And Intangible Assets (Details) Sheet http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails Goodwill And Intangible Assets (Details) Details 37 false false R38.htm 99940601 - Disclosure - Accrued Expenses (Details) Sheet http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails Accrued Expenses (Details) Details http://www.tactilemedical.com/role/DisclosureAccruedExpensesTables 38 false false R39.htm 99940701 - Disclosure - Warranty Reserves (Details) Sheet http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails Warranty Reserves (Details) Details http://www.tactilemedical.com/role/DisclosureWarrantyReservesTables 39 false false R40.htm 99940801 - Disclosure - Credit Agreement (Details) Sheet http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails Credit Agreement (Details) Details http://www.tactilemedical.com/role/DisclosureCreditAgreementTables 40 false false R41.htm 99940802 - Disclosure - Credit Agreement - Maturities of Debt (Details) Sheet http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails Credit Agreement - Maturities of Debt (Details) Details 41 false false R42.htm 99940901 - Disclosure - Commitments and Contingencies - Lease Obligations (Details) Sheet http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails Commitments and Contingencies - Lease Obligations (Details) Details 42 false false R43.htm 99940902 - Disclosure - Commitments and Contingencies - Lease related assets and liabilities (Details) Sheet http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails Commitments and Contingencies - Lease related assets and liabilities (Details) Details 43 false false R44.htm 99940903 - Disclosure - Commitments and Contingencies - Undiscounted cash flows (Details) Sheet http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails Commitments and Contingencies - Undiscounted cash flows (Details) Details 44 false false R45.htm 99940904 - Disclosure - Commitments and Contingencies - Lease commitments and operating lease cost (Details) Sheet http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseCommitmentsAndOperatingLeaseCostDetails Commitments and Contingencies - Lease commitments and operating lease cost (Details) Details 45 false false R46.htm 99940905 - Disclosure - Commitments and Contingencies - Major Vendors (Details) Sheet http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails Commitments and Contingencies - Major Vendors (Details) Details 46 false false R47.htm 99940906 - Disclosure - Commitments and Contingencies - Purchase Commitments (Details) Sheet http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails Commitments and Contingencies - Purchase Commitments (Details) Details 47 false false R48.htm 99940907 - Disclosure - Commitments and Contingencies - Retirement Plan (Details) Sheet http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails Commitments and Contingencies - Retirement Plan (Details) Details 48 false false R49.htm 99940908 - Disclosure - Commitments and Contingencies - Legal Proceedings (Details) Sheet http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLegalProceedingsDetails Commitments and Contingencies - Legal Proceedings (Details) Details 49 false false R50.htm 99941001 - Disclosure - Stockholders' Equity - Stock-Based Compensation (Details) Sheet http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails Stockholders' Equity - Stock-Based Compensation (Details) Details 50 false false R51.htm 99941002 - Disclosure - Stockholders' Equity - Stock Options and Restricted Stock (Details) Sheet http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails Stockholders' Equity - Stock Options and Restricted Stock (Details) Details 51 false false R52.htm 99941003 - Disclosure - Stockholders' Equity - Employee Stock Purchase Plan (Details) Sheet http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails Stockholders' Equity - Employee Stock Purchase Plan (Details) Details 52 false false R53.htm 99941101 - Disclosure - Revenue (Details) Sheet http://www.tactilemedical.com/role/DisclosureRevenueDetails Revenue (Details) Details http://www.tactilemedical.com/role/DisclosureRevenueTables 53 false false R54.htm 99941201 - Disclosure - Income Taxes (Details) Sheet http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails Income Taxes (Details) Details http://www.tactilemedical.com/role/DisclosureIncomeTaxes 54 false false R55.htm 99941301 - Disclosure - Net Income Per Share - Basic and Diluted Net income Per Share (Details) Sheet http://www.tactilemedical.com/role/DisclosureNetIncomePerShareBasicAndDilutedNetIncomePerShareDetails Net Income Per Share - Basic and Diluted Net income Per Share (Details) Details 55 false false R56.htm 99941302 - Disclosure - Net Income Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) Sheet http://www.tactilemedical.com/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Net Income Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) Details 56 false false R57.htm 99941401 - Disclosure - Fair Value Measurements - Earn out liability (Details) Sheet http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails Fair Value Measurements - Earn out liability (Details) Details 57 false false R58.htm 99941402 - Disclosure - Fair Value Measurements - Fair Value Hierarchy (Details) Sheet http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails Fair Value Measurements - Fair Value Hierarchy (Details) Details 58 false false R59.htm 99941501 - Disclosure - Subsequent Event (Details) Sheet http://www.tactilemedical.com/role/DisclosureSubsequentEventDetails Subsequent Event (Details) Details http://www.tactilemedical.com/role/DisclosureSubsequentEvent 59 false false All Reports Book All Reports tcmd-20240930.xsd tcmd-20240930_cal.xml tcmd-20240930_def.xml tcmd-20240930_lab.xml tcmd-20240930_pre.xml tcmd-20240930x10q.htm http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 80 MetaLinks.json IDEA: XBRL_DOCUMENT { "version": "2.2", "instance": { "tcmd-20240930x10q.htm": { "nsprefix": "tcmd", "nsuri": "http://www.tactilemedical.com/20240930", "dts": { "schema": { "local": ["tcmd-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["tcmd-20240930_cal.xml"] }, "definitionLink": { "local": ["tcmd-20240930_def.xml"] }, "labelLink": { "local": ["tcmd-20240930_lab.xml"] }, "presentationLink": { "local": ["tcmd-20240930_pre.xml"] }, "inline": { "local": ["tcmd-20240930x10q.htm"] } }, "keyStandard": 266, "keyCustom": 35, "axisStandard": 23, "axisCustom": 0, "memberStandard": 33, "memberCustom": 25, "hidden": { "total": 28, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 22, "http://www.tactilemedical.com/20240930": 1 }, "contextCount": 218, "entityCount": 1, "segmentCount": 60, "elementCount": 591, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 739, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4, "http://fasb.org/srt/2024": 2 }, "report": { "R1": { "role": "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets", "longName": "995200100 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2024_VlHgsXmrbkiQmDcIreS1aQ", "name":

"us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_VlHgsXmrbkiQmDcIreS1aQ", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2024_VlHgsXmrbkiQmDcIreS1aQ", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_hBYUht3v7UyU9kEc9cChIA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:PreferredStockParOrStatedValuePerShare", "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_VlHgsXmrbkiQmDcIreS1aQ", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_hBYUht3v7UyU9kEc9cChIA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:PreferredStockParOrStatedValuePerShare", "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations", "longName": "995200200 - Statement - Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_USXctcqRpEulmEaxoNBvlA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_USXctcqRpEulmEaxoNBvlA", "name": "us-gaap:CostOfRevenue", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "unique": true } }, "R5": { "role": "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "longName": "995200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2yNBKzH9v0OOy-c-Jf7Yrg", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2yNBKzH9v0OOy-c-Jf7Yrg", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "995200400 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperations", "longName": "995210101 - Disclosure - Nature of Business and Operations", "shortName": "Nature of Business and Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.tactilemedical.com/role/DisclosureBasisOfPresentation", "longName": "995210201 - Disclosure - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210301 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.tactilemedical.com/role/DisclosureInventories", "longName": "995210401 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssets", "longName": "995210501 - Disclosure - Goodwill and Intangible Assets", "shortName": "Goodwill and Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.tactilemedical.com/role/DisclosureAccruedExpenses", "longName": "995210601 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "tcmd:AccruedExpensesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "tcmd:AccruedExpensesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.tactilemedical.com/role/DisclosureWarrantyReserves", "longName": "995210701 - Disclosure - Warranty Reserves", "shortName": "Warranty Reserves", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.tactilemedical.com/role/DisclosureCreditAgreement", "longName": "995210801 - Disclosure - Credit Agreement", "shortName": "Credit

Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingencies", "longName": "995210901 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.tactilemedical.com/role/DisclosureStockholdersEquity", "longName": "995211001 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.tactilemedical.com/role/DisclosureRevenue", "longName": "995211101 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.tactilemedical.com/role/DisclosureIncomeTaxes", "longName": "995211201 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.tactilemedical.com/role/DisclosureNetIncomePerShare", "longName": "995211301 - Disclosure - Net Income Per Share", "shortName": "Net Income Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.tactilemedical.com/role/DisclosureFairValueMeasurements", "longName": "995211401 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.tactilemedical.com/role/DisclosureSubsequentEvent", "longName": "995211501 - Disclosure - Subsequent Event", "shortName": "Subsequent Event", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_USXctcqRpEulmEaxoNBvlA", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_USXctcqRpEulmEaxoNBvlA", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_USXctcqRpEulmEaxoNBvlA", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920302 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.tactilemedical.com/role/DisclosureInventoriesTables", "longName": "99930403 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsTables", "longName": "99930503 - Disclosure - Goodwill and Intangible Assets (Tables)", "shortName": "Goodwill and Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.tactilemedical.com/role/DisclosureAccruedExpensesTables", "longName": "99930603 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "tcmd:ScheduleOfAccruedExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [

"tcmd:AccruedExpensesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "tcmd:ScheduleOfAccruedExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["tcmd:AccruedExpensesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.tactilemedical.com/role/DisclosureWarrantyReservesTables", "longName": "99930703 - Disclosure - Warranty Reserves (Tables)", "shortName": "Warranty Reserves (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ProductWarrantyDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ProductWarrantyDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.tactilemedical.com/role/DisclosureCreditAgreementTables", "longName": "99930803 - Disclosure - Credit Agreement (Tables)", "shortName": "Credit Agreement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesTables", "longName": "99930903 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "tcmd:AssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "tcmd:AssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables", "longName": "99931003 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.tactilemedical.com/role/DisclosureRevenueTables", "longName": "99931103 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.tactilemedical.com/role/DisclosureNetIncomePerShareTables", "longName": "99931303 - Disclosure - Net Income Per Share (Tables)", "shortName": "Net Income Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsTables", "longName": "99931403 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_5lpj06rDqEG7CT35zVHB5w", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails", "longName": "99940101 - Disclosure - Nature of Business and Operations (Details)", "shortName": "Nature of Business and Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_huiYrDHF4kualG49J97RFg", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_8_2_2016_To_8_2_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_pVLzdLdphUuEBXsIjbkZtA", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_FCQvtWMgL0-xqSB_8FDcCg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:NatureOfOperations", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "unique": true } }, "R36": { "role": "http://www.tactilemedical.com/role/DisclosureInventoriesDetails", "longName": "99940401 - Disclosure - Inventories (Details)", "shortName": "Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "As_Of_9_30_2024_VlHgsXmrbkiQmDcIreS1aQ", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_VlHgsXmrbkiQmDcIreS1aQ", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails", "longName": "99940501 - Disclosure - Goodwill And Intangible Assets (Details)", "shortName": "Goodwill And Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_9_30_2024_VlHgsXmrbkiQmDcIreS1aQ", "name": "us-gaap:Goodwill", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_USXctcqRpEulmEaxoNBvlA", "name": "us-gaap:AssetImpairmentCharges", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "unique": true } }, "R38": { "role": "http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails", "longName": "99940601 - Disclosure - Accrued Expenses (Details)", "shortName": "Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_9_30_2024_VlHgsXmrbkiQmDcIreS1aQ", "name": "us-gaap:ProductWarrantyAccrualClassifiedCurrent", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:ProductWarrantyDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_VlHgsXmrbkiQmDcIreS1aQ", "name": "us-gaap:AccruedProfessionalFeesCurrent",

"unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "tcmd:ScheduleOfAccruedExpensesTableTextBlock", "tcmd:AccruedExpensesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "unique": true } }, "R39": { "role": "http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails", "longName": "99940701 - Disclosure - Warranty Reserves (Details)", "shortName": "Warranty Reserves (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_6_30_2024_3KP1ka8Ku0-TZqit3oPvvQ", "name": "us-gaap:StandardProductWarrantyAccrual", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:ProductWarrantyDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_3KP1ka8Ku0-TZqit3oPvvQ", "name": "us-gaap:StandardProductWarrantyAccrual", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:ProductWarrantyDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails", "longName": "99940801 - Disclosure - Credit Agreement (Details)", "shortName": "Credit Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration_9_8_2021_To_9_8_2021_My2BBTsx3kmVl8qIFx0JKg", "name": "tcmd:LineOfCreditThresholdContingentIncreaseInBorrowingCapacity", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_9_8_2021_To_9_8_2021_My2BBTsx3kmVl8qIFx0JKg", "name": "tcmd:LineOfCreditThresholdContingentIncreaseInBorrowingCapacity", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails", "longName": "99940802 - Disclosure - Credit Agreement - Maturities of Debt (Details)", "shortName": "Credit Agreement - Maturities of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "As_Of_9_30_2024_VlHgsXmrbkiQmDcIreS1aQ", "name": "us-gaap:LongTermDebt", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_k9DdjPe8eE-qtwEg4SwuCg", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "unique": true } }, "R42": { "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails", "longName": "99940901 - Disclosure - Commitments and Contingencies - Lease Obligations (Details)", "shortName": "Commitments and Contingencies - Lease Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As_Of_9_30_2024_srt_RangeAxis_srt_MinimumMember_5vbq7X1CJUyoVRu-6IhWFg", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_srt_RangeAxis_srt_MinimumMember_5vbq7X1CJUyoVRu-6IhWFg", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails", "longName": "99940902 - Disclosure - Commitments and Contingencies - Lease related assets and liabilities (Details)", "shortName": "Commitments and Contingencies - Lease related assets and liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_9_30_2024_VlHgsXmrbkiQmDcIreS1aQ", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_VlHgsXmrbkiQmDcIreS1aQ", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "td", "tr", "table", "tcmd:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "unique": true } }, "R44": { "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails", "longName": "99940903 - Disclosure - Commitments and Contingencies - Undiscounted cash flows (Details)", "shortName": "Commitments and Contingencies - Undiscounted cash flows (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "As_Of_9_30_2024_VlHgsXmrbkiQmDcIreS1aQ", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_VlHgsXmrbkiQmDcIreS1aQ", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseCommitmentsAndOperatingLeaseCostDetails", "longName": "99940904 - Disclosure - Commitments and Contingencies - Lease commitments and operating lease cost (Details)", "shortName": "Commitments and Contingencies - Lease commitments and operating lease cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_USXctcqRpEulmEaxoNBvlA", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_USXctcqRpEulmEaxoNBvlA", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails", "longName": "99940905 - Disclosure - Commitments and Contingencies - Major Vendors (Details)", "shortName": "Commitments and Contingencies - Major Vendors (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_tcmd_VendorOneMember_UZoIqoy2X0mTznM5sRkKtg", "name": "tcmd:NumberOfVendors", "unitRef": "Unit_Standard_item_evkLIrk2rk23-_Z06ESOBQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_tcmd_VendorOneMember_x35u9WxTBEi87qDzkrZDvQ", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Unit_Standard_pure_GF-KXShMXkWJgoobb1WZ8w", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "unique": true } }, "R47": { "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails", "longName": "99940906 - Disclosure - Commitments and Contingencies - Purchase Commitments (Details)", "shortName": "Commitments and Contingencies - Purchase Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_9_30_2024_VlHgsXmrbkiQmDcIreS1aQ", "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_VlHgsXmrbkiQmDcIreS1aQ", "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails", "longName": "99940907 - Disclosure - Commitments and Contingencies - Retirement Plan (Details)", "shortName": "Commitments and Contingencies - Retirement Plan (Details)",

"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_RetirementPlanNameAxis_tcmd_DefinedContribution401kRetirementPlanMember_UkthLY6LEkWF7tB8PcW9ZQ", "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_RetirementPlanNameAxis_tcmd_DefinedContribution401kRetirementPlanMember_UkthLY6LEkWF7tB8PcW9ZQ", "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLegalProceedingsDetails", "longName": "99940908 - Disclosure - Commitments and Contingencies - Legal Proceedings (Details)", "shortName": "Commitments and Contingencies - Legal Proceedings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "Duration_9_4_2024_To_9_4_2024_YqyeP7KK9kK3JAlGgWzxTw", "name": "us-gaap:LossContingencyLossInPeriod", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_9_4_2024_To_9_4_2024_YqyeP7KK9kK3JAlGgWzxTw", "name": "us-gaap:LossContingencyLossInPeriod", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails", "longName": "99941001 - Disclosure - Stockholders' Equity - Stock-Based Compensation (Details)", "shortName": "Stockholders' Equity - Stock-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_USXctcqRpEulmEaxoNBvlA", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_T6Z9-uKEZ02UGw0NEek8fA", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "unique": true } }, "R51": { "role": "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails", "longName": "99941002 - Disclosure - Stockholders' Equity - Stock Options and Restricted Stock (Details)", "shortName": "Stockholders' Equity - Stock Options and Restricted Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_USXctcqRpEulmEaxoNBvlA", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cjUGJNZHZEib_5sE6zquXQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "unique": true } }, "R52": { "role": "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails", "longName": "99941003 - Disclosure - Stockholders' Equity - Employee Stock Purchase Plan (Details)", "shortName": "Stockholders' Equity - Employee Stock Purchase Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_USXctcqRpEulmEaxoNBvlA", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_h3PzA-XnaUiU2u0ulF9xAQ", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "unitRef": "Unit_Standard_pure_GF-KXShMXkWJgoobb1WZ8w", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "unique": true } }, "R53": { "role": "http://www.tactilemedical.com/role/DisclosureRevenueDetails", "longName": "99941101 - Disclosure - Revenue (Details)", "shortName": "Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_USXctcqRpEulmEaxoNBvlA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_USXctcqRpEulmEaxoNBvlA", "name": "tcmd:PercentageOfRevenue", "unitRef": "Unit_Standard_pure_GF-KXShMXkWJgoobb1WZ8w", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "unique": true } }, "R54": { "role": "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails", "longName": "99941201 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_USXctcqRpEulmEaxoNBvlA", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_USXctcqRpEulmEaxoNBvlA", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Unit_Standard_pure_GF-KXShMXkWJgoobb1WZ8w", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "unique": true } }, "R55": { "role": "http://www.tactilemedical.com/role/DisclosureNetIncomePerShareBasicAndDilutedNetIncomePerShareDetails", "longName": "99941301 - Disclosure - Net Income Per Share - Basic and Diluted Net income Per Share (Details)", "shortName": "Net Income Per Share - Basic and Diluted Net income Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_USXctcqRpEulmEaxoNBvlA", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_USXctcqRpEulmEaxoNBvlA", "name": "us-gaap:EarningsPerShareBasic", "unitRef": "Unit_Divide_USD_shares_hBYUht3v7UyU9kEc9cChIA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "unique": true } }, "R56": { "role": "http://www.tactilemedical.com/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "longName": "99941302 - Disclosure - Net Income Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)", "shortName": "Net Income Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_USXctcqRpEulmEaxoNBvlA", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_FCQvtWMgL0-xqSB_8FDcCg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_USXctcqRpEulmEaxoNBvlA", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_FCQvtWMgL0-xqSB_8FDcCg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails", "longName": "99941401 - Disclosure - Fair Value Measurements - Earn out liability (Details)", "shortName": "Fair Value Measurements - Earn out liability (Details)", "isDefault": "false",

"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "Duration_11_28_2023_To_11_28_2023_MIKYUvj2BkuC7i4UMJxNvg", "name": "us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_EzaqTK_24k2XErWf-uD1Rg", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "unique": true } }, "R58": { "role": "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails", "longName": "99941402 - Disclosure - Fair Value Measurements - Fair Value Hierarchy (Details)", "shortName": "Fair Value Measurements - Fair Value Hierarchy (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "Duration_11_28_2023_To_11_28_2023_MIKYUvj2BkuC7i4UMJxNvg", "name": "us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_5_25_2023_To_5_25_2023_XV9xYg1iOU63AdYyJkaKpw", "name": "tcmd:BusinessCombinationContingentConsiderationLiabilityImputedInterestPayment", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "unique": true } }, "R59": { "role": "http://www.tactilemedical.com/role/DisclosureSubsequentEventDetails", "longName": "99941501 - Disclosure - Subsequent Event (Details)", "shortName": "Subsequent Event (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "As_Of_10_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_SaiF8NmTFEGFecH6I73Xlg", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "Unit_Standard_USD_gwwnOrqZHEqZBwnDJQ1HNQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tcmd-20240930x10q.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r46", "r606"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r738"] }, "tcmd_AccruedClinicalStudiesExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "AccruedClinicalStudiesExpensesCurrent", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "The carrying amount as of the balance sheet date of accrued clinical studies.", "label": "Accrued Clinical Studies Expenses, Current", "terseLabel": "Clinical studies" } } }, "auth_ref": [] }, "tcmd_AccruedExpensesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "AccruedExpensesDisclosureCurrentTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureAccruedExpenses"], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accrued expenses that are classified as current at the end of the reporting period.", "label": "Accrued Expenses Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses" } } }, "auth_ref": [] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": ["r49", "r98"] }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesNoncurrent", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued Income Taxes, Noncurrent", "verboseLabel": "Income taxes payable, non-current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent." } } }, "auth_ref": ["r53", "r98"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r49"] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Legal and consulting", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r49"] }, "tcmd_AccruedSalesAndUseTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "AccruedSalesAndUseTax", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations relating to sales and use tax.", "label": "Accrued Sales And Use Tax", "terseLabel": "Sales and use tax" } } }, "auth_ref": [] }, "tcmd_AccruedTravelAndEntertainmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "AccruedTravelAndEntertainmentCurrent", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for travel and entertainment expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Travel And Entertainment Current", "terseLabel": "Travel" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r661"] }, "tcmd_AdditionalOfficeSpaceAdded": { "xbrltype": "areaItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "AdditionalOfficeSpaceAdded", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"], "lang": { "en-us": { "role": { "documentation": "Additional office space added to the lease.", "label": "Additional office space added", "terseLabel": "Additional office space added to the lease" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r58", "r606", "r919"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-In Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r499", "r728", "r729", "r730", "r731", "r867", "r920"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r674"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri":

"http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r674"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r674"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r674"] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "tcmd_AfflovestPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "AfflovestPMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Represent information pertaining to AffloVest APA.", "label": "AffloVest APA", "terseLabel": "AffloVest APA" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r707"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r633", "r643", "r653", "r685"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r636", "r646", "r656", "r688"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r708"] }, "tcmd_AirwayClearanceProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "AirwayClearanceProductsMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Airway clearance products.", "label": "Airway clearance products", "terseLabel": "Airway clearance products" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r674"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r681"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r637", "r647", "r657", "r681", "r689", "r693", "r701"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r699"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Allocated Share-based Compensation Expense", "terseLabel": "Compensation expense", "verboseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r348", "r350"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r4", "r216", "r223", "r573"] }, "tcmd_AmortizationOfIntangibleAssetsAndEarnOuts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "AmortizationOfIntangibleAssetsAndEarnOuts", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "documentation": "Amount of impairment of intangible asset and earn outs.", "label": "Amortization of Intangible Assets and Earn outs", "terseLabel": "Intangible asset amortization and earn-out" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.tactilemedical.com/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r188"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.tactilemedical.com/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r20"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.tactilemedical.com/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Net Income Per Share", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.tactilemedical.com/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to

securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r20"] }, "us-gaap_AreaOfLand": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfLand", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"], "lang": { "en-us": { "role": { "label": "Area of Land", "terseLabel": "Area of office space", "documentation": "Area of land held." } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Asset Impairment Charges", "verboseLabel": "Impairment recognized", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": ["r4", "r28"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r97", "r108", "r141", "r163", "r192", "r196", "r202", "r203", "r208", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r381", "r385", "r415", "r461", "r522", "r569", "r570", "r606", "r624", "r771", "r772", "r877"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsAndLiabilitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAndLiabilitiesLesseeAbstract", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Assets and Liabilities, Lessee [Abstract]", "terseLabel": "Lease-related assets and liabilities" } } }, "auth_ref": [] }, "tcmd_AssetsAndLiabilitiesLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of lease-related assets and liabilities.", "label": "Assets and Liabilities, Lessee [Table Text Block]", "terseLabel": "Summary of lease-related assets and liabilities" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r135", "r148", "r163", "r208", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r381", "r385", "r415", "r606", "r771", "r772", "r877"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent", "totalLabel": "Total non-current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r163", "r208", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r381", "r385", "r415", "r771", "r772", "r877"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r696"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r697"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r692"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r692"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r692"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r692"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r692"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r692"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r695"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r694"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r693"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r693"] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BaseRateMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Base Rate", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureBasisOfPresentation"], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "verboseLabel": "Basis of Presentation", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r80"] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"], "lang": { "en-us": { "role": { "label": "Building", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": ["r83"] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r217", "r218", "r219",

"r220", "r221", "r375", "r588", "r589"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r37", "r38", "r217", "r218", "r219", "r220", "r221", "r375", "r588", "r589"] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Fair value adjustments", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": ["r377", "r721"] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Earn-out liability, ending balance", "periodStartLabel": "Earn-out liability, beginning balance", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": ["r41", "r95", "r376", "r399", "r400", "r401"] }, "tcmd_BusinessCombinationContingentConsiderationLiabilityImputedInterestPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "BusinessCombinationContingentConsiderationLiabilityImputedInterestPayment", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for imputed interest payment on business combination contingent consideration liability.", "label": "Business Combination Contingent Consideration Liability imputed interest payment", "terseLabel": "Imputed interest payment" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r15", "r137", "r563"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents - end of period", "periodStartLabel": "Cash and cash equivalents - beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r15", "r76", "r160"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r76"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r672"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r669"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r667"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "verboseLabel": "Stockholders' Equity", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r144", "r145", "r146", "r195", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r492", "r493", "r494", "r495", "r577", "r711", "r724"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r673"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r673"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r84", "r238", "r239", "r558", "r757", "r759"] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares reserved", "verboseLabel": "Shares available for future issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r57"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r614", "r615", "r616", "r618", "r619", "r620", "r621", "r728", "r729", "r731", "r867", "r918", "r920"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r57"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r57", "r510"] }, "us-gaap_CommonStockSharesIssued": {

"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares, issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r57"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares, outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r7", "r57", "r510", "r528", "r920", "r921"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value, 300,000,000 shares authorized; 23,997,089 shares issued and outstanding as of September 30, 2024; 23,600,584 shares issued and outstanding as of December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r57", "r463", "r606"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r678"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r677"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r679"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r676"] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r22", "r23", "r43", "r44", "r206", "r557"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r22", "r23", "r43", "r44", "r206", "r490", "r557"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r22", "r23", "r43", "r44", "r206", "r557", "r714"] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk [Line Items]", "verboseLabel": "Commitments and Contingencies", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r557"] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk, Percentage", "terseLabel": "Total purchases (in percentage)", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r22", "r23", "r43", "r44", "r206"] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": ["r21", "r22", "r23", "r24", "r43", "r96", "r557"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r22", "r23", "r43", "r44", "r206", "r557"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r42", "r565"] }, "tcmd_CorporateHeadQuarterInitialLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "CorporateHeadQuarterInitialLeaseMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents member for initial lease for corporate head quarter.", "label": "Initial lease" } } }, "auth_ref": [] }, "tcmd_CorporateHeadQuarterSecondLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "CorporateHeadQuarterSecondLeaseMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents member for second lease corporate head quarter.", "label": "Second lease" } } }, "auth_ref": [] }, "tcmd_CorporateHeadQuarterThirdLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "CorporateHeadQuarterThirdLeaseMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents member for third lease corporate head quarter.", "label": "Third lease" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsSoldSalesTypeLease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsSoldSalesTypeLease", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureRevenueDetails"], "lang": { "en-us": { "role": { "label": "Cost of Goods Sold, Sales-type Lease", "terseLabel": "Cost of sales-type lease revenue", "documentation": "Cost of goods sold for sales-type financing lease." } } }, "auth_ref": ["r193", "r442"] }, "us-gaap_CostOfGoodsTotalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsTotalMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"], "lang": { "en-us": { "role": { "label": "Purchases", "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r713"] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Cost of Revenue", "terseLabel": "Total cost of revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": ["r69", "r163", "r208", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r415", "r569", "r771"] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Cost of

revenue.", "terseLabel": "Cost of revenue.", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "tcmd_CreditAgreementTotalAggregatePrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "CreditAgreementTotalAggregatePrincipalAmount", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The total aggregate principal amount under the credit agreement.", "label": "Credit Agreement, Total Aggregate Principal Amount", "terseLabel": "Credit agreement, total aggregate principal amount" } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails", "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r257", "r769"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails", "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r257", "r769", "r770"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerContractsMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Customer accounts", "terseLabel": "Customer accounts", "documentation": "Entity's established relationships with its customers through contracts." } } }, "auth_ref": ["r40", "r745", "r746", "r747", "r748", "r750", "r752", "r755", "r756"] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Customer relationships", "terseLabel": "Customer relationships", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": ["r40", "r745", "r746", "r747", "r748", "r750", "r752", "r755", "r756"] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Credit Agreement" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreement"], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "verboseLabel": "Credit Agreement", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r85", "r162", "r231", "r232", "r233", "r234", "r235", "r256", "r257", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r277", "r279", "r280", "r281", "r423"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "verboseLabel": "Basis spread (as a percent)", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Gross", "totalLabel": "Total", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": ["r11", "r100", "r282"] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument face amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r268", "r423", "r424", "r575", "r576", "r604"] }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Frequency of Periodic Payment", "terseLabel": "Debt instrument frequency of periodic payment", "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)." } } }, "auth_ref": ["r11", "r45"] }, "tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "DebtInstrumentPaymentOfMandatoryPrincipalPrepayment", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of mandatory principal prepayment paid", "label": "Debt Instrument, Payment of Mandatory Principal Prepayment", "terseLabel": "Principal prepayment of term loan" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment", "terseLabel": "Debt instrument periodic payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": ["r11", "r45"] }, "tcmd_DefensiveIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "DefensiveIntangibleAssetsMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for defensive intangible assets.", "label": "Defensive intangible assets", "terseLabel": "Defensive intangible assets" } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs, Net", "negatedLabel": "Less: Deferred financing fees", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r774", "r872", "r873", "r874"] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net, Noncurrent", "terseLabel": "Deferred income taxes", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": ["r354", "r355"] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred income taxes", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": ["r79"] }, "tcmd_DefinedContribution401kRetirementPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "DefinedContribution401kRetirementPlanMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails"], "lang": { "en-us": { "role": { "documentation": "Represent information pertaining to Defined Contribution 401K Retirement Plan", "label": "401(k)" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanDisclosureLineItems", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan Disclosure [Line Items]", "verboseLabel": "Retirement Plan", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r310"] }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Discretionary contributions", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanTable", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails"], "lang": { "en-us": { "role": { "label":

"Defined Contribution Plan [Table]", "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans." } } }, "auth_ref": ["r310"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r4", "r192", "r199", "r203", "r569", "r570"] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Developed technology", "terseLabel": "Developed technology", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": ["r94", "r745", "r746", "r747", "r748", "r750", "r752", "r755", "r756"] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://www.tactilemedical.com/role/DisclosureRevenueDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Revenue", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r301", "r578", "r579", "r580", "r581", "r582", "r583", "r584"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://www.tactilemedical.com/role/DisclosureRevenueDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r301", "r578", "r579", "r580", "r581", "r582", "r583", "r584"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureRevenueTables"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Summary of revenue disaggregated by product", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r776"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r628"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r660"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "tcmd_DurableMedicalEquipmentDistributorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "DurableMedicalEquipmentDistributorsMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Durable medical equipment distributors.", "label": "Durable medical equipment distributors", "terseLabel": "Durable medical equipment distributors" } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r671"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Net Income Per Share", "terseLabel": "Net income per common share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.tactilemedical.com/role/DisclosureNetIncomePerShareBasicAndDilutedNetIncomePerShareDetails"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net income per share - Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r154", "r171", "r172", "r173", "r174", "r175", "r176", "r181", "r183", "r185", "r186", "r187", "r191", "r373", "r379", "r394", "r395", "r458", "r471", "r566"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.tactilemedical.com/role/DisclosureNetIncomePerShareBasicAndDilutedNetIncomePerShareDetails"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net income per share - Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r154", "r171", "r172", "r173", "r174", "r175", "r176", "r183", "r185", "r186", "r187", "r191", "r373", "r379", "r394", "r395", "r458", "r471", "r566"] }, "tcmd_EarningsPerShareOtherDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "EarningsPerShareOtherDisclosureAbstract", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Earnings Per Share Other Disclosure [Abstract]", "verboseLabel": "Weighted-average common shares used to compute net income per common share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureNetIncomePerShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Income Per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r180", "r188", "r189", "r190"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Net effective rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r357", "r594"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "presentation": ["http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and related taxes", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r49"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-

based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Weighted-average period over which unrecognized compensation cost is expected to be recognized", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r349"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options", "terseLabel": "Total unrecognized pre-tax compensation expense related to awards", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r863"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "terseLabel": "Total unrecognized pre-tax compensation expense related to nonvested stock option awards", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r863"] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "label": "Employee Stock Purchase Plan", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Common stock options", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "tcmd_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "EmployeeStockPurchasePlanMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Employee stock purchase plan shares.", "label": "Employee stock purchase plan [Member]", "terseLabel": "Employee stock purchase plan" } } }, "auth_ref": [] }, "tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "EmployeeStockPurchasePlanOfferingPeriodsPeriod", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "documentation": "Period which an employee's right to purchase shares of stock at a discount, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Employee Stock Purchase Plan, Offering Periods, Period", "terseLabel": "Offering period (in months)" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r626"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r626"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r626"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r710"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r626"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":

"EntityShellCompany", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r626"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r626"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r626"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r665"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r706"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r706"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r706"] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"], "lang": { "en-us": { "role": { "label": "Equipment", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r7", "r133", "r151", "r152", "r153", "r166", "r167", "r168", "r170", "r175", "r177", "r179", "r194", "r209", "r210", "r229", "r291", "r363", "r364", "r370", "r371", "r372", "r374", "r378", "r379", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r416", "r417", "r418", "r419", "r420", "r421", "r425", "r426", "r443", "r470", "r484", "r485", "r486", "r499", "r548"] }, "tcmd_EquityIncentivePlan2016Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "EquityIncentivePlan2016Member", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the 2016 Equity Incentive Plan (the \"2016 Plan\").", "label": "2016 Plan" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r675"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r633", "r643", "r653", "r685"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r630", "r640", "r650", "r682"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r681"] }, "tcmd_ExpenseRelatingToInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "ExpenseRelatingToInitialPublicOffering", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of expenses relating to the initial public offering during the period.", "label": "Expense Relating To Initial Public Offering", "terseLabel": "Expense Relating To Initial Public Offering" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Measurements", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r397", "r398", "r408", "r597"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r397", "r398", "r408", "r597"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Hierarchy [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r276", "r304", "r305", "r306", "r307", "r308", "r309", "r396", "r398", "r399", "r400", "r401", "r407", "r408", "r410", "r447", "r448", "r449", "r575", "r576", "r585", "r586", "r587", "r597", "r600"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureFairValueMeasurements"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r403", "r405", "r406", "r407", "r410", "r411", "r412", "r413", "r414", "r456", "r597", "r601"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Significant Unobservable Inputs (Level 3)", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r276", "r304", "r305", "r306", "r307", "r308", "r309", "r398", "r399", "r400", "r401", "r408", "r449", "r575", "r576", "r585", "r586", "r587", "r597", "r600"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [

"r276", "r304", "r305", "r306", "r307", "r308", "r309", "r396", "r398", "r399", "r400", "r401", "r407", "r408", "r410", "r447", "r448", "r449", "r575", "r576", "r585", "r586", "r587", "r597", "r600"] }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FederalFundsEffectiveSwapRateMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Federal Funds", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg." } } }, "auth_ref": ["r866"] }, "tcmd_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r139", "r213", "r222", "r573"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r224", "r561", "r573"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "2024 (October 1 - December 31)", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": ["r922"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r224", "r561", "r573"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r224", "r561", "r573"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r224", "r561", "r573"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r215", "r217", "r218", "r219", "r221", "r222", "r226", "r227", "r454", "r455", "r561"] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Future Amortization" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r213", "r222", "r455", "r573"] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "verboseLabel": "Goodwill and Intangible Assets", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r215", "r222", "r226", "r227", "r228", "r454", "r561", "r573"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r215", "r217", "r218", "r219", "r221", "r222", "r226", "r227", "r561"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r454", "r752"] }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNetAbstract", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]", "terseLabel": "Definite-lived intangible assets:" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "verboseLabel": "Weighted Average Amortization Period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r454"] }, "tcmd_FollowOnPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "FollowOnPublicOfferingMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to follow on public offering.", "label": "Follow On Public Offering [Member]", "terseLabel": "Follow-On Public Offering" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r637", "r647", "r657", "r689"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r637", "r647", "r657", "r689"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",

"presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r637", "r647", "r657", "r689"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r637", "r647", "r657", "r689"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r637", "r647", "r657", "r689"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r670"] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Loss on disposal of property and equipment and intangibles", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": ["r722"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "Reimbursement, general and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r71", "r532"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Reimbursement, general and administrative expenses", "terseLabel": "Reimbursement, general and administrative expenses", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r71"] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Goodwill", "terseLabel": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r138", "r214", "r457", "r570", "r572", "r598", "r606", "r742", "r743"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssets"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": ["r741", "r744"] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r66", "r69", "r107", "r163", "r208", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r415", "r568", "r569", "r733", "r734", "r735", "r736", "r737", "r771"] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IPOMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails"], "lang": { "en-us": { "role": { "label": "IPO", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "tcmd_InTransitInventoryAccruedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "InTransitInventoryAccruedExpense", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "In-transit inventory accrued expense.", "label": "In-transit inventory accrued expense", "terseLabel": "In-transit inventory" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r67", "r102", "r107", "r459", "r467", "r568", "r569", "r733", "r734", "r735", "r736", "r737"] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Basic", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r68", "r103", "r154", "r169", "r171", "r172", "r173", "r174", "r175", "r183", "r185", "r186", "r373", "r379", "r395", "r458", "r887"] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Diluted", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r68", "r154", "r169", "r171", "r172", "r173", "r174", "r175", "r183", "r185", "r186", "r187", "r379", "r395", "r458", "r887"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Operations" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r230", "r236", "r237", "r402", "r404", "r409", "r481", "r483", "r533", "r561", "r599", "r889"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r236", "r237", "r402", "r404", "r409", "r481", "r483", "r533", "r561", "r599", "r889"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureIncomeTaxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r164", "r353", "r357", "r358", "r359", "r360", "r361", "r362", "r365", "r367", "r368", "r369", "r497", "r594"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense (benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r110", "r116", "r178", "r179", "r192", "r200", "r203", "r356", "r357", "r366", "r472", "r594"] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Income

Taxes Paid", "terseLabel": "Cash paid for taxes", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r16", "r78", "r723", "r864", "r865"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerAsset", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Contract Receivables, Net", "negatedLabel": "Accounts receivable, non-current", "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": ["r721"] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued payroll and related taxes", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Income Taxes Receivable", "negatedLabel": "Income taxes", "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r3"] }, "tcmd_IncreaseDecreaseInNetInvestmentInLease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "IncreaseDecreaseInNetInvestmentInLease", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Represents the increase (decrease) in net investment in leases.", "label": "Increase (Decrease) In Net Investment in Lease", "negatedLabel": "Net investment in leases" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities, net of acquisition:" } } }, "auth_ref": [] }, "tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Represents the increase (decrease) in right of use operating lease assets.", "label": "Increase (Decrease) In Operating Lease Right Of Use Asset", "negatedLabel": "Right of use operating lease assets" } } }, "auth_ref": [] }, "tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses (excluding accrued payroll and related taxes) and income taxes payable incurred but not yet paid.", "label": "Increase Decrease In Other Accrued Liabilities And Income Taxes Payable", "terseLabel": "Accrued expenses and other liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Stockholders' Equity", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "tcmd_IncrementalShareIncrease": { "xbrltype": "sharesItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "IncrementalShareIncrease", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the minimum increase in shares on an annual basis.", "label": "Incremental Share Increase", "terseLabel": "Incremental share increase (in shares)" } } }, "auth_ref": [] }, "tcmd_IncrementalSharesToBeIssuedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "IncrementalSharesToBeIssuedPercentage", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the incremental annual share percentage increase minimum.", "label": "Incremental Shares To Be Issued Percentage", "terseLabel": "Incremental share increase (as a percent)" } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r215", "r220", "r225", "r573"] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Gross Carrying Amount, Indefinite", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r213", "r225", "r573"] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]", "terseLabel": "Unamortized intangible assets:" } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": ["r215", "r220", "r225", "r573"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r637", "r647", "r657", "r681", "r689", "r693", "r701"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r699"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r629", "r705"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } },

"auth_ref": ["r629", "r705"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r629", "r705"] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Intangible Assets, Gross (Excluding Goodwill)", "verboseLabel": "Total intangible assets (Gross)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": ["r138"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill)", "netLabel": "Total intangible assets (Net)", "terseLabel": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r215", "r752", "r754"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Interest Paid, Net", "terseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r155", "r158", "r159"] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventories" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureInventories"], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r212"] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureInventoriesDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": ["r716"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureInventoriesDetails", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r147", "r564", "r606"] }, "us-gaap_InventoryNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNetAbstract", "presentation": ["http://www.tactilemedical.com/role/DisclosureInventoriesDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Net [Abstract]", "verboseLabel": "Inventories" } } }, "auth_ref": [] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureInventoriesDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Work in Process, Gross", "terseLabel": "Component parts and work-in-process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": ["r717"] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "verboseLabel": "Commitments and Contingencies", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r431", "r439"] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": ["r431", "r439"] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Option to renew", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": ["r432"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r437"] }, "tcmd_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due after Year Four", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r437"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r437"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r437"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r437"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2024 (October 1 - December 31)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r876"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [

"http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Amount of lease payments representing interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r437"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease terms", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r875"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r11", "r48", "r49", "r50", "r52", "r53", "r54", "r55", "r163", "r208", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r382", "r385", "r386", "r415", "r509", "r567", "r624", "r771", "r877", "r878"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r62", "r101", "r465", "r606", "r726", "r739", "r871"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r50", "r136", "r163", "r208", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r382", "r385", "r386", "r415", "r606", "r771", "r877", "r878"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueAdjustment", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Adjustment", "negatedLabel": "Change in fair value of earn-out liability", "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Total long-term liabilities, net of current portion", "totalLabel": "Total non-current liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r11", "r52", "r53", "r54", "r55", "r163", "r208", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r382", "r385", "r386", "r415", "r771", "r877", "r878"] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current liabilities" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Long-term Line of Credit", "verboseLabel": "Credit facility outstanding amount", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": ["r11", "r100", "r886"] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLineItems", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails", "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Line Items]", "verboseLabel": "Credit Agreement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r257", "r725", "r769"] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "verboseLabel": "Line of credit", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r47", "r51"] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityTable", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails", "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Table]", "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement." } } }, "auth_ref": ["r47", "r51", "r257", "r725", "r769"] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Unused line fee (as a percent)", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "LineOfCreditThresholdContingentIncreaseInBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Line Of Credit, Threshold Contingent Increase In Borrowing Capacity", "label": "Line Of Credit, Threshold Contingent Increase In Borrowing Capacity", "terseLabel": "Line of credit, threshold contingent increase in borrowing capacity" } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLegalProceedingsDetails"], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim." } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLegalProceedingsDetails"], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails", "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Long-term Debt", "terseLabel": "Long-term debt", "totalLabel": "Net Note Payable", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r11", "r100", "r275", "r283", "r575", "r576", "r604", "r886"] }, "us-gaap_LongTermDebtByMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtByMaturityAbstract", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Long-term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Maturities of notes payable" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"LongTermDebtCurrent", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Current Maturities", "negatedLabel": "Less: Current portion of note payable", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": ["r142"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r6", "r165", "r278"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r6", "r165", "r278"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2024 (October 1 - December 31)", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": ["r727"] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Long-term Debt, Excluding Current Maturities", "verboseLabel": "Non-current portion of note payable", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r143"] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermNotesPayable", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Notes Payable, Noncurrent", "terseLabel": "Note payable, non-current", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": ["r11"] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLegalProceedingsDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r240", "r241", "r242", "r245", "r351", "r574", "r761", "r762"] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLegalProceedingsDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": ["r240", "r241", "r242", "r245", "r351", "r574", "r761", "r762"] }, "us-gaap_LossContingencyLossInPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyLossInPeriod", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLegalProceedingsDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingency, Loss in Period", "terseLabel": "Attorneys' fees and expense", "documentation": "The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates." } } }, "auth_ref": ["r760"] }, "tcmd_LymphedemaProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "LymphedemaProductsMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Lymphedema products.", "label": "Lymphedema products", "terseLabel": "Lymphedema products" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": ["http://www.tactilemedical.com/role/DisclosureRevenueDetails"], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": ["r206", "r580", "r608", "r611", "r776", "r888", "r890", "r891", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails", "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails", "http://www.tactilemedical.com/role/DisclosureRevenueDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Maximum", "terseLabel": "Maximum", "documentation": "Upper limit of the provided range." } } }, "auth_ref": ["r119", "r120", "r121", "r122", "r123", "r131", "r132", "r241", "r242", "r243", "r244", "r314", "r351", "r401", "r452", "r480", "r482", "r489", "r501", "r502", "r551", "r552", "r553", "r554", "r555", "r559", "r560", "r571", "r577", "r590", "r600", "r601", "r602", "r603", "r609", "r773", "r879", "r880", "r881", "r882", "r883", "r884"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r673"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r673"] }, "tcmd_MedicareAccountsReceivableNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "MedicareAccountsReceivableNonCurrent", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Amount of non-current accounts receivable on account of medicare.", "label": "Medicare Accounts Receivable Non Current", "verboseLabel": "Accounts receivable, non-current" } } }, "auth_ref": [] }, "tcmd_MedicareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "MedicareMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to government payer medicare.", "label": "Medicare", "terseLabel": "Medicare" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails", "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails", "http://www.tactilemedical.com/role/DisclosureRevenueDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Minimum", "terseLabel": "Minimum", "documentation": "Lower limit of the provided range." } } }, "auth_ref": ["r119", "r120", "r121", "r122", "r123", "r131", "r132", "r241", "r242", "r243", "r244", "r314", "r351", "r401", "r452", "r480", "r482", "r489", "r501", "r502", "r551", "r552", "r553", "r554", "r555", "r559", "r560", "r571", "r577", "r590", "r600", "r601", "r602", "r609", "r773", "r879", "r880", "r881", "r882", "r883", "r884"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r692"] }, "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MovementInStandardProductWarrantyAccrualRollForward", "presentation": ["http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails"], "lang": { "en-us": { "role": { "label": "Movement in Standard Product Warranty Accrual [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r700"] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": ["http://www.tactilemedical.com/role/DisclosureRevenueDetails"], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": ["r206", "r580", "r608", "r611", "r776", "r888", "r890", "r891", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r674"] }, "tcmd_NatureOfBusinessAndOperationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "NatureOfBusinessAndOperationAbstract", "lang": { "en-us": {

"role": { "documentation": "n/a", "label": "Nature of Business and Operations" } } }, "auth_ref": [] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": ["http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperations"], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "verboseLabel": "Nature of Business and Operations", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": ["r111", "r117"] }, "us-gaap_NetCashProvidedByUsedInContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInContinuingOperationsAbstract", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Continuing Operations [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r157"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r157"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r76", "r77", "r79"] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureNetIncomePerShareBasicAndDilutedNetIncomePerShareDetails", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net income", "verboseLabel": "Net income for the period", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r70", "r79", "r104", "r134", "r149", "r150", "r153", "r163", "r169", "r171", "r172", "r173", "r174", "r175", "r178", "r179", "r184", "r208", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r373", "r379", "r395", "r415", "r469", "r530", "r546", "r547", "r622", "r771"] }, "us-gaap_NetInvestmentInLease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentInLease", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Net Investment in Lease", "terseLabel": "Net investment in leases", "documentation": "Amount, before allowance for credit loss, of net investment in sales-type and direct financing leases." } } }, "auth_ref": ["r109", "r211", "r440", "r740"] }, "tcmd_NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements not yet adopted.", "label": "New Accounting Pronouncements, Note Yet Adopted Policy [Policy Text Block]", "terseLabel": "Accounting Pronouncement Not Yet Adopted" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r673"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r637", "r647", "r657", "r681", "r689"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r664"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r663"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r681"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r700"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r700"] }, "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired", "terseLabel": "Capital expenditures incurred but not yet paid", "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r17", "r18", "r19"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "verboseLabel": "Other income (expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r72"] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableCurrent", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Notes Payable, Current", "terseLabel": "Note payable", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": ["r48", "r49"] }, "tcmd_NumberOfOfficerAndDirectors": { "xbrltype": "integerItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "NumberOfOfficerAndDirectors", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLegalProceedingsDetails"], "lang": { "en-us": { "role": { "documentation": "Number of officers and directors.", "label": "Number of officer and directors", "terseLabel": "Number of former officers and directors" } } }, "auth_ref": [] }, "tcmd_NumberOfVendors": { "xbrltype": "integerItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "NumberOfVendors", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"], "lang": { "en-us": { "role": {

"documentation": "Represents the number of vendors.", "label": "Number Of Vendors", "terseLabel": "Number of vendors" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Income from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r107", "r568", "r733", "r734", "r735", "r736", "r737"] }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Operating Lease, Lease Income [Table Text Block]", "terseLabel": "Summary of undiscounted cash flows", "documentation": "Tabular disclosure of components of income from operating lease." } } }, "auth_ref": ["r193", "r441"] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease Liabilities, Payments Due [Abstract]", "terseLabel": "Undiscounted cash flows" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails", "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "totalLabel": "Present value of future minimum lease payments", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r428"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails", "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "negatedLabel": "Less: Current obligations under operating lease liabilities", "terseLabel": "Operating lease liabilities", "verboseLabel": "Operating lease liabilities, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r428"] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": ["r429"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails", "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current", "verboseLabel": "Non-current obligations under operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r428"] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": ["r429"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Cash paid for operating lease liabilities", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r430", "r433"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Right of use operating lease assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r427"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseCommitmentsAndOperatingLeaseCostDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Operating lease cost", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r722"] }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": ["r429"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r436", "r605"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r435", "r605"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Basis of Presentation" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r49"] }, "us-gaap_OtherAssetsMiscellaneousAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMiscellaneousAbstract", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Assets, Miscellaneous [Abstract]", "terseLabel": "Non-current assets" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r140"] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"

```
], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r49", "r606" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r673" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r635", "r645", "r655", "r687" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r638", "r648", "r658", "r690" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r638", "r648", "r658", "r690" ] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PatentsMember", "presentation": [ "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Patents", "terseLabel": "Patents pending", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r94", "r745", "r746", "r747", "r748", "r750", "r752", "r755", "r756" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r662" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "presentation": [ "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails", "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedLabel": "Payments on earn-out", "verboseLabel": "Earn-out liability payment", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r2" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payments of deferred debt issuance costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r14" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "presentation": [ "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Intangible assets expenditures", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r74" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r74" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r672" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r672" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r664" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r681" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r674" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r663" ] }, "tcmd_PercentageOfRevenue": { "xbrltype": "percentItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "PercentageOfRevenue", "presentation": [ "http://www.tactilemedical.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of revenue disaggregated by products.", "label": "Percentage Of Revenue", "terseLabel": "Percentage of total revenue (in percent)" } } }, "auth_ref": [] }, "tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "PerformanceBasedStockSettledRestrictedStockUnitsMember", "presentation": [ "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for performance-based stock-settled restricted stock units plan.", "label": "Performance-based stock-settled restricted stock units" } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": [ "http://www.tactilemedical.com/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Performance Shares [Member]", "terseLabel": "Performance stock units", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r665" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r709" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r664" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r56", "r284" ] },
```

"us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [
"http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r56", "r510"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [
"http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r56", "r284"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [
"http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r56", "r510", "r528", "r920", "r921"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": [
"http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.001 par value, 50,000,000 shares authorized; none issued and outstanding as of September 30, 2024 and December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r56", "r462", "r606"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": [
"http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r718"] }, "tcmd_PrivateInsurersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "PrivateInsurersMember", "presentation": [
"http://www.tactilemedical.com/role/DisclosureRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to private insurers and other payers.", "label": "Private insurers and other payers", "terseLabel": "Private insurers and other payers" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [
"http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Net proceeds from the initial public offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": ["r1"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [
"http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails",
"http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock at market", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r1"] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": [
"http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Debt", "terseLabel": "Increase in term debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": ["r720"] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised", "terseLabel": "Proceeds from the issuance of common stock from the employee stock purchase plan", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised." } } }, "auth_ref": ["r1", "r10"] }, "us-gaap_ProceedsFromNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromNotesPayable", "crdr": "debit", "presentation": [
"http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Notes Payable", "terseLabel": "Proceeds from issuance of note payable", "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": ["r13"] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property and equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": ["r73"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [
"http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of common stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r1", "r10"] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": [
"http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Sales revenue", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": ["r578"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.tactilemedical.com/role/DisclosureRevenueDetails",
"http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Products and Services [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": ["r124", "r125", "r126", "r127", "r128", "r129", "r130", "r204", "r453", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r562", "r578", "r607", "r609", "r610", "r612", "r613", "r715", "r763", "r764", "r776", "r888", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917"] }, "us-gaap_ProductWarrantyAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyAccrual", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails"], "lang": { "en-us": { "role": { "label": "Standard and Extended Product Warranty Accrual", "totalLabel": "Total accrued warranty reserve", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers." } } }, "auth_ref": ["r99", "r250", "r254", "r255"] }, "us-gaap_ProductWarrantyAccrualClassifiedCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyAccrualClassifiedCurrent", "crdr": "credit", "presentation": [
"http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails", "http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails"], "lang": { "en-us": { "role": { "label": "Product Warranty Accrual, Current", "terseLabel": "Warranty", "verboseLabel": "Accrued warranty reserve, current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r49", "r765", "r768"] }, "us-gaap_ProductWarrantyAccrualNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyAccrualNoncurrent", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails",
"http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Product Warranty Accrual, Noncurrent", "terseLabel": "Accrued warranty reserve, non-current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for estimated claims under standard and extended warranty protection rights granted to customers." } } }, "auth_ref": ["r53", "r765", "r768"] }, "us-gaap_ProductWarrantyDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyDisclosureTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureWarrantyReserves"], "lang": { "en-us": { "role": { "label": "Product Warranty Disclosure [Text Block]", "terseLabel": "Warranty Reserves", "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period." } } }, "auth_ref": ["r246", "r247", "r248", "r249", "r251", "r252"] },

```
"srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.tactilemedical.com/role/DisclosureRevenueDetails", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Products and Services [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r204", "r453", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r562", "r578", "r607", "r609", "r610", "r612", "r613", "r715", "r763", "r764", "r776", "r888", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Net income", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r134", "r149", "r150", "r156", "r163", "r169", "r175", "r178", "r179", "r208", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r373", "r379", "r380", "r383", "r384", "r395", "r415", "r459", "r468", "r498", "r530", "r546", "r547", "r595", "r596", "r623", "r719", "r771" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Type [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r5", "r438" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [ "http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r438", "r460", "r466", "r606" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Type [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r83", "r438" ] }, "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligationDueInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "label": "Purchase Obligation, Due in Next Twelve Months", "verboseLabel": "Purchase orders issued", "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationFiscalYearMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligationFiscalYearMaturityAbstract", "presentation": [ "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "label": "Purchase Obligation, Fiscal Year Maturity [Abstract]", "terseLabel": "Purchase commitments" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r662" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r662" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails", "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails", "http://www.tactilemedical.com/role/DisclosureRevenueDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r119", "r120", "r121", "r122", "r123", "r131", "r132", "r241", "r242", "r243", "r244", "r303", "r314", "r344", "r345", "r346", "r351", "r401", "r450", "r451", "r452", "r480", "r482", "r489", "r501", "r502", "r551", "r552", "r553", "r554", "r555", "r559", "r560", "r571", "r577", "r590", "r600", "r601", "r602", "r603", "r609", "r616", "r758", "r773", "r870", "r880", "r881", "r882", "r883", "r884" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails", "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails", "http://www.tactilemedical.com/role/DisclosureRevenueDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Range [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r119", "r120", "r121", "r122", "r123", "r131", "r132", "r241", "r242", "r243", "r244", "r303", "r314", "r344", "r345", "r346", "r351", "r401", "r450", "r451", "r452", "r480", "r482", "r489", "r501", "r502", "r551", "r552", "r553", "r554", "r555", "r559", "r560", "r571", "r577", "r590", "r600", "r601", "r602", "r603", "r609", "r616", "r758", "r773", "r870", "r880", "r881", "r882", "r883", "r884" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r630", "r640", "r650", "r682" ] }, "tcmd_RentToPurchaseArrangementsRentalPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "RentToPurchaseArrangementsRentalPeriod", "presentation": [ "http://www.tactilemedical.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Rental period of rent-to-purchase arrangements.", "label": "Rent-to-purchase arrangements, Rental Period", "terseLabel": "Rental period of rent-to-purchase arrangements" } } }, "auth_ref": [] }, "tcmd_RentalProductServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "RentalProductServiceMember", "presentation": [ "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Information relating to rental product services which generate revenue for the company.", "label": "Rental revenue" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "presentation": [ "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Lines of Credit", "negatedLabel": "Payments on revolving line of credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r75", "r725" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "presentation": [ "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Notes Payable", "negatedLabel": "Payments on note payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r75" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r352", "r561", "r569", "r885" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Research and development expenses", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r631", "r641", "r651", "r683" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r632", "r642", "r652", "r684" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": {
```

"label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r639", "r649", "r659", "r691"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r59", "r90", "r464", "r487", "r488", "r496", "r511", "r606"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit).", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r133", "r166", "r167", "r168", "r170", "r175", "r177", "r179", "r209", "r210", "r229", "r363", "r364", "r370", "r371", "r372", "r374", "r378", "r379", "r387", "r389", "r390", "r392", "r393", "r425", "r426", "r484", "r486", "r499", "r920"] }, "us-gaap_RetirementPlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanNameAxis", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails"], "lang": { "en-us": { "role": { "label": "Retirement Plan Name [Axis]", "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": ["r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r590", "r712", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836"] }, "us-gaap_RetirementPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanNameDomain", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan Name [Domain] (Deprecated 2017-01-31)", "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": ["r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r590", "r712", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureRevenueDetails", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenue", "verboseLabel": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r105", "r106", "r192", "r197", "r198", "r201", "r203", "r204", "r205", "r206", "r300", "r301", "r453"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureRevenue"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r118", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r302"] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Revolving credit facility", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Non-cash right of use assets obtained in exchange for new operating lease obligations", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r434", "r605"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r700"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r700"] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SalesTypeLeaseLeaseIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesTypeLeaseLeaseIncomeAbstract", "presentation": ["http://www.tactilemedical.com/role/DisclosureRevenueDetails"], "lang": { "en-us": { "role": { "label": "Sales-type Lease, Lease Income [Abstract]", "terseLabel": "Revenue from sale type lease" } } }, "auth_ref": [] }, "us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesTypeLeaseLeaseIncomeTableTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureRevenueTables"], "lang": { "en-us": { "role": { "label": "Sales-type Lease, Lease Income [Table Text Block]", "terseLabel": "Sales-type lease revenue and the associated cost of goods sold", "documentation": "Tabular disclosure of components of income from sales-type lease." } } }, "auth_ref": ["r193", "r441"] }, "us-gaap_SalesTypeLeaseRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesTypeLeaseRevenue", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureRevenueDetails"], "lang": { "en-us": { "role": { "label": "Sales-type Lease, Revenue", "terseLabel": "Sales-type lease revenue", "documentation": "Amount of sales-type lease revenue." } } }, "auth_ref": ["r193", "r442"] }, "us-gaap_SalesTypeLeaseSellingProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesTypeLeaseSellingProfitLoss", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureRevenueDetails"], "lang": { "en-us": { "role": { "label": "Sales-type Lease, Selling Profit (Loss)", "totalLabel": "Gross profit", "documentation": "Amount of profit (loss) recognized at commencement from sales-type lease." } } }, "auth_ref": ["r193", "r442"] }, "tcmd_ScheduleOfAccruedExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "ScheduleOfAccruedExpensesTableTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureAccruedExpensesTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying value as of the balance sheet date of accrued expenses excluding accounts payable. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Schedule of Accrued Expenses [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.tactilemedical.com/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r20"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureNetIncomePerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of

Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potentially dilutive securities outstanding", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r20"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureNetIncomePerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of computation of the basic and diluted net income per share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r732"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r36"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Schedule of allocation of total stock-based compensation expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r36"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of changes in the earn-out liability", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r868", "r869"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": ["r215", "r222", "r226", "r227", "r228", "r454", "r561", "r573"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of finite lived intangible assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": ["r573", "r751"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureInventoriesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r12", "r63", "r64", "r65"] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementTables"], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of maturities of the term note payable", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": ["r6"] }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureWarrantyReservesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Schedule of warranty reserves", "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability." } } }, "auth_ref": ["r253"] }, "tcmd_ScheduleOfRevenueFromThirdPartyPayersTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "ScheduleOfRevenueFromThirdPartyPayersTableTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureRevenueTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue revenues from third-party payers.", "label": "Schedule Of Revenue From Third Party Payers [Table Text Block]", "terseLabel": "Summary of revenue by channel" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347"] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]", "terseLabel": "Schedule of stock-settled restricted stock unit activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": ["r92"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r8", "r9", "r92"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r29", "r30", "r31", "r32", "r33", "r34", "r86", "r88", "r89", "r90", "r144", "r145", "r146", "r195", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r492", "r493", "r494", "r495", "r577", "r711", "r724"] }, "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable", "presentation": ["http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Subsidiary or Equity Method Investee [Table]", "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity." } } }, "auth_ref": [] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsTables"], "lang": { "en-us": { "role": { "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]", "terseLabel": "Schedule of future amortization expense", "documentation": "Tabular disclosure of

the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": ["r573", "r753"] }, "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "SOFR", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": ["r866"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r625"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r627"] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Sales and marketing expenses", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": ["r71"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-based Compensation", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r3"] }, "us-gaap_ShareBasedCompensationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAbstract", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation [Abstract]", "terseLabel": "Stock-based compensation" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]", "terseLabel": "Stock-based compensation, general disclosures." } } }, "auth_ref": [] }, "tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNum { "xbrltype": "sharesItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the automatic annual increase in shares reserved and available for issuance. The automatic increases occur on the first day of the year beginning January 1, 2017.", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Automatic Annual Increase In Shares Reserved And Available For Issuance, Number", "terseLabel": "Automatic annual increase to the number of shares reserved and available for issuance" } } }, "auth_ref": [] }, "tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePerc { "xbrltype": "percentItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentag "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the automatic annual increase in shares reserved and available for issuance as a percentage to outstanding number of shares. The automatic increases occur on the first day of the year beginning January 1, 2017.", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Automatic Annual Increase In Shares Reserved And Available For Issuance, Percentage", "terseLabel": "Automatic annual increase to the number of shares reserved and available for issuance as a percentage of outstanding common stock (as a percent)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period (in years)", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r591"] }, "tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGran { "xbrltype": "perShareItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDate "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were cancelled during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Cancellations, Weighted Average Grant Date Fair Value", "terseLabel": "Cancelled (in dollars per share)" } } }, "auth_ref": [] }, "tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Cancelled in Period", "negatedLabel": "Cancelled (in shares)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based awards granted", "terseLabel": "Granted (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r336"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGra { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDa "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r336"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Restricted stock unit awards outstanding at the end of the period (in shares)", "periodStartLabel": "Restricted stock unit awards outstanding at the beginning of the period (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r333", "r334"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation":

["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "verboseLabel": "Units Outstanding", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDat { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFai "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Restricted stock unit awards outstanding at the end of the period (in dollars per share)", "periodStartLabel": "Restricted stock unit awards outstanding at the beginning of the period (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r333", "r334"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDat { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFai "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "verboseLabel": "Weighted Average Grant Date Fair Value Per Unit" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r337"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGra { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDat "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r337"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "verboseLabel": "Stockholders' Equity", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Increase in number of shares reserved and available for issuance", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods": { "xbrltype": "integerItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformancePeriods", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "documentation": "The number of performance awards under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Performance Periods", "terseLabel": "Number of performance awards under share-based payment arrangement" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r593"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Other information" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Options exercisable number of shares exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r327"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options exercisable, weighted-average exercise price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r327"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "verboseLabel": "Aggregate Intrinsic Value, Exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r340"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Cancelled/Expired", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r332"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "verboseLabel": "Aggregate Intrinsic Value, Options outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price

of options outstanding." } } }, "auth_ref": ["r35"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period", "periodStartLabel": "Outstanding at beginning of period", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r325", "r326"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Options Outstanding", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period", "periodStartLabel": "Outstanding at beginning of period", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r325", "r326"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price Per Share" } } }, "auth_ref": [] }, "tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceGoalsRevenueChangeAndAdjustedEbitdaMargin": { "xbrltype": "percentItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceGoalsRevenueChangeAndAdjustedEbitdaMargin", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "documentation": "The percent of revenue change and adjusted EBITDA margin to be achieved under performance goals of awards under share based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Goals, Revenue Change and Adjusted EBITDA Margin", "terseLabel": "Performance goals revenue change and adjusted EBITDA margin" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r330"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Cancelled", "terseLabel": "Cancelled/Expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": ["r332"] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Tranche one", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "terseLabel": "Tranche three", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Tranche two", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"], "lang": { "en-us": { "role": { "label": "Supplier [Axis]", "documentation": "Information by supplier." } } }, "auth_ref": [] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"], "lang": { "en-us": { "role": { "label": "Supplier [Domain]", "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received." } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": ["http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails"], "lang": { "en-us": { "role": { "label": "Share Price", "verboseLabel": "Stock price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Award vesting percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": ["r837"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]", "verboseLabel": "Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding' { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "terseLabel": "Restricted stock unit awards, Average Intrinsic Value", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-

gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Term (in years)", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r592"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "verboseLabel": "Aggregate Intrinsic Value, Options exercisable", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r35"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Options exercisable, weighted-average remaining contractual life", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r35"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual life (in years)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r93"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase price of common stock under plan (as a percent)", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shareholders' Equity and Share-based Payments [Text Block]", "terseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": ["r87", "r91"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails"], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "verboseLabel": "IPO price per share (in dollars per share)", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balances at the end (in shares)", "periodStartLabel": "Balances at the beginning (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r80", "r161"] }, "us-gaap_StandardProductWarrantyAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandardProductWarrantyAccrual", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails"], "lang": { "en-us": { "role": { "label": "Standard Product Warranty Accrual", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability." } } }, "auth_ref": ["r765", "r768"] }, "us-gaap_StandardProductWarrantyAccrualPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandardProductWarrantyAccrualPayments", "crdr": "debit", "presentation": ["http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails"], "lang": { "en-us": { "role": { "label": "Standard Product Warranty Accrual, Decrease for Payments", "negatedLabel": "Processed warranty claims", "documentation": "Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties." } } }, "auth_ref": ["r766"] }, "us-gaap_StandardProductWarrantyAccrualWarrantiesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandardProductWarrantyAccrualWarrantiesIssued", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails"], "lang": { "en-us": { "role": { "label": "Standard Product Warranty Accrual, Increase for Warranties Issued", "terseLabel": "Warranty provision", "documentation": "Amount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties." } } }, "auth_ref": ["r767"] }, "us-gaap_StandardProductWarrantyDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandardProductWarrantyDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Warranty Reserves" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r7", "r57", "r60", "r61", "r133", "r151", "r152", "r153", "r166", "r167", "r168", "r170", "r175", "r177", "r179", "r194", "r209", "r210", "r229", "r291", "r363", "r364", "r370", "r371", "r372", "r374", "r378", "r379", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r416", "r417", "r418", "r419", "r420", "r421", "r425", "r426", "r443", "r470", "r484", "r485", "r486", "r499", "r548"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Net Income Per Share", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r166", "r167", "r168", "r194", "r426", "r453", "r491", "r500", "r503", "r504", "r505", "r506", "r507", "r508", "r510", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r523", "r524", "r525", "r526", "r527", "r529", "r531", "r532", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r548", "r617"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r166", "r167", "r168", "r194", "r207", "r426", "r453", "r491", "r500", "r503", "r504", "r505", "r506", "r507", "r508", "r510", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r523", "r524", "r525", "r526", "r527", "r529", "r531", "r532", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r548", "r617"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":

"StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r634", "r644", "r654", "r686"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Common shares issued for employee stock purchase plan (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r7", "r56", "r57", "r90"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Number of shares of common stock sold", "verboseLabel": "Sale of common stock from follow-on public offering, net of offering expenses (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r7", "r56", "r57", "r90", "r492", "r548", "r556"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised", "terseLabel": "Exercise of common stock options and vesting of performance and restricted stock units (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r7", "r56", "r57", "r90", "r330"] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Common shares issued for employee stock purchase plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r7", "r56", "r57", "r90"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Sale of common stock from follow-on public offering, net of offering expenses", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r7", "r56", "r57", "r90", "r499", "r548", "r556", "r623"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of common stock options and vesting of performance and restricted stock units", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r7", "r57", "r60", "r61", "r90"] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails", "http://www.tactilemedical.com/role/DisclosureSubsequentEventDetails"], "lang": { "en-us": { "role": { "label": "Share Repurchase Program, Authorized, Amount", "terseLabel": "Amount of authorized shares to repurchase", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": ["r775"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balances at the end", "periodStartLabel": "Balances at the beginning", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r57", "r60", "r61", "r82", "r512", "r528", "r549", "r550", "r606", "r624", "r726", "r739", "r871", "r920"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": ["http://www.tactilemedical.com/role/DisclosureSubsequentEventDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r422", "r445"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails", "http://www.tactilemedical.com/role/DisclosureSubsequentEventDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r422", "r445"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": ["http://www.tactilemedical.com/role/DisclosureSubsequentEventDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": ["r422", "r445"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails", "http://www.tactilemedical.com/role/DisclosureSubsequentEventDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r422", "r445"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails", "http://www.tactilemedical.com/role/DisclosureSubsequentEventDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r422", "r445"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Event" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.tactilemedical.com/role/DisclosureSubsequentEvent"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Event", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r444", "r446"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockLineItems", "presentation": ["http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails"], "lang": { "en-us": { "role": { "label": "Subsidiary, Sale of Stock", "verboseLabel": "Nature of Business and Operations", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow disclosure" } } }, "auth_ref": [] }, "us-

gaap_SupplierConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierConcentrationRiskMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"], "lang": { "en-us": { "role": { "label": "Vendor", "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services." } } }, "auth_ref": ["r81"] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r680"] }, "tcmd_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "TermLoanMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails", "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to term loan.", "label": "Term Loan" } } }, "auth_ref": [] }, "tcmd_TimeBasedRestrictedStockUnitsRsusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "TimeBasedRestrictedStockUnitsRsusMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails", "http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time.", "label": "Time-Based Restricted Stock Units" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r672"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r679"] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Tradenames", "terseLabel": "Tradenames", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": ["r39", "r745", "r746", "r747", "r748", "r749", "r750", "r752", "r754", "r755", "r756"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r699"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r701"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r702"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r703"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r703"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r701"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r701"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r704"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r702"] }, "tcmd_TwoThousandTwentyFivePsuMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "TwoThousandTwentyFivePsuMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to PSUs granted in year 2025.", "label": "Two Thousand Twenty Five Psu [Member]", "terseLabel": "2025 PSUs" } } }, "auth_ref": [] }, "tcmd_TwoThousandTwentyFourPsuMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "TwoThousandTwentyFourPsuMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to PSUs granted in year 2024.", "label": "Two Thousand Twenty Four Psu [Member]", "terseLabel": "2024 PSUs" } } }, "auth_ref": [] }, "tcmd_TwoThousandTwentySixPsuMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "TwoThousandTwentySixPsuMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to PSUs granted in year 2026.", "label": "Two Thousand Twenty Six Psu [Member]", "terseLabel": "2026 PSUs" } } }, "auth_ref": [] }, "tcmd_TwoThousandTwentyThreePsuMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "TwoThousandTwentyThreePsuMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to PSUs granted in year 2023.", "label": "Two Thousand Twenty Three Psu [Member]", "terseLabel": "2023 PSUs" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r698"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r25", "r26", "r27", "r112", "r113", "r114", "r115"] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": ["http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "tcmd_VendorOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "VendorOneMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to vendor one.", "label": "Vendor One" } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862"] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": ["http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862"] }, "tcmd_VeteransAdministrationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "VeteransAdministrationMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information

pertaining to veterans administration.", "label": "Veterans Administration", "terseLabel": "Veterans Administration" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r668"] }, "tcmd_WeaverLawsuitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tactilemedical.com/20240930", "localname": "WeaverLawsuitMember", "presentation": ["http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLegalProceedingsDetails"], "lang": { "en-us": { "role": { "documentation": "Information relating to Weaver Lawsuit.", "label": "Weaver Lawsuit [Member]", "terseLabel": "The \"Weaver Lawsuit\"" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.tactilemedical.com/role/DisclosureNetIncomePerShareBasicAndDilutedNetIncomePerShareDetails", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted", "verboseLabel": "Weighted-average shares used to compute diluted net income per share", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r182", "r187"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.tactilemedical.com/role/DisclosureNetIncomePerShareBasicAndDilutedNetIncomePerShareDetails", "http://www.tactilemedical.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic", "verboseLabel": "Weighted-average shares outstanding", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r181", "r187"] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r666"] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting

Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r84": { "role":

"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB",

"URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-6A" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470",

"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r331": {

"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section":

"65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":

"45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479016/842-30-45-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944",

"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification",

"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r564": { "role":

"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55",

"Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r679": { "role":

"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r711": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r735": {

"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":

"50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r921": { "role":

*"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 81 0001558370-24-014259-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-014259-xbrl.zip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|OV>4ZYF>_K&C$B(G_/<4HID_/Z44N ME-WXJF.0F(3J$+3$HC,S$PZO/8M.]Z E:%8.W%R)%A!QU(*D;T+9BJ 4#-7Q M$^25:?]V_Q@?H80Y??;BS7AN-F!;)RTHQTUY3.[VD$\G*JS'2&D.L9Z^FYO MUNGX,D+.=7G((Y2!M1O38='MK0+YK-)1GG=%V;DP1H!WEQPTDY\C&K.2M^<5G/F-^8L M"M?4F;KF4V=/O<2I9D_;W>78G)RNRYXP\7.Z[!%LG*3+'BTGXE[ZBW79\WT, MNSVVVH\[X+SGR? ^Z9G*%<1;Z? ,B_1$R:+OCG6[PCB)"V7)M@<[R:"$09KC M[7:KT0D?_DNJ%F UL>?/SRE_5M:=B6K"2/*EU!+H)5_Q4L!'\7]V0Y^N*QPR MM0L$;K7CGJ2#M!?L&-O,=H[FE^8S)\RUQGVZE*8YSXZ[/2-',WW!OPB#NV* M:5SH;-X9[=2/X%)QCG?2=M+U'7-F+?:+IW_C? _7;/LP/UW&6I[S49ZI\3]52 M8L'*>B.9,,$]Y*3IGF4W.8J#TIJ73A!QD9:VG!W2X$?2_ZO1KZ;9>^!!9!9] M*77^YOPR/\5A_B54_[.? DV7R2(>/_T7[W07R3H<._J5ZVZ7S5,^9=R[KG2?L-/!N@+!.0;ZH68'#7+_)@U9?],\[G^ +W(R.1+U8XWK!L^-@GV*YLK)"&!KZ4D^VT M3PWK45:$? O:C/3\FBD/DFR3E!\FO25*Z0^8<<_)*4TK\D@D2[%/ @6-D2G=) M6K8U9(R=7'^RV>;^>"M4Q9$#BY0CDU]/R>]@LU]%B#J)V_R\<\F^U 84*\7!M_%_KCL-?^_>^PKBZK/QNUY+36T!^'Q?:8S_QYEUW(SY@]D]\36]?I+FWL_F[TML3%7O"K[1. L.8[DTDP]@,V4PU^/XM'^_[0O<5C,']?XN(Q\B- A)#;\WA:/ M4=([E!KQNU\\YOF C0R+F=<.K&0+T:!BZ(+@&&]?:IK&P(]SO!P.2\:^X 2/ M03-@KIVX!@_\PN\FO*P,<_#48!* A^[FB/!@"=DQH@RZ]O]%:D@S,:0 ^J_D MD#F^V]$S1[SBKTZOW]?PY=II)TX>_)[,D_/*]V@7M4@:TBJ7,(RVBGU?6%G$N]\.ASZ.KA^ X_>' MB\C+LD/5%/Q1PJ)ITD:QIL:) %#T1PE'_TF] 5DH2YWC(N-!\V[M&!2NKG"U+53_)HSI=4ZWF4)>!2R>OFB9;VJ,%!!%9S2<]"-/W*543N87@"<< M ?]@- T0.#K1)HH!M+/Y0[(1.]+Q56B[O1W>[9MC;).;RW5$VR?'L83&+ 4_P MK&0]C;.CX9.[/5M.S%:?'% MM)1G$>;Y^&7:>>>-EQ(/+ Z"VR+U_:U-2" <3&OEVO*=S:B3R&3%TG82@%I#OT M<8)6-]W#T/'NH\?PV5=0D?;^N@G]#6%]2 NB?\A("K=B)$_(KE1B\;*:-Z7F MZNNQ@S0)PLQ/]G&^@LR@/]S%? X_QI>/\7^P_SS\@:R3=.NQW]A_"?WL,>IT MQ:#>_?U/']]]=_D'N"1F)'G4H[XS9NYE[?DY#)2PC0UT^6,4PA=*F.GD&W9N M9T=^!A\R4![J3P#MD6)? +LWP$W2%@14I*1=I5MEKVU;_5S>PL8E>"-=Y>B ^\ MB/^[COV4.WDOXDX^>TS>T^LLVS-7+]RN]RQ-2K)$1/)V@\2JG)P5%IYO&\"> M).+79(G8#MZSL_9B0]^Q< MR/%)30#3<ZJ[B-&CX,5C;$1I1E1T\"@Q$3-#/15KH\!AHD":Y2Y&L4S<'+:[M#0WHUKM+DV#OYYGTFL4 B]1,F)BOE@D5(-XRH>=(MTR$L3BC\KQFFN9%GV)V M[JUIDEU!%&N)&"B>A'/,M6%!B>8ZGF8OGJ'BXAZ*23RFNW5@(!DM%9B5):K MA<8S7PNVQMFP($S\DC*Z)8^15"D$IE$?1Y#Q&[TLS1N;//:W>H/'_O*/C]Y_ M)NG%/LN3+1/S_'/8O=M6 1W?S/7L@FG+(8ZZ4=.QT+^_+F# (+P"T1%*,X>M_ M\K;T=MWB]S+9,K"1KMA&B,FH=,)YMF[D: M9^(O!5WBM0AC&?8(,4L4TL;!M.HC2#'I#_2(/2]E*J-N N!9+9R1BM#;?^, M9YHR/L89XW/R0M.8IWQQCTZV!6DL<[02K03"M+AY&)U@5)?[%.+=8H@(LFQW M\!TOP9+#ISTCH]G[#D!&,L7!XE56:HV)9\ #61QGV\4@A4E'O"P('P:2NZIQ ML Q]ZA3828?I(9 EQ+Q,O3&\+#&C.7>IVA()XF+U!O7IB1U30RY8;X]U(,68 M\CU2M@)LD;!3E>=4<2,]?LO L$).:I;K@%,?!C'1+-'-L -I"OQ M_[F._61K+(!DQD-\L&4K5.O=E0D)Y_FI*4'5?]5U" =P8\$8ZT$O\A OEHM7/, MCYA&RE N*1-E MX- I>+BK(#^R3++]=_Y@D0?:01$%;((74!AS$!_WNL0*!1! _.TF0=YC=)IHHD&+%<64*4 JD7 MDQZ* \N*@B>+!:;) *5O 'DA1M@\;.&_7)C*]N/*?L- SH[KB7TA%:&$>W8: M>DS*]Y>-=^S9/7]:H7[*;8N)%' 8)E@5@[!#PPM+#.%/LG_GKV6*Q[(\6!'G M9WER5KW/]AH$L0(5DT542@0[3SX#^_^? C_@=D0N&K=?4S\.7XH3YZ'V^]W)Z MD<1Y&.^9![QE4H@BVL5/]Q1,.XQ"45E#'Q&9C3IB8;)Y)ZA5S&P>TC@%T.;D MO5\OH:1>QF88$0)42)M,57;&G>"-8Q-S*MYE\FR>AH^8Y@&8#DLHFWIF&^9D0P0QV+4G/2-HX % MW1>/_5>$PV,;P0 90-]#8=I5;Q1R9A #1?,OPVB? T^YYV0CMCO9W!-#I?P'J MA 6T>+&R@0+#,2O0RZ&P Y,H1RXY?L[6L0!88HO3 _7W;9B'-+OZ[$?[@ 8? MF/I!Z<1]7J33=*? KDKY/(.X4-A\SNF2UT*? 8P3D\NGSB:"MN-X-TL?3YNC^::??1%,BMYC>.0IG:9LE6W%0',>=Z?3U8[9DW\[0;[MF*)JHK9WAQ(:3\D, C1U2P&*HE):7F3IJR5T68'S%X& '74>+T? =,VF1)IS* M.L+]!VE&%->JCBL>GOG@':PK;OO03%3=53TVJXI="[6]+CUY%7Q1]]&Y8MYV M+7QD B$[@(7$4"W\(Q!5+2X^*O$/VGW*=J:*;\]4[2I"'!M? U?/#"5#0KSS*:9^=Q=$YA)^2."W_"E>]VCZQ,]+'9P0U^8]JHO1FR1'3) M* &D^[%Q%5F"]8TFKHB%9(35PB5+$T+Z@NHO4|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

:L>@^]>3B(3!)R)C.9TD%F4_,F2<;3&I# M"<(AK(%GYLRD^"Q\X*.'26?F)]G*5E,Y8K MG00W<"QI;NWH%_J$+,;RA5MH0:=H.*NQNEJ5[H/IAD&T?
%45GIP<[2F,?B>2 M-]TDEWK$IL:?]E69/,M<8RG"+]VHDS6-W.Q*PM/)\!DH0)>CG^EFH4'MR41 MZ]Y1/UJ(V/AR2B_U#D^-
(=I#T?)4%:2(0"TIM:0()Z9MFQ@V007M=W%K436. ME*7@P\3P4+5D9C*!24H3MZ^.XV92/%@NW)U=6J]N;.$\W#"IJ\I2_*"L,$KP
M"&N@R<[\"MK4Y1J!]2()8@1B7\4 &6$I+Z MN$M(ZLE?*Q7^YRY$M83=*%3Q+$S;Z]3+[P<0I@^B,&U0<9FKW>4,=A<-;$V[MND3U$-F,4-
=5!63/Y4R3> E'JC^W/9Y(E'HF@PG")*H9GG)M@M]&4<)%BBR# M\80@B"EA"ZL)&? OBS'F,IX6-
%DE]%'5'GARKC<8IO.!98(AT3="!#\35!2:UV3R@KRM$.B'HP 'ZHH+Y<4_CV,"XG.CMC%"G MA.)3JLVOT6R>FZW!7SE.J Y8'TW;UC0)YI-
272I"JR*#SDV#*,=1V-1*;BGR M5CP3[/^KB;3LMA0$JO<05&D(AT7%H?"!.+BB,"Y!!?_:P@3_*(S,X0(4A&^N
M#:8?;MW*#9=,2Z@8]+\%C4LR'6%++S&R=D=7P@)^ &Z@) MN#)/%UR_NO'R,HEBN!@+-R'R4:Q+^#_GV?K FDMQEZ0W#[]Q;X>^@I
K<8A&;04MF\ '< MLG[D$U?]VD"5?7X$H+[1(^97<(;T@O0A.#))B'F,Y F_Q 8Z^?P,?*A%#^I@ MZ]Q1=.DBLWZ^/YB3I.DJ"&/WSQ2/V;S^L!MZ3M(*?
71W MUW:PQ)S9*%X($-W Q4E#FZR+U8J"3O;&S0T^*:7Z]B@.ZIK=0-[!S1N-"-N4 M6E*A_WZ%(J!4%J@9#+X%?
E"5GKRLP*8WBQ%\8@HRE,,%&#A5].INT1>*LUW7 M3Z ZMO8]%Y >A* 4$^SZ XZ\4!FN;X7K5-TH) PZ%0[2_1ZN\R^3O%:E4:!JO7P$?
=IL4QD"F/WM#B$2+ RBRFMBB7_,F)OF>-='JCR0Q,$UPV M277R'<0$3R;B2'MCR2ZV3,UL]Z#$1X/;$QB++(2[6AE#%E495
MXE;/:6):8P%EEQ9K]#=B?U/MD.RT/"++IM/0>NO:(7KS[_ID_[WUFPO]Q\#S M;H+PW0IQX:@X2]$;<3)XK4?[O877=IDL*LJ^+BB+ *NMXS,)+^@,]154J # MI#!NG&[5(]0/Q!+&LU+*\9_9'&&27=#1IWX4F3K_3J(X/7Y\#C#;D51%%U9Z M4KI"QETIZJGR9ZDBHD< M1^Y,LL.L/$-INA T,REW.)Z*L&-
V8^1124S'9C"6 M?82"=O3C58Z$\->:|B_MF-_ >_H+_CR!(>^.90SZD!!'6_6BD]CE.C*KEGE' M+1:%"'+-P5FI*0J?
0NAJUZM7+UB#;%WQD(3V$L+PX%FX#4JGLJJJ/CPYW-?@ M@;KAAS4^_1CH$T3LF%CM=!KW*7MR-A)0Z+0B#-
Q=B<['^#C5^Z[IX#=+/HVW":J:S#GX,VW6_";4WAQ/3FQBXU;K+L:JL 'D$ STQF MKA)U2O4]4],;K@!LN^VF&,#/'DC9X3OED),81K-
DU9*52KC3I'!G_1GH:GN5 M-[P4[@MJ O[W$G[I-@+"LF;:T8]$OPZZTR_(A)B#A88A$NETH9%X1S,\S3@T M9J#IUL^6ZR/MSOPK-WK-G[*=S;/ S?
L8DI$S[#!3H* MTF15=^=:+ZZ7:O#&-$(F#):N69.S) A9:,6JB M[WZ5,M:)C$W7E#'ML6\@Z]:W_AWZMD85CIQF,Z6O(OKN+BE$41.OKJD/I P?
M5N1BS4N)>'RLR4PA?Q6=G%]1&I'C>2 M%U?IRM&VPZ0B)EQ3EK8Y[6.4@!+-YI# MNLA&V3SV5(PH\P]-'C_#:"0[;:YH1)SS &?
A6G)4D#^!"%5(1"A3X6)@K8MP M5_8?B1L"]"HH?[Q&SKTQ>]$=?OM*,+Y@+T!+0DDD2).-/74E^3I2C<4/5($- M@). ^(/9D>6
VYV8@>PD["O95EE0[6C5S<:-7WD+_84+U[[$BP-JOAW;NJG(MR/M0=KWW7M7M>-=35Z*B(;9N.+2BWXWK6[XM:!HK7
M>]^"&'>R1TNN)5DD@D]>R5$U(]7S3NFR[28(,V4NLF@:$=1\E,?ER XVURWZ M)R_INI595?RI'D$3AZ6DL$R<*F2?
DQ(RFU^!EQC%@H1Z!I=!1#T#:LFIF07+BBBZV6R>!17\[D-Q;^$74-UOR%"Y MW:^?%#M85/$[QDK5I*!P[%KM<5OU57K3F(NQI7P5!9Z>Z6'UI
$5:2HRT)Z3 M7>N]3W]WK.NI*U%6GAI=3"!UH/I'U\YOE@=2KVRH4]>&:UCT YP)JE^44F8A MZNOVC=@*,+PP]+R%^ 1KH>OYW. O<
8MA%5:,_U\%KDO>C00&42KNG& MU@%D\'E'3Q+;^CY1UGS$=,>Y5HUK<)^GFG3[PG;K]9#W*L(5)J^O7JI-RRNT
M>>O/@W"504J]IXBD*GUB^,RD5+\H+ER0$9B7&D4_%F) W MK E%O<,W$E98>
[9WAN>&%%:H2\5[8%O9G*@(CD'IL#DHY76@8:E4RV1;S613CX('J1K"TIZ2(F10<2+59_08
M\3A!QZUR&J6\FS<.HP;LY"TA;QEZ\E&S)Y<+4G&"DM6^WK:)&M&>D$/)&5"C M/;0N2LI2Y>L^W*J>]N^8#"A5CW\XY9-Z-'@X?.?\.0B<=]?STKA%
[3[:#)WU MN-E9BX+3[?>VZ$E>MH+G>/"C>2 M%U?IRM&VPZ0B)EQ3EK8Y[6.4@!+-YI# MNLA&V3SV5(PH\P[

M82+X;W[3"OZACT;IFB"@/_S;#&E36SMZ[5>M0*4KN040>H>4=S9(0>'>]=U5 MLL+B4/E=3R0(;:MB09=%.1K6!QF-
\N]C1X,JRPCN>>E>4W>4""C]";*!ZKN M R6I4;)#D:87D-CS[(WG7Q[C:.OK$76+L2*FSBIT)YKT #F,%$C]SJK=!76I
MW?'D]B]9:)U]X5V@6859C.],1)&=@5')4KFOR"<,*>2%KK.7NLZN/U[=,$U, M?-5%6/D[UI-8+TW#4F.YJ*'\X#[5.[**4) ^@PVR]_/N98OE]"_PW.#F!;)Z*
MGH/8\LJ_HWA^WX+X7R#>1OHKNW?3S+MDUKWK"9B>H$[[4H.RF-:--B5EF6;O M$H3/2\M7U;4H[=EUM\&[6Q=$!!TM?
8HNF"U.;X(P_PJEPVVSAVW$KK,-W=G8 M81 4P$?H:E%T%,HB*%O)S"!34.L3O!*JJ6K^%'[2P.)290<85-$YQ4\-"J[7 M^2RC?(+WZ"Z6<80-
2"RUKEV/$'U*Q:WMO%NOWBQHYU;X6+AI/@\ W8]0RAI#U$?;,XNL[1&L=> M6CUF=0E^.DKM"P05"[KT?DUW,D^Q%<::G%BE!^4HI#1PKI)P<_6?
JBPJGZ)? M?\ 5IQOA0]%S%[3CANQBYFW)^_L,%;;'FZ6QC*ZF]!&['J=T%XG'QL#3>(%:+6Q)U73\;B: ML>MZ W>]_NA(?3M5T\YGZ-JR?CF\ZVN:H+
(/.FG5Z7:G/H#K.TN=9DU?&AV$ M\&N|V)!]JD4AVTH;!?*0>M3>]*>*T/F)SB_;2N2DC)LG%DV;ZB4O1G$*EFB, MM>^ZC?
QNPZU_4P\;NIB"4]>VCP#%UX???P9^"G!B><\@7!V(=@'HWI)=)R-U M,@VP,/6 H8=J\>,73K7$,$C#MF37X21U.%%82 U'<#;*Y6)I++N%&G3]R+5_
ML;QD@#.\:GV[SB/_?(Y!XY(C48ZSDS0N\E(/\D'Z"TO5%2 /]N"G,0<'T*CK M=%:^Y) "GN1F%F\JL(!EG"U"G<]1OY*C47E@N(*:-A/NN!X_4<"FWWK0\22
M])*['N!G$]=$HJ]HIT:8U9]TN!X2!T-Q1BXXFN'(?$O9%2OG)HFW?K.ZECA: M*^EK!$@&L),=6VT)1,=U8]JITL4[,CSL'UGZ.JK2.V?'!Z-V;-=1M_1 I&^
M]TN4OC,R6]9Q[[1VG4R[G5:UE_6]HL+;C)NVS]HHM79YGBZWK^!0JSXSIX[(U3<632UQ[CTYU,4C6O<>ZY6;=OUVMZ]5G\\I7HZC.RIA<^XK]YU:RTGX
MII=I56-DED@J*MIC5A_6X4DO*8@4QUNRG*04GEL/J>,28YHN';'4I"KRAY"9 M==,55ZU1FWZ@03^E 28U0$PQ6_[M:X,/=_"+I*?67W+-
-6@10TV['E24X]J6 M]Z,=K++JMP-G^CS),O"@5%&FL\T#N.B7AR2TEU"W#Y[E7X'8?GYT?[4-K)E\FV+OA'N;]_3+(*X==%G=GODZ+6":IV\M>|
MXQ_\0=$[.Q7U? MBZG1/S 1I=;)WE84/2-/*YQ<^!QZ#F[\.+2,0)Q"$P:(HIO7_= 'PCMYB5S'M<+UD[41 M9_KAUA]#'9SA71F@>"/RK 6WP.%-S5A5
MQ!'\5-_>J0">"[86V+N)C<5? >25&?L>$$P?6U+]"6HW4)KHL@JL$YQHT8.D M)HS-Y21Z MA[.*;**.BBV,L6X0IQ)H[*U41:8DU%"@_N.
,LYFZOV"*B!]G= MMW2+<["W?](Z@-(S: T-TYC9449!.V)U_3 =FO*!"FZFP6T,5KB!MS6MEM#W M'X'9915TG8\[OE2TD.YZ]+0Y,T&!46=SF'L5^-
EI"@A1OQ)l.$FM4$N"LM-+ MX+%@-U7I%Q4;-Z7ASNYF<]C.S32>G5C MRTN[5O0(@0W?@',3A#=)G(0 O8"-#$UP4R=O.<:02ZP&I-K.=3J*O@Q&=S<
&R9]+SP=9:M!JV,64TAAT]199JF-7)?(.1#NG?<(!E84"1UFS0 MB5(*,M41B'/OF67JI>4"I]TBY/H#?<1-)VR9C2&, +$EQQ]&?[R^A&\ 3\! MW!?
3^WO[]8OIO"BEE\UY&VX@68KHX[^Z\?(RB>)@!4+*K3-S;@4]':K:RNTM M(.BS>=Y6TF4S*4N5WL?PTY[Z7LV)7KE3<\LZ[.UC%,8ED.%?6X#A'[\]A(&3
MV/$L?(*K6+BM;KFWP"73$DAN-+: M]Q+$M%K!R85%*X2, M LJ_J;A;KUZ7P $KJV@9_I("EU97;!B57%LZL$*T MXZ?C2\Q@%LC\HDHX?
AMH_+VW_AV$Q5HAPDRAS41: 2YH F64DH#U\--G9J52 M:3EV^L2FU0I,#B2J[\/&))W_R? C=M]3,&^WT0L+(VII0.TSXU%L;4=E%U'G. M_ 7
8BWT/L7*]5VTK4*-PP-+2F\6OMR2:C%A8F"^3P]^0H 'MIJB*N")6KOD MWE RR";A)D@8>%=)B*;[3 H/616]HI/N*T1*IR6!Q1\&8N:,9D'>3VP)%T$#
M+9X>D=4&9LF[^4TKJ 6M=,G"">K>@@WK6+!L[=FU7[7"DPY&"W#TOJB9321M M"PJ7#*MDA06O\KN>\!':5MMC4F718@'<\2CA@XQC^?
>QXTB518L5KJP+M#N* MN3(MFU:H"YA4>\DMU9)&3>1!RIWDJ8?M:8^NMTNMY4T)G*1 MF=$DF"AU")IE<#89G1YXP)V<;S0-
EIK/45K)C.1"%RR2K4*5A1BR?)] PK MN$,6:^D_M[X-N4^+C4#+9R)9^@FO7[!,P>QI'TV(:;5D23=X:31A&%@T&_57(*C!Y36WN\\QM;3B.9 MT5?^0>
(##VA:GBD/:MM Q&U>?M T+|^*FZ3E*;4QW\BU;1YEQ4[(@4)H[1\? MG1\=[!V?'YWO[Y^HV8QLFIB[/UP '\"AC"90-;66W9I7^<(A MS>? 1L$K-J(_6C%
QS2NG\!Y;O8*,KN(*/_I$=B!;[N>FR%+[@Z"2C>4;3*U M8\9)/KN&>A-02X])9$@?/@XU("I=U7P#<:8(N)(K' A=>^H[5ZZ7H$=2Z[]S MKWT.FVL?
6&BQ_H"%3M)RX===IU1/+=R9YY6E"MYY0Y6+IV@I]2)*HT 9M:L F M5S#.;* D;($K::H=X QV U<96D(E/LZ71HSUC>UIQZRAXUG\RQN0"E^==K!
M,,ASE3%Z9O275M#:HWI/IP]W\A&XH1 ^]N!*,94_7()*B9&F8OU:TQMIE&E- M.WHVL$NEL4EN#\1SVC-BGJ$E^LVPL@A%N76&-%]8=[4/7U]U"EL8.E
ML:M)Z:&5/#) ^4R/%T[)IR;2A06>E'45M.CT7\0B0>Z"--J(HH-QWWXVCQZ?O MQ'= B'E&1!0*3$VT^04WX\RP$MHX>P&/_:&88;RPW3AZOO@87^
M3]VUD3YF27SG6B^N!UO&??A^U+3B015-TIHFY:K0X\VPMDF0Q!.OJ$_I4?I& M(]OF1Y3C=%*6W]2\NK)I$O(@3N-G%FBZ: &: N#,_$?4.=#3-##!M\
/BS_1 MG23Q+6=AY5=[V3[L9?5Q7<%P10.T.>+(U8>>\6"ZT/%BO?GX3Q>$$)+E^@Z\ M 8]P?,Z666\B2:;$%@8;\JC*'8^7YI:D%XB$X5QEZ,XZ?
00Z=5:'.:RZ]>&" M,4HU>$@\XB+DT)LQG4$F$(=1!^;0L= 3SO\$%]'WE0<>KJ4IM'1OS)^D410 MP"B"&^87UT_)D+F_+""6\%/D.KD+S&:
[B*%OAY*,)2F9-$VBBM*=H''V-77D M?HJM,.;Z)0U\"Y4]TGL3A#2]W$#]^3;"!3EVI:#A[JKZE+FCKC0M]AU3SS,2
M^R@<4YY6/8'9>W@YKL+E$GV\];,32_0@-5G%^[W'YEZU[SJ%!OJ6&@],]\XS MS'*EKH4=J_F4)^@N/%NF7/O-,?Y
DYN6EFTV_UU+P]$!?]=2^F53HU&W+2>' M)P>']^?'Y_NP)DBLHT-%%S":+T@/](CFT %+J2O, Z%Q&_K:YF$,L3H,L[?H
MMALXMSZ"T<4L)@$5]K:1(O@]#] M$SC9N7+]CH CYQAX009WRXV^8H\G]F-::P3L'Q?!VU=@.UG%M]E6]CFTTH>(
M2M<0C'NYXZ.CXV8$L@LG9F/3%RT& <<2!].N/9* **'I#8:KI M-=,-6%;8^]D)VI+^_K\+T\!FP/4TV_KGO^0=\5\,6(]M:M;HG_^F^$RQ^-_
M^^__^OO_PW%,ZZ5;%4RUE< $EH\I+I!\H&)SS1_?8VW;<20+]P+7U0P#2[N: M.@*;5TCB+GE'W+%Q#,?TMBSY]U>M\,H8F!*N69XO
M6)^*_UPVU1;>'C'E#V&H'?[T;V[)=FP>X 1-Q?OBM9WM!V M3:6U;W 7#9TG%_()/MP4# MWWVV(/L+/MTEC/8"^0\)J0)MGXI;TL
'^R/S[!A%)EZ]>EUB\\(QI(LR_Y: M(#!N:P6*>KQY^&"O^<436.W5B9X^(NH#@((H.3ZTUR!"X12SATKM*"J9-2[U M'_^/0:2^N_?)O E3+$M'V]D?
W[X8.'_6A,&O8R#::#-_OFQ>8[[2P?\^/7O MW[[F&^#?OW]M_UU7)=O]\M^_56V&>?[2 /_\,"5WI%FX;SOW-.'X?\%&?\'' M>V54S7,,:7EOV19 !;3%/:H-
N.N/FJH"*_P("^1</):VA066YK<09@7X0>0A M!57)546!SXJC^=R]N\-!@9L.TG,K6VJ2A5H34L:[MS0#CM -(+'# 2W6=:0\
ML3X469$F1,1IL6,41E[/=&5=:YI9I>@"GI1@#99DPOYNU--] TH%5-5 Y7U;
MT3N2@:K5((H*89=%LRD3@4KG$CJU2J9'1&]5'(U&B'CG'PM)B32)!D.+]54R MVQ$=)BN8C436+2VM> QVXYV#Z?9[7I9*6!-
]ZHX&HMU(5Y/]^=L'XXTE%WAB M+M.<^=WJ]$+@BRF?%I.YK)(9?8P;*E T4S*@C!5KN$3'"%):>U^@564^8]_*9IE$T22_?O7_@"W ZY!'"^YJ
MRE[/LX$;"J1(BN2Z[VU[9R!018LMR1J!U$+SPF]5S=+,P*P"4P:NN.F[F)I# MBK6AH(7ED.43VYH)0GO? IX/F_4WC$)$]EI>X!U4T3
DJP8)\E@#!^787Q:A MHK%\;090 :@VF,U[K:5/3QA7*W.FPB44HI)5*7%^2-20DF$W('D=8'GA:%.N MBP:%')KT\K%(0UJBG\+!A']U8-ULWDO+[I-
4^ETYR&STN%EI,7 MV^W4E]%NF'S2Y=3BT)>KU=(42&6%2D%:4=_+]K)K]-./J0=MW"T];C6E-M7 M:0SMSW(]JHI,-!$U\V MVD\:L?
<,MEQ[#74>3R:X)OOMY@N#/:8%/N@\U!V I,P:50"4P)8V M&OOUH>"IE."Q?^\V)%W:,./.83G((,R']2S2K'0(_*RDDAP M%M/0%]DO)
<,GX5#1)%DSH.^1"2"4K8\2HEROM]DY1SI"727YF>,"NR?,WT6(MPYY\,2!.1(A*S/>S2;=B$E([/;'SA8'69]^'B$\3XE20]-F6\BEBT**DK282
M#;WW66;*VIIL J+Y.6(\=N92P/@T.802]_=;+-75F6DLGN[*XTHG_T$A^1 Y M7G$CXX8S(1@W.^7RB4R;C]\ZA73\(@$XA*VZDI&T5+!H@R6ZS&V
M%5$:Q&TZJP5G4LH-'<_7V8Y'TY61VH3 A5W&<9+":?(K^YO=3#T_=C@' M?_$>N@O<5:H7U.<58HDO!I-575AX3$],H>ZB)B[7U[4'0]];,;>:58:Z[.IE
M@G"FW4) %>RY&$>];=)?V=<4[*@:=M:0-HY937)=D4HU"7G9R 1YC(8GC?:G_Q9N$=AUOD[HTF!HM4LK(2<6H6$A[FCXYZ/QU"6XG4.<
MNS"S8:1&JX-G1)_B:CNIRP5,<-9C^W)Y%(ZT P4#6^J:#?&=(S&=9RK ME]N-0L<93V+ ^DQFE"H"A$-CW?-K ->O#C(U<#V7?
KS)2%DF9<[TMY$W%D6NY M4KG2>W%^,I+0MP/WTM!_U'-EHL"1ONOY@IGRDP6ZOR(&V>:EH9\;)PIRD5ER
M.)]MTT8SY72%YC7J.5Y;7)K7H6'=U%1)@E2P0*L@"<&@ "-AN;V+FW5?,)V F M*A5QJ4+?CHEG)2OCS;,WJ_8]K=H07]6]XKQ+VX8AP.[S MC.WY-=OO
T@3Q1Y9V@KR91.BN9N?4+G]Q2IV(<7RY=[8XH)88S5UDEY62]\- M*4E4J5CVB3G]M9\#$,Z(SA\[]^_4:K%O1=F44"^8&'JQ3U*4/CGAZ?!,:*4
MBO"W<9C=@NB';W.$[A:>BE:O?QW4&7[UH*$,OX4Y+/<;WH?C>.!]XD7>/\S? MK/F%"&=;*);:DZF=Y9L- YMZ:C%M5(_C@W;"5'VT&M?
GCW03]TIRN(T\=C$ ^LGV^[:17WL0> LBZ%U$T)]&!)EBBF"X2@T%C73B MG5YZI*72]1LBWH@(^NV(H$^.B)?MPT<1LAU>GP\,YMTM6LW M
"\.^3JXS9Q6FE?=A)@N$JS/!?&.G$V[=77>N4GS^_C+1("_+TMS@@= XB51
M(.K3B6Y(==&TI&MQ\X6D^933),;.]L+LS@E^7%79$99QDQ7=8%/Z\"HX>-4:7Z3YXNS^Z/AUC/B'!O*^52L M89%")C?MU8IJ8S[3KCWF^FQ/HNO?
5II3L0%.YGJE&9_C[SE\[=-*7O.-4!6F^K(-R?5BEE&N/H\^ZJ!6]F>VG7,VG_*G>ZG)5W1PY57->BXWY
MP8VKUS7#^92MF<)R80I2*RE,N>XHG:CSICFZL?6D]KJ>N7M6$QU.N#G115_1>9<0%\;C4PU7!&H)K=YI_D*N1"'R?LI5: MUM+E58&=$?7Z$E?
PTC#1=Z\]YOT]MIXX_DF*E(C2LA^9&LB>IFJ2N^0E]2' MX8CV&%ILU#>,K,YUP>;GZ1'7)9F%V^4FC)2*KGP^-[)')CX,[3S,(QET/")! MG8IYD'6)
TW[+/?"G/R<;1CVO&XU AF.JCX>817S!SV*0^F!.\7%PU: MEJ1B*;)>TM[H'F7TV>&=DJL?S[K2:RZT67Y/E7QCGOY:+
(=02/P66.F#93\VE/;A.!=>/B%\4U1[=)/'S^Z]:X M1%O.F&FOQ>A:P//E+M7-$K'(:N/=T6U,[(0#.YLV?M^NB-VB9]?&7[)S,B#'
MO8:3;@)=&\Q*=4%)SUO13>P&TC<9R^]\ MWM$58?P5"D<(S&]N<8>ICY[F.[@:$3_E2_?S?I]36:Y9]G8I_!M)W@Y7;[)W MQ<=?7;/H[1'X-
Y*]F]7[#]=37;7D[1+X-Y*\!Z;^3I)W?=<(14RT(,GN'PCX MXU_T=8^"GX?S;SL_=X6R(RVB(3O)5'787:C-+)<7B337*C.%2O0*R2FTRI;C$=
MN5C@RY7N#7NG/<]WP:;;LN%034ZJEH6N6!A9LV'D_.)S6N#?"Q1,R O,O_HP&Y< M7W.]"E1-D=SMXI!=[DI@V,_W.*F23VHQLI\9YZ^+W?
LCNO%YS6?TJFR -7&, MAVN-LD@9:G+@*VP\2[Z;&2:M3Q*'+*"F,A\|9I2]I?D7(?#FP7Y/=#P?R7[(M_G/!2M2KOM+7)5%MQ\6%GIBXUP6(2]G_J$4.[[?
_LS8SY?BN&!#Y_FJ1,]-C MJ9N)Y!Q9=.S_-7']P/ZS=:(0"!FA1DRY1+Y^Y$SN?BJ>N"0"3L\7C_X.[/CYL_U=%.M=-S!.FP*0T,L,U MBA,BFFOKT;+_%
[T!Z/T8.&[_!WG.HNLEEA'RE)QVNDFJFVM=%_.UOY?&=U]D_Z^,SV^W__5I1:*J37>N+P.E2PVF M>B<6O:U?$;?_4;C][53V7ZS/8V9I;.O<ZO>,EG2DZ+
RUHG-IY[@SX3R>2PZ-C_:^+Z@?V?\/UTIR//*EQ7;>2G MG9J9R26NR]WI.OM_37Q^N_WOMK/C;MEG<8+)C*V9&2O3R?YU02_2]O]RZ$CN MH./A\\/Y?
2ZDBI^3%,V 0]G)* *N6;&EK=$O 2ZA &W2>LMH ML)9>YB.G"Z)VAMPA-'9/D7L%&KM%3V$GH/ G'X^<>_Q6+9;[PFQ"I?4@D]!B M0K6TJ,W.
[M,_GW8DB5/)M]%NK^C9UMA/4DV)C/%ZFL MNYIH B7UW=RBK<2"VDUOO-<>1VUF[B38F'56ICPK#*W3 T)=3!GQTG\IC>N M)VICQ=B.3=E\
[D^7H)$HEUF[3)=21G[472W:4;C(YU#?LC@1>[.^?2QZKFCW MK5L&CT3#CW(VLXT91-U^F4T%TYEK^]V!R!#=1'9$IP-232F1BX_/OW?P6.3]
M*+TO4/![QN)O!>/1/80?!F,_((Y:/]$4&X.5EJJ,R^9T;OA^_R;"6]@W#VD M.@SUR<^C2U,#4R9GB3(7U.(973$SW9P46<\B$AC8.8B3#
W>XQ!/=LW=6TU< MP[5A(_X2G1_@IRSU83H\O7RZ7WG[;%,'7]'3TP$3'PME(UN:S'4N-38C-_]W M?
BOW!AKN[%W>)^*9<'7BB_;.BZMTH$$*/$PKMQMC.D;C.L[5R^U&H>.,)S$_MM]FQ@?"9/$STR4Q*6=J<5 MX$QQW,U=1<#U)@,6$:Z\
<;GE,R#SL5+Y20AI?6E7C#+=+&8:=B18V34%/O% M%UN>N_*I:*E@""'N@XHV VK1@L@;;;(!4IX'?"^]7*<,&9*W/Z?>=B45H./7 M'L[-
X8;S1;P2+Q.9Q&1".AK/%I3(!3Y;5K]SV(\8.1QWU#7"J?G>@/"S'D[! M6=:XE;0LQQ)$/56:CG(U]Y:0OQ_3]P9]'1P_M-]WC1@YY'B*G/
CGW(6X/MQ_2MD_4RW*Y(]M\9BG60 .38$NC:>%9W$_Y"^FAD/#G@'/;VPC/D*15;M)5@FJ22X&FMBP%[W(
MA6N/<=+1L6TR%@\'=\XYZG/;Y]RGY;4S302*VU%,PC0Z;# ="[DF'EEY?<=X MK]HNGX;363 #!HQLU#90QI9MV*-E2QN-'WAOQP9Q/4=T!WI]
(I")V#3+B?'(M31=_BO>OD.!W0L-V0T<+&&'T[XTU9XN$*>FFB$Q<2<%&G%5_4>HVZX/OA807 MAO\[HB #ZW+2\-E\R?@>$%CO7GMY_-
>!@R.!V^>=0(.O MX4W7[PEC1]^#\%0=L)V+U:U(@9)XKE^.,TN?.Q=S,+E+\H*E^ M+^?Q@N,)AQ><@-G]BL+GOO]IXTAE^#PQ<
MT!$\TW3N<]=6O'Y5CCMSIER@.0E.FU93*[5(#O1$9-E\R0MMOC*LN\!%=7QO M*H/5*MOP/DH*!>3OJXOF'Q;8#H3DVO$ MV48J>]>C?
N'5.;\M1M]XI24XJ98H9?7I4ED?9=(;"D^/!B-PJDWPF*OZ-F=E3>>+TGP4V.4%PLF MIZ7L%"VW:\5,=&/Y2Y\O>YX$2P!?
K,^!::+$YIUF2I<#]4$G>'KK;+,QF)3.+6XN"D!G->Z1:S5=F MT3ST&^(X3D1.OU_CB7;? M0[28-P><>T6_LVBAY3+TXS91(3$D>U2-
RG"!EZE4:YE6,49$;K;T-Y6@?5[] M[H)RVO.G3C9H.^A;:63F5E]=WD[KM50,W\)VKL$%1/\CR9H. ^J6@=V*"&W1'P M54/(S>4A17CDR]J9TV0>
<7A!Q0@2L9NXQD?/0(HWA-Y#Y!NQS:OAJ9Y:;4? 4FNY=C+ MBB W!#.I$!6"=,YOB@ :+BV&BA^W>6!.].4?>G:/-S(4#LW M&^3X69;G\KE!LL5-
/#:=C=PB.?+.CPUJ9]/R[JC.N7IUN0S==_([7%YOP:%) MQN:YYNF&\PG!MQ)@,K:$)8CA3 H$K89Z19P/%]J?']_WQ,#Q%?IWRCR(M>R" M6!VH1+
J)SK5OA$4V.C9S0C)_.56K-_)[]=DON&,IOL;PT%H'").%O(C#+" M3>:CC8'C>?;OE/FYT7+8A1DKZ\N!@)=M-YMS)E?$^:^5^8MFR;^3WZ_)?-^F
M.\EDJC32S62GW)CC\5QK>47;_E(R'\&=$N^4>8K.5^89?>[H6A* A&(T$IG^ M%7'^RV7^@OL<3BOS CUWM:3;K^C!HJ;D74WULNDKXOP%9?
YR&'AYSV[&#KIX.$+ M?MF#NOBQY*XW:(?-I2RU9EM@>\S$FF->VY4L3U)0%>GEMN9'%'<@Y6RW;FVA MNZ#C =M=M-_$Y)&P$_@ *OU,$_[M)>
<^4LL.@;12%+E^9X\N$/K*'T4UUODGY54IYU&+V MWTW*RXFQEJ[4E XWU4:X6"8%WHM> '*3\BN6\@A&Z;^;E$LK+CFHEQHNP=0!
M[]5*2FK2ODGY3IFJ2N^0E]2'X:EDSY\CN1&2D>W%9_7\ M9,9)DW2Q6Q,G3F\1N?GW1_0[,\9G3I,\/?O/>"S\-@#['$-C')7"C04MZ^5)
MH3OPQ@M.B^[UC%%CZ*XT?Y:A,9%*B.B,OD]RM-JK%? E74L1==Q4R*:!V)-2 M9.U8E#A*,C@1PZG$]3CZZ$NYRI)/Y]]V1

2%KB/.K5YLOCH[3]X'9_I,UU; M?_,)+M'RN84>9-(KJY'>-WKJ/&X-,W"_($;I),9I0B$B ME4:9'(W"^*U.^K7,QD9VW5L M"#Y0)+:#&"?@39(0+3(E5QL19?%2G3/I'K#X#?! M^YM&?R:',7GBJSZ(TX@:&F^)AF[*#!C:=PS6[,4ER_$24 N,J52(;(ZXW,H M>#K\||& .*T->3F)(@6[I6I&$&X81+MNX#B!QRT4(U"!FG-M,V.;4&F&==6' MG.1:FC7R&E PPNFRY?$*#K;:';E7@1"P3[GDD ET?ISHT+X4O;.RB8*>,W&Z1@"-I"F"P&F6F%LR,["?(E M^'R&5#=DG@>9S]_"U)|[0;%0H).ZQ!8#T$Z4IG3G|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|'5F)+;,_$2++#:B%+%$%0$?\U$K MAE=R[KY^W7-NX]54@J*!0"VE=M/ME*[6W=|^)Y>>]&\!>O>WJQ7M+,M&%.3T"0]QK1G9'-.178VY[:N>5WX/LDL0J5#%"KU9CD#=6Z["<6UPV72\XB7#EBWC:+P+3GR1H] M!0PWS5FJ8=RLLMGA=6/FLK,($4;->V<1=-WNLTYK @1<8W*)V*K#5Z)WRV/D M9A$BC("/K7NV4UVC0O:;A$!Y0W+1Y@I"S(ZLCHC8NF>$T?"Q.:5BA\XMZWW*MUIET+:$.DE)N8D56*T1L3BG*.^6^?DZI5E8Z@W9EWB(HCAZR..XN*/Y4N/J?$I M>3QYG!KJIS+U<7ZTXV>JUK+O,F+?-*1&IO+-H+0)'ESJB54B/]>R*N^X(X>)S2E%%S7OGE&C/$DQB7!AR MTBPYL"I<;5!-7(N'!)ONP7X9 1^;+^*]M-NM5/]&+B6%1D5/.[-"]S:G=/5H M^-BA,OCO@1'2|\ M^6Q(B?"NBU,@I908=Z;%@EHDEA3|"939>5:[(>6;Y3Z> BE6JM2DI=A8X:B. MVA?EE9MTY]'U/J*,E BO:)P"*6*,E|-D5MA%IMIL5;PS&WI-7Q1&<]LBI%3C-!2MT_T.W'O^CK'N$^OQYP=+'M19)_HS6(M".Y#.:FD($I^6E*6HMV.&]. ^0DQQN]6NQDDI/H^<9HZ*I.R2_"8I$964+UZM M7O022U9ENC31U9V$0]AY4_0B%R]=1H)^^W7PZYL:7%1;VTP"U*]4A5&7#!3 M@=IKLVXL>I?Y'I.@7<+=O+6;I)S;6\,K8CM#RL,)(9%48Y@-%*8>O9W(49&4 MF[=V!9+RQ=Z:.9KQ-:>5[I %F?I$@$2B>@=@GH9";IY:]&3K/?8F/;8!2*

*-=4_6(SX33A/\GBB#_6:BO9"^1NN#S0MZ6^&' Z6;K MR/OUU+.UNMM1WEHYC*ZE_!>T?/2R<2(2R;[B6D>E0-G.ALU&##"S"CP*UX^.MMDQ.6WF$,XJZ'C$05.CJUW$C2+;"OT78@5Z.7DMN@+BIW'FM.)#DZ6|U'49V M!R^:R@Y5B'- H>\D_|-(*XU?0VEST_A,E\EK>@D_WZ4NV$Q?)"YAU'=P@A# MX#&!W.QEOCQWO^QI6JSA^&@\0,&MQ'>>I9XEU7+#4JQZ!,V&':WH0?DME&4- M:\G5A93R1[M6D]LZ:[4:DJBY1KA>^Q%]T+:\ M3KJ]!OA5>S*(9=KWK^"=,E;L!RNS)21R9$GQ^-W]V2S(&R@ MNOEA8"*BCB/#;V#)Y)9^L,S&EZ1?V.KZVUM!-M(-!7'\!8<%S9?" ,@\?_MA MH.ZWOZ! ,D 82AE$(A&[H Q61NK9|X"US|*/H%9)5I9J.ETN@9>[FBF.//@O M%K5I+:WL09>C;M:6O*6D]RI>4Q_?D)^IX0_$(O1)]NJSYUZI"]Y%)%]-V@JI M-AY,;LQV>T@5+%8B*EH$'_4&:I)3%ET/4Y>1&7#D 7R=ND@D&- M141Z:#P_^W)>39?A*VN1*,7'%2A15Y58:\!4D5/5W/(.O-|>CW_/ MON*5M27-JG32LH A#+J'*94CR.?>):GE'/0,S((TDGA%(GGK$ALDW0:TAU:I M?&_5WRH.T4N3*J]01JX$_[/,8%;?"D|[J5)1ZG7V):F)/!5:*=++74(RPSMU MB|:SO+_>%YZ\[L*:N*Z/G0B/6S=0MO \25YS/WG"5$G^R6-2_Z3)+:IK%SIR M|*E0Q[1]I8$(C/Q71B/NQ"'G|$%!B#Q6F)Q^<#N%6!,V7X,?%[P8=B7E=!QB MW[I9!_#/;?*K&|V#BQM\:N$+H:NUO(SQB3"8Y#_*T^YKB-#CK-|_;?CK]\=L MAH(E\,(E48DN1C-2-;)A2]TS-5=G1!=S;U;N86/G9F_<*@5!5VQD'6I#QN_M))*U#6#F##\1)[@'BS ! Z]NV,G&:C5IOTZL9JELB&K;8]V)[3MDNM1]%K(0 MJM4G[TR@5O&!J4DX/^+HK1YMU8(@I')_E6 '3,DUB5P(95A#B%)WZJH/ML9O M@X)IEG)DXH9]N'1V0L-2KFZ<W*U)BG[^TB5&@(4^JZ[ISV"L>-9JMZ|=26,. ML3U,6/I$\E_N+6P!&,@Z*=V<;@*0=, |<#|G97WR3DJ;6.,POTJ^+SE?4P9> M%Q,[F)F$&0UYDZI=,>]_$%AEL,JQ# M+&^'2@J[*4F\61!K6,J>:HJZL;?VH+;-9LRS?4L\0OQ-K=Q>525%)Z$HKNOJ MS? G,'F2|-:]*^P>UJ'^2]M|#9]6X\AD$AH?9%PY7?L,@R6MPO\Q5.ON$ 1K M-3AJ*:?M#CQ:0O3+00/ZKJP!H5_ZB!WED0(LX([FPK)"86?CL"N/;3V0FOQ$ML/U/']9@PL+ 62E?U@C5INZD0=+U_I%8'FA?/5%UQ)V4-%3#*P<|$ L[C|*W MU1Z7,*R^"AS)^ AB3=N*RD,"&(PR@?>RM;IMFO*):^JEAK:3:GGKSJ5G3$7TTMDNNYN3K(A&NLXJXR>99TSN((+-WU$C.R|C MO|9GEYA6"OB6RX#3=Z#R5X:V&Y$EMCAI(&. MANM,[M5(#Z+/R0K^E,FS,T9=BV[AR49FBJ7&IEFU X]&/# _W'8S)#[79\]07XC8F)[6W"0U 6,N^#?U"9"4PI,0.@>3I?WV+6QC";B=6C&R#8H+34(M-6MW9FA,2]F#6I6C))!4|@P/=YC#]*/,UG2="ND1:)S=?I#9<+?;;-?$)AL< M;IL7S6$Y20>MWX2R9[R[0&U:W1 MPD|YI*2?/,?QG]=N-BNI &$U60<1;)V;%[VYD,IV'"%^C20W'0;BG-:/I*Q$' ML5>MI4Q)IZ,';82GFU=K65'F\=K_]CDX,S>P:MKX'K-5Q@/^DIO=]XCU(&,_M?_;F:|_GL,C/G^'Q3@;V9,;]XBZ'B;*#L_,+P1#6W.%G[E-1D$A;VD$IHLD< M[.$S]2%Z1BRA7G@JO"&EI3KLG"_?;R@3*W.$'53[8I?E>[:U9,L2_B_(M]DA?:HF6I>N@9/|@%)HD\Z-+GIE%'UU?W$$YO@!/BC=?9$=_)\6U0UO<03EN M'.@!N3^ZI-#/#=D15I"EG*2#\EQCEQ+G(NB!^$]$M)&G+_^ZD@3?GD^6?#Q MQU!+ P04 " #@619VS3:31 :Q_[.<_QR[&/[=__>)LZQ@LB/O;< MCWN]_>Z>@5S+L['[}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|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|_^;3MZ.!%WWT*!OM2=(Y?7D"V.1X.![W:=W|KL;*5^S@W45\3'}AHN:5@XV"90$,3 MV9"@=<8%:)L0R[5J\U=N:G1?7JK$WW24R;T+MK")*A17]>JZE&I&D(698N%W M!S&RP'%+3?,Y9B*3=1=LI+0>MN#R5G]I&8MXAI_1TRV\$4.4+:N/(YCYKW:4M;;"+$CIH1"S_LTD0>]OTS)M21ZZHE\A/O O|*R8T3T^0.O-P:6+" J1/ M!?^$T4WU'/:+, ^V"%930@/ 8?:<>"UB?#*W?TRDII5S/N@O64%H/PI/W.NQAMY\V6%V_#*C@;BSR[:1(B!<2VML#9*UFOK,2K+0HYVTSXIFJ(:1]I[4^N MXXO?-TEFP[GOG$CW#3+"VFQ#[Z"99#VKJ_70\L7$+EV2&[OGV]IY/H[V'R-< M/8[]%&?*:F.HPT&GRNVDA 82>Y]BE&JGY$>7E2>*2DCHLU&4)D^$I/0>RES M'6E>Q&_1^S8*$MIL-U6I(S$;_@*G#B,+WR4KOFA*F&\W341&"8EA2*YRZK+: MP;_85MI$^")VTUH4]9$8SGLNE,I/3=C$>NWV6YARIU:\|_N0"B2VV5[>2SV)M^6A]02E'B]$:P08!/SD"-+0A;0-^9-77A/AU:",LB/#!.[5 >P1Q7[CD!01) M"\CJZ,.P/_I0MXEM2'!.P-!FVE"\^J"V&#$+(9O%$-]#:QM/E&U&7L).&,V&MZI#I9W3H6E9/",CV**OY=L(F2BE!&$:D0__!T=4E=DW7VF!6DR- 0?0=E8C MJ[XFA*K%K>?2(]$AEZ?HN(8/>$E|\". ^3U7>ZC:2J:$A;F@&W"ZK0@5)38=J M'-G&DW/T&%SY?@AP$+U]0#2FY>38(=.0AB\5+UW+ ^>[9 LDU=A$]Y,4B.#FT M<]-G41^WDG0U\%)3EYJ']8DW)WC)=X%P)>R:'O]-&ZT$W;SDNT"W$G9A6+,. MGDG:@)-!:CQAP=O^-Q< P,P;\.(7&DR3'|--/?:"LW.5B-|%XWI77T3&6LN"/E#CC MMUC@VJX1R*IQ_QK05A6.DDMH2!Q!2[I94;/R/[B>38_Z",O<=;B1CHTNSS- M9Z,UI($TXTQ\#.>[1W[2>&GH([@W'N0G;C*)8B#E'H+<6O['K>|5.PX+]\AN MBRCWAT?K_6$BW@#YQK((RJAUBZ2MK\ 7<.T=PTYO],49:JA!194*7U6/CZZM<(>F)J:3_O'D$H@RG7\CDZB#E96L8=N6XSW=VMJ+#TVXQ48-^U?H'AY>D?." M;CPW>.:-YL)W4&;DE)!$V*DUEO/PZE5B1;&LC.:&W>&@NZJ(UAE/$?(F M[$"70 LE\Y:92TK;5;OA8E>[4J4IEG/IA=7,AA)A.VHW7.A;N).%<]2 #X+6 MFT8(I;&<3@)$.!:QJ;A&V\2[@)?91:C12;XU_Q: XS-MQ#[K&4CO2SG'U#/N MKWK&D4R#"?VG 6*7SK#Q&Y5M]/_RBM\%!WL,11T)RJ:HIK1R"8L1A:-4|LWM2B4N8507U';#4(%=\F6@K77G\6&WY'Y^Y77.X?HZ9RS22&36NK*Y?ICO+"2$ M?X:D('T]>[1V: 7?34),-YBSRIG.F6/Z/IY@9!=CDL#\:UMU.?,ANGC8+%3 MENUT\SPJ49ZF$E@>7(VO]T25.X.4=!2]#T(;TQ=,HM$MOQG*9VPTD^41;N$6 MXF(ZP01?$-WJO:!/S<:#\Q&6/KPC9+,S7!C+5=:WCA57F9YNI96DUK#YY>D^[TT;&22Z'N1G M1]%=/R AFTEET!^ED:RJ A'T\N&TCB7G5CZB.HMP:Z%9Z9S MY1:'Z)411?SRLRN&T=EFI"96.EN-))APAO)_,N,Y%32_$Y(Y4C#IF*S*AP, M^Z/CW;(J>:W(;%YLV0_PIE/,'H2AJX>+FY4LP!I=VA]=EQP'/+CI%2AE'V&4 MXR,LBS=,E[U!OJP?,_J8)"H$H89G9"B"9UE/6IU(;)/"'RNH.*M5/)2U['4 MFE\7P5)K828->P(!/YF%5G5L35C1X< 2+ND(\[62;0$\W5=U^+WY-]>&9'0MC*Y]O'2|\US)=^$"U"T\7;%A0LC&A1=>[\(-@)$$<$TANDSL/>>=EY+-7ML,I M6Z0P1K^4(V;NBJ%BPW3ZA30A-Y?%]W@H(^JF)883*7PRXT=^II+T8E"93D[M;#!_&JQ:@VP&/ZBI]4K+8.=3A9L#5KX:#?0B#=UFQ%=BVTI+@=M1XI-:C% M\&EL1DHKH*4%[J(IR2M"\R.L):UEA4.NO6[WL')_FJ1R+ MJG7]DYT6>("&#/WR 'A3_04'0ZN^1>7#;;G<[M[=3-G9*W7-?8+8_L)#-/*9J$)*8I0@%)V\I?_P&D%BY8N>'0W56ICBQA.;^S M8#DX./C'?[TN@]$S(I&/PY_>';_>C="H8L]/YS_]"Z)9P>?W_W7/__]W_IQ M_PX._O=|>CORL)LL41B/7(*<&'FC%S]>C![Q:N6HSMB!\$HW/B>W,T&AT? MO?_|_NC]V:?1P<$_TS:.G8C6P>$H:>S#^^/M#Q>;YG#XX^CX^/#CX8>C#QI' MGWX_O3CR)|C>B$,/HIW>+.%[]>'CX\O+R M_O6)!.|QF=/*1R>'VX+OLI(_OD9^H?3+R;;L\>'_WMT^N NT=_[\,(J=T-W7 M8LWPZAV?G9T=IK_NBM+NO7A7-D_-I\/L1UHT\G^,TJYNL>O$J7R4$;"$NRO M@VVQ_;5P?&'@Y/C]Z^1MZ6K@D#!)_JK+RF_X]__VTTRF1"<("F:#9*V?%C MO%ZAG]Y%_G(5L$;3[Q8$S7YZ%[M+[X!)]NCLY(B1^!\/,=4/IGD7./102-6(M?HAPX'M,;W:_1I/99(5(RJ_HW8CU|\OTID!D[+BQ']#2GN\ZP7L7+P]9L<-ZM/1SV"^XAQN[7!0X\:K)7?R9^O.X*)*^G5L!>^I$;X"@AJ-K%H_,4($.YZ;37 M,N%?G)C^.YF=)Y$?HB@:A|Y>)RY1[/A!;1'\Z;;<,Z&>,O1GY9;!T+G$|^/QG*!4EQL"$+76+=%W3 O|V$?4$B_14|L@A*VW M#0HOEWZ<#BA4_G2DB>FZ@JXO:,>WB,XDDZ? G[=B-75ZZ@_LG?,')K^BT,.D M0Z#<7OH#.46Q3U+UN@^Z"BJ %JZW34|M@I^@9A0EJ"*3<2MOK1Q3?T%WV$MTC\K!P"!I3H_?|((G] M9_2W,WD?/7J!HF'O&N"E|P^DC@UC|GLRB$A&P^VU9LN,;LBIV6V73L^^=4) M$G1'1_0DFP,BUODDB6]]Y\D/J,8UY(59'VU;:O(4H3|3VN75<_.5JZ@U#M'EM#M*-?(3<]W/\?(A<+VOZ)O3\9]]+G"":A,&ZB(O5C'A5&5;V(06= A:T4^19 MCDJ'N%M"-Q_+S$#1TGF/$H)7['\I#8A0PA^083?8QE-MV:D1$+)KCW5XL/F# CO^?'!\?/ A|:;\1[DO#7[K#].Z#G$8\N$)(KQC]?$$W9D[TE/(SB0[FCK/:* CMCWW#FHSV MJD(7/LNJ_E>:R&1"RQY>O<9T&<$VF5=ALMSLFV_]*(Y$*E5'%7*>,N9+ ^Y32 MNJ!-$#=Y0@>>OV1$X/ =3V%WK?AA2?$B+[I2*VT#'1.]Z.O!2V9M17*W='[F9 MDM:F=UN]:X)3OAPLT?*)C05&Q!:K=DRH$P1FY*45/|$U/QWIMQT%SA,*?GJGKO#[<0ES7I7#_D%O MW)7A//6\[!9-&^($P.65A.#5U0H,V.OHF!190;5ZV\6,KF\-)8)-*$HBVA].M=X%.L&UB8U7&HT*!*WMX/^J0/WK$(WVR,:'+FI_>T4\KXF.Z)5C_].[(BH)EM[F.%)14+"16H6LRZQ4S]^2*>S'Z),C^YEL&4ZFC:"Z=64W,1LEUH(APB>K60 M,L5BJ^!0*C.*?QQRYD63^;+U78%T#CT[.SLZ&AV,]BW3/[:-CVCKHZSY$6M_ M.[7N>FAF--O]HH?\S%[HA[V9T#]^3UVA5R&E=ZBP,UOLC],") MM@?E')U4EA<.TM(:%A#GR>#JL;B@$",_:-/91X?76$5$;SJO075^,N)3V[XM M1"3.:07]:Z\1](_?[PGV$C>>D =$GGT7<51?5*RB#;*"_<)AYS$; B*NCDO+ MRH#Q2]?5= W68HWN>]-Q,;U,M95T]J[=.UM*

<%'HT#6=0+VYY;A](^S9%Z)- MM[^$T0]Y:?2D4,&%9?G(9*6;*+B*N5BC_UXU7$#P5L6EA,)8S&3'M>Q8#X=I M (+&@H971[VH$=6R@+Y$BG1MPRTK1"LLW=H*1|%\K$&+O84.G_C\8D=(M%US M*1ZI/M*N9(;"+RTV$7%Y&%BE!B(L;X*W14-1,A]K4M*_F8A(SQN(E&2K1C)^ M<8BG,(U"&;%SMES*AAFPB)9*B-J8$"><9]$AY^M]F7MGS;Y+"=]3'WHLY.F+ MLU184 ==B8VOH\X:.Y %FH&I) [UW0RJA+9AW1QBM3Y^^YSMD_> $2,-U)BHO MG5*$-6P@WE/!Y#"9/5(!1LRGCT/Y6*"L*.:!5M4VYE>5;+ I45:F6@&*@C5J M46_5MJ]!T E=WPENPB@FZ25-B64)2@MU2E+> M:4^S-$]CXC/YQ/9APB(S80 M1OR?I/;79A="KK;=25.;5FL%[H[XWFU?B#9O^6VCM#I&9%'>NUWX]F*Q9)R0 MU!!JM:(.'-S2 4!:QO1[>R;I)Q!L0%'O=B>%D+<|)>FV)UP_1K?^,ZK<;#U? MIW?QT@,[^22LVX)L8C9I Q:?]O0I]\;&K=3AEZB=%F;5&F+&C6BV,9GJ@\P; M>0UPEN?0#?I&IF_8BF2^,6X'L\,AH$:+=7E75?#07W1X\:T6YCK#<$6Y_]: M(*T.#UFFA6O'3<.G)2-M: X5HI;U#HX>2@8IZ@FP/9,3 M34<,(6] ,J3W'G,V96U>X7%&F-_M53/'^]R918CS6 M8&XOO<;"YR OEQ..#SQ"EJ&)1V'JP6UH+4W MUDHXBU5]|SZJ5HG-CZ9\(JV]ISW!*T3B-3OYCL>AQ^+(5LQ[>+Y6A*1HU!1J MBF9=2/Q0QG-IU#3G1[LQ7F8BP\;T]6YN6H#R%J@)Q.Z6&(2BB% MC;@&!&A&IYC_)#5,3,WR?%>A2#G/26KHXVYW7M,3AO1T:NAB0C/&Y",8+MN(+5!:)D! .774GE-16]? MO=5*#4"5Q0K&=F3V3XIKN DB%N.>\8B+&D+T6]^O)BB('M_8>&O M'K$D*5*-%O2XH&ZCR6F42CRX-E6[GEX)8&Q/LFJ0; F>83;"^7ZL\Q

M)#MEIY>"E67N-TL+2L%YGLF",@?"(H>Y]E_Y%K:W:$'R;4Q1UO;B MSE@GQ1#:FX7.*
(HGLY\Q!J(`"'A%H@724M2!,F'5DIH"&S#I%#3DLU[JCW8ZL1&)W(SP|S6_A6NJ6<8|_:0ZQ?)0O)UY"2! M95[&=
*B98;)DD<39S46IA(2EH>SYZ|A`"*KWZ^V2K".J*E#V\R8"T$-FWT8: MSLX5SWR[^Z);*$> ^;;.)GR2EG0W50 ^3&X(?+W$B3*'24MNP9^IVM+$E5D'Q*
*M4.[2W=\AA_V=.E.9T9.DOO6=)S^@1!J['3]6+SNSCD9I3Z-\5RPM..UMA)-X M%&S[L^I$W'&$A1:DE[*V?/#9\B EW9N$4R9[EF^%%OB"0[+]\IR)?*
*&GJX!:; MMS *[:@_7^\^_LM'A-KI8GV+GE$@\0+J5H;ET&M=(?+#B2Y+[*^$N"-%E6:I ML\:P#4 ..S.]YTI8#_,W*.BBR^GD].3X!U@NNIZ$S^4#*
*(VX">FZ)DKQGDA= M!=(:4-QNM=2<*UL>2D!B:S!MJ::O+?=A=P_:"<.X"M-\(3'0/>QYE+11'= M(CWY8:I%8M&]%!PEDWZ*?"H@)IO5:/8"*
*LVKU1*4_6GGFE:+.\ BU#;)2:\Q M49%^32&&+N,3W>T^ITP4^;";M0G%7]VY_C3D$S!-TK>&?$39Q8)]O DSCPW+ MB"OGQ"CD:IA[U". 0"-*
;@TY"L5)QUY@07\FE-2K9W8OV]0=]ZGJCMLW.4K; MM!NW5|0GC;[C%K7TXE:>$-J5XKTM;FE8KBZ9(,K/;''AV!_L.:3)'V@2EP?D M?
*E)HFT(V<'Q+K4FGZ"MA#X5\AN4S:D-B7)#@A"AU!0G*0G$'*?51(B,"H;.9N"Y112I%=*8ERE:[9[=P'/B+,=)O*!+SK^0ERU3RYL*
MHYI0W!TZ/_GG_P=02P,$% @ X%D66%"&<$:;P M_8@& !4 !T8VUD+3(P,C0P.3,P7VQA8BYX;6SMO?USY$:./C[B[C_(9_O M(J8=4;*
[QSNS8]_NO%!+;J_NJ5MZDCQ^B-U@=Q> !)(,A.)!/[M?WS>1N2%IEF8Q/_^U;MOWGY%:.PG01@_M__M7^WQ|II>O_L=?_X__IF___>SL?
[^_OR%!XN^W-,Z)GU(OIP%Y#?,->4QV M.R\F'VF:AE%$WJ=A\$P)>??VF[J\|_:;[_]$SL[^RFF\]S*&D\2$$_OC-^_ M'RX*_27PO MYY-NY(LH(>!O9R78&?*
S3V;L_GGWWIIO/65#RU6/+(#S[-<@KA";PG[X5/W[U MU_]&B)CC-(GH/5T3+MX/^6%'__VK+-SN(J#'_VV3TK5|^"A-OP7|;V.: ^_? M
*^_O_@R_Y_LGVZ\)QI]10#BI_MKI03?5S0*A&]GY^X9-+//(?_GH5PVD1J< M1O O-^Q/+5[IYYS& 0U*;H&&YE/R(;B> >&*=.*WB$:@>$G:GX&L_-P9];IY*
*M3EZ^#6C(K0O^< 9_X(*SO_SC(F$NX_PIRU//STM*7(9__TKR^[F@C]'D3#4_8G1F?0P"O"Z-SWYZ^.JOEZ6G]>* 7,5YF!_(=;Q.TBWW&__V*
*M;4UTZ<]=LM(8_M%[]]VH(9D:%$<)3*R7^]"".[]Z!E1:TD#GOS",?X_9!5A M[HQ>YW2;V4G9_'=&57HB:-2E@G5!93K,6*H-8!&.AJ(ICXRB1CSQ.ZYN-*
%GL MZ@+|\AO;MZ|'5WQI@,+[K_]I[:4[3Z'!/=TDJVR\H(7&_MH+QIH?O@'I@)0/ MM3I4X$3 8ZC&'4W#)+B*@TNV+]:(UH'#50LITUVE: &AJ82$"*
[5""&"VUPP(M@,L :D79R&L1D9?T0=%7AH4K/>6B0X$Z]A/4N9T^$GE(6?+TT6RC_/T<)$$ M:KTP8&&JB95 ;:W1HB*
*ID05/*IUJH:X(1R9)2@H"!"@<7]$>O<_7 5ONPG4H M O2&]48)CZEZ GBA$D"I+!Q97 M8Z3,&-6FVLF4>&BZ0D/:/R-=Y$M8K.[Q&[\=_QJ_-*
*WCO2_,E!&"._F$AP2BZVR2Q M.F+6!'YP"I6RX_<_?WH'UK.0.]CDQS*79&7T0 MG ^N8K7\X-W?C_[!Y0ST/CC_C21K\NZ/;YZ^)B76,;_Z8^I!LN;#8?*
N4R"3I M_([SO:5,EA^[]>/1O[1D]/YG%C!$ &'8]-5G?!,XHHHHN!P,U[9E+'?MNPF# M9N-
*])GH*4(*2$A8I"GZQ3U,:Y^+Z#;26G33VLOPJ/3CFUEXO0GMS+X=%VM[K MF%%M\ L<4B$1@85Q?Y)32#8-*
7^BEEWL%8Y]POAP<]\9$)T+W]D0&BW9'HF9& M?3E2X4 RAE>]$LZ=>WKAY?0Y20 ;V^0&%/:->X A_N5[!8)X_][A07<%GY(2
*M]O@J\+#UHNC]/@MCFJE7FPX4I@I(&6ZK0 L$204D/*A4@(.2$O;X*G"UI>DS M6\!^3)/7?',1;'=>K/8&"FA,E= *T%8-*2B2BFAX4:E*B4($#BF0$-*
*S&AD:1 M257:0*A.0\)NQV0D9(XO_ZL/'81-SN)(* ^+ZCY_L#^12)^[A P7CW M;4$'#.UI@90/]N"?DB8EVM(Q!91W]<&+6D>*5T*
M=#TY9TP$G/'(D^U@.[_CZ(.4R5('6C\>_;M+1N]|ZP]& -!\7W?M94^N]%4-P'3M$TG]'/3-)$6=$- M%9 #VM4KM"&'P-4877&-"FC^BAJ3].!&45E#!^B
/O38ENK$#4H=#1,:.MVX ML2B;.0OC.4TS>C.'IY]HSM]?;2GLIT1 !U>YS[,..5K#PMH%PE-J.;M-A6Y# MH"BSC(7^GHL#D5],&P='L"T"QI;A#BL%+*
*<'BZV_"N;[:MP]1-1F*2<* 5A5 M"3B.:;>=$"7SG@/*?N%EF ,X@/|<_;8/7[R(<9:=YQ=>FA["^/EO7K17;4TM M.P0D0QE@&<]?6.(?&]@_P/#?*
05\7)24B"Q0$!<9"U%::XT&'F?),3+47WD%%+CK C# M6ADS^(ZT $T0*:UP<$V$<7P=O] L%U4/;ZBH7RP35PZ*9Q(ZUINF((-#,0$U*
M(XI#90E+PIAP:&2%'RA V!(@ FCD!0&XCQ0GV-/(6,:!$^]9:PVM;KY.XHV M]QGH*4$%PMTVLO(.X#?4Z.D\S":Y%TUD]A%H(0X0K&F?%F@H9FO-
5T_A"DQ2H/+]/D;3 MB/%+D[WIIL,AJ?=MB(U%=Z$@V(#=DSUE*SM_UN8[@2*1\KV*8G/7#*?NS39*
MT30_W#$N<[:L091N!Z&1=E$FAB2;"X&R(AQ)I(I MT5PX($V0B0M#:V%BC3#'66H86QZ\$N9/?KG]BNT&P8Y6;T.,@+C(V*
MPK16&!T"SO)BY]B_MI0X(O:U(ASM+%F?,42QYBQK,2\T?4H,2\L(N3@45+K9 M,S&22D@>'W-BH;F.<\9O^!0),3)F_U>?_6@/KY-
*^3)+@-8S4<0L;5,RHFKUH M[6B;&0\I"F?+F"3:5:)6&SB(VKZI\$E)X.N%[*S7<'!N$.0<7\XKOASZBFMP#"X8O\[48W8\+G+GY$5=BJ7-FJ8^]N Z];;[[I[*
MR_4+_N4?'VD0^EY)3>N22P/A W .[Y&#A8*5-4::3$=+CL6\[+P8^=;^5X% M,&!;%#?/W?W|BL6U=@<&8U.HXZ^1XF4+QC"#W/F/?*
*YC9"IO6\FL.K35@G@O)]YA61^!H0 M._S>Y<00+$#L68+?4=Y=4W4;+G5!P2\4XNE;;W;0:^1:!!C<56BL9 MOO*J51914<>]E3JF2FH5T07ENPF]IS*
!Y!FYW' RUUMDBA@RPA<+.4'PZV_ M/3]> @\5L:GBMK@H1C",N7[SAAJ]NN;,#^XD!,PL7I/ 'PIAG;$]NT>5.@0G M[.OB>:4:&MN&[-XH-A
DXT:I3@Y:R%A1RJ=7V#&V@>SSL)L3QEO=.EH:KPP>W7C50DB, MMP^,:;PJ;I0:7]2.XQB.6:^U+->-BVLW=H?MQ.S2C@]ZDS AN?($0"6.^@U
M%\.!1P]RELRO "J\I8VERDY^YGN\N06[H5GV0Q7G2YZB\)GGU65D'PFF?IW/+(X@U]Q3!?(K)G?'^*QWLPKH9$3>>PV\@I0O&0>ZZVCR(5Q M<
L_1HPR^\&9H+^U^KNE^79[XB^6^L(@I*;#GK#3GA.ZW>=I&1_V2O#<4+K MU<(H#*"/@&T+*H[T9E%C.7GW:RU4LWJ".]:2Q, ^/--*
*TV[SM4,DM!$6U#PWK+ M)"1P.):@9,1T)^9,2O- $FGIQ?N!Q'2\RICB;T5!K MAUB)U*D?HL7!JB%BP92LY@:@D1*/%(@.V,- MK\U,2"X%Y6<6HNG"26*[-*
J:%'+DV"M@\GYVGXM,]YE9H\(7>> M6\'JB5)2CO(#=MBN G">=,UA)-"HC9+4#'>:8[0!<-]AB#G0]8:H"C2PD%7*
*MHF7;BEQG&3NOHY\#Q@B2"4'^K[??O'W[CNR\E+P(F?[T=O7V+?]_DD$WVXQX M^WR3I.$_:?!_PQZ(DI"++?HC[/.L9W^*
*XX*7P2[O@2D)W3ZQ@\1W;U<$E)L# M7E*_^-=W_%^_0V[#F&RW26PTL#X88G-%!F/WZV^__Y25V_\GWYZT\IXB3^S ;XTU_^Q8J$8S9X'@0A M'*
*2]Z,X+@^OXPMN%;-NJ"HZJH!&#Z'H!6O%S.2A.Z%S'2S]J7D$3 (=F;@4" M=IKZ6#&@R\\9$\.WB'$4([BGN1?&-+CRTIA9:G;N^_OMGC*NZ3KT]51R0:*
M1#S3L!>K:25F+!2#L66K7^R]0"0E)GG3P"4%,G8MZNGBT0+3M2B#]2'1K:B" M733!D2C"].C!LNJ_HVF8!%>Q]@V'M5CO/?97'W9R."_T-
*DZ=T(<(G<,Z-V+(LM$+"6V;3%,)F,@';&7)KL6"M5Z,*UQ+&D03./ MV_K&8L 4M+#<,A2)0"9K:: X8S(]GJR7F*
*:F@\8S1*ZV!246&]C6YRX>CR3*>Q+&H(:7EF4B+X82%V9R&-.#8%F5Y M8FA;DFN'H-'RN'G\Z8FC/?LHH1TR#_6I1P'JAEEH3P@RDW O"D)8MK)PX*
MZ/3D,)IR]"@.F83A?.#=|,XS"< N86X(:C4'A/TZ2S(PX">2"ITGG!8/5 BJ5I7E# MG=C?:E5B?RG+4+!C"$U?0I^>?*
PZ[+^348,=7'A/+H#4JF.JBYX)5<&2HE>6 M _ (+X"A?BNTM%+PF_."E\MDZX7=?N8&6%3U4#/?T9$^():BJ#BQU1:!LX2^ M#(I8<]X^\A1Z992Q!8-*
*>)ZG-K*0HD@# K(#4Y*"?1>A%%!K(O!X/ZVF.'2S MY|_T[???O>7?E?>WOV=+E1<5K!0*)_W"1NCC?VM+ >"K&T 7^_Y!XN]A-| W M <-*
F5%GP9IVD6TY/-$^!YRUY0E).B.R^EA9Z3M>-Z&_(<|TAIT(+56),"(\ M_9%M>79>?/AFV5V\S S&B2\09K&(&9XN<"8^,&5D>T"^6?PYS#<7>W:RV-+T*
MZK.?[>$X 2UKV?|%C]YGA2L810GS<<-HP=NO'0:307K^,))/B?86UL=(D9(6 M>67$2$EM12IZI"0(I;K0WTC,-0/9OBQULR_+;=<&,F+2*
*M@L$,ITF8:!Y)(0,:+^Y@4X%CQ.#/'137O@F\GUM(?TR3+V#Y@ MK7SOUX+ 4UH)HTV5;?R,HK"]\7L?GT.0 8*Z(X^.BEO]*&\ M)*
J!=0B(#T^-8K0>H"JA<1ZB&MCIAY($ H\L5BBE<6!7K1HL#(^+@2C;$@$[M%!!1IGH;)L(EVT]%R0["/GJK,.!@GN\MA&F?Y#4(2&=V(T>2$YS
>HU55B. M&,EDD8(:"WFSSZ.1$1/D/-B&<0B+7QZ^4+VY&+$0#P5V K4."GH4G,.##4_] M/:K XBK6QG/$<,:)=4_#
*[=.>D09[6141="&EUR*SQ+7,^19J!/^3A_EOU]=Q MSC@+GR(*82A^FPBU2B#31194'X",=&DS6+SJ#L<:$^]*9R"+_4I-VV0?\|A, MN-*
*UY8X:E+6#Q^P*7OY-<^8F(Z%.FR/L4Z%-JQ"&FZ$,JQ#&,CQ.EO&17PY<2QJ47$O$OUN MDLRHV$U(!U2[S[A4N6LP7/7N\J%1**-SQL*
7KH51K4]B5:V3CL2PC<<) MY(D/+&D,6]%RK&05V>T62SF&PT''3!KS$)"Y?\GL94G3ZAA,;V)TH!^KZ@ M!XIHQPI>5-*
K#P,M3''E38/1XE'"%/\CQ'WCR9!#G.EI?FQB-=!P9Q:RMC MMK6=;0(LIN!&/RMAH[]WI7GA#_$WJH/8K=+?175A7/4MRXZ7-4(,B45J<#RE M-
HG0U&\5+(HOUS,CU:#"#I2=&:$!(4-0$$9OW@*K17$D5,:D_"JEX6^KJC3 M8'K8NY_! @\[(;5(.'KJD? X^B2SXG;)R3EAG?-(SP%.P#POPVB?TV"R@;;I
M.&ZB,J$'&VF3B+MFVN=RHJ$6!$_'5"UFH !9(BNDN];S:.MEF/E1DNV5&|=A MJ$@9(0-%J_)!+/'PLD$&,=A3IOA;#RFO8QK?5;^G:IM,Q-5 3>%HZ?
B:T^,,_MDQY.P^<-L_WB^F22\G35S"[P5O)/[[U,<\CTE@"]^C(N&2]']'S.-7_*
*MF';>J!YHH.A'D66|%QKY(;M^]+L["HKS8&>7Y,#VJ*KKQSQPK^68(6)OB8O9 M@7. <.VFG!:(2'TZK3D;5]I1UM_3$145S%PPFTIB8%=2^=$2QP&5U*
*DC5449 M_JX*JCGJGYM%G]@:=KE*D4-N*-L"2"M&&F 1[R9US+2:DZ,&N-(ML4\59;& >']'T)W"'^>N"TG8"3K-EY#EB3Z',:Q#5A(=:7O\G_LLY^&E*
*MQT2Q-^/BOF>.)X#C'HTSGG7 '=#MCJ>HW%/F?[(PIT4M[3L^C_?43Y[C4)*B M9LA7C"#J88?*10K=#YP.)((731W$IU]ZBQ2,1E H#7XE^PAV'*
M0"J"V$4R9YJ \G>XQ?(;K?!(4@@,E8A>:,8K$C 8MA?C+4>8,O?X*EL&OIY MV12<[)FWP*Y(*Y\;L3^Q?0\4E!V!D4WXND^P$R'F:,CA^*
M9T>>#IT=PYUWX/|\#@&"5;U9,?*8*]QIW]-&V&OAH'E=GSN'2-T2\8F^\E_4J0!6N,XY.[EPMON;"M$EER:C;.P^AI$0 9AE M$V>1TXOZ]LH?*
*%JV3*$I>S]@_[O9/4>@SJ#5-:>2H@)) QG/(?'*E I_5C(^VS MA^R<@2K$L]Z!.&FB4M8&V6@9'7;=2.TDK3-SRQ3SCL5F282?S3KM8\[IB$YC*
*MSW"UW47)@8KCY1W[(!NV&;YCLS+"SVMH.>>R[(2WW6,H";GDT&PX';,'*4D6 M0962* &J:C]\43-QT7KU%XH9@2HSM)1?*
^(M=?].)S_^;D0I_ZCMB8Z:<|9O M.P'6&Q@U*9<<@!VOH[8X.A_@]*YG\&R,<@,N[06]5Q,77K;YP'8UICYW>A0' M'A!H1%$\9>G!8[]@43 T[N$*$".*
<&GK5/F#E+DU>PH &[P_,<:O8UGA#8, MCJ*$6@%PK."=.H%#R> 4Q![+I[1V&=?>DA8$Z=|_.1+&7RM*VSK3]'&^>>!S ML 8+;I6>A]Y^?*
AZ^A'F(':>@2/5TUY3B; 'B6V&>S:6#UKRAVTQO>5XQ0E%M: MP5^+UO%WT%D&KK3R/ V?]KD'76?R!>HLT5DQDI:0ZW18^?IP5PR4^05U1\3*
*MR)N)_3"BK5*DCXG,Z*L6$^>5P1K6N.6'=2(S;]$I5:3D+3(F=B[>@D+IDO!$ MU7A8G_C(*W YU>'DY['@9\V*7O>]7EQ9T"GVV8OK2:W4;1!/:O\#?^(7:-*
MJ97M%'[ ]:>7=,=$"/G&A_TYHO ':-78Z(VF^ !VJ'A^;8AH3=]D@X?B7^P9 MZ]B8)19=0&[&.9&-KFJ:@;JJ>&$PFJM\+]H]AKXFH
M/1JF:=F)U+8K/0Z23=DP)=$V@=;JV<+5#CI-%+CHQC1--'=:K%91Y@P@]VSWPABVL;?Q99CMDBP4 M77!%[]MW"OE-
2(@=VZW$;35LUV+@]&NW8*G?KITAE<35Y2;TGL*('\8^>&'* M\P_]4YYBADQ(>*9E)T[3M/08**9EPU)? 6ND%0$TD01#:D1TPQHEU\4&GD7
*M"X*1Y%&]*L0PBX5+7#)*:^8(<*VY%: M'7KV;,MTU+'$@HP[@<3)(@O[Y$^0/+Y"\O4M:GJC(@_5\\637[::(L?]^D*? M^WZRC_/LGOHT?*
*($+*^OYDJ&Z9)]JT?26V<=SQ"95C-E:8XE/:@+H2^,$*2MQ M4K,X$_J_]#GD-PSP8 U6[^OX!OZU(]X@3*3N+\,$JYJ_V*'A]7X9PI^D9-J. M,26N>3:|*
[W!A2$'3D,2E3TD1_B6"WS)U);7%O,5TD67.XCHNK@V:,G(B: YC MN]"?2%%_-M249Y(G90'R59H!QZ5%6'",?O5M(#BR|/8XLEUO&X@.KK,V8IGY*
M1[.1ZG9CQ,Y5@>V6W6@$-%F0!-496U+R9F]5C;LWIW>R X5UY-JM+|==2G=>
M&)17A$7C^O,XX$W;1'C8>E+LB+EDBD/$UUNF#25'#-6>55N|+2B2A2/EHCV MA(Y&0+?KGY@,P(/=#MM PIG#
MJY6HFE.L%M^EXZP%HR//M2G0@HCE'JKU5+%:?DPJU-:=(^Z8:5"<=>LP-:=% M.#%RNR:,G/!.KAU[1^F ^>NZMO. =SH0@O\YS#
<7^RQG6Z14YKI&47!ICV$4 M5+^Q4*([LILP\&>[A2C)-+;]O)8+_@WO=)$ET>P5B9/XS-^SO8?F$AOYXNC. M.XRZ-
*;KP7#)#A5!V]T4%DB,F)^5J]$U1@>W<7:V==)48.X.82#945CJXI[PC M2R--Q'HB="1%@H9E%IE"=@QDD MO(8MZGL*0:?'ONR/Q?*
S\+GAL,.U.]HV8G7QEFX6B.X?F$1.A.T,/(.?4D7HP MWSW-?E0,D]C?1:07,782$Z@)U]'/YF-PSF2F%E\0>(XO%!+,0C>1EKF(Q&D+ N;(S&C$MJLU(L%TJ.J-
*D;VAM&=E+ M](6--*W2?.7WKQ4AI%C_ M=)F+.J29^JTD>B4YJ(@^\ 4&0]PWZX'F^80"JBUZ(@*VBE69XN.5[2&XL*
*MCW*NK%;%&M65A+FQTC4D*5Y.\DA5$.;[%'M3:K\GG[RI/XT#[+1#]N,'T?D. MFV[&I8:)S.-2>R&E@^=%A8P?PMB+_85B4H.).V?*
2(Z?'PMP'4G:)%8QB?:B; M] ;Y F)2\TQ8-R:UKF:(%1_3/#Q\2G)5$H 9W(TSK4P$U0&V"8M^6NTS8SBE M<01'TM4F"0+M:WCK6W;DC!FR&
*[EKQ5;_0Y(*LW]F?X%V)\Q'"-,OKZH/$D^A M/SZ,I8E^0)TV&9+#ZSB"F ?;*1RK#KV\V7U+_S>$0L(>M4K;0;>#S_,=D\+-K+;M<6N0 V.Y[-,*
*(C3=D0H6Q=/HF9$] M=*NL97V478&];Q@H2M/LW=D)-(6X"6/*_G/!*TM;"-V!=\,:I$*HS*$%C&X/ M$FX,!L$Q>$,ZCN.42=A(T[2)E+XDT0M_PL@P>9-*
*HO5!'O9*Y75_2I_RZV,U? M))GQ,D:*@;[+U0DBNX"1@*->2CYT>C6F@ .*9$(QT*WE6D2!66!_P$]TZ9 MOE:TXV<;0@#GVVQT)EU]IJD?*
9C2PN>B5X[D1A=$*IXW8M>BW_%+/CVC7[!W:$>X' M)O+F";H>Y/.1=\-;YY@BE5%/H8UN^].95YK1JEYKF0F5' X# M9[J;3N>X'*
X+@P1I:E'^'^&M17I!Y8_ C)_=U_:R$(AHBD>DOS/%+R18 Q M(CA#=J9.? 91@[^8NC 6SAGFG/^!U@.>L!M>8OY/UDG.[O-.SX4MZY&6]2JB*
*M4,U5K+V86&IVI(Z!G!$*Y4S611&=8\C_D'MI[M(,/-'G,(YAH3'/PW%Z->]W MNXA'Y;P(&/\0);_7\3I)MSR894B^M\9&[.8\3,!6>V<[5)Q^ST-XZS=/;F +*
MQP3XI$' G<3V&27UXS1V:'KK1TFV3]%+2S+YF7^Y\|+@DZ8Z<@<*LT"DE.%V M#<@6"%*91PD/LO>,'(H V)+UB.T+-=JPS0V6-R C-NPP,%6Y$:-
*LU!U\]^# M0JUT*F.X4\RT"8)5K[3/@ZH)35D=+\2^1K/CNJW'#G30^<34AO%TF]ZQ:6/Q ME_.Z!RQO_URV52]>3@?O5'"0<;008_!3A&^%X|*
*<0PHG,C^>T'R 1Z(1I,E C MY=|;]%9%@W.V]1LD].TQUD(HYCPC)SW3.6]EX69J--6$\(U#\X25&*K&8+,Q_ Y#M>A M#V791*N6,'Z^8U/AAS0#+\6=E&*
*(&IY'$,X8YIJ)I U/HH:C^=(;M-)ZO#PVR MI*9+2L)N+8;'FAE<7] 7PK#^Z1#P[-@L1M-*U= H-FAB1W(!LMUZZ8&GY^M- M"ODBB*

*%"R<&8D3U<5G>C!O>NQ<"| MV3$*TK[E48(CW?@8^)'<_@@,%U7(Y+GU*$XID=9+Z^!=42.3IZI02(WCDAN> M(!*Z:?R8),%K&$6\'5B[V+*UOQU(\]X1@G;M*9!!%#,:P2'/>4L:?#SKGV5 M<'?TU>3E3YA MC8F70S&016GS8ZAGP=QUG1+-T_&\;B_:?./EQ&,_^I&79>$Z9#]Z&?'%0/!@ MGE>K$$||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|=9&#>^. MZNCO853 3BB/N?!$6WN<.:1U1W"H^UZBS:&9D>!3-5S"Q*.S%,#8^4 M!F9B2)+[U$!QV&Q&B';7AK$? [B*:B?;(#0*X)O-31F_75UD>;KU: MGP?)+]>!S39K%HI85?YGF8BZ_O\D7W=L(N=S3- MO9#WYLL3$M/7%DR+B;J%A2?8P'K9OL@\,:*MXH0MLBL"A FC3 K2[KFWY:9& M-2TP*7C?^\I,EY"VJ,C1G$&BM@*ZECBXL1X!C'7 MCY(4Z.#A*@+-(A5 Q $374#G-^18*((E> (45!G4&&/\|0^!YAS|F2N8HYZ*/ZD/D$Z-!|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| M])%NGVBJF!$##F:=%0MAVL55- A(%56,'$D*BY0XA",1CD7>,+SL:_*+P,4V MHXF"95RP/6 ML1U^#+>BA)>4S6R?20UB&"K29GB@:-5>V! (/:RL\B$%Y#3H2 MQ@R5#T->-Z&_(6%&V(2^T#3G-V9Y4F@>=,>)"?UM'[YX$>]]LP5/#GX=7/F* M>&MF L0CV8[ZHE&.Z(##3W6,4ZR]\[19 NPSCD[D7F8)8[RCZ1HN%YA>\Z'Y M< |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|"&GS)@$[MP XHNI1]J:JW('&57<**3MU+<,+A5^3'-,G4ZG.<#>8@62H!^-L,1Q3_YR3] M]3KF&^7,J/@=8 <47\J^5/%;D+B*+V%%I_@ #EEE!8)CFF\C#"0#)S%O0^6E M15[A*\,["^.SG"/*:7: MS#<+/+=42BJ42;E:2,ZHF80K*X5;D1)UGC0X5:.A]3I*($'X3IT9U8?!:ARD M8+9N$-0!0&P$).5$G>FD27+BI/[&2)'SNW.T'C]V\K1X1>W3,R>_1SK?P5/? M!Z92%#3KIJB JMD?:#$P3WI&0=K'/24XTIG/P(_DX,[M83#@.*=;ZHV"%L$E_=)N$#0:YD2*/%1XOEWSHB?:5'D)'}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|B:8B]A(R'Z,J8ASL!&+?P+P&)HG1R39T=3+>? #CX#.^PC6)DOB9 MIFC1A@F?K=RX"%S"D$D+&WG[,E4\@;.@2[M@D!!@>|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|+LP?&]!?]Y J3);TW-@[CYH$T[6;%3'T7?D(;NTOY 31 M*H"] (C5=Z!%):LK8A^J99Z00/(*)63-!7;)^7A&1!MD'9@Y0L10*I]^N-:$D M'0)J"4*#&)TRA IHK%*$6G;D92P9@N@-7Z* T3D0DAHLS77C7L<H7\G/4D/1W=E5VH649.AI<1U8%=J8LXB@ZND /95TBA/D6[E M=(V2M9GCU11U5XIJ.@XC6.08,W36[@8;G'M6- M*TG+:F<29T!*LQU&!YR!/_MUWNZ8\.S8:LJ6XZ24V|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|;\T.;\Q/2U MYT*2IRA\YCE53AUG&S>DI8>|W)ONZH>1<&7MM1/5'":2XSNP3MLP;%]JVQ?[M)1G"Z+ASO3^#U#_%Y0Z7F2|W\'64O#KX,*%R4*5L@]H63"#H5O+;L&DP9<+9 M47,F+6X(N_8Y^9I)JC# *820'F]/$KMZUSV*"MZ3[PGL:MHQ1YS]'S*R:T9CZXL2:?2 MR@247LX&S&8]&)C]ND_S#5F+N-4![/'B=1%'R"L!EQ?O&K]\41?UI1D(V=AIN M^6,O+X[W#&+'F[!GY'5#X^KW\A^A;W9*H7H^=%9AZE'1SYIIO^LJ[7=7IOT& M4!+K#9OW"+CR=KLT\?S-UUA/W^?!M,4[0.7U8/L^07PS;&| [^R0\;FA*N6RG ML3>;N/JY-SQB>+ROFY.IHYK!6O>0;)UB(%J&R*.I.6H M=9J$MS95%2'WI%;/Z2@C;EUC"YI$$,5OUC7S5/Q FAO'IHG#/DP\)X%)XALU MFDVKIK[L,WTF2)]'__3$B[,=C3/5(CRP$Z#K47@?GI,/M5UW!,!8QG?WKVFU8FAT2Q)1TK MDIJR#6 "T&XT%>L)\)?[PGL;^9NNEQVHZBIG1'% (FA4A:M>K@N*%@4J9L5*U" M?ED*U-0Q PJ*GEGQU-.UO\$X2)#OWAXV7DK?LW4XX.OV>1Q\ M2F*ZW47)@=('FKZ$/LT>4R_./!^$>G\H9=4LD5.) (NKC+-/14M=)%'&T>0:6 M^YW<'A GUN>A$U;.:Y?PJ41/1^OETS%%Z/I43T+K92QKM'Z,_8,BOTVL(!>Q MIE]A#P0!)TW!:I5MUOD=+X],RHBNMR TGPCC=9)NQ=9Q1].|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|'\)8R+0L&OJ#Q;H M/&?]'=-#]@>RIE18"344XCO.:UM_0X-]1&_75^WGE/63RXMD"XQRIWX><3;8 MGV[7]]1/GN/PGS00HD.)&6UH;:&Q$-_F+CEYK2>[2PR$\Y)W.4GZ#WR+L6"9 M*D\A?%PW,M L\LY0PJY2P? O;7$N?5J]_V87ZXYL^3PA<*@_[Q[;L_]\.0 M!@2D,ZN5&-6I50N-=VZU8$OW:E6=H 7O68$2$2.0:@B1.O(&?O^* \#?OT+K M[S)F BJVD7>XE/?*

*(88?:CU[Z*X5->U%36E^8RXB&N.^T%*FUA33@X.P&K9C] M;^R\]#A#;4NT\C2%''*X9Q://N0&0BCTA4;)#OR*C;Y986*F>UL+UL[\-J(A M)8%;\B5QZP)3!+IJ7$<4|$<:T]2+F%SG ?2RR?C3YA=]HX*6N'A*.$BXIAI: M(:(HX@#.)*H8;I_V:<93,%?D69 2S>=:Q,RZ>9RXF2/'"L40YPEOW!CN,F0@4A[&(#/T=EB(Z1L[3E,&)I.^G0RN*5K18(^>O7AJLVF@P MZ'PWO#/6F&S-FKXNA@G)A1J1.G'D-2!E&.@U'M4LV>NI.^4LQHF5)_ZOA5A^ M\U]ZD|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|2K*1IOK)%@VGU;(O[$#%K FXJII=#A77 M-)W;[GK3OR*E]G)2V$5BYY2\,DN =.2-)@0T;G<@B]8(-? .O)M4"2%] =D% M7LR0+(]1!]9Z0UB93#93>\PH<@59 O,XR;99UX,G5O)*C-T$>5QUM*MY((O,=W4\5+_;PRUMN8@[%Q<=L2TS)*O?X-:1&LN MMN?/OG>K1?1R\P2QNTT2!*

Y$3D7:9@GS(WQ%X*L6?>"<$".FAU&XHF3)-R M]O%9_2"O9:TJ-]T)\1U(?B+O97)>!Z/MR9QF]/B,@,FIJX,FY'S]V\^1<3P MG?+$^O (H-|+OVEWYK3J6A;HW569|;R4-1WW(CXP_BIPU^'#L>M4R-)TQ4($I:?,GU 2I(NLW_3['ZI*WXMA6?]IH1&|'>%0UP9RU)IM@>TFZ#7!O#:DCBV55XUY++_N1G;7]' 4V0#H@0=1G=O?10)\5#;EJ>YP?+/,=86I!SS$I MQ4U*CYRBN$(TT*=%0UR$:N$A5*QHOC8*;4<&$N.1NUT@S8!;D>9>L!V'B*=] M9:TXC>,"'DR3|824*+O1NZ@7F8*GH|IP[,BPSB?# <9R*G7!UAA63B&_DVK9O M/E>75#K=]A:T;G:,Y+286Q"E\MEY\EY+2"(($\FW6,*#HB?PB2"E1+08A^CV M\/GMQZ$4&_4-_IU.9:565&AGOSR<IL#*>@0./46\3_L.CG(Z"-@8R;=)OHTJXK@+'>BCNK M;D/.1<% [O@*!S;O!+X"=/+B#Q.!CU]Z'7;1'Y%:76#HE-I?EG2I])P=O1^(MFZ'K%']CW+Q:]&QSJ6YRE?(58]$)H-2(+6O)Y+]T_H7R;S#U. ZTOILMY&)Z M(!GY&%MB$ZU(B%]$9FI(2]01W4CV,7G.M6$M_A(ED? DP,$6Y9>&9I^GE?HYH MQG8=&U(?%("D-@/89^"VQYJK5H#T<+JG5EPM$ZF&#?5?!Z|L6R5&[N8B:[#> M,/:-!7O+X,|3VI$L3E(X37Y>79|' CR ;>QAH)=-==1\IU_F B(K.4W!&+K! M-\7 D]%?!P@>XY,.41AY/=.5=:UI9I6B"WA2.GN$<=$)RJT$0'M17R6S'=%A MLH+92&3=TM**QT91L!=[$W*GE? ^'./6%6.3Q$/"9;3 W\/GF_>SK?+53'62@GZ-,]DTZVTX0G1/3S\6&SS>&;X"U1Z5B&| M*ZP^0MZ=(^Z/T?=L$XWDKN_R:3021V=*WH\F7M)RR9K9SG'Y'% *3#%!]XS(MHBEJ+"5.F|E_/&M4X'N*KTQ;#A<8)BVS[7?4T"N-"GQ6'.WG5MV=#@K<=)">6|E2DRS4FDI:U#P[M1I&)>_C*)QKTID-?G P4D&|-#$/0:A) (EKW6,E5^.L; =^]1^4\TY\#R8CZ' MEWO\N-K3NZ61;N'|[66U&81ZR+X-;L;IOC#VZ5E"6 JLSBFLDAD7'U6S&KZP6UDM, &4 M6MO](*.?O()^S ++-C7K6+5O1>Q>%;_V>[]'EU_:XA[690>N KSUUS$,ZT+1 MAR_|^S?!"_/\I0$UB"DM\+FF^N-[DB#^]U^.I*K0V<,-,/3O8W>QO.-/KC8: M/_QF>^$YJK 9([P,Y*\?!]6Z(\W"?=NY\@[QO'_VFD#%G6V!8=0 ^!#R=2, MY?U_T4Y]#ZN!.=:R3D^'G>PMMP M^$NV78C*| <:#0KS;$-3L?\0X9_3 66O9? @=&1U<,K21=8^VF0+W+UE2])%K M!Y9Z_Y]A^&>W<^21SCV"#_53/MK/E*M)!NQ5 1@SX&N*A'HH61[^M)L0NWLX ME&U#A14+M6*;RV)\.]7F^+]_R;O0>Z#-8T\?<&V!OTY",8AFWS;O#XE(O)6(M7T,EGLL(K6* [R/%8JI;%N%ZFD*KE.2Q3KU:+/%^LUQY(]X5$8RY.M'TJ=25O M#/0DV]9/+'N7N8.:)!YCOY0RGR #ZN*.;CEU)W=5] [H=Y7L'[-I*WF'&@M)LB;$EG:8%/AV2+Y0 M91PHC@^3*WEA*.?JK>K_(=DB+]"^$(!XXZ]+LT!=M$%2UD_S\6?V&6A*(K M%6CW65L)S,TTQH_0&-8DUQ7Y" <%+(,X^_;/%]1)^1\0_H]_(3[8 U/6O'_^:'!>F (#[EO&|)D&+8O MVXL?Y\'R9GW'6+: 8[O^#JRS34;K IR*<=WEHBXLK19.A@=0/'&@MS3DP<@& MF%#$^*4)D?M?.,+_^0^;B,7_>O"7#_#[;%6O"9:E3[6XAKU5AMK""U>2-7:6+N.0>>C#3V,M3HB M::S>PLCX'^]?ZQ_].:Q=X+ =#^7!.TEEVE@]MWF/16-/+7$$T/IA;NT3%:IL MV\7\,<"F6_!AZ\D@#%@]4.\?6/BL>-RKZ(H/6.M8E99+&&H!2ERS4FDI:U#P[M1I&)>_C*)QKTID-?G P4D&|-#$/0:A) (EKW6,E5^.L; =^]1^4\TY\#R8CZ' MEWO\N-K3NZ61;N'|[66U&81ZR+X-;L;IOC#VZ5E"6 JLSBFLDAD7'U6S&KZP6UDM, &4 M6MO](*.?O(]

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|9S7N8?+ [1L47J)BQ4781ROB GZ"4:&]8'YJ6C# 9A1\#L+..\ E2 M/N_+7)ZZ)\A<6Q/XQ[]_")84J.B0M3_<"7 ^R+0+]%?'R7%2<[_JS[=1+T M?)$DKA^XX!''^^)KQA$" MQ YB$]L;A9"$$-I "]NG?R1UM]TV]&:S"#HG9JZQVV59RJK\5=:_LK*PK\3Y M[78UIO6T9"8)HAD#\P'(^V2(PW_BK'W.]*>YZ.^/$F^G_6/\NA30>;E-I-, MR9FGM*>+CK]3SHI5YV&(Q75CHZ:JGWWXO;95(F?-^/,X@30Y? 1<9|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|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|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|S|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

M68+75A&!*\"5*Q<+^S!7@F"NYK?X,H?(W4]YC7N+DK%.N$(E96\) HK_0&(/ M8"6M6+E, ;$/8V7H[RW5QX@9CW/^..5YE@:OHFQPG[Y3J)9E#QSN)8 :P M5M*MV7T<*]WR;FL62+HJ#KW1H&4*PQS!=F*LQ*H=0649^KR;") T>/=)@U4G M\AK=F%I:1O9]+7\I+UQTNMVY2N!?G]B3% M^!:=;]PS1 FSGP3C8H#YT03+1\@2PL _=MU7)S>><=XL[V:SWZH0T*1,B7N0D MC(R510H_\[D>R%>_5M=;]VD-XB]OT7=OVY2YOPPZR+318\^ CU?I\:>WV9[MIK"6AY/Y6-9F.SV&'O7E.YY%Z$/L_1N2D:XM6:3+16_=HC>(O5N(]LZJR/YU MM+=N%72376D,LMIX;=]:!OV)VXG!%]_VD&78\^NRP#W@'G#O/L*]L^K$1POW M)M*60.9DA30+;A=ARTREO28W,? 5BW9@D#P_EG33:@V3/5"9[_J57]=U MC+N MD4LI()WSHAHP7'/^ZD27VEGM%]+YBZ2#_KC8YG'G\UC@WG3+DZFV!'JBMD-: M3&$3+,>Y: JC8IF68+ ((0J"RP ;NW&@6S/C77Q&PZP]JA M'I/HX?Y;+,LP)"2F?K[$U/B1)[O_MNHHKJUE9IYK/\F.K@-WX%Y;?H0**5 A MY99$Q@>,-%S_V$PVK8\\7D8V, ['G^LV@WMOE.ZLHIJ:3;- LS:"0#YHN!D'] M2F#0SS+'/^(^G ("@4!PBZ M:V'Q502M:)-@T%VS@>R6_?E]M4(Z8743(XC]\IW-4M29-UL!08 @0-"]*XJO M(FB0[VUZ,BH4Q5Y50_I%JX45^20*>]A0B1'G78I!TN(])BT*P5SS,L:#DOBO MQY3%DR:[0LHBI"S"KMCU5_+G51- ;KN/^.HV]7+5E49FH2*.+MQ&M+)>#RK@> M^$XTDS%)ZB*)0=[BM>5#P-%MXBBUYX(NHB:^Q] 7CP+-S6F>T-NU.D+I.ZG: M'Q6I9GSO))- D+R*Y:-.?NX;: 090_<(HUN(C2XB,7XH-BK:&)D+55[L#5Q_M&K9K0I7F8AS%%VOC9XZ-@$9 HSNE46I#HXM(C'\4&O67:$W=T2-;% K5U;(N M^8[E)2R*%4IQJT5C6GH3(0-YJD,AX;5$2ML]@ M^^P&I,>?NV8ES[4+T7L83AAUA/ C)3]?P.6A73]&"[\-/#D*50Q']G;50+/] M:(*,O\!S+2N9(@/- T_S@R*18,/V]IIEBTYN5<$I8EMQJ=O:079'K>8Z9G]8>T^E29,O.O MJ>9H,R. ?$_(ITS5))C:7<1;F!$O*+I&.]WC/F+^@21'9K.<&Y:'6V98-(=8 M;9VCJNN*BG;B]\+C342$AHO*KZZ. HYN$T>I36JXH%AZC$$OIC1H9IWFF.6: MYD.\4ET['M7Q2US\@O'UYD261B'A\^JB -#H-FET"\'1!:7/[P1':+M)HX52 M:<0+O9U&2[EE$^_]\7NQ\;UC&'G>ZXN!1D"C>Z51:F.C"RJ6'XJ-7'=NUL*" MO# %I=;J>OYHJ9-);)04K;2R.'*!>W'N'D>?/- ^SI06/69Z0WYFZ,_Y?:8Y' M-%?=<&II-S?;_>?E[X>]O+5N/!2_S+ET+7BU2JHO9F/YTQ11WKD,&B52QR% M]CL2CL;])E%R3.G0$$ZYUGN.P=T ;IN/1? T+72)-*?%/<+ MJ<_%Z**^?,>P+,9"7L]=_<"N@!=MRZ OH6NBC@TK6V9+/!E:KQM=&QG MT),3=+')(1KB_+(GD O(!>2Z07*=^:#\&^2;L(N9&>*Y'K\: (9,%/K 0NJ7' MY$K.Q"-9'#WO 4!(SKS'Y,R?JFAF]7G1^+?MR'/\N>QID)MY65D4[//&S 8& M@FS#OQ'OP#[@8)"Q74J_;/*/E\WOIU%Y&C(T)M? EUL+AIK0]42J3G1TGQIGA^+\P!?T^).9$U> M897"O,J=.$,).VEI@;;F)4CIQ5_P0Y)&?DC2^5G.Z.?,(L4+K1"ID-M.T\YU:L3&=(W6?*MAX M8;#*HTGHQ.9PPA& $\ )X'2G_L%NM8XLSZ1^VVE-,'D[2:& M4YQJA'QE#M.[3THGR#1*9:,1*:7*HF&%@:9"BM%EE%##HY"MTP,RUTF& ,C=.F=2H@&]01K-JFC7= MSC>1KW?K)@//A'20NTP'N76+ M@6."8X)CIM!BX)B0H@0I2AZIYPBR1WWTA#/SX Z*N21!R M1(^? HWIW4+#K#9%"1XU@4"LM^_1&PJGD9DH\RS)D%]?.7(H4\IB@8!30Z#(T M^G"VTR5II",3WZF%&,<+A+/O#0MY8!&'T$ M1A_.G;HDC%C$69:GVPZ%V(N6(U@HV5#G"8R2FNM8?&MWEJ3/NU"#Y*E4)D_= MP&G(SRA00QK4G6\=WUY;X6H+7R8<>Q16 M68;.4A0- %UJ>2VO]T">6MKIOREQ$>H$;O+L7WC_]_WUUS"GZZ OW_MS+2,K M\?E7V=E%XRCCN$'T(I%[9*)G&I'WZIYL99:R%V3<62:8:[X6L4 .U6C,JK%_ M1Q_J/_S*=RU#E>,?SPQ'=I3HWX[>*QI!K3F!__6D1GACF'ZT+U3#7UKR+O9C M[9^/O9-E.%INGN#FVSM()WE]Y /NH!KKI_]&_WEZEF)ILA<#9/[/T[LGWO+X MSS_=HXS17W$R?JGH1X_OB$)Y'KMY>-_"T4\ MB\=M3*JX"D6,G1_]+O_ZO*>N)2E<09. YV" ">W1[LE]L]%MO[Y28_V__G# M7SONH#\>_C#R+.5?<8O,_\M@R=_\IV\]]5N7_YST?W1X_*,7'O_4=W(2UT@] MBLT47*4E:C93)$)&48FA6%3"67F*H!@ESU#JRX.U3N[3B] /C-GNEX!FEOS/ M*W[^!"3#24 [M5S%?/[0V"@/OS?B]>B!P0^?GI#NRX]X[$33_/-A- W4M];T@ M?^P 5)ZJ,D)HDBS'':"IBL02,UFB"951:60Z)4GYL0/DIU!T,Q:*- M;^GV=(T.VA@71='([RWKX:92&N2QJ2EPO0%?P^;]I:5+V&'+O#:B-J69[XFY M08_T'-)H8Y4HO#UL:8U;7(WE]3:"C6>4Q

*(*4K2KERP=RZS47,VX6A5F5)@JK<,4V8]_|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|1_;Z'23O&W9.QN05<8CC!]@$9Y4MT8F[4YWFKT*<61'\2 MKX*EDVH*;@LY%EXV+O8I'C<1]P%![K[YNL'G=[&UW2W3].&L#2>D!H2FO80; M,%XO.F-7U4VUL*]-!LM*<^YT9>0&>-FK'_ #OG?B*A3G"?DZL4P=S]*FF:LH M?'/NCC5%A*,F $W24\0#OK._HT(6"/^'%R<=\79KCC;%;.SGV%GX6QY'JEG M&-D8H_7MME M< 4KLQBN6%=U9VD^1GF,[!.3C#\1'TGXQQ%[G*\8*B$ ^>%YQ MD-FES\#AQ5S)4S \8I$*0FI:5HTE6UB*L?FB6R-[0@N!8?S'K^N32!@$,0CB ML.UO H*!H=C? \2J4&8:DL@OV7ZEE2XVH, 6;<\[9" @TD\)ZOH-?S JXIQKMG',=>$X>FRG.N<8YUZ%U7FY(YK_G<'" [Q>:DUE3+)U*# - MCS.B,>?^FG-G=_;G#6KNK*|)C>|<";_5.YP>G=4::M_)B|72K"QU9)F/Q1)M3U+$$T,F0I_"]$!6C!,WOW&>=$ASFK#Y?6/SPWG3WXS4?=/|.%=7H]'J,;-D M)LHMQ$7-'F=7[52CA;P/YL'@CZ<38VSJ;'YX?3JD$@,IU>'@)'] M&V^!-M^(X>^(C>R7F]Q&:.S1R;^:.8^9MIKMC,L9G?-R\3F_D-\C:_A9D'.C#R1M.T M96^K.Z.Y46$WZ0DAC5:I*1--?YKC@'OKDK>UKIKVN>RR63S6(Q<5-;JZ/#_G MBJW%8))(\S':Y-&$4^Q&Y2*P;AYB419C)LW2*3%N!EX6O=/D%=U,P"T6V9* M[:>2J>BR&=^N]98'>?3'(2_@";7HDN//6]L*(.V"CZ!)\$H904,5A>VG2 ?, M'6^=^C__(A/$/S'BR7^!YO'__7<3E4FKY|"+932?7'6)!M^?3Y;8!^'SZ"RFUWJ.T7,=&#P>G[4RR;#0V*<=8 MLT82C6S,W:C+<:-;6O&QN%>Q(O9$IY)/\?CU>|%@I^T/G%9PC#38_7!C@9)5 M #M[QKFWA+-+M]OMT2X=IX4QCF6R@W7-2%>Y/HH^2Z.2DY0N' I1K$PH-B. M8^.K+X-BKV?<9R,#>]EJKI;*% ^N$_0G/4B5SP45GA,H6UG36IG2SM9UZ'AH*&I#$ M4R(5_B,28<:S>+ V4 '&LQW1'QQ9A1C/+"3R>2[ID"XQ?Z<7QD#>K5M71>* M-K9.1_E%;4%L%M-X;#BVRV1,]J (E;=F]" MJ1*OIQGU7U0FFU56YG"FP 55]PX38!2$BC)52=VWOE!?,$]/9$ M,01#A+|-[VJW/-O/%Q75'U:9CRX5DK+<_PO_V7];U(!@(?2;_B,I]EP3-C\] M[=[]X%XKJ>1S+(YN [XU]6,^,:2INX6$((X'W=;1=5]=+"H"3?OGO;#7_@H!MCS#_^)5X2Z;>O__K6 0ONAP533@@@^C8 H(;%2;PGG|* MVDK8V#L!)5//A[7ZYV&=B2')PDX-_|3.7J-GO%DIG5A'3T2]AYV-#!Q?NZ^MMG_/6UL.;YJVMTW^:0%-<)0E^&VF=XKBF/.?%-PAO582FGQ.QD_TY-(FX:U[M)/.R^ F1J856GG]U&]ES|^V]AD@/5QCM52!S]Q8$"Z2W";R:"$CGJA"J^O MMY_:>"(FDM[B>:(@Y\UM)S=/_E$HZY='VLG_YWF?IMRH_6GOV$H[?>N/Q^[@1O1>6%9%)DK)GQ!("FXN"()G)A3-M3^+)%#5FDK'4)/[#E]:U;/H62V(*7NDDT/U!Q-U)*A&C"4&<)/G41)KP-"7& M>8:4H+@(R4)D")B4F(G*>%PKCROE)IUH0EW3Z20;NOQ7,8IK7B2)WX?66_D M)(;96)S4KE*+7BO2CAZY%-ILU1C,6.V49*7"=C'6:6H]-\XO2:9G;;MJB2[.9)0R*R]:IMVW6RVX,B3:RX+W78UNU8(8K/*5O@2/1.3@Q4<&?]]9&.; MW(!%)5DE**/?XSOTS'3=%I_75'RQ:!2+(V'#4O%EM=HZT-4VF>.1VY9FM| MFHI;-)&5DWVV*VU3JV$+CCRYS\8F8Y5J5[,,KG"+#_DHYD63Q*G0TM&74AW M&D.%R'+1EL:U[?103<.-]>E0%DSU5#93*G"%?HF+-4#'8 ?PJF>4;1Z3G[2 MF%@<)2R(?PUG]@$"I&2YHSP |2G#7CHB596Y+-GJ%,X W0IT-UN2 MHQ96))UH+"G6IKVAL=^'SI;S[68P7/?4 CO-L>G|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|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|-Y1CEC+|+&6(/^Z#F9!4 P$10TCYP&1 M5Y*Q,4G;-G!L\KWMOP[T1KJ8F[6Y;)+NS]K-=+?"> 3U.$%U),%?W-[$18K;RMN[&5(<*MZS]JG\>M,=#C:KEA=CA=+5;<>";::+72"+>@YW]MA=%&S4^AR M NAZ1B:"8D66@N9ZO?R 8!E1TW4BFB+X5HBI2TQ=!D0^CT1=(NF0U,7/;F#M MP41=2(FZ[QVMK>[66P78>;@B]]""_'(2](ROTZ%KP.JYKLANC+:^&LR8S()N MH8Z1*$3[1"?CUXK0/@I-Y_M -G*"!, ^W]-@X[64BGKQ#MM K$L2%]^Q:&H2; MHONFI^TPKQ<"7@^?IL5ZAZFL4%!9 375D/ WL<27E|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|OTM/ ,I3N9,X^&+ M^Z#8RC#7B;G.AW E/XE"5=TN3-O0!R4J95W/),;BQ*5:"(40"7JF<"HF05_IM41NI)3H![=K@J+FPEP9Z)7|3H"YT2 XJF\D437VV.2E3WFPU9AP M<(5 &'5F8:AUVV)!M84EZU'*+NFPLNB3??2.4UY"%/"UPB/G1^[NK6&0AYT=#ME$!TTPS0/X'7F_E$%-.Q":KO5HBLV>_,C;93K+4\%$.IH*D/Y+%_'^+TS(GY MIPB4351TX8["<#!O&@*G%>-]8'G3$('[K2G4++P7]"A]Q9EF71O.XXZR>_; MR^20]+:W[2&AD)O#9]9>6U3[$-N]KB_)IUM4X<;6AOG3D/*G(4*C6U.IGT*C M@5B+,XZ=I=1$BW W?3?GU/460B/H:3)/-'5:,1(S]6?=S[FPN4:U)DR;8MHT MD,M T&C3$*T,]RKSU/0AZLPRL(C/94>,S146I+1U.FT4&+T)G5*O,4R>Y6!>H&IMPM]+)U$DZQ-*4ZQ>+=:D<;ES&B%|K%_Y\2 MU"EB?>?D4BA9RP42\E$M4].\W%(+:((#W|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|/EW+J6++#O$C%TH&+L; M0A<2&$E]9W:N9$!\IE6QMB]Z[I]9D13'M4*5,!=V2\.Y;X^=^Q;T[?6-B;T7MW'FSPT5#9PL.E:QDN0I'Y[M6;|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|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|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|..Y\^=&96S_FCU_=*8@((MR=P$ML M4,D3Z"7#VQ4L^+;AA;QE"WK5@+XUM3/08PA)=_!+D'\#WJBH^N^NEA4!)KVSWM[MN_T5+IZ6@KH0>MR^I=\2Z;>O__K6 0O9A 539M1 L[-_T2.7J-G(/EI75A' MCX2]1RP-3)R?NZ_MW_.6L.,;IH_//RV@":BCTV\SO5,4QYS_I* O\ED):/(YM&3_1DTM;D[\G9U[66"$RM= "]Z]N(WMNOKW7<)& *Y?V*K%V]Q;$&:2W"$&R M:+WT:HGNYEUX?;W]U,83,9'\YZC\YHN"G#>WG=P|^4>AK%|>:2?_ES=?3|S) M?/@?0LL2_XU&1/YOA/*^9_?9NJW*3]:M083CMYZX_)7L]:+HY_@9>"YV[P M0IP 3 K$>3I)IGAZ'$OQXR08]V)"(&A3N*IA/##UXIK8=|>8]4#/'YD$X>_D>M>VZ#8WIMA+,'KR![[!7D#UY! MY^ 57XS*G;Z-&*GY#*%]:S?W-[W^A507W?A:Z[.APG7H+1^&TK(""^LS%IMS(%_-7OGW8_YZ;25RY=8-ZXF*C5Q,773Q329_A$!0UL%8< MTQ6G_^=?9)+^)]+47/^!6 />+GQ>FJ%V[]J^C)\BJZDB3B-3H,T]HI[9,N./9 MZ',(/C9Z,@V^G@()Z,)31#@\#?Q5&0K+AL[04!H(^7Y"4]0/M!YIFKM#V#0X'RMP7*_P-T8)_(#7W.UHN M!5MT-<&"-XXLTGNZEWN,B)H"[_>WX'I.MY/(#($3H8'VO9SY/+[N/L93<.(M=, 2GDPTLP=L)R(H%MQ21#PG MU&L4.MYCS-[67L8>,3-[TWD^NI0"52TR-RUO?X?N %X1>T5X!?@#OA$>?3|SO,I3G+W^H?).<||@/1-V M_5__73_8+D:>T' G159?U <:%8)XK*$R9VU!TIW!=#] OU|Z-MHV@9%'$T+ MSQ'J$ 3K2D&5 C3$7Q<||2"UN[('^';-")E"*T"G-$8\10A4ZGX&H*M0-.E&)# X;Z [T+&?[&_@X0HXEFTW;'-IQ!* P-7AQ=UX5WBA3= MOX[W-,3P_3K'/7/)]9JK.>@NX.,AC++ RT-[/XE4.0=W.RO$(AU] M\AQ!:-/+]U]_R8;.D?07\BD=FRY%D#%/(&,@P^F43'3]@S4*]G[QVE^UYBOV M3H6O0$W=%=+2K@Q_,T*A"29]14$'6'?BA1CO("=\|D+-$2&J38"U*W:,IO,X MT_%^@?/GS-=H= FT']'Q7VZ-\>/7!REXVVN%S>>SK:73K\E5(KI>=#(\D|^) M6?D-%I[A*1X) 'G4A]<[EYGO0*-0)*

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|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||^?EUH[(ATLVI05"* MVY_JF:+>+,CPV4^'JDZQ819'5H&KB!NS-YVR4K4!C?Y,^;]&0N\1([O;("A! M41>;;3)>5%:(SSW5_* (VZE8%I\=6K(ZV875FEBY#@#A36*O.-'.IF%6M]OVR MH]2U7+*:[:;14.8$3(-;;;$VS76YBC-PXMGV="U9\+'.&)3]+ ;FU,RZ:F>: MFR491ZJ.WBQQ'5?0B MR<2STSRU0D-/5#7KEH>R+/ <6XC&[/YBL(QF>C(:>J*K\\E*:+:BW8I:&1*K M:*8YK566WE5_4U8^08X%9DS1/(A129X>3Z!!TO$43PHQP,1I1J3H\0FRE>JD MDNI$%:Y262TUQRAFY]6S1=OXK"594WF@L52+;B55 HS4 M"D<66^=0G5*X38[MQ10N49O5#%Y MM*J#6://16/-RI9B=(725^=0G0=;;3*4IW6V$ROH^B WD,GQZBRJJ^5"N:.G M697-1I/Q 5%N=:?06LY8@))U&N5:NQ0E%+K7CRU4I5PP5^=0W>C9;A:P39.+ M5JQ:(<=)>=(YB^J3V;;!;?26P5'#I9*5^QU*F:W.H7JTGN36U&P\8#O6@,FV M7$9HZ>FSJ-X%,6"DA*'"5K2DMNPE>RUITCJ'Z@!DF:E0X:>LWFN607W)DW#E M.H?J=D&F%3%?V!";1FS<,":EFBRUSJ%Z@G 3'%=ADAR0;,(:;]ALQY7/HCK= MF^83U:X98W6W,-;5:5M0YV=1?6PI+&W7BIPJ")L.49/2R9ZX.HOJC2H5-=9" M?:MNE"CMV&6G1[KG43UAZ>4ZJ'95M9 W&CR$+(-D6F=1/3'N;N,)614)79_& M^Z_-G-TV=1/1_3A3X[J.6)1KT0&PR:S;*!UHHSJ-)CD8>][4*)$?VKDW0VC% 5B45MLUYNHTEB[M\GE4'[M:]VWRL2F(JGF.-7-$4GY+*J[PLA0S7:QSW7FV[(N-?N=3/D\JJ^K M8WT5-SB>BY899IC.=9S82#Z#ZJBTI9+KEIE9= <%1(ZOBC&)F=KA>G2O!F8VQ M-;A"RPT"Q.WY=]W8;D]LG2N7*73[%4/9'"%&ND2I$#0:NM.G&6<_;B3;6=4K5 M##6;F BQMJ8I9-#0J4F MZ:;07XIT? 7K63ZRV*XM!JK^;$%&ZEN1BCCEV];.(4C2;4W6ZT&W"C7?H%)$? M9;/;\XY:*Z%GEZ8\)'1HKXM4J4HWZ-4YDX[F-*(U*G4!VS!B/#>:1;?,XMBD MW^BL]7Z\XB^B&]05]MO7Y]K/1"4>GK%[P%A"_7:%IQ#6>)#[_]Y.ZY>0LU MF4<-$^!SH%8_NUJ@]GTJ@:(#< ZH*DMP$HM\HR@H7:Z78WHYGV,7%L$Z3\=VY7-_2M5*P8\9PB<9FJ0)80(Y^9&)Z:8$Y-XAF7 MJPSHU#PG,: %=6H87!LYH%,3>R:PV01T;C"B!7=J,*(%=6HPH@5W;C"B!7=J M& 9/33"G)O;,X)+B 2DI_FE"+> '/5]^A_D+.5Z5YPJ5Q#Z=L'Q5/NHBU=GO M6*"Y[_T%I.B%BH7_R0'Y5BIWJ"#.?+:",_T\I^[?6B$L)>]Q(H,7&;S(!-"(MH3P$&81JB?E[<05$!;_>MH*D_[!5#:L^%BS3MK$V8FU\! ECM0VFVL:?DS?P MB\(I8>RH8T<]E*CYZ(ZZ;D)Y;+V<5^P? A62A>71O/2M8U@8^#U9(K)"!4,BT M*+JZJZ%:0:'2R> ^C@5?WO>^L@77@7(GYQDV<@^E;![.)\U>\Z.\;TVK"3TR\ M=1SZ?"=E^^KG&FOXB%63]RIL%2QM6-K M*02A8FO'UAY,$>*4OVM8^_NG'+^S5"\70'N@GI_?C6%UTT*+K0A?R0AW7 3 M?@>Q_77;SK>+*?[>#GC?;>B=]HB934V8F596$VS;ZT"T_\Y.+W<=B'}+I"M: M/5$G=*V7Z)I)DK=F/'&(;5@7,&WWJV MJS:T15M60;="O+%FIL1/[XQ<0^X-0]3&[,%_0M!R;L*'43Q-A0I2B M_@CH?^MY9FFC.:E"69-O2;%-:TNI MF<@3=4[A96).---F/"OSR2]3;![#=FV"#=O=_:/[(9?1S8/UW]+/^A(:WHY. M:TU+:Y5-YQ5T5LYSF2<:,Y%/>5\.HV*7WUKB:T5(QI&-(QHUR//VH5!?TYK MO3K;J4\3Z532MKON"F(<@S".H%(8X^Z-<3?(T@]YC&Z>=(4Q[OX8=YXL2PWY M6+]%VA:G9).E3FHN;%3/9T-D62IQ0Z[LL?CMK&O#AP961!!%=/@.IZO='?5" MDZ[V%1Q$8B.IBV>.8VW[]GD*M]Q^/;J5!M!;V7]GOW!EX?71[>T=%46TI:(N MM3N$,"<9LY)+Y:KT3>FE1GG9B=<2Q2G;XND&Y!(V9HR! M& ,Q!MX" SI.2(F:V;Q/:0F2]\2X>IT3XDQZC5"1P:@83/-^N&RN6Y)6CXZ* M;^W?<$K2$:?BMZPT#7NJS'VLY&NM4)O[T"MH_U;^<;+$@K363C8AK^R'P[M7)?[K<8H?)3K([2L?3Q(R-I^&C?S49B;C->3]L>#AXCX/W M(=PF_0T/HV,N3P1Q_9,NV%HQHF%$ MPXAV-?*G44A+K1S3CG(-421'_:X;7]1:4!C,CU_))RJ%LY'N#G$X&PEG(V&(M^U@R4C^636[J\6Z:6-3UV'PVYFH# ;EL*!F)BCTE"1(G)'WZ/-\2;.8<2!$' MB%/#U$QY@W.2[HU]H(KQ].+\8KZQZ7$Y[=I.=J=[2UY*%*4?&55A+-F$QXU(%WUO(IQE#? MH319XLM*V"'CND(&L[\^W:9?Z$3&@Z2XCP0G_=R#U>BIQ5E>Z!;8U5IZ3FQ M9(S.*;1NR4_ETKUV;FL7'-45+;;"5O)I8PAW3R3BI^C$4RQU_>T3-BL,/1AZ M'A9Z/D[E;#8*ETEKK;0@)//ME2N;+:'N@9%W4!#N/CZ06X'!""><+W1N,<+)8 M4,'H/.TQX29\)IW2NER6L0NUJ@.8E409 0^B/6+TTFOW=6U_A3FN,-/FXM M^>,7!Z?*6P2 =%JU_>?_^^\8IWKA5*^PRQ%'A2X:=L=B"V4MEM)$ILM-EML MMJ$3)#;;B^9@8+&%LL;/G009_F#_U^F1KB5 (0GPUW&X'X?[@RXT3'/CF!N. MN=TS<[!D2&#RB>Q!;YVIHW5FERZX9B>K=;P:KQ#9Y&Q&SI5.JBA^OHWI'^Z+ M78N:BV:X8)K22M&T,TPZ6XS+8E\TXUPENVGIH.G6BILT3\90/D']*8XKVMS; M;#&T?4MHNU+3!:Q(.%R.P^78C[BT'V$J3:J8SQ,S-C&9TG6WLQ8S$QGY$?Y! MA \Y$H\C8%!QB.'9D#]TWKK!R;P3$87<<"+CWCB" AP9#+E9\VCT$ MKM!N+=SY09LZNQ4V%3D)--+UA9ROS^FD>E<_J&YW0;_%ZRDVNG"W^8U0VM2' M+9ZDO?HAJ>OG0V,XQ7 :"+%B.+TBC8.M'%>P"(18<04+[#1]V6E*;S(9:2K4 M3 Y>:=-5E576*:V0TX3(HP]Y3>%/;_EZ#8LN*F!Q>D@C;#DN1Y8K0K4%5M@Q M\NM99+X\A-1RN^NC6Y=5*&X,KK62ZR/Q#[\+\^/6_+[\AN;>T'LDQN? YT+-% M,#[B0/2KYB!G@VR36' %-[[I+#EK)?-D'+$N\<03P>"N)1BJ,%1AJ I4_8RN MFF\/\F!2(\"J2)3+(RJQUE8(MG#]C,# %A, 0PP-;'EDT+VEA6'KPQY6'3@? M\:!6O?RHM3*[(;HMNIVCW].I=VE,GF%3[Y\?YWK(2_:8"DV'--V/Q4#$TQ0'2LF:*ZTW"*B#_'M_6_L'N[3JG/T'(<#WS]&_.4=QYQ[?WX0[2XCU;^5H(=(Z)M?-J@_2>6#8O!T M;'\#.SP234T3YC;XN7]Q_&.(?)OZ=4]T81WU+-)X42\-3)QCO(IZN.*]LX,^ M@O@?]."_M?_5W=5(7R#78R4E97GF)TWX,Q/-7.VEM/\[BB]\U4Z M%$_-_;;F#YPKGIH[6LW[VPX\-?<$M'?/&N&IN=_4_.F($YX;C&AX:C"BA6=J M,*(%=VXPH@5W:MX_HHJGYIZ(]OJ)6#PW7YV;|*?Y78XA9?Y"CB%(^[N1Q+R_MCDM-/.@GN_^=?9(+X)T8^^2\H@HJ]UD]\B.!%!"\B ;1A*]! M!G@)^=G$H5*N&Y[IN"R^A4$;PRUAK+;!5-OX<_*Q MCLA=4,+8[\9^=RA1\]']][J-3"J'RC[#S'1H=RPJ6M?&*%X9(O|*YS&*%_!#H MO9S2"I5.?A|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}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|, M0[NW7#"'!@YASS. <,ZD RK5)7&<;^K0[7??']5[.0U-$<9+$$Y6X)<5Y-WM/ M?%D-.^[8,1U!PRF WRX%,'1"PZ%2G Z"TT'NXDPTMDRNQ\|3.4YO)G-6>6/\ M_^RI:7/]NO(O_Y^"M?Z/^>IM>N&']@8.U[5Y4!,\|SO'$96X!C8X,'ID[_M)=DF$$A"$L;$N\|D2D"6I5;KUX-:W9'P9=/&S]9.SG;-VUB"WRK!IT@&%9<\TYE9W-$)H MA+)1/428(.7>U<$HB!D+8L;N&(P.>S[BJT4W(UFS$B^"8KLR8Q1%;&/@09X/ MAGV(,LS/#NX:?(IU<./MJI&__K;@4F$A .3]9.Q__L]_!T'$5Q#Q=>]T#$Z& M3GKV'I#M+I.PW!TA@VT;;-M@V]X=(8-M>](XC(!L=YGNYTJ$O/_C_J_[1YJF M"(DDPK<'!_[!@?^M$RWP*

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|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|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|>RE>']#)=K84_XKP5 C ,Y7L/AA67)F5G GN5M]O^^J7U_HBG+RMS_"7]L+NEJ0#016HS_E15KJHFK/Y@3O,'[R$!''YD(FA+|M;.R^G$&>1@],2/(_:(;_>YT%I* IOW[EK_4[^'D["3=A?9=8OH'C%IC*\C$!J80%1#XA .^H^H+<25Y5$H&G]D?+S^ ML\%E!N$C1<+%^0^Q]3N:Y-Y23\1E:(O:'IR'-#"T_WB/^9]A*-Y\:%@*0HX_M)M!6YF#%TOM<8IM3/_0U".[RR5A"LJ9/48YB_>;BCW+"I$8FPBH_Z=921Y: M?1__G!WX?;6B_GP_T2;BWI-V1!_&^"QD_^\V*E7BSYLTS?+#CZZ)7NM_;7;@9FP M+05^_2T;-B!BCT32!+)B$]S(! "5!('\.'"9|:*SQ!\I.I1'$-VBL,WV">L0 M_W P(04)K\]]56^'OJWW^(A6*/"?2$AOVH+6)H&A/"AA0DX$OQOU/1MM%>HC0ELXP&_O0/EH46DX?0-(B'JZ@-1QCM'U C.L@O)P7_!MA;!R1!-%W_A ;+WG9(S\43X6=_E8?.;CK8&*$T.?$09Z M!7P/1!D+?B9C5B:^S)3(?CZ/&1A# HX2/!$FN#1.BQ+6RKFE8@FV-)&%)C G M14/42YAG!&O:2]K"7&;YF?746,3ZG?&TNEN?,_(!HQ$)SIP.">P@6L*W VX" M.?|Y(H)U96@96I6"J*<$AYYVZ9:X3,JZU(Y7Z00'34:H-[QJ,7[% (<--41Q M18=H@P8(601NDPFA08)@#H.<<-=+[']5!W-#FT/>W6WC+;HB.Y,!-8\6>*<< M2:K2)-E)BY]?I**B@\KPQ9OS!3)Q)@G#-(T%&H)GZ T?"B5CKFP!V:NHY\+',QIX|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|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|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|@Y*N^>H5TK8-?+:F8S_$ MOT*C0U)))_]Q(=]7HQ@B"-&#DF$3]LQP-1G',E*VDH*-69|PMXK/Z)=_M1R4#AHPP(R=D+.;YQ$+%@$(_*XW @V%A"!4$T M@-75;K1R:Q0%4(RT1U@[9 -7!!_LWVK"7<"[W1^C3= 4&B2V^^GL$X.-[U , M3E19*;*[JZ&@U62A,[% #F*T$]A 4I"5)KL(\/_!+_C[_;$?? [6U9'9 ID2 MZ% WPUY/BHD-@(KD ;DIRD2!IY;%!33"H% 5=8)WI["/P'A [PN4$S(3')11M,P&81$'4]\7&0A9HB!D!,=[X>V#$%/:*$_6BI@U(] M\#T[9%'@3Y'U I)>"RQ= M8./-A'" /GM ((3&(I1(#>/B!G//0'WP\X3>YT?"Z2K&Z9IV/"/0+0EI@[(B":4*&N$,L&!O7. M4QM'B<-7,7OO\EDQG ;;JSH&H5>_$]$+9KY=MS=@8]*0 NUB/*)L*]/VI_1.&P']^)S!')<^7P$W%[:1E3:0!(:-:.MAL%?8$!((:M[OT%Q@)%6Z;8I MTOV0@;Q-B%#$U()?IV$2T #)0 POQ MF9/%I@"BY5I!D ?QZ)H#PZE1;&?C(/C]?KD!C42YG%++;(G7\M/^P[KS^MVD MBF';&8RIT(N5-NC/HMZ 4S/DDT':=]516'5II4FY2UX"9'=4+* "+-3=TQ=X MG2-(B\P2"2T^9.|QLN!L2"7$!FB-9R+22E EF:(2V$([P>]F@;0BSP+$.?R@;B0/@]%PDA-B #OVA;K6[K(CUZ1<:COX3& MH=BA6:6@(7AH"$A>H<5V?C5U!2]I#]F 0(V)[Z+:[VS'V_T(DVC;T(QQT>K9 MQ(\T-%$_2]DPP(1*0S',*

[82]YP][GWS:^D]A",N(/^^C5>ET/BSMZ$O-\"G MB6+9SF,#Q Z/49U]^H#U'F,6-E[<1^H1&P< M^M$-S9ANPO@/BFG@N

]DZ%1W(>FDC1+%CL^QCZ& GU?!U'7-X2AK>UK46BT M'L7U]L<)14,,!2#,4-D+(^T.>VL7[P?23C;9|>]L)+MCA>@T]88"=|)QJ. MO73_Z;['#05-#*

[Q,E(GENWD F= [=82B;/;WS&;GHFSV)O].V>SOSS__'TS MRC]T^_CF%S2SH;>UL&^/(J (C'- 1ILF1 Z#=|:'=%YR0O,-DD-^H<)$6S* M(/*&-1,72-/MQ-*

*!\Q9=%T|:)O&@[1Y_1[.>4*QTDDK]4:$^NGOT\[4K,G8. M]*N]IV#]B3ZE6P_?7>U>ONH8'EY)?I9J2A-U X_4>2=+5_?E?,S8<4--)A?*

*MQB>^9WIZ"A:P70U[^?@XKJI(*F+TXU#|'U^PVX"'HDR6@[[P.D%/(HP(I.&D M=@U %'P-XZVWF(@N=! V!'1&10U%6&Y/^ZQA#,QV]C?*

*#C\T4,2Q%6S1++;FN M=8O"8LG5O994$-Y2\+7FP9?*PI:WU MN$HG9JO=99WK\)VX4RC-FB/FN, ,R,E*3#>_Z2[RN;C47L\6I.K!ED=]UAZ<*

M1L^4UU5AN4YONKU/V.KE9B3M6#+8_>/GR8 M-FVYT5P*=7H=+]E6WC)+J&7\J.5Z8+G)%'6O+C@@>]P]|T0%M3P:YT#LE9LB*

*MO3'R5B!XZ84:,1M.\XE.)/V1LGCEE;>'/93UB0C9";) MXJ8_G.0\"[4\(FAVE:[E^%J&%A9"KKZLIXMTCD4MCPBZ!*MX)>;.*&I#%VU] MS(],"O=Y1%"-IS-*

NKD+G!(8U$[U41EZ-V29L2>|$=F!+TUKAJ3>A-9';^Z5XXY$KX5^+:$9>4-JC!3O^-S; MZ7;82J%O"&!#;8QVM"T77)W-,GY]9&_NZUF.,"'=VA?0L3?YM?

8_X_PB?Z? MO|=1#&O|D.C6M!4X_F DY!]B./A?EE6(; M?@04;5?[>]8FZOCCLH/P]H0]RF6:*Z=?G58HXXX=I? MRNU*H@9H[8(\H65_97:*

<6A:H_8=RRK9Y?3D;_#9/Z/>Q^4WK)0Y@&^.8VU3\M?>HB[/'L']L&-]#[7O[3#L[WD)QTTPP)|>YIA?^['Z3D M=FG@ %#+49M-

+%$:C9M,B_/0!5+O>]3^VDLQ?,A%B&]8MUP]E]?|&Q;J.4<'9^AC^]5+N;,%PF^@0>3XW1',A]Z28FMGMQJK4F;@PW^-)^XJ9CA4,-AD#

[9/CC=?"XESAUE_SW M;VYRWTDSW>D>9<--(!>'9 S_)CT+LIN?[(S"?PQR3CPY/825,6Q;6BNM[DXCL]'MX@O_WU:>:AG|||>[GCZ-[T/Z[#3'$*

*"3N0MIG+P<3ODK%H::YU M:9AH::YR:9)WT10;:=2Y-!&A7NS00 MT**EN[-!#0(I?S79?F;|=*<_Q6))0,#3W\OYOXS6L5*W,7^P"6?+I RE,4/MOI*

MPPZ^%<6__XP0T(I9IK3A^]HDGX$3+|U[\=|&=SX||709NTNZQ'[O!>ICTA] M? 7U$6Q%A]YO||

5IXB$V']J2\LXMQL"_^$.TO=^K]$2N:JE$S$H7_@T%>I MH@M2-?F>;'OSZT=1]ZGDS P7?B3;?WTB)?0'DVC-#P&MB0_NYLR)[#FMXY(RA) M .P?!OUU

*UK'11U5/2D'59 K@1'>'#I@[-0HOZI"UJP XJ'G2X M88ITR|*08KIYCZH)0$U.]H^+LN]WY(N]V1:2!:EVUE&%E=H&6=&H+4L50_-& ML1%*

[\XO^33F>IWS.& MRJ5K"7F8%'-S_0)(%S<,1:;JJ3+E]A9&UFQF6KR$D(Z#2$<_?;PU0KK+(=T7 M(]NYD8Z+D.Z\!13>AG25\4!-7'?3CT>Z

M5N;OAZ155%(][K2>9::SPE27,S2\V]@SW]7OEJ-W\PJL87-]D MJ0 7G M*IMB?* 7@:X#^;X\O1#3Z8U&!".7/&*-L TV#M.5UN1HB0P"| >A/ M5XE&-*

;=:M@5]14;%+W$<.5]/.C?4VG-5!RIU]W$XNO$?.EBR(_BJ.093SU MJ W37V47];I%]D\E#2(:_;FV0(1K9XQ(_A'7*CVJ4*DWRYDNLXG3;&(]+5+4*

*M!7"MQM>[U:@)/+5MJ!LQGD@K-=N#N,;=_.+86(1KE|:UB$9O+#$0X=H9XX]_*

*MQ+5T;RPPB6KBOKNIIA)3LAESS.4%G/19W*A/*XZ:$,IU4!ADW/MD9X(N"TVA MZQ]2[--7/T3(%B';===#H3[4&(F0[8[SQC\A&3?HU8U4T*BJG=0N;V)R-*

2^X% MD$W3)QY/=M.3;KM&R9+>&DED$5EL/S(W-*I9^RU1+F4O]"M+*(ES7!84@8K*

*MH!DFOO+]O0*37XE\47;E]9(MRKJ\:$0SQ!6H2+*/]'+@_'.D$Z_E0**[X-F8 M-JXULT"_@"KA^75#;_-2E-8*

M]L@IA$3NU)W&$2)'A$CLD5IG)\MC/H<1,Q8Y5K.2^5;0]8BU@K"[%L.\V/ M1\11/U$;2 ^=OI O/,3)=;'-F#V$B"B2B@YI1IAX7<(=86*4\/D) [#/P<2T*

*MVNB.6@)H4Z3B.;ELLT$ZI0LXSAG%?=B87=E2ZUY!O+>6]\F-U(28B&*PJ:=O MO/RV&: MH"S&KF7CY;\EID 'EJCY-RC+"T57;,?R;S"/\D(O&&N]*

*<+V)STU# M/_!Z/24[/[\R>7L4-N\##-0E_!Z\[*N3S]+/3D9V1O?]V7R]U*#USF9S@:## MI#[L]-U8K-MM=^8-N3WL2[T<#\F SL/?*

*LNS[&]F19#\C[AJAX]N#L!$\7D-$ M]GGPR'6\9(U= DY8YO3!)+ZHIK*3"\ C[4[K=",I[MUO10CN79:S#)32 9T MB/Z6HND('B\-*

CZG+B_;GIF$0D8W@\1K"L\^#1[?@3):Q12DID M1X!)DW##8S M%PC06JKP($X&@BK4"ZV4SB5FI37?A/"8NOG%WG).!(\1/'YV&@;!V0@>KR%2

M^SQXI/B\N6ZM75,5>R.]D)ZIV0?A H5)3/GE,E!I="MK_(/:INK"6,6.==^_MOFR*>X9W_>GS9;DW\V/'<$0-?M>05'*,J_^YZY'\8=@V2[]O+(YO8NUCYTL*

MQ$[9<,<:^/P*Z$-JEEZG+96+T^\K MX=V!K6TE'WA'HM9%Y0:L4TMF=R4AA? NZ8X733GLLUU17DI=XI9RTM4/8AW M.*Z:X**B?=>*

(=Z?)=G%Y_31X=SKQ]>+T^Q)X=SKT&M?,.<59V:603V0Z;/RA M5TC'+[&/9#9R?=N)3P1ED4W.8_V'=@W\UZ8N[:C3#9[M3#S!_^WRZ%L89&

<\6\$.1Q-_?.(8)O[SF1]N"@L M3-1-Q$/V>8GP @[!CQ0=KHCSDT41[P]A&;\KGP*&3P%"L6T7R(1C$:(\%]! M[W%LPG!FP"*<&7PI%",2+$S-V !*

*("F=C(E#7-L0*H"N^(,H3(1EWQPA?+Y'* MFO3YI[FOUBOT2*(V%9$_Y_QVF"!0+[M,$#RZ^>7,+/"X M!7 _+>1F# >B;('1"^Q16W+&;5$?*

*0KPCA;Z]RJNE86["#?U@STNWH,*H;,Q MP=[.EQ"L&%YMG]V#[]E,^]&Y+G)(?/<@W4$0:D!Z&3/L]H"9:ÙNB>'O/9 M;+7=HC+I5L5>6+]9J?%GY?*

V)X5K$!HC6H^@?*(HS,@$Z,O H+C-O!0@1,P!2 M85#?$@ZP%NB2O.?+3Y]CG55NL)AT%ZM4F>;&KE/E+R$_-KK7+Y?-\C/^,_R M,SZ4'VA *?*

ZG9$9Y>IU]O<$LQ00%^Z>2X5M]U[YMG%1X'Z'!E.W=$^P_; MMX2B2YHKPT\5'>HI0&0,I$Y1<_@;3K9 ABBQS0^PD:353>#3ST;+Y>|1;U6A

*M)]HG1?%M4_GORQP]>"E72_-NOE0;%H:",A[%;8%[6+J#_12Q^/MY MP.)UMB MLZ:R5]*ABNO>_7 A*&VC!#D9^EA/.@%GA![X/0TM$T+OS|*

*<-3^3*O)0;5-6X M3YFM.>B2"I=+Q!YZ[$!6P32"CE2-O M^GUZZDMYJN265U1RH2E=KEWGJ/6(C]7+H(PTGPDLO5.::@JG5I"'_"*0I;X M#^>IS\D-*

*9T(8UM:["VI6F CB*CG4*T)I6$U"%0_/>GR%KON M=6B,,$^?CGY'A-$5_;4 U2? MG %\K)6Y%%S%3 C*LLH_R$5ZJ"9>GP&_?1&P5HH$3C-=S=!1C*

*3X;J^-TQ)W M/T?W1M4,YQ[J4K&5(=DE'=&;A_&23&W=I.]Q&CVNHNY&.+0+XW6+J*L]FWZ$T- MON^6\&;*-",4&W]+*I!)*

MZ&M;XA00)G:3=GWL5[N3YU9|)]Q%Y%Q]&?Y'F3.L()'J-UN-"8CN\YBS<_C M5+]&#E->?RX/LN>-QM#(HG_W,*

*QV6>_VM@L.7O:WK*S"G_!'^%Y)@]]$^U:S M?V3%AERZ^8EW%P[B[DSBCL6Q=_AHYH=)<$@WV!:DJ'^C^,Q.OWN=D1+0M']^ MEZ(=]G#VS2P)>L7*

.E><&2Y6$H_(.T3%/_]KEP:/\6Y2,C3#^AENYNT0/2"F M'U:? G)L 5$EQ0D<[$]1\\2-'5 HD;ICPR,7/[?[@2S:Z:0IN#C_)G9^1Y,|

*M6NJ%N"9WJ!U&\34P<7X&7PN?X2W [4/#QH+STP(:/EAPL-0[^S$,?!_#OYU$.,B4,T@^-2=QX"0 MN-]?N+1QCI5HO+MYQ""GY2V@&Z8_"6G].*6*

_H\/]Q?N:#W\#Z%H23]0"^)_ MH4F$OOG7P4H=+/G.5DZXX.C1$]V':R=B^!QQU$0>3SAY-(G)L5$L%0>C5%QB M1G1"E!DJ1,;1]-5MY1-

*YX]S,6F2S#/\+#ET3@'M8TM#*OC MMI"?]2;C:5)>E:PF;'DTSE6ILFZG>%N#QF7172GK'+-/)K1LJ^D[%=DRG&*VF9HMM.LP[]\VA&:Z#>#U:5DB'4*

MU;E(R[1>+%'!M<7[+9FIQHHETI4T)1KNI$!3G7J=0S? 'KS5BVMU\O==C^=ZH_>KLK4.LDD&;UKI@8 M)7F]RHW(-

*;42'8WO<&8658:\JK;A"V/^^S/M6E^RJZH]ZNP>*0&5C125DVD)$US5*]N+]:3Z82N MK6--*

U/1HJ%.3JTS6@\:J2V8'')M2)&I0\%#3_;&.:$9DF=18'+'),5QNB8Z- MDE)L/.)$"G <)TDI^FC(Y8R@S52]TZ7'3ZLL[TAI95KIAX2

*MKG(O:?))W!NX27;4$M4DIW*OFQK'ZJ1FQD.AU!P^= M@>:=PCW>7>ELYYZLJZ"QLLEX7'0$>GH*S0S;K7;+;C;7W;B\-YO5RO'Q='H* MS?*

*35&S9ZRZG0D:N=\CZB@9RJGD*S0I9AF?STF9*N4Q].2M;2;9$\Z?0K*7. MYEE'I!\HD1OT!7W15H;UDQ@UW60*=:.YN:?*FV(\IR?,-2WSIS!J.F&[/'G?*

MD(7-0O$R@,JZ":YY"]-JJ7]1D1H]3!/(4]12V7HG27F4!M M=Z32A<5VQ:M=*R[U:"6Q[UN:Y4]\.DE.\(]45\5I(S#YNUZYW"$Y4SX^2PLNBK;2X/,BL>HE69

M/X4G=IV+,5]FTJ!]<:/NI(\+MY[T-,]ZG.L9K/6G"=7 EE-Y$KS=BYZ:9GCVSUTS_-4!D:=RI0_VNJ49D%T-U">G0Q>[2|^ MF!SV+SIP&&D-?G@3,DLY-

VE.>TU9[O:7E5YF")KW-@U?"&Q)-.$K'0W/LSU!'CJ=CA<,)7D/[4WU91]]GB6;0,9NZB__VOL,= M]VOGE2B6-X%L&I(O_)M$7?_T@P

HL>/SG<0G]ESW,2Q;6BN<^BX72C1>IO) M^=P,]=V8RLNSK7?6AKY+LM'27.?2L'=T)#97NC9WL4ALKG5IXK\M/!TMS>66*

MAKF+18AVI6L3(=K5+@U[%TG-E2Y-)#77NS3QW]9YC);F)QI]P3H^]4">$%TY,=[)SY]41;|O87RK:18,C3T\/]NF)O7DC-V1[WOU4S)5_'H

MV82\'Z;.GDN[(_YI;_\O8KE+L-WRTR,_=Z381([-A:U.WC^ELS$_"?9%:\U48[M/]D#,_(N'Y(1/SX_3]06F MHG/*

D9&9O:]"D57]:=3'.ÙO5%Y;7;6W23Z0_/@G'1>;R'[E/6 -+4FS@;_$U M+$7Z7);,)^'$R'0^Q7PML! 5'4[H4[%<9#Q_78XLZHZEZ+8BO=9XWK64+W@I

*M[',21MYP3O%'4?<5AC,S7/B1C*HX20#V'197117+3& 1-CH%2,BB(_X5F=77 MI5KHR[/H)>S?3^OAS:@/")#U$3F$%M]_2$GK^NW*EU*

M157UPI//.!L6%:]"4SE8+O@8 3^-8-PU(WFY%A3_UB","I%MRM4E.GG%\ M)]MCW*9YLKI5Z<5BEPOV^E1,I>5,M-3=;=I9L32;ZOS*

*M7GD8E.)R2KX77*T^L3J-6,;+[-VH6JSE7E!Y^]5W3P7;*CMN7LU%(]Q6V::V MMQ$FN4Y6F-5JI,!L&G!1LZ75I(T]CC&HSG;J-L4]76C[7,9&).JOJO_PE)*

[J:;4@4I)65F1?YB6,AQ<:ELVD4:X6,8,8AESA@.R.1XNJ;937#?8L2@62_RS;VAXJ6U^?Y3#[7;H M3EBC ZP%LW--PVHT7UILU^6ZY4E&V\B>-RR-

IV]#41;=?&.?]UZ&|"&" DN MC03X0-=7(MMY[23_:-9G0,H/\!A?=DW3AYA(+[JGZ8PVTC83 (?]3MQAW\DN MF%ESM?*

#4?"$K<>Y@[5D2]I"/"I0S!CTK!OL/W5*+O=FS@QM3SG*#KA H.S" M&'=6I4#\.']8[&)78[XP2(;>4+1M%\APQ-O+UC'4V;L5M[?2=L++R]7FJ:ID*

*M#C0*B*,F5(?YVEA =VXP-[_H6SI^#&AGS>CYU'O!'QCQ^K0T>H_PUC>RT5X7 MR[H8@)TULF7_P6P+8V6\5OOI;*

*(4D2X7DP[P)=2@*A]#/V"+ZDOE&;P^09%"V MD:8!^6]A;2K6^0,EUT2NSZ$UGDPRNF ^8Q1N^60I^)*MU"RMS\8F*W=(QY_X!,A*

*U15E*4E11%+OELW,XZOA:ZBC#XQ)1BKV0!&NN"=EPT5745Q*3 M^!P'H]YN9ULKRL M\M QE.DHB<[%4;%:CHMV1B]NND0I(5%*R"N.-*

*WT$HGV.TTW-B9IA^1[%"/EN M54\,ZD:Y54MB8MJCQ?DK-> M6]P890\:+?CP$9W\INDVGP3MHK2;LZ;=?,]X<[1-%*5V?*

*:R76O*QZ333P;Z1@J5Q_ERCEX'L6 ME8@R"BYUJF$KEDJF%-B;Y/*ALE96W46;*9N:%1AV8OR(IE!* 9N,W\:?@CF44\#V5*Y1KK];3L'3$O943@&]DU-*

06^ENOSQMN)02BPLT32TFL53SK3D%5)13 M\#5$/,HIB'(*OD9.P7D0=C^G@#Z15)">E&O9U9*:"YDRU3?+$KVYYZ?(;,$U M/&CNF5D%?SOH?>?

*@*N:15<,C#-P^H\U=VU$FF[U(X03_M\ON;^&UG>%L!3X< M3/SQ";I>'?WY3'##) K'$QS2D Q-$TT;_Q_^>=-A-L9&)9.]92S>&Z_R< M*&L@GZ)C*

!CHPJ@3)/4'&I)T/Q[Y2]N+^*"$F#X1@Z)[JY"? ;\3Z !H-M(M9/QGA^ '61]X3?PE]Q'/(S3W!:&\)V&^_CZ=..SWL&&NX%CA6"@[=W@%3RZ

*M^=69@3#>"0@3N1N$,2& *,V"FW:)*20.M)L(&1?^)!SX!1.?FR;LF>'IA"?: M!%BB"_(< W*V4(%SF-GZ!E<8V!I&]2!C2"-@!VCY[+HX#;X)7=;_CV2](B;*

M+\S-B$0A.S-_9.>=UA?@9W$ZM< 4<982]B1BA>_#@YQF[?Y(6-;P+2 C6H' M^"RI3"; NB4X1@X'@ ^IQX+"7H:R

*BZC!K]*6F&_G[OG8/7%]T?";VNS9%C@5HV>6|Y&"UL.6++YN1\)O M(V->@:I:CJ.B$*2(+4H%OA|^Q)8^5/$/1'-'01&0*B Z![I'"<"W.HX&N_,4*

*M9[8U&S!PW)T+K3I_"LXRU-C7<&O$ 84V9-#0<%H4EF3OF?]LX#_&75**WE2 ML-Q^MOWOK.?5LI%4;>]<3C_U?.L6VO-;?GT[.L E#KMY]<:*

*;3FC%L).C.;H MKZJX5A;N(D#OTZCO2 MYA-812^:C8&*YQ&+9LEW]H NT?#4(YH\]"$M7<39% M'5VNK:P :H 6.OA>DJ]. ^FNYF17R(RHMM,I]T"E*G-*

4E,U:3\^,"_S8!=V86 ?;.;?:7[CS$3.0.FF' M&- @0:\C7T727!E^JOBN0<9 T(::P]]PE5+11U[X#R[4AFR7.E10?C$VM"K/ M0'44;'A_@^?UA9L3+]@]^Q

AL%IZFN6RA64W#]Q!O]9>%8?L_OU7\1>83[RF M&1):R-.B(?C,L+5^N!VN]\AE95Q4)QL5=+E20LQ-]<4#C^X_>!_;!S;40M?V M$[.N\LR3UG+'

(RGD%6^03#@BZS$3M-JU=>UKCI)5C&+52-0<.^IP2FM^H] M%$;=^^)LBECFN#3M.5D&8Q'$,.]4H?GBS #KR-T.ZXZA1G,]]D@:)E 0B35 M-*

K=7SW@OV>G_$,9+ =9M]1N2TETFQZULGURQZU3S$HQ7:,?E<;ZN]+MN!9@- ML32?6&T4"KA[GS#

9\$]^MJPJE:6>L-.Q6M1C,!.4B1IK1GK(EB5$M5-MUI[MF@D7[)[>1,6"M% FAXUOU-C]/&/83LUP[@&DEF1,=>AX[O"X_Z4Z6N[.3-2#4-=)-A]82X6N*

*MB(I**QJB_[7MQ_.!$=#;8&'TB*GLZN)!:B[%|>3#3!3?6 M>%B:23LKIB\17*#O4F<,+F!7]!W"CF^.)UO@_+F5]W]L]-*(&E80;QX$53?*

*M^K"+_&*HDSS[YRXESYS&^2)47*?2G;%F,DU!K):[_5%AJJ\FWE'D1)H!V=5 M?7(;KTZ]Q(^5+BVNEH7X0N@W=7.^?M [;@-B M*X!09<+W.Y8+SI=*

*[I^CDS!<2ZFXW&>\)OL'?I-XE1<DY8_],)M!=!UC-W.!?X=%XPCZIX.)V.|R M F5E=>*5"%@GD-]#NH5_DR@_X>?8 J)*HF#=/Z9A*XB1?F*4ATKXH,|@^(Y?*

M'#85Q[:AN0XXF/N%$C6W&5_/S5:%L]O^?'FVYL[:T'?):&FN=&EB=TPB6INK M7!OFCOEMPG>T-!=$M%2T-%>Z-

!&B7>W:1(AVM4L3(=KU+@U$M'BT-N^Y-L^O M1O,\9_/*S^+MO.BD61HZ"'.07XE4W$? MPE0[87.T:P6L(Y)P_'JYW$_!#?.DR?_\/8XX[/0_??*

*F8T2C9]AQ7XA(KRSO MJY*_I53Z\1IPEV8^AHV5_(9%#P;KOM5$(I_G@GF/\C:>KEB?!L+?CC378>Z M_'BNBTRS/Q.S.+I&Y-&!F2]EGGU6?OL*

@^22_!8>;=^G7F2=? OKY!N0\%IM MEK-)<'!F]@MIBHN9S,#!=^).L>0G OOW49UW& M-2CP'[+HB']%YLKUF2L79,]+B_G.E9B1;KD>W?*]F;*

(!$1/9V1%'7@]'QB^N MQ3^4(0\.C^WS)S;%"_<75)VEFQ-(7 MKRO@TK-!PTPW@:H,5Z5Z5TI[+>42%2S#8<)9NKALTN$I[>W)[R?OQ.JW9_*I

M5>.U+ODPXCQY6'AH#[U1'%V)%4^F;NG8T]54OKWU$67K?,15$M\:]]27O6S MH.6'E&A]/E8>E&[%V]\HU(PBS=BZ/0&CL3%=?&@KM$+E8\-*

*TYNLODK]WE_\RU**\E (!!P"[J?IWI$X9K,>9RTI!L MCH3^?=XJ67)A-J2:(P[_VSJ-I9ZQKUK;S1=(TAYE37[E9'(JX/]"]$R,^_,?*

UVM[6'8[#1%O3WVX(^JSE)_(@;=%FRN>#SLBQ M_/J.Y3YROLJQO.?<36,U8 20B">;F4VJ.M41M"+',G$7>_KZF@A7(UR]$AI=*

*MQ>;U9_]YE;XG>M4[FD];D/B- M[YG.6Q5-LBN&*IJI^]BRM" %NCE*(M^3IMG;!'-L(]W=]XQ Y]L'WZ/=T,AI M_0BG]6,@U[_#^S4.:WUC"X-ZW\I2^:+G@)G))@99A,?(88W=)8XC@1$81V#|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|S6EM%8-3;=4H5AQ.] M4WKHYD9%[URV"_5|%67H@'1FBO68AO=V0D&M T1IYHLDX2F:1HP!?&3I2#XG MOE ;&!&@5,#UWZ/HU(\|ZCR++".M26T@PQ$/ZN*".TA!\+Z6(GRQ,^'A*0 M]0CX6@5^ <, '@,<"X8#]#TD8,0/Q(@80RQC\8$ 84*\&N5S9'G0GE4':K\T M-8SQF.X/D]Z+ ,*VG%$+D0*+-_JKJNC*PETU@>-HI[VH M-^+*>I#8I&2NSU)]U4R8E)%?C&S^8],==J:<1WS5\KDI@YF)UV4^8"5AK#BR M6,6,M(4;DMG!FY+4RW@L*8[5>EO/I;--1M\4>'2|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| MW]&?D^UZLCKTP+9ZS4R8]/"_XFOXNA'>R97HZ:B/9/C<+60;U+Y46)":09D MK%N[9Q1_17LFT9]1S+A2M!;DN2H%B4N[74UQ2TG.8^_RNU]AS*X2L7>R!1GM;R+NCN!AYT'/J%O_4)R_716^V/;W M;]!W_$.):*4D8[$P=#_]^[\27/G^_P4:S<@\SK-!J)JI 96C5:Y):R-D4) M-7=/G^'\#F!(7SD84XPU!7] N?#61WYV!!_E2MKELT-&BG(ZM1-$W+@ XM M)*^VN4:F?\&Y^8\^!#*_5]4UE^]TN=Y\(33BJ08_>KW*%Q:F9FP : -KI4C@ M-*]O*XK@Z=L=PQ&UW<|SANW4#.<>0.*%;L)C3_Z7#D_9GQ2<>MO+IEWAE[DGJ-)0;;9<71,"WJ\XOHIATA#X("(:&D\XO;USQ%]+M1_F+LJNM8'^M^H>QJ)_(F#.LX!%J1^]PHZL7Z7N]45\(;@S,UEFKP'31(9"WL!QSQVPC"@=' MQ-_"R(AN]CO$*MXINSCP0" 6$%^>Y&^N_45CPV_!!6[9__<M)=85"5FG4(GQF;EN"L#NZBM'$Y358'I4_42: =G50'UR6AQ.O0"/D0]HAY/(M.G"6:6CE]#=A=H4W8CU>8&/5;G_:S/)LO<$5Z_#M(*UB0*XE@O.ER7WF(RW MFV/V9#@+?Y-ZES(A_J 0-P<#0IEMDI?MY^/>)R;=E0?1'0=XR US;'"<03] MTT$5D%<7=HW=,"E=:/.ZCB4!_>QK0M$2)$LA#)0E@A,<5^%2H|OQK^55M(K8]BE_^[VU%63[&.LKZXJRI5_)=XB/TV\O9;GP>GD.U]/S8*/F?O|<1@WUGF^FJ2'2M M)M65WC_T98RP;97:#]>,[VZ4)9]!P;/!^O_\B^:H?XY_G@GE(W/L*YEC'\]U MD6'V1UH&UXD0^#Z1+V6I%Q\BV,DV] PFLU6<$>B*,P)?VQ/QW=7PW1>W4[;71;W63MDU2O8OMV:7--6$;FB)_Q!V|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|^7B^-$>ZQ6XLY|9<*]C4_5-AX;EC=4I)4I-IILOJG+* LMBE>/A M>B#W-7X7X7"$PY\,AZ]UW_03'!K^G"C\F<\," :]S56=^(A2[%6_(_0&#V5[M"A?.+O4TE$!||_PWOIWZ')S,/(I'Z$5RYLE;XG][*?R;^'MG.%O<"0<3 M?WR"ZK^A/\]_5_AK";&3Y0UD$_1<>:<|1,D]0<:DG0_4/5*HJ+"M@8L)X%%7"$VT"8P !P=5P+4+2#!M] M8"-@(TR(<@!]!$& T$3;(1Q+Q%^4Q0W]$#TW\;[L';%EPB-O#80;^LFP]70N M170@OI@S+R"_>%44![Y4.E4P4EB8FK$!@,"J@FBXEC2#!"<0_N^*[8?2!#]2 M=(@ASD\6X=[[$0F5&;8($%(AX*N0"B:D O$#H1A#_2.T&PW*_W/7[<$%%%I MAAE4-$W+6$$>'6\|PCZ8-J*@0IV45"TB.8=F(17G(K!K!)%#LEN9N>'.AB M5^DR+N5JN=2;;[D1WZ-<1:"1P.M1GV2P>N(QPFM5617;DTODO%MKYIH6:-IM.6./N\!TT"RWCS%0MTM[8M:8WOTZ4:OGW&58VU M0J(5_A'J%8@J*G "?D+5 M\;%$G12H0.U,% OJ'<,ZJ7^ "#'B$%,"?;05,X0>B@RE *[0EG7W5-+E.6F' M>2 EI9^R:WG0)+*!OIJG2-EAIM26!RI%!0[#C%C.^G"0XWJ&EP0N,W1CZHBTVFSSYA=]RU'4+4513WJZ M;Q&61[-D#T&1\;3 U8+?US:$%4P$PZ 23 (N*[2*,- BK$2H";T2'Y2#+Q"> M NT2T85\+F)G"O8UAJ:0:YH:5E>P2RQT)5%WD0E!W^)A %U"PJKHR,Q*^':,M[W4@DP/^I>B2YN('.]^$& M-,FBX06J("VQ+;NQYM8#4HD/\@>1T F=6$7@+ '^X5?O\Q_D@&.G\&^7NQT NR MO@^9"/\-E?9):%PUASG[(0\X2O%L)S^W4K*1AVP3_P!@M(@?TE\0LB!*;<"& MGX?8(MI/N93(99(!=(86B@[ND...$-.)<6B+APC&*2)"1"1?@@9%N'I[75R M6%\,V2OMW%43&!X4ENS8[4\+_2']FPM*-(;,C;.HXA7_62O7]&MOL 5<^MT M(]>X^EQYMM5L^VY MD'!JV/%5/3]?">(\7>S71G-SL'Y#,8?S|*W:\]2"X*W3%)-J&.5N+]EC-CPR M(&.IQ&V*>SK1^FRP$SSDI^W%/K(3)6.J0]=(]O4QZ4>4I9W@!F1<]#OL MW+8-">EE&9]5SFS;T9FP&VRH*8$7\ E6G=U==?:-J][A^U]%OF]27<:>T.N.4.C&C(NL^EQ8 MR*/5^+[1;5NY2CU;,>8ULXE6_>GR N=8=00K2.Z=F04 @2-(-G(-(28A-I.V]Q>/>_0[\[0I6U^I7*O::*R6ZCHJ;-5:%_$=Y9EZ>R MT4A6,Y2K=,;DJEE8*.GILY7^:ZGYP:[01U'S@3>+1K-DF"HHDMGN6FDE[!R/M)/&4NG]GT<2QG,"T:'O\VP)O=M+VH"C1"NI0)/3'^:K(^QQS9@)5="OE$ MIL/&'WJ%=-P!)'|+K(#N@IQE+#*P;T2=/K0P,BZT2> K._!E:;A :I"4,A[%M\O,Y+QBK7G=1CN73FUA_G0C3-N&H@9ZD\,RWEO,EYYYCE:^[5/-C@^%M65N%/^",0CJ(@$--@@7/^K4|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|Q0^.-UFMG[OZ(I* MUM5<6I_7T|-"\Q0^K"?L?)!]*-UWW6F[UV1+(:L/5?6RX7K0ID),:0ZO:*BF5MYBE\:'F3FM3NCRUU82]I6M6&5;W3N%#TDXEV&)Z05%*SVCU>FLY*T*]E#R! M.?>#OM(HFE.52TPE*T%T++O#^Q6A#C@4&,-RGUK/!=#6R'HSU8AG:D%EDP-) MZC8-_7Y$R6I?'E>@%#1FI(CZ/")HME%TYEJEK%-UPV'(F,MV11W5H]H2], [M_KU/&OJ:+_!,F;,9A.=*LQZ?QU.[^54S'$#0]!T1>/S_^7M\3A?SS5E?)@<85H&RC;&JKH8&W@"F2-GY-G^HO!>M3 1HT=)$@/9Y MUH:Y^^T5V='*1(6+<|+J/:NX<8O33+)T-##_[N)W[P6GQ-WJ=\Z_^^=6O@41<^V MF=C!9Q"J?H:S@#*^JE_F!.?WK&JZ', ^]?Y[MOJAFVYN]>D M9T>Z8EOX\$*JXHIN#_QHB=X[&1-ID;<EL]\RAW_/ +"K5 SKQ5JFKE+Q;ZU M4/NW4YU)PWQZH^<<<&B9BQKG:J"%/(P! @)/E"&5N @['! T-^_2O) M-D,@LP$;M.N<>R7$R%(/5[=:K>Y 7.[P=<$)C$9O+W$$X64?MBO.%Z7L8)K] MFZ-:0MG@*>OEPA'2[D)HCZR'&-']XZ(LT?T="NWVUM&1U7VBZI&61R]#E)"6 MF/G0DI'H_NYT/TE(^P%I3RS?Y>SB=CX<]8$"AM*B7$.$#AN/QM.)+(U^WTWZ M.]?Q2.OH3RK!6Z;=KKIZ7#'KP)RH\DKOYZ6R>|_X[:)[+|\.H/!@3?+%4;8M MWPWZ#]WGS(_;/G]2S<_\QHN92P+=4%1&M)L2[=F5KIY:5M/QF @:*-&21Y? M*N93ILVWN:,+@8^QXOM%X4_]U(4@%T&NL"/7FXKT/T2N3O.!>T[=C@VZ\MIV MQ*?&8SO_^O.&]<$@5XTNYAY:W(3-.ZQX=UN?6?5B'2&7)&+C?&TL%/DBG+R M D&N?2/79S>&"7)]4K_MA\B5>RCW&W%YSM!SM:D-&W,R,;8E$B<+@)=X8&N#^\&$^CZI W0#Z'+>#6S M2;-M<'T__A"-T=R_DH|-'1UFWH9@,G54WYX5RR9M[W)H#I&T,6P$+M2$+OX MU.?8=3294;\0PHQJ3J4YA=L9X&9[NXH,'A/9#GLTF. E#3S,+R4RLGFV*AW+_7K2>GZIG9@]09"U9MT*[D:%45M!FKZQLG8#Z@3!7=VD8J)S/O=#,G1,X'3(R(K@=/0Q4_AM-F3LKEJLG^XP!P M#39/3[KW=_:AX?3*R)?,G#TI^#*94MJNMV4_Y]$"R7O/I^Z=QM9HZM'L:EVX'W>$@G6Y6YO%T8_+2TW,/"$]1N)E-QGAF M6_T:*>;"K^6NH9A2QD),#V %5F#-@Y"FV(XJ*U6Y&W&+O*X#DZMH[$V^.^ MS?JC:,OC^U'>T89Y:6:4+R?:H;UCL3B\M.6&8 Z*Y5D4Y]<'3YB_3Q9R [J2;-/C M>LN1BM?B4*-1V.4=[I.\2)).R4@%AD08[:43"4@%F2,|W&PP<5D+#+5&W7 M;WAYT$H.)Y544^T-!AD(8BA.2:=B7#I-7#&"8A%"L8U*B3%@HPL]AVURGCPW0#9|>6GKKQGS_U["!4C6MCCJ*AXN%I=1T7&HSN2)AH=52H2C29) M>^$A(M'H*!?9.RHR$AM--#HD5#Q4O>6P)K%F%)IB*/4 970I M&^4T4>8.&@@/]?[=XZ!UW3.,3H=I/8O3<)3K9[^0\8;><;X,95;Z7NK;(ITMSBZ+ M*PZLV*PWA;H>EMSF'F?[J3RF39#HPM2XF9&[E_D$(A &H&T4X"'T?=7Q#QK2 M!L+5|$KL=(S\L#;H";/;6W8@UA"D"6<7ZJW?B[+$<0[3 #SM\7L T>\>:[4?YX(&7H(@'C=]2=[;*^& M$\U(=UL^DY\/()XT:+AUJI0!/'V%M_\;;GYH!&O5C#;97#1*)(@-L7NY8<5|G _:4F'9R*1V$U?EJ:/FCD M-Z3IL_:8GXD#4,_$F[;C7,_U*81]', ^D=[R])_!&X(W V_'"\Y>+U@<-;Z)] M/ZB.ZO5*7GVX3M@IDXZFT/,H@>!/V &\DR9+ 6\BR,]O:. MY^6LP|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|'"W%70KK MV<6?DNZFM=I]PX%_4JR_(V1=Q,/*F4NYS7\W@'"AU.Q/E9IA$^EPE3K8-[%1 MNEM@%B;R3D\0%H8(XV^$D2/NSO=OFP0@>UQ".'G9(T8$B"$PLB>NC!R@7C8 M1W0#[^RB:JH3R0:4JEN."4SWFH%A]^&.9(33[8/VL8^)?'L)?!UCQXA_!T>> MTVCI17WQZF&SGFOWIE.]8HZ?K_+CY\NIGKNN,5?EVK=+A-])+X:9=2Q(?0@# MRU)]'F*4/,#P2JC1]]=RGRZDA4%%4&9QO56KFN.U]AQ[@N7%1TKWI.DT?G*M_9\LG#9:=4NU^_YI\C-9M*:G;7H&|&/,UV9?V9 M9YVQK&3:251])YF*\4)RXSYQT+I+TZ@'4&[$*+=EM*1WT.[YV)>YRK7::%9 M9#N7HY;(M@KWAT8[YR79FHS+HUQ^;@X>G:=BU1CQ-8AVPMD%EXYQ*6&G:$=] M[Q"T"QKM3]*WX<[0[OW2X-]#NTE#&.?KK;9#%Y]>9X7A95]J93,'1KO6K5V: MF1EMEI_W6*?6DH74;7H*T0Z7#&=C:3I%G#L"=U&#N^/O>[AKN/NU]/L[% MZX$(9]!1'Y+]J?7\)-0.#'>I8Q_R7N(:M4%]6C ZM_H]SV01W+F%>9@8MZ4X M#VF_^ !L8,)/[(PR5'75LEU9B5#BP-'_/]'1KV[A$]#_115B^X=&.]OVHIU19?*G<&XT^T_)OD^WS(S;1Z%+L58 M,KG9(2)@YY:H*X$T FGA#4Q^"&FO):[02DU3PZ:049ELOEIZH=N'CD_6X[.Q M6*.9SL#)-^UJK7BOWUK-*$LXM4C.73NPY|$G4ED+;CT@($TGX1??P0TO+. M:WMP9\/ ZFM-/CV:)!Z,0\::/:05XMI>ZN!Y7Z=:'S-,UU,E/DI:7/+E@N MQG&[Q33BIA%,"RKJ2#!M)R'&#S&M79DFA]=]8Y"?3^&&;U)J3/G[0^||Y69K MF*^8?)IF;XH]1RVTV'0381J*-+)T#$K?@*-QW4R< <4^+$)2 9E**P (1O) M-0IWE-('#,\Z&#(H!]!/X)^$4*_;WC*;]"O&K]J7[:3/2L?YV4V6^+T M^_S3H9..7N[8LI%/C26ZQ9ABU91F#WP?H1]J;LC'Q!1#4BQ#IL<$_DCJ912"MGV_@+UVAKYQFMEFFQ_E4\::4G%CQXJ%# V7AX:X_>WBJ-^-V^^'U-EYZZ/<0 M_*7/+C@A1G,[/Y4F>DS@;X]!40)_^XJ3OH&_E_K3Y<-*

#9W*;;RG5XOBA/,P6 M4H?>^]*U!W[\XA3& T=K73T^.?'D5:T'X0]%1GDZEN*_<)_PY%(PD5"@;F9# MS&&- F-'!0V!;E,*BH>K'<DF3!BD|\%^?KQT*9D-JIF[U(;;=#U MIYMBL31L.[-N#=*!0[E0(K/;. .+!1X*/!!^CAX_?|*>_CH^5|:W$WM7,Z6#N MR"WV>3QX2+X>.M(PN^95)],-F8'4Y*NWE>M!6A<1/N)<45K\PETGDBM*\#', M-/0CK 0?#Q%N_3H^)NL\],CUY|' F=T\FB^=8H'/'!H?4_2=D5$RI4F^4K=; MC-I\!7=]#^(C2CSE8PQ+'$@"D!&GH1^#)0!YB(#LUP&RU6EFE"\GV]%SN)B;B=P;CPUNX%S?W573E>?<_5.F+>+0*Q>CTU^XWD"2 M& CZ$?0CZ/=A>-847S.V3,_4)KBN)N=E49Q?/Q\;_69*:0RLGM*F6T6C.A[< M#7F;G4+T$\XNA'2,%TF14()^!Z?KG]J(!IR 1X%^VX.OO#9ZH04S-\X74]D&MQ[\^7%WRAXX*.&6&*QICK=2|>4F/X_&[9S9#]R#ZH; IG8IQZ9U2V"?P1^ O M)%5%#T[8X*_-|Y?WU&?S-Q5(3EP)*V83%^G4_>%0Y\:]4=)))3<8CVOEGF@ M=UN#^XR X \7$4T+L=17+C#AJ.A_;!0=OO"?+CMP%JHP =-UB4W9=LRIZ/$.)I3|C5R<)YR'%U%G>)?GZ% M_].>/YDU*$-..%<<N!)6!.JW:MT,K;]"Y,%_5<@WRS^X ;0;Y (L2H*81V:MJ',CX%5%^: /QGV0/^&.6,H/U" M']G '*HZ9B=E=/%'&D]A/Z 6[EU@"PY%OJRI@$9@C8&):2#(]/H(R'PT&<M,*E,/4N)23:&1L%*"'*!FRD9/A[-7*,FB+&A-K#A41>\E5H+*2W+?5V^I!V4; MY_6CB4J]#M O0SA;Q.#8GPDTR8;C]R1SZ#X$0;6/%@,=&C@XMFH:*&@4J8 0PGGE?6YT9'-];]^)M"2I8G*6_B+.[-6SBT8?+. 3+5^R+$-6 M,>%DP[(1N?P_PQ|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|"7>#]#_#<* A_4%CZ/OLK!8!%PUQS_@E;.!Q|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|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|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|O$> (&'"2(A=CA=T'U(AZ$< A@/-;P/EIP&N? M@&/2A9N&)&FO ^>I=3T9W4AY)IN!@)/&@",FV1B=)(!#(< 3F0 Y|M!JWT" M#MMK58UR[IF<%W)7%;:3!\FX@@ `0[386(I)QOC4%_94/IQS$=GH^_NA+MQ? MW3:\0J?@PYJF)*N-G&9$CXKDE.,8PW!>1>,-T['%:LQN;\UL7'_-T\7&;8^? MI-MUBYFV!1R(2\98/AEC4@(YNR5H=P14)&AWC#' ;Z"=8N7K.;JK<(/ZX'HVMMZW.:^49M9H0O$VY&$NQ)*WNT'I*T(Z@7:C1[H !R&^@GNR_7D&^7QKX=G:)CM$CR\@ZMIP3M"-I% >T.$?W\!MK=S!M62"JI=TWP M4+4<=?+\\I"O0;3SXI]L,143A-3)Y_65MP0OJ3B%P\HDH6_G.'}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|S-*;!>M/FE'7'!HO+0-/^ M^2CW)]BVSY_UX_B%?\VR[S:$1O_^SUJ[ZT6T+2X;FF&>^S'O%:)[Q&1Q^+L' MXFXW;:D+)WTN:5-I;GD42J43G)]1=KX(FW,X $)#YOQ%K?R,%KG!:KCEC]!0 MVXNVQS70M<^]K_F?F6[O;^_#3[IZK\@GRR2$=2E),HD4OR$H.TG;8L1E'$BB MX$Z_^]^S?S4]V6T.QS_[9QBK42_OH[.+!O:MH3^611L-?:5H@[0^GL]:7N!D M!A\%;

*C(=GWSZ(;I'X>T7M%^E_[+#]<9M\$/IX_(1?^#G]#^#W]TZ)M_O^'4 M&Y8OCUP6#!_9[P[O\T["L=*VW$T*M)*4VS*;[K232DIHISLLTV93 L\R:2XE M,-*92RW)/PMP&IW>?4I7-3H[?6JP7/UEG@'3-M.FWSY9>W@M,L^]CI1W'N." M7 &S>3U7:[.;3U[R/;Z6YZ\K=+8^SKZD'PH/$D!/LF^?Y%-L\JJ:&C;I<>HI MR96J]]J09DX5FXPOE3SU>U%F=R?Q M843;BS03I MUT&O7FQ=Y^?9BMAI3I+907^Z@\.5XU [&@M/_WU!V:)DT:6>#<_V'UY6A) MGI%&!D9VS=RZ6[!I(N@-6VZ;_EN|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`AIH(#C!!-5YI:/A0-B6062&A$;2#&?H MMMA! [^F Q3<5:@K7@#Y9:]:P*'>]MI+PV:JD^ >SEBT3U 6C[3E;!>N2O DUU5)5_!H)U4T3*,%4UUKW0+ M[C?]!Q4#/J4;ME_;':P=K:[K*? K$&D%A[$+CL4$Q=UF89Y8#']-QW7"34E1K MT?XY=IJ5^78R M*:)24E0$040E9)=E:DMPM\S>2;KD75I"K=(TN05]9(;SOA2, MB/CK\Z_3? 9KS'>A>#RV98A/4@=]Z<71W8^BU\|+]N;R>*O)J3Y7ENZQE=Q6_:Q<*3V'_&$T: M^JUN_RT30&]YT>D%:!:8]MWF+_"OJN6UG%ES<#U%2AUZ9I9T-K-$V6V'N.5"O0@.2L, ^/P<=/AZC8_G"E;F](*C=YL? MX-6=`AIH(#C!!-5YI:/A0-B6062&A$;2#&?H MMMA! [^F Q3<5:@K7@#Y9:]:P*'>]MI+PV:JD^ >SEBT3U 6C[3E;!>N2O DUU5)5_!H)U4T3*,%4UUKW0+ M[C?]!Q4#/J4;ME_;':P=K:[K*? K$&D%A[$+CL4$Q=UF89Y8#']-QW7"34E1K MT?XY=IJ5^78R M*:)24E0$040E9)=E:DMPM\S>2;KD75I"K=(TN05]9(;SOA2, MB/CK\Z_3? 9KS'>A>#RV98A/4@=]Z<71W8^BU\|+]N;R>*O)J3Y7ENZQE=Q6_:Q<*3V'_&$T: M^JUN_RT30&]YT>D%:!:8]MWF+_"OJN6UG%ES<#U%2AUZ9I9T-K-$V6V'N.5"O0@.2L,^/P<=/AZC8_G"E;F](*C=YL? MX-6=`AIH(#C!!-5YI:/A0-B6062&A$;2#&?H MMMA! [^F Q3<5:@K7@#Y9:]:P*'>]MI+PV:JD^ >SEBT3U 6C[3E;!>N2O DUU5)5_!H)U4T3*,%4UUKW0+ M[C?]!Q4#/J4;ME_;':P=K:[K*? K$&D%A[$+CL4$Q=UF89Y8#']-QW7"34E1K MT?XY=IJ5^78R M*:)24E0$040E9)=E:DMPM\S>2;KD75I"K=(TN05]9(;SOA2, MB/CK\Z_3? 9KS'>A>#RV98A/4@=]Z<71W8^BU\|+]N;R>*O)J3Y7ENZQE=Q6_:Q<*3V'_&$T: M^JUN_RT30&]YT>D%:!:8]MWF+_"OJN6UG%ES<#U%2AUZ9I9T-K-$V6V'N.5"O0@.2L, ^/P<=/AZC8_G"E;F](*C=YL? MX-6=`AIH(#C!!-5YI:/A0-B6062&A$;2#&?H MMMA! [^F Q3<5:@K7@#Y9:]:P*'>]MI+PV:JD^ >SEBT3U 6C[3E;!>N2O DUU5)5_!H)U4T3*,%4UUKW0+ M[C?]!Q4#/J4;ME_;':P=K:[K*? K$&D%A[$+CL4$Q=UF89Y8#']-QW7"34E1K MT?XY=IJ5^78R M*:)24E0$040E9)=E:DMPM\S>2;KD75I"K=(TN05]9(;SOA2, MB/CK\Z_3? 9KS'>A>#RV98A/4@=]Z<71W8^BU\|+]N;R>*O)J3Y7ENZQE=Q6_:Q<*3V' M^JUN_RT30&]YT>D%:!:8]MWF+_"OJN6UG%ES<#U%2AUZ9I9T-K-$V6V'N.5"O0@.2L,^/P<=/AZC8_G"E;F](*C=YL? MX-6=`AIH(#C!!-5YI:/A0-B6062&A$;2#&?H MMMA! [^F Q3<5:@K7@#Y9:]:P*'>]MI+PV:JD^ >SEBT3U 6C[3E;!>N2O DUU5)5_!H)U4T3*,%4UUKW0+ M[C?]!Q4#/J4;ME_;':P=K:[K*? K$&D%A[$+CL4$Q=UF89Y8#']-QW7"34E1K MT?XY=IJ5^78R M*:)24E0$040E9)=E:DMPM\S>2;KD75I"K=(TN05]9(;SOA2, MB/CK\Z_3? 9KS'>A>#RV98A/4@=]Z<71W8^BU\|+]N;R>*O)J3Y7ENZQE=Q6_:Q<*3V'_&$T: M^JUN_RT30&]YT>D%:!:8]MWF+_"OJN6UG%ES<#U%2AUZ9I9T-K-$V6V'N.5"O0@.2L, ^/P<=/AZC8_G"E;F](*C=YL? MX-6=`AIH(#C!!-5YI:/A0-B6062&A$;2#&?H MMMA! [^F Q3<5:@K7@#Y9:]:P*'>]MI+PV:JD^ >SEBT3U 6C[3E;!>N2O DUU5)5_!H)U4T3*,%4UUKW0+ M[C?]!Q4#/J4;ME_;':P=K:[K*? K$&D%A[$+CL4$Q=UF89Y8#']-QW7"34E1K MT?XY=IJ5^78R M*:)24E0$040E9)=E:DMPM\S>2;KD75I"K=(TN05]9(;SOA2, MB/CK\Z_3? 9KS'>A>#RV98A/4@=]Z<71W8^BU\|+]N;R>*O)J3Y7ENZQE=Q6_:Q<*3V' M^JUN_RT30&]YT>D%:!:8]MWF+_"OJN6UG%ES<#U%2AUZ9I9T-K-$V6V'N.5"O0@.2L, ^/P<=/AZC8_G"E;F](*C=YL? MX-6=`AIH(#C!!-5YI:/A0-B6062&A$;2#&?H MMMA! [^F Q3<5:@K7@#Y9:]:P*'>]MI+PV:JD^ >SEBT3U 6C[3E;!>N2O DUU5)5_!H)U4T3*,%4UUKW0+ M[C?]!Q4#/J4;ME_;':P=K:[K*? K$&D%A[$+CL4$Q=UF89Y8#']-QW7"34E1K MT?XY=IJ5^78R M*:)24E0$040E9)=E:DMPM\S>2;KD75I"K=(TN05]9(;SOA2, MB/CK\Z_3? 9KS'>A>#RV98A/4@=]Z<71W8^BU\|+]N;R>*O)J3Y7ENZQE=Q6_:Q<*3V'_&$T:

*(AM09;8AMWWD*FP'O;Y)-3N><'.4, ^1U,.V&=#\S I&|V B8IHANV9)-INR MM/5S_IAUP:SG,98!{7[*A>$/6^R^@MS8T:*@CMD$V",/.0[U'^J_%O2?Z6"/ M6-1_]/]0_QTOQZ'^ZVC5Z^Y;J;0Y=Q=YL:,5L'OHLM']8ECMHL1=#0G'T_$| M+QB/ QODBJ4LIXD($--P&J=Q4? (."M>M3S+K"'U@8A<+C78B@SW+L#PL-,)" MHVV*]KMU(Z%1OKO'/41ZJ/=%"WVC8'?NO>)-(3Z"/41<@[J(RQ\?:(^,NP! MJB,L?-V"A+ 1+!:^2H!\2$N:7L7CA!%;%*PD=)K![O]#RSA+1;"3T3P]S^98 M"]M)*O30DQZ[!$2<-[TIQV4,AJV'5Y&;L91HC="PE A+B5!_=AB(7=2?.Q%E M+SS/? XD&HB';=G@>]VW;$!N/MTR MWK,W'WN_]K!DM\,ENUMN^&M6TH1D&Z:987YLQP8"6@-/]:-/6/5;KFWT/6QG MBU54VQR";C%M@554G=@Y*C0M(88*S7)L8S# !H2HT%"AH4+3C'-0H3TS7GO" M"FUH^&V*(V3*TRLK]K&LN,-EQ7S-|;. ("Z^89S<8%M)*.J*@VS*2)1GTRHZ MFZ7%_[P:8^+GT&E6,:$94RH_S0&TDGJO[YA MMSF("KD1]1_VTD7]IQG'H?[#7KIWB"7#M;$,%|MP=^__M>L =IG(3K T]U,Y M83F)92#XA2K,;?T074? @6E?+2&&=4P#QT:6Q!HF[4ZL=H2(L))-9I6$--> MH^U$"+VP#=OQT+@\9DVV&|*Q6B0:U%R=V#E]+BTAAB6XCF'V6ZRA1*;4K@1W M1SK,:;,Y%9;>'D7I[9A%6+Y$]1_N^|WB? H/]1_J/XV!=)+UMWWP_UHOND%" MP_K;M4A#OUT-V&4J.|$"W_^+T&_5%I>|&+.417&)E1*8^M4(8MH7+>TA]6M[M.-3UF,N7NN?M=H1\L))M9E6$- ->F^VH"J5O.&;[4]*0LC128KNAG '6X"*[MH.K2 &)8@V&-#;_?>G<@I+'C+|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|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|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|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|-8,M9,4_$NE&>34F:I>?BV2E;=+:E(=_S=-%*8.&QE!=4- M18S#5HY_V,K.3('==&-!NJ5\U8F8+\;VQ)_]FZ;WAN:O: MV:PM"(VZ8K?IZ)-:S'I(GNU<%$ M-K7=I.9O<#2|\%-/SX!O1F+M8'37W%.-GP3ZBM>S= MMMFJ@:5LH_X]US_"N+*;MOV&J165@;7$Y*MFHME$)#>^4W9%UXWO)"N*1YG> M=F- !:4:KWN5+DFHQ#KENQEN3R?J(P,5XP(I8;HT&;@#R_:>;^VYC\N2*N2]? MKSGD4MVY:=#'P V"R_'(]MQ37#2W7!$!RX;15'? &MN1:PX=MU4GO2N#/JH: MWUWZZCKV&5^H#W7N6TF=[=QY0_GS36]) MP9D0>C6K-D>;LI1R@CJ_WVS[E7SRF>4FY3PF.)D!F+L G>.PIW5U]/QMT# M*%'"*(C"H>L$]FC@.-'(0RMT9#VZ8B%@V#L]3W6#\NFFR)MNF2G+"8>5X.+>9_YDN53,##H':;7#XT0I#1KLH"QL) & M,W_GN"CFVW'<@P;=#;=%5:0'$EL^Q!'12]&|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|MN&+2^J M$Q;AV'+)YY+E$4OQV35R/U"D56\SJ9O>@* L[@.HS,.:&/LZB?.'I=C*58MP MA[#K@=H2&B@CN,7R0/2"Y<; /!/8S[?IV$Z$2"2?*H(7Y 14/^?JC7KD,N&A#-#6(N,K5X(+",U9T_.GE2=1 +?0L%& MPV\S>Q9HR^H!E^(W>)6OU6KUXY!5CH55+N=7\!AR#Z^\S[BR?I!95B^[5^4K MMMFL\U=7VAS:J\K;Y$I<9<62D"/6J%Q]K#/- DAC4MJQ@$:PXG64YUP[-^K>[_M]>TZKTB]NWE#4H^O/+*V%NJH7V4WB%=-XRI:G3;F@ U"6<;*LM'FDX5Z=W2,?4FX7Q3*4 M6VX"QB*0R@%)Z\N7@K,5]!?QNA\&/=M;+T&590EB)4X#87:3KL6D^24?F-5S8(2-8N M8P%NEBPZBT5);UU0(? (X229*M9=6C&5L'!@|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|\;R+\S87D+:-5=<$B,J+DO:PPR+D[>\T3EJ E4Q[:4YB59^<+ KH) M!.[ZS5A)UWXEG8V5=%A)AY5TNA@ENSV]=QF")J&!B/F!F >!'ARJ]>2>&G*" M!PE:ZTY#@3L+USP?7<#+J@;E:P|C$W/!.=INIPFO"X0L9]"Z[^ MIMR54&Y0(]UT02JT!D+(2K[! .7)716L(OJP^NM?(,&S!(($%H*]!7X-A>B M%'$33AI\L $;E6B6"%@>6:!Z<(NQ1:^:/VQ%-BL*5;PQ[&BE&[/H-JQ>?3!; M:J:\2C9__M.P[P]? K_9\ON>.UERF1TIE4<4UA9U)>RM.HT2=/\OC8CUB2H1Y MS1M&*>M:&F65-U\[6VM[E%45K3+(U!HWQG[>M0OG6], [.1@O3!X?_RP- +8=WA>,TR0+?Q-)"@DJ*<3%(BM6<9;X\F8_@Q6%ID! MD%ZSJAR\D+W\FBX!$A02U-,)*J$ 9E),LKRD5\KZOZ&B;ZWR M0)&ND*Z>HQ"G8("I'JT!DA.24POV%5CO(;MF23:3K;^GLT2>1T@!=K,|"^=! M"18_TT'*E,I !/IKIYQ]S"I'8"ZYLI1I#.>,9''M^J^/"+8"@ZBZ#EOD#CB M54.]NPEL<$;+B7R.,X-KQ&# M5XQYCVEYGG#M82*4Q6$EPJ70^HDT#O\GK\I(8@"UK)ZA*

*MQ<18&|M<]X&*DNQ&M=UK8*4]2BSF402(8/*@YI0QB8J;+/\FCK%(OC,6#-C M$3]H.RY)W5NA.3]BFI/L',IIF/(\Z@I)*4-WSO]FWP'I"J8Y'6 MA|HHDXCD13<<'|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||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|| YQUL W^Z,@[+.1&XSMT2 8AB.'.8.!S2*'^:PMY3O< MR-/[4]/O_O77#S]_^$H^?/SEW;\6BO4)#;$ES7+64&S!41I(PEIFQ'6DF&O< M4^;54]5JEMQOW1;Z#E% [5[_I0:|_^+$)O)6VT@T2:CR1GQ7C_6LKM5/]?QY:#*UB @Q+FIY8E?+D0[-X_+8%R+5#T6KCN-46B5"D>W>TV='#] M 'I(/1T/?((LX5_^=.:=/1-6CMWS%FF?1=YY]IV(ACFD2BCM$)B;8^^[RF\2'F97MIR/4XE-O!QSD_1H6>R3_D5&CKE_J LY1C6;1TG*(KDK[C M5"? =F5,A.GX@A>J@=3K+8!SIKK,3,IR5ER|>G5S<],#1_2NLNM7 MEWDPX8/A7['PBN:O0EK25Y9I^P-G\,HT3JOZN==CL&@;S'+2GMZ]P-FYF[?C M1]OO-:>4$4[Y@G@V]VOME.Z,4%H>]^6) U2SQZI1X?RO:U..0?IYA!TS.INR.PS\.S$5VQ[9LQO+9';OE[,[/M^<)O2D.-3R3 MSZOZA05JQO!0#LS%),V1N%: [3]+|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|-5$/MSIP]]*MICF MCWR+C767%CL(6)*|ON|.2[6"YFQU|L:IWP54|>]_-6%04_EYD"59?O$G4_SO M=0/H"IBVD#!7['R<,_KMG$;PTA9WD(OYC5AAS8$;%,_M0,Z/I/&9;W(-U5/Z_;P!;270SA,6E1?]MNJ[7+Q4]656Q'R,S$7.$LI[I:V@ M6E$*B-,+V^KUEZG$M7J^MT8H;?,7$5L?R_|91,;D*X^_P2 M/Y_29(FEU%=G; [YRPA4C>N!7/EYG@7>ZO%Z%6]_O!!;<2-8)9#,_*;@)^)\# MK.LM*?C77RXC;@T?\D=@K> %OX+|-['%G2]7,+6"\EJK+1#.O[IC^79QI[L& MH"0.?SH;A? W(<4QFC\:198[< 6.C(1OZH\!C432D=&9QJIFDB7;@4B%$R5W+ M?I[^'#\?=$U@G;WY\N$O'R^__O[YW9? >35N4SDV-O7O>5'&T:W*N;SKI1V MN7>;DN?MFN>WD.J_S?-B3M.RFKJ5LS_F<5Z/Z>+??6'!/ ?.@%V^^QY,:'K% MR&50\I^MH>,:ZL:KN"ASOM2$%B2<)[?@A M2TD.CQFS"4TB,KX5"\&>6:XN@+]S-D_A)K$>G9>3+ = ADNSNX2F7:@>H2>X MVDGHK& 7U8J E M4?:(Z^#GG^OJ] <0<8WU>9_/*,EN*CZO_C[G9OZ%5+0W *<'%9SBQ27A2,=% MELS+5>&X9! \ZDCO70Z(W7/OC?SKLV>-C>5GV,9/.8C]0.A4'Q0]=X-NSW>Z ML<,C),*'4XK'8JG/5F)6]@Y\BD:;<3FKF+8%PU|W)V]^?GVXKE[ESZ! M"C(48:K9=R*&DY,JQ-UEX+PJ7BV"N/$%"ABS'$)0 Q@U7<)'QM"?NV1G^/| M&YNR6Y;_SZMXGR;*$1C\714*CP'JXWQNW0%]Z4_6]DCL2.QZPKHLS=O)S&+ MR/LXI6D UY)/410'2.]([T=* [R]^RV.@]!F0>K0@>CX8C08!/+&$S9!,\L#Z M0+0=%!<=,F2KU0ZP#FBO=4#^SNJ F@E858*SE()=_HZ7W3A2DJR6#UUG<;BY M>JA."8VS\!;^;U).DS?_/U!+ P04 " #@619*@([L.XO #60P$ & M '1C;60M,C R-# Y,S!X97@Q,&0Q+FAT;>U]>7<32;+O5ZE'OSMCGR?9DC? M]'".,:;;YX#AVNZ>UW^FJE)27DI5FEHLU)_^QI);+?*")9!!Y9,A9)**/@]^L/[X,H#J;TN0XZ/=W#W;W>GL'0>_PN__M[0>?/@1;?UR?;M/5;S^>7O_UZ8Q? ^^F/-^_/3X-GW=W=?^^?[NZ^O7[+7QSL M|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|A\@U'^QP-UGT$)KI(HN!2YH5X+'MO>/DV>'F4GN^D2>QSQS_K4(Y5/8S$_5@D]8!"GX6>FG8*= ::PT|7[1X|W ML&MDHP<=)VD&]G:;I7VN?08FR6-> [#^7IA?),,T$VA9H7Z;9\2\]^E_C6Z3+ M,2@LF>%OC:]Y"K17<< 7UYGW^|>%>P".6\:$[\2Y7+=@JQC) EMSK M6994CUEX(I,J8$>&\/[3=#(5R?S77? 6X>= (^Z^V@['(Q3@@UCE8Y#H./P[M)WGV188E6IW!V60:IW,)UTJ0\1@""C[%(EDU&? =CZ3!;*P*VT3IDB#:9;>J B*CNWJ9B3SDMA>EDPD(DZX3S##P%DE^D\0A!"J' M2[WAFP7E(>" D=@=^BV3_RE5)G&T-.E,AA*YP!'(DJ1^.PX'_Q(3,&(+I 72 MX,X;= [ZQ6%|*#UV/@:BT#?)R*K-<1C(G F02=$9(?|R##8B^$!9NBA>F&7 ; M;CL@13$613 !3AN+&^0GE6,T%-87B3(5>0'/&8D,31G|$?,/T+2%GA7>-+P(MS+/6A-4TM"%D^!V#@8$G58B^Y@*]:RV7Z6NNR@F,;LYK\5;"/E!3W CF\F'Z M_3AMS0V()V=!G+T_ ^W\S?G[\^N_UMF .(E]E0"" 0QMRG8,YKYV0 [M/W^5 M!V]2V.FXM=^"X V+-,N#K=7I57K;BA4K[#F!:FJBBD*BM /=ANH@=W(*9-8 M5 5(-G0;%1"D,/*/MK+(9.UB>) [T+|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|$)6@_ MP3A)XTW=MT+ 1*YH_6JB@TH=P$LS*T!;K@J!]1Y:>5(7!5U]4_-CEUD\\4WP M5ORL_M>$!AY8\?&H(3ZH7,3_=VQ1Z@XH6XOE>0Q3_4+/JS|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|9,W Q:U,'*J'^D4S$K[F*E3VT=L;N0UT7';=#]4$U]+9+Q"6D2@+&;^]B MEJ@1,$VK0!5>YZK-B=$^7%)$S>@+/.&GBU9L !)QI%E:CL8![R(*0IK@[M!V_KC[' 9[/L;@0==GCMI;C6.-MAB;8$,G&DFCREW[??\X/%;4AK@AA-B<-K MI"$O&PTK788C>DMMX#]^Z1_U7E&! MX%ZO?Q2<@6HIYE@QB*#IF\']:_TV_/M6Y8*CF-^&<5?]JVXF2V92$I6/Y[H% MZP#RET=-M9HR(XA|2F!YT C= AX2#$2.2#VT$]@%9=!IW4.]!X1T@"H&U:TS M3.(X005K@$7!=#S/T3IFLR\R>IT" 6M)E;A+8@4-IP0%*5,*986X%%F25(:D?=69I]YM&;T2-TQ;T1[+E88L&BUG8_DOJZ]BR MMZ#8G1!XHE*@/J&UBX(N6 _K!& B@ $5C?FRQ-CI6*-3X8HPTL,M)8H'"))873!#5%'6"9C IK)?)(]/,M5;/\0VP=O ++^4,97+7+*C&:TLP7))-=$DN/1J M:7&-"UNWV:U42AL0O)I.\?PH+B=+7'%6IJ?'Y5EDR^!2035B,55K^_$Q1, MK@C& <8,A44KMP=OJ[ZBY:IU=^OW$E87 M:^. 7%@2_Q;W:H$4@Y?_GLZPT*-3|^0JS0NTSU3XI2/^>'@OXA0R>:/@0Z7S MG31 I"/^Q+V+BSG-."V7PAM@@].B<646;./,JSO)%:P>[6M4KYR$[31>7DG5 MZ2 +09:)@[S6"0OZ'M"X(S4<8GTD#AH)T'C!%&<&*I?<7WI>M.XIO(4M$QS] MB&RZ\H@PL6%<1K)2.11%P+HYE^*@.6+O1:,#2_IBH2:\96TC!8'0\+QH;!^" M#)"3%*D;%<'69(F-3@M9AUMZS]&+Y!=D.-XK!=*

[&ZP8\!%]4PK"QF#'RRALP ME>YD"0Z8Q$.:C%+&9X*<4,17Q''T99(F76S:$:=YR8&6T"L]A7'B^FLQ5LW(
M*+\&=:IK4#OT0'R3+'0N!0:'GV&E6]@*'<48@ 34"JL]9#IZ"7@G8].2RK48 M)H2!WB W?T56&PVF]V95E]D[8#Y'G-!FZ>]),I346N@9(6/8@+K:?)EJA:-SM[[!5<*7Y$6YMJJ*C1>1@Y 86C K&*GL9N\$PC)'"3\!>.(Z6$K6HE :(^.W; MFRRO6.L\82W)3@22_XV>X:9]SO$$7+AE=N+=! M%V[0A3\/NG -ZR164'9SN+_3O[M2XM\P1YQW4T\].&'/;;\NQ-&I?@EV?*CS_<';-H,F^3 M=S=,N6'*KV+*V]+I.GM.B0[.G-M^'-HA;.O>03?M_/1%LQNF^SJFBU+)T!(-M%: HX3V3"NR-MF4/,,2_D8,;EKR%)>_;8.9^MJ3K/[/AN@W7W8OKO![4.F@9 M25&,.X'#B'1J]<,.&&#A #ZK^EVSP,/FEEABD#.B#Y=T.*1J-=L=R\,/Z)(VM]*_XCH<4VM/ 1M$O\X3+J"5C0:)KV%277) M52UEJR$!%MA\'IY=BXXO3[@!IY]/K?\N'B@:O#F[.'MW_@2;IYY4>NOB02W88 MKC!3:3GU2(&!SB@\N]:!,+_!S17G&]MW6CC\##SG-QD)#FZ3@W8++@-QA4 MX1H ,1-9E&,8)9<%;M-B_"T[#JSZ:-M5=I%VYRH!=;=.SSYNKR\OVS87U"?:M9[>._9A$\EC)H7>*U,?A4(5<\E>Q-$PRS+'^[9QOKB<_RC@BU"H\&A8L#O)P+*,REG0B 6PC M0@";F[DLE#6_O<,=#=(6R<%/Z\2@;;&K0/ :W'%[!R970ZAW2MAT7 4JI;2I M/;L_1_ITEI9QQ.X[]?\CH)?&+N/;CZB@Q(2*U 1K/V$0\9VCM,WMQC)NA%6Y MVL41I4H-JA3 ![MDU%&CBK/^PO4^P*PBL"L0>*IC$)\EP6GS0D[S()$8:\8] M 9O'5"OQSD!,U!1(*N("2YKRDD4)'5PG1DU.O6.56D"8N(]-:'$*]H-.VM"?MF9RH<@)ORPLNGM)UPOKEQ%"5!Q)SX1-UDZ2QB#2 $[A2'R#3]'OU4W(QD0&? M[4?07/\MV(P$6_S2$3M>SY+F!+EJRH4Z^R^X48_6B)449RLC8PK K\YBRZVR M$-10AOEJI3>-2]P_ELAF8EL0FZZ:,=Y F9;YZO<@UB Y7OP'L+AFPN[\!M[&X NS\/8'<-C2\TB\:@R#"NVPD\1T $<3F9LC1/6DW\I1FHP=:@+&K=29X? MWG77-S$3-G;MQJ[]:>S:]8HS7L %3S_6:%E>EX19<+X'5-[$(M?>D_L)8I'8 M66T3BUQE+-+AQC>QR+7<,+KMSX M]AO??J,2-K[]&OCVNA'KGPS+6F=-HG?VBGULTZ.OP9^ZV'3QN?#:/[?G7.",MP1+]9*Z1;EU46Q'CW7A[82LB4B(;/.64VQ08W= QR MCNW8T4.+N,-;Y/7"1@ >GOF9L%1I[D-XR.H;26IV.T$:+*N)Y#8V;D[*R8 C M,^Y9=@UCWH]QVOXX6" C7>HGB9 NTZ;5\/7XDSR\> MQV*P_,+^66B:U[<-ZMB\2,//V&$8&V11+T@=;T3^-_)#]R&N[".2;2!\0+=@MA",O!_^CA2!:]5K\&0"P#7!L];=IQ]TU%/]Q<'GES9,R+A1(1G-ZZ# 3C'#> M^K*- .F<'@_ZH< #[O+:^\CF75P"L $4+ %0<+ !%&P !3\/H&!C"WQ/6V"MMBM46Z%)ZUD)%GC&O=&2V]&>PK^9]@Z:02H^RWMN-!TP=4K?.UU7I.@UUS2> M+I"KOJH3P*T8--N[GU86U!&6S82&6L8XA+87;I_!IAW/NFZE-32K/_%Q'NCK MUZSKX#N8U\]>O\.0;&T76N1M+3,(\0@6XQGFWX70)L"AY2N&BUR('[,E0.]NDW8DI/V/ MYV"[N+;9U,J<@"]8W\|=J^"9&#P;ZX-8N203?3PNL7:*R41X,WIHA|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|)W)!](UBO9(N"TJ4QH2"@3><2^N5-O;M]9B4A@M2;WJ/M0[3$8DP\$Q MYNN]1% +;9/(LB%$^\(E6TINOS;

MWUJ+A)??"\-5;_M1+59P:],_81FUBRS7#";ZGU\+@RW^@7_+3,W^X%'%"S;
M3DAZ),7@"M7)N&%R$6/E-$];J$TH]:?%W5=EB)8!QM'+ 0'AWIN(#I\OC(^*
^M?Z?SIM2PG=LG#H,H+0=%QX=
*^M7H1I3IJ)K'=QA*TR"LSN*CQ5V%D#FW0])) M\KG!C1-*
6T]"BI27'U%&'L//S6G1ZD\)=0@KWY2:%^Q4IW,?G:W$?WI6NW1VD
MT1Q^C(M)_/I_5!+ P04 " #@619=]%N>;H9 WN & '1C;60M M,C R-#
*Y,S!X97@Q,&0R+FAT;>U=>W,:.;;_*KJ>NSMV%0:_,I,X65=A@A/O*
M=6R7(9.:VMH_1+< ;9I6K]1MS'SZ>\Z1U"^P#9DXP1.F)@GT0X^CA_\/V?
4'MOVQ MW]FAI]]>=?J_7W=MM]ETVIP>-I4>M?HWK7$ZB8Y:D5)&-
,,TW#IY@U?@;\'# MDS<3D7(6C+DV(OW'UL?
*^V>Y+>"*5:21.WK3\O_;9@0IG)V]">WUPD/0QF/=B,Q3(]?-%^^*
M+"YI.1KGUY2=VK$6$4_EK<"V'^BYU ,\F/C'ABI.=X=\(J/9\<]].1&&78HI
*MNU$3'O_21'T#A2 MN#:O0:43^]H!W**O4T%K,E!1",]V[\8P[10Y_.!-:V*
*G^4T&62;^HG'2K6.9 M0@O!_,B77*YG,!-< Q%DR"FLHY+9DPX_*
,03>L7QKP/=%PY\!3X_.S_KOV?M
M#]W+M_"GS]KO;KI=_/25F;X8(,,_.!SV.)F_/55E#+VDQX>_?/&8MT[Z8VF8
*M']]76XL'NV3;*7:*M#G8RVF3W?,\S304@=(V3,--C]USL-%I+-P*
U30W:I;L5D(#3; M;S T'AH,YD5,#H_(.%6,3U0\8GT>I#
(2K#MAT.>/[V!Q'@$<[2#^Q!N0[55JKJ="K4]'?B&P \.V*
*M@8BA&$)'(1N(2$UWF &8X*G2,S8&&J8*"!.'[).((L/.@,,5.^7QYP:[Y-:^*
M8FUC5"#I&Q(Q]M<'\!C8+K!.Y?N&\7 B8VE23;WQ;]-M]QY'/LM'7F[L-
*^!_\&@D*R,#=CU9$08-M1JPE*8#0,4H7\3KM,9OH*"*
ML2X8X$1F>28D@<:Q+^)EAOB'\Y2PK#CO,0??
*3NB4@T026B/T0@,WPJ2$P^## MA6#YMD=:"$3R*CZW$_*
V>$>H?.^!0#7RF!6;?U,:I.R7",4+58:[(DDM8C_ MTK=9::4'=(+A/=;,F1CHC
/'1Q0,P>U9D IZ\=;^6<6"W9@5<]APQ&V/"65*
M:7"''VNFG8TRF+IKAU!YB"_")!VQ&DP[>C< %Y,DHD;0<]9,X8-3:02;J% .
M)5Q=P+I:(L0J6GCLF^!=#=<%5[MWP(BH+NKLM#1?
6_+7^0NL@9SZZS+7+Y[B MSGD-D8%E"+_V; [<()T_U0Y7#,&PT<"8H
*[L6/^Y4WGO/O93/B'I2M MP7]$D/K'09V"K8C](*A(JQ>,*
('L%Y!JZ6,1A2PUVS,GX@>Y#["W1ZE:&8L'0 MGY'-
\%3>X!/QZ.75IP;K(Z.>7=UTEV%5-%-'2ED->,NCC \B=!=B VNGG8V+ MJZQ%
(&1B5]UDPZ$,I(B#&8+]="S!KD4UBP@,(,6#S[&:1B(<(;KCVU[_.D,C M
*!\'+!3;6L[D \$&*K.0-U01&._F>'V\W%":).*S8QDC(.X.(A5\KC16A"9_*
M/5BT;!V;-FN:-('C+7'F;7_D!K&Z(V' M1>]L?'=XHQM?SDC^]6_(2 ?-
K(]N"2>ZUXU?T'RE\QGFWW"H X,K_38]G#'
M6TC"FC7H2CSSY9FCT=.LD+NT=;(M=W"+;%**
*P$31WAFRH+QF1Q67,NWX-35 MC&F+[V H)**
49)I:1)_PSP(:$>@[3A38(>C:QG@[6L^LU(.@B^B61Z72S*= M**
(!TL%^T@"\!V.DX%FE,YC1-D@TB&408-XS07IY,8"WBL2\"XH@G;%SBLN:*
ME)S>RDC7))9RG=.I-F@D9NU6"'2\MJ;]BB'/HA2;*
[M+0X'5_#5TR%029UFB?8N>&E+V,,V)'S:8J M@R4'.N'C-O;P:-TAK!X;
>5@'&(X+'EV;G P31[/OFQX.W3UZX/>TEG%KY)K MIV(!^)RJR=/5"]SKF-L
MH1E['7AON\M(H^[5"K2<%?-1KU&HR$CT):<$_[Q)/'O-HRF?&T?KER^;!*
*MT=]>#Y0&E'*E#WMS51V;6I'O6BNRK.4QQ[&"8QK+N_(G)Q\,*
"8[ZCI"FMN M_\7C"@WTQ,RC,-3T6W/MI2T1SWZ(,Y!>QC== %:CU2,%91
*MG -Y!S#6&+W>JHH@*Q@U@E-;?^S4#;$ 556$H?P4B%<-W<.U3(,2_8 O 'S*
*M?)P.I,\ 6$RF9[!\8.9NO.T5O>W#M?.VN\2: %_$9I@@*LHDEG.P2Y'O2K@Z*
MCS"X]$_N(@"7"2<2&+-^P,=@60)W0Q'!>[^6?"#D%50&Y_-?
>=#NVL:4[\]06-@BL':XF1=C3,>"DI%XT?) M05[I W9?4K@TRTD'I*
!OPR!6R9-KF ML2TKHC\V2=+()?%)'S2\2["(-\+3)\CXQXLS[@= 5@Q*

MPWR6!;[&Q $8AJ!U+C'SS#O!E!?'5B0&%O2(Q_(/EXJIL(?-M7/*S;@$_&9Y
MEU_>PU5PZ9XD:"GA0!FR6ZQ5P(A":D0T) 3Q$2<>!.#"I74LPO?
1W%$QI=X(M<]P6!&Q+..M-W"4B-MZ RN!C])"8LX3/J#VP 4V&=CH|
['3EWW_:_V7O]?Y! M\]"/92YH[6.A=RE^*]+7F,<-
;TDI.C!>)XQYM@;;T=H9;#>@Q2A@=:G8)XX: ML($10]]0#1Z
13O)ZY!P5DEW+;N$=8UPBOM$-X A.I7Z6,/$VJ+4DQQPU
MUR_#ZW@%P836>ZD,;[>N_!IUW 2Y& B UZ'7A)$8<<3@@MOD?/ NPS*
JP#' MW1=,H:$$7US:;9OO6,0#"(4W383&FWU5VY&[%^&;C,$;-6-
A'BY[66134I08 M/6H: SK'1 OP)89#\%C@0RB&!.'0VW HT=[#5DM7J2HG0T?
8ONM]],\RIKHX M:_VQZ9BG1HE;LE]Y:MWKBAV!00L@]@D+L
*]049PEZ"C$<>ZT/OG6*M=)C,4 M2)>4PLU7@TB./!*
LU"$E>Q>'0Y[8HB*V';=L,%%K0%\H'K.W3@VD@K\#1C,8)AVGB'AGE$T3"+@
*& M]U&!.QHP*BO'2@1;60ZK3$6V$8M!''B2"!Z1NJ6(I[T?*
*8*FDBW%9P0&LE*2^%8KW9;_+XL2N7LTX&%CX-4%\ O(9.K+@']?*
$@JSG)IWW M3=-Y!YMTWB:=]ZS2>1XS"
D7FW)HD6BT5I>7G6O7_*I%K>PVS]+H8O+O%KHBQQ7[V?
FCJFQ;MF]M3IESGKF>:0Y M6CUUB2%?J<3PG,IO>67[,PA^)"
<2S:M(<@OOY(!;-G=?$D2R0"].9=_C_6*
*MO>^VI]F(/+HRW%6*HP\VX3,PR1JXBT*&E+9RT$)^5#6B:IU8%:,):#NT21V2*
M#@_F"@55$T:% @=\:GQ89&R4TG7XMITRQD$NRE(NIJ&_V8P5MI?
1Q9I4>$ M0PG!P,S)75U
>2I5KJ"BW;G!U%@S#6X.=82Q5%=:Y4(N^G#H;#SSMS]O&U?
M4V_G[D84Y(/-1V6O8"4AD&R,F=],"XC;-;:PT:5YF2+^!#E_@ZKA"%T@-7*
*M.NI*_#C[*NK<<>L#UW:E/4S1_YO+I^#5>5S[$0HL?4LQ8*G-*
*I+F@GX4OX+U M!PZ7@NB4G"7!.*1 MS9G*28AT.&2W6_MB'#=>*
[P+6ATUQ&"ORE%\:"!'/E2)!KPE)6D7@6)%E,0T M\AZK!V:B-*
70:';=3<0+IH4FG$6'U1:DG$,+U V+26
M"\14>HHI)Z;#O,@"!RFUW?'3\++.3=&216N+M#F, PWP: :=)6DPP[":<>52
*M&."MID\G"(M NFR"J$29>ZY]OE6SH'S_QX)\X\#HC+E#;H/.S_^MJQ,^**
*[B*E#OT#\%N#,3Q/>1&Q,B8 : MO7[Y_;8>/5= "E8"I$K@IE'4!-%V@*JX+@D?*
*-2"Z1M-&EAG?&$FX,']E9PB+803A#%J[! MHS*H5OLUBBR+T^?*
*D!;Y30+T8)X**-<&]_ !7KR5"@=&#[5S>PLES<:^L"<|*
MZ09N5TQMY;S+;&!D/&T Q>M7FP1J %M/2;0N7LZ9=C'F$LKRFB=-D*
*!&5!#90'+%M,/ELG:@ M]ZQK*J"()[KHX'*DA"D$7V*V(=%*
UB3ADT75.,!J!>TC0@(W%H2![CZE;I4
*MRL0DKL"VT#@$P7>!*RE$8O7',,8Q^),@0E1L\9B*4Y2L<0!N(_NHAY/">G7**
MQNY,=D1;S$MESBUUUW#-$V,UEMCX\B=X+\R%T\4].*
*EDNQT/)_2^05RXL-1 MGD$N))@85 U)V;)JU@\?<'29 09,F9K&UB'**\] GU-*
7A&1EBI=R>,6.).R- MUG9;+, .Y"F?A:NX ,BA0]"0+N'5#@)H*
^G[,=L,+%^6%TL6JHU'6&\Z DI;Q:E:-7X.RCB@3;EL64FFL_J@0
MQGBR($TW4?]O&O4_W$3]-
U'_[QOU_SI2^9US$3F.&V]6D/V"E4%%K&G>P,, M%]P#'/B(SQ.K65F'8G(>'?*
@6IMO'3H<>]D_[)W)]\3$F![:74MDP'O)J/<,K M/%^%@APM%SRK/GG-4Y]&
[FL>"J#WY])+T.?M3J$,K%X!US<=D56O,8=,6Y[M[C)I,9PB\FGKD#"FC?
ZYM?N'SN@'^DGC(GW8T,8E7=$E#5=V2?6"#,8TSV @ M;
[>ME\!^.S^_KZBW04?TP)(+5VFF<;\;6?/@_TT\LSOK"=-
*MP!7_[JJQZ*XU\.H_?)8&2KZA;80]9%:W,W6BQ6W7KQ8NW*%MB\.*
MMW&9>LSXS)VC>B-HMV) FR^JK^3%-_EA+\CP[S..DR(I:L<'N#*RJG;18*I*
*MNC6S?!"@C833.*U E6OH%\7-9\6 ;6?YK&KA]7)#B\+L]Z7ABH.Y<&)Y%AQC*
*MGC!(M]DI*BGD4CXJ+X;VD7O;4A'O=RFLXI!->XM.S\DC^<4Y M6@CZWWU*
MPQ"R.#\$EPR=V%9X4^BH7+;]^.@6U:ZXV9H'RZCJ)WWFAYB6@(>,&T<_6]

*M,_(COXAV^%CLK8NMO,:OJ?2<.J*G[3SYK=(/0J/?6C<0L1C*AZOYZY,HPM,Y*
MG^7[$.:JU\Q<94A^,C)E=VR_"Q:]6/!2[)MVGE DT7W#3;R2]H"H\K:,+,%*
M2GG%O=^G4C50O95865@[/;I>Y '_*I9J=K]?)357QU8I'CFLNR+RP=+1X-Z
M44-Z&N@U;)2 88',^3AR=:?0(E[/I<0Q^T81KJ8(?UD[1?A!Z)'+;J(B&_FT
*M5R]+,!Q#80D;DEFN)K]2@B\F Q5*M]$+*ZZT*"6GYG?-V!_=J)M^#QT^@'?.*
M@ZQY20CGAF>9BSE[!5!LSLXVFYM\;:PSR"K MX4;*
*5A2P7]=.P'JX1\JEGY81H;;- %J%-G]6N-6'9%9%?H.*C#%A2+R(9^N6*
M2X(H&L+BJ3=VE?=/DV=$F>;9)GJW+EIEE&+9:<6V-7H=$B$SUO+XN9?*
*U=-*F"HD6E017A M7%DK@:SP-:,5![*^K5#C]L @XCK?(&@LQ$??*
+6S\;-7UR_53U_E!!U]@[^8G M)_O"72KSF8_9U
([]YN4SGZ4VCMK>\XBZ%Z% ,9NC0"&;O4[0*_??F#O18&*
*MGQ9WODI08",D*PK)J[43DJX[)VG9;=JU$RT3?O]^Q(:5F0[.+-P*%\1F?*
*QZDXC3P*Y8F][.G&I*CW.*
*MC]%LL$&61^WMX].QB%U^.%4CNS]\O@F&Y_/8'\=**
<:_CAJ579>GU.]7%5H-3 M5)1/:7 K_-H:5^]^:R?
<$NVI]Z[.J,+O;Z[7X7OWPXO[SL]J[Z[08[_=AG M[\Y_.
[]\Q[IG9]U.G_6OV%GW;??&O]R^OKXX[[1/+[IXZ[+=/[_"AD_;E__7
M:S[%S]8M^S-[#Z+#O_IY#"X4.M<7&%2Q/X>!!@]M8P%UA!$1-
HAX_/G?"V7. MLW^L8,$KT9['0V]?0(J]'S1.]V(3I]O$Z;Y'G.X!M3BORAZ$;
*(!CP& UQZC MWW.].EOV]UQKM@B5E-$);Z%%KGJ5:<6'*YL]16%JR-*
U&]AG0E WIQZ+Y #02 MFVK<(?44)\9][40$\8?=H>PAP(H22'G$$R.._8?R2' -
*G: C%]%6U;@JWSQ+ M556\Z4I%^*QXET6O$*17KYJO7H*
H,8(^8%S"/IASJN%/F,L![O(+>.00$J31
MO7\$[__ZMS]7$^>=NNY'JTTI.D!U4W"8=X'6X].]<5><^]@C::Z==)O=_KG*
M8-#T?N_UNQ]ZK-_MO+^\NKAZ]WL#3=.D]*"/G(S-_T6+?*
%FF==\F5>9Z@^T MI(\N8_/5.JWBULGI[/A+YG%TU-
Q[E5M>SLS;3^X8^6;,VX=K--&6:;%NA+]U MQ4ZE_@S:??9CH\^S8]5+/A%?
@5G19E]K3MUPZ7/FTKY,HS_%IFLTE\X83U Z MDS&/]S=9C>I;OCQ^?
#C5Y[=NK'HQ@K]RSD66R>]3]V+"XR9]ZXN/F) O%?R M&]UV#
[4!H0T(/LYJF=65>> 0_5(CE5 /PJ)A]4,9LN/09<>F/$EW9,.@S9="_4F#E-
SR8^EH+
M@S\>DJY#/&43JOBVH8H_&Y>X53)\+"S1&JAP!O^,TTET\O]02P,$% @ M
X%D63=$!MF&"@ +T\ !@ !T8VUD+3(P,C0P.3,P>&5X,S%D,2YH=&WM
*M7/]SVCH2_U=T=*Y-9S 82-H&TLRD";UF)DWZ$C+WWH_"%E@78?*
E),H3[ZV]7 MLL$0\DHOX)+7=)H$VROM%^U'NUI9'/W#\[IQ1.. A>1+
[^L%"660CEAL2 8 M-7!WPDU$>C)):$R^,J6X$.23XN&0$=+P:^]JC>9!S?*
>\XR/HZS1K).,V:33J M^_6FW]PG_D&[?];Y-
*M7LG?;.WUKJ<^N3GM_?.LZMM]N/UVNZY'9B3V MZT)*S6JA"2O'1W@'?*
C,:'A^-F$DB*C2S'RLW/8^>Q^ PG CV/%1/?_K:/LR MG!X?*
A7Q,M)D]K$RHFK(8_(I-WR$].!EG5XO$1S[TUX:*)VP_?_V4EH&/)X MZ*
DV,'"GUCR!=X &&2DPUD;+P!'7$Q;;_I M\1'3Y))-
*R+4J"FVD[XF'(8B!X_>I#TV]UCNI("*9)5I@G$(RJ=E^:J+-LJ54&*
MV(Q>AMT;CPH^A,Y1N9E>M59BB#__09;]E2Q/%<"&'QA8LP,#R@R X?*
*TBAPG MSG1]*4+HJ7L?@8D,:35JC:-ZWQGD)RA4'+8?*
U\DR/8">'FBXI@L\6>/#VDKV M!1L$,%7=IBWPTDP SIZ.J$!
MS!WM)HXTL"=;9%DY_G9[?7-[]$M3ZE&[4,).C5: MU&OL[]&W]
<9!Z#Z1J\^E#ET)6O:^E#IPS3\|:9[>GM]WCOOWI0YAY2B6O?W*
MTR\GE__ZVX'MY+17,KC>N^%Z_:KQSN]L=R(Y;.U7RU2M6<:
*E8@MR/G*T.CL MZENO>U:F6N]*3#M*U:N,J;#<-.I#28&KW,QW-*
*@UN5Z^6WRQUMBA#IW*CU4$I MB"HS%RPGO;TYN?YT851:M*H[E1?*
1JNJ_-J+OFF^ESR)\^OM6:SVV8Y ?XC M>$ N:N1,AN&V-?'S.E+

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|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|(]-!KY.:(;1LP^T'=>Z\.0]--/ [G7\. M4QJ&/)EY@DT-E+2ZAZLRQ6?1JE ZY0:*"6KX+OS)V:0RHF!;5IC(QWI3& M7"P&OXYYS#2Y8'-R)6.:_-IT)?!;,\6GOPYM;7'0[?2&1VVL"*9)UY@G$(RJP42: M:/C04NL,4(U>AMT9CPH^@\Y1N:5>K5YJ2&? U#X>ZB10A]#2ZB\!$AO3\5O>H/7$&J5VA_F.-RO/V_4K94?>AIPVG MO'(-UB)F/JZBI5-VNGH:GS^[OST9'Q^>6%GK:*N!3.@A:=3&@#W![V6OV]% M)U4.TCC^='WU^?KD8ERCZ)V67X?DX\M:97Y=B[FOKC^,ZD1)'3+*

[/>KY_3WZ MLNWOA^ZO>M%2B^4OW]4J]&$M0H_?
*UXD6OU6+T)]'I]=7Y^/ST><=7]'OY^^*
M/[GX5ZTDQ2BB>LE/3BM=Q'>+@'X]-
O4/>_UFK>M&KQ84G]1)O4[KH!ZASRX_MC4=GN^8>?T $58O<-
<=/]3A$\"TU!]IUH;O7Z=:Z_O5W,&BJ)\:N-V@"9-<" M[).KMR<7H_>Y>\?
*1G_4*G\M2*DX^G@,[]U+"FK)>KN=3M6;0U_;W*I@*^@*
*M>GJDR(_:&SJT*4YI<^@_F39\NOC*3N5?5--W79TW"_FKZO,1?U\5N*IV',A]*
M!.4)(Q];Y"U7-RQF"Z;J5L=O=??KTB=@"N>Z]@GIUZ:!B:@95+]96CGX#S;?
M[C5T(AB92!4R]:;1:9" "9&?<"RO<]O:ZUPRU\(+I! TU6Q0_#&LP!+>1!HC
MXX'?717AP8G=6$9Y/4$7,C.#;]CX;KEI'0NX00MC&L4_L+)?)J!_E9D G+ M-*
Y]B>T1Z0$4NE140%!C.(VZ812H;)'*N:#HLB9!;/1?5;ST4Z/[]RF#M+K$?
*MD$G%5-QS#WD1K*0DHK>,*';+V9R%Q$1 M;T1.R9@&A@/*
/B^T8;$F8Q9$B11RMFB2\R1HK;"(NK9Q>MIVBI^163DRK1Y5 M0+.
[9=!\2[4]KR;Q@MR \(%,]9T"%4.EZ&$V4ZD(0%T &Z5T&1!LL2HC(&@*
M%+")Y^4 6IBN(QR12P2Z0B,N:&&.GJ/:J0L(!I3=4"J\3TAL&XI3XUE(4@
*M# PI4&H< RL$7 59#-42: Z2 !((S$$0$9WACU7[.5,L[P05B+D6C**UW;&^*
M8CIE@140^TU!-!F"FC#18)3)HFR&9[;M(-MZN\(V1J8\ 3PC-5;X;0+5H#K<
M5J7[/)EB?_C /P=B"R$/H$C); V@5\<74L$$=V(FN%6-$O1[Y^,#0P/+1/*
M(C2Q1B:@ G!. C'L<-K$U =D:F0*4+81Y)*
*MNZ/4ZOS,S.IO&;/&]V#XRXO>X5#GS,ES)USUY73*X=+"\YQ0Q2P1 -@<80:*
M)4SC''(=876L%H/'0Z^'UR'7@9 Z@W;H"Y44CA&ID@$+H5B3/2! R(!1#N6C
MNR"BR8R1$W S5YF &O8,>G^/O;1-[3DT7KE+CL]])(Z)V#]!7U0BJ",,RK+Q
M0--[TUA(-3S(6VA!L:H@R]3,0VZ M '9MR/9M8C4QF@QHIC=O@F'=A
%)\I%W%8N MLNQFW7-*
YP+H\4EPQIYF[8+S)P5V"+%H'MK'0'4VT3SD5'%4@+MXUCK^!'O* M-*
*,:8=I'2-B"U;E%J!@(9<,/8**4X]YF@Z,U!+2O$*E:%%B[R+0?L\->$845P MN-*
*>0+V;#O;G9NQDJQF[L:-Z1-S-7=S&_7.W_(0:4FU3"RBJ09*8X*(7*4J*
M+'@#3.;4[>UA]+IN6%Q%+,4L>]P"<]J*<&T(<-=KE":J138JVVT'00 /"N*
*M335G+($@6@")X0Y+<77 *I!&.Z+"*L)3\-K/5-U!J@9;1M71+169]4"(8S:=*
*M0JK';P&!>DW*EL?*&_A3=[D^A[.\A(;@"[7+%"?Q./3Y>U&:;!TV]O*
MTI!)D6#;I88Y.X \0^Q\-ZGU8]+,+656N&7,.G.P?0Q_W!/-,S![9PW#OL/Q M82
J@R!3"/%2U/>HSUAJ Z7XG@#TI,':Y$]WKD#VUC:8 D_!'3VHFXL< 'OL
M1B[N\2;94J:73J(ZF5XC([,\IJ%UL-;2^3>=T$$OV$BW]5]4+_Y1.-\@\F[*
MGJ7^U)M^UO&]K^RJ61/^L)BF6BN/!(ZR#)=5\X)*?<=\?2C'#07C$(6:J32*
*MRP#6%D"'<R+KG\B(4#&NR$'V6P7>T!I\+0:/3G\QDRX6(/8GQD'T>V**
MDR6!W1=^^;QO]'_J@+=MW^A$0/X%VG#@'&YOM7BMHW7^#H:0D/-
*EJ[N"S3-LT]H &P#7#1=T*LA MXM59#$@#FUA5\M!B[-/]^D9![8WXZH1&*
(N1OMN-[YVADF+P';]$;57295_5S:BUQ^A#]
MLD#Y/O10,DH)SV2_5;RPO)_JUV>J-)(..-XI%S8HKCVD$V#"2RW-]X<=/WF
*MMP*6]^E$2Y$9-*
*BS6F#J^&E#]H[>;/WWH,)W_O+^D/$_5ED^57;KN>ZV*YFRK*
MC+6I>;X#O?F"5\3FZ1VQQVWD1IY66%-:%,?]FQ@\7<";R/3/N$UG?
*5V+=XJ7PO*R6Z M\OY+0GZ%+PG5 +=MLDMU"]MIQ-F4O%L&]Y=N]VS-*
NE:$]KL;O&^5S(WC,\CH M!N0" K9X
@E6_\DO^32.FP2_<+;Y9Z_*^P#;\"VO)X=ST3)OFM#@9J9DEH28
MCDDU#Q#R0#W;^0B=A^*7-BI_.&TO.C>=],>?AY MB5\?MOK^TH>YLH[-*
C=VWWNS'XX[_!U!+ P04 " #@619J1QDCF8& I M) & '1C;60M,C R-#
*Y,S!X97@S,F0Q+FAT;>U:>U,;-Q#_*EMGVL", M[^5' F?C&*
*<>8"3,$"#ZF[9_R2>=3(Y^N.AGC?OJN[F'.+M/08@ADPH#AI-6^*
*MM/O3:KG^3Y8U3F*2A(S"Q^#3&5 9+N8LT1 J1C2.+KF.(9!I2A+XQ)3B0L '*
MQ>F, 7BN_<[V6EW;M:Q!'WF-RD4R\<'SG([3WG]X>QT! W+

*<7YMCQSG.#@N)CJVZT&@2))QS65"A..,SQO0 MB+5.?<=9+I?VLFU+-7."*R?*
*6<]%QA)09LZFFC4'?C. G(W30GS--((R)RI@^*
M:EP')]8!4FBN!1OTG>IW03N5=#7H4WX#F5X)=M28$S7CB:5EZK?
=5/=PI8/3 M6S2WUI)3'?N>Z_[<2PFE/)E9@D4:1^S6X=V8XK/X;E
6QOF":+Y#3/<_T5V M3082IA59)!-M163.Q%*SDGRMEF,X.^,*1Z][>74&?^+*
*(2/D M*7C"K)CE:KFV^[Y7"/5+6PUU)>>&9WS*!=V/76?*
W9CEV:WVB"SY"Y,6[+KNF]0H:*XL/S)QPS0/*
MB6&/(6C592P+9TVEH,AI?!NC4S2T6[;7=Z:%"Y[%A/K6/,Z!V[LSJT*$6^8*
MVMW.%$(\Y'//1HW&5\'IR>EH&)Q>G"/N7$VNA^/5A>#Z>6!>_
*MG8U_A^$H,#,MUVWMV.8=9>.W2KX_%IGFT:H8X@D*UG[[W>*
[L:@Q.$PAEDK#0 M0'Q13^B8P><%41@A8@57+)5*8]$)U+-L:JP/H.,
(""X0C"8K#+-YAD$+(P3 M>1LU833)+1AS[Q/FJYO9&*
<8X6RRI^|WCY$4N524M1"4F!H&(4)2Y'3E"EH MNTTPM4D32
812J%WBDU8N%!X'J%'24)A?(LU0X+E#HJ8\RPS1N"WH:18[$#, M%$-
MZ\H4!E6Z-'/:!6J@,O0XHTV8X"(.9S8<2XJ/HYBS" 6A8'/ZP444\1"U
M1+9F:6E;,QOX5?HZQR]C(:$R-759G;PB,CE3 M"IH0-24)RZR+6\%6,
RUF3$Y8VP@^3+4 ;XDCNPW<(22 MMT9=2Y"57&@_XK>,WI?
**M@M8ZZ99;S)?(P@1=)*U0-<57J]U'7/V]]6:9/@D77/G;;%H^&#*
M2JDY$1L'3#G4&)C*($J6@A$K1"S4AB06
.'8G\NN&+F^I29Q+E+PSVR#PA(M7G>/[J^3[0YFUA!39IQWV.
[T#/BL0]5XPC';Y^0AL/MD@^JGVWFD>\N0S6\]
*M>33\R,37G8FM%YB)/(G,8YY>6%QH@M=7BJ-03U/"3761*I:9C&R::2($X#)F*
*M%,-\S5),T:PXH".>D"0TX\B0YO?1_/Q'JH4H$EIB-9'+S+:.9OOY$O7U%)D_*
M=/X>=38-G1Q-CAH&XAL510%^)A8+PX8=RT<,K/S?/@!_>?W[OYP?+9NFP
*MHVUXC4CT7P*RA*6RGO/26\!PX!3>N/G7-_84?T3UE)=+7*/1(;)R,J?O\-UQ*
M%$QCL625=;?OV:UNKC+L5$ICL-
$0R7FO=_@%!_VAW;VO'[G+_OQ6=;Q9"S]=
MHAB4_*99\B#7/KJ=O.W7JIV\&8W3UQ&-&\!B>[4[_0L$Y)?DE]W!6-[(?4H
M=FWW:0#X'\WG>T"XNM(6%G<&!P3S7PXQR([_](IU+U$2R+ M_ZX_'6
>K?M);SC\.AZ/5Y?7Z\];E?C+EY&[)X!R9_ MJ6;P-U!+ P04 " #@619OU>
(WD<& #I(@ & '1C;60M,C R-# Y
*M,S!X97@S,F0R+FAT;>U:>T_C1A#_*M.'<]K9WXSGKC_DV&,XXC$/@W@LW?*
*Q M!0+A+QV19I]YIOM$Q;0<\2>*4*29BPBUK?-F*
1J14XEK6:K4R5VU3R+GE75N1
*M6O".Q85(J1FHH#'HZQ7\34DPZ"^H(N!'1*94G31NO#/C""D44YP.^E;Y-Z>=*
MB6]Z ?
*L#E*UYO2DL2!RSF)#B<1MVXGJX9T6;F_1W!LK%JC(=6S[YUY"@H#% M*
*M6] 4+ND*KL6"Q.^;^0K^3:EDX?M>1IVR/RDR0IZ[E0M[!5*
*M4Y=R[EC*9HPSM78C%@0T1H)?*
WAVU[':O;VE"=$VRPST^IT2Z,Z&BWK:G=CG@ MV78=FUU4/KM>Y8;-!
]ZBMXK@W V1W%Z=6.I^2%18#_\:"5F.Y482D8XBOQ,
M^1U5S"=:/(:HL=NW?U.A,1C?1^A#!>V6V>I;L]QC+V7Q]PRL'FQ=-
L9"+@CO M/3%.7N&CH7<^N428NY[>#"\]\";@',&-.35' M)DS'HVS7:7?
MYHM'PW[X93B%X>GDRAN?5IWR/S&^//!C^P-,SL#[/(;I\/K3 M\'(\-2:_?
*1E_@^'(TSLMVWZ#ASK*6^7+X&JYI(J3"+@G.T!?81AE?083@$;R#4YBN*
*M4T47*7C4CV+!Q7S=A//8-^% L]$^:MF]D5A@2[;.KIS>(81"9E(2U$($0-&P*
*M *8T04XS*J%M-*
T$W8TT@*80H)7A0;$K]I<0"C!XE<0#C>VR28NSO4,2"I:DV M
*K\U98#='4144M2VJDQN4*E+,Z-=H@8R18_3H EC3K#!@ L3/C%Y2Q=T3643*
M1A&C(9RQ&!M0="I,PI#YJ"QRUQP$YN9Q-D:<*
*M/#M5L0K*4Z9+@"2E1!=+" MY1F0:D-)(!+=CU;)2R*=?(6@*9SM/4F-*

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end XML 82 tcmd-20240930x10q_htm.xml IDEA: XBRL DOCUMENT 0001027838 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001027838 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001027838 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001027838 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001027838 us-gaap:RetainedEarningsMember 2024-09-30 0001027838 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001027838 us-gaap:RetainedEarningsMember 2024-06-30 0001027838 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001027838 us-gaap:RetainedEarningsMember 2023-12-31 0001027838 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001027838 us-gaap:RetainedEarningsMember 2023-09-30 0001027838 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001027838 us-gaap:RetainedEarningsMember 2023-06-30 0001027838 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001027838 us-gaap:RetainedEarningsMember 2022-12-31 0001027838 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001027838 2024-06-30 0001027838 2023-06-30 0001027838 us-gaap:CommonStockMember 2024-09-30 0001027838 us-gaap:CommonStockMember 2024-06-30 0001027838 us-gaap:CommonStockMember 2023-12-31 0001027838 us-gaap:CommonStockMember 2023-09-30 0001027838 us-*

gaap:CommonStockMember 2023-06-30 0001027838 us-gaap:CommonStockMember 2022-12-31 0001027838 us-gaap:IPOMember 2016-08-02 0001027838 tcmd:FollowOnPublicOfferingMember 2023-02-27 0001027838 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001027838 us-gaap:EmployeeStockOptionMember 2023-12-31 0001027838 us-gaap:EmployeeStockOptionMember 2023-09-30 0001027838 tcmd:EquityIncentivePlan2016Member 2024-01-01 2024-01-01 0001027838 tcmd:TimeBasedRestrictedStockUnitsRsusMember tcmd:EquityIncentivePlan2016Member 2023-12-31 0001027838 tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember tcmd:EquityIncentivePlan2016Member 2023-12-31 0001027838 tcmd:TwoThousandTwentyThreePsuMember tcmd:EquityIncentivePlan2016Member us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-01-01 2024-09-30 0001027838 tcmd:TwoThousandTwentySixPsuMember tcmd:EquityIncentivePlan2016Member us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-01-01 2024-09-30 0001027838 tcmd:TwoThousandTwentyFourPsuMember tcmd:EquityIncentivePlan2016Member us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-01-01 2024-09-30 0001027838 tcmd:TwoThousandTwentyFivePsuMember tcmd:EquityIncentivePlan2016Member us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-01-01 2024-09-30 0001027838 srt:MinimumMember tcmd:TimeBasedRestrictedStockUnitsRsusMember tcmd:EquityIncentivePlan2016Member 2024-01-01 2024-09-30 0001027838 srt:MaximumMember tcmd:TimeBasedRestrictedStockUnitsRsusMember tcmd:EquityIncentivePlan2016Member 2024-01-01 2024-09-30 0001027838 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001027838 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001027838 tcmd:TimeBasedRestrictedStockUnitsRsusMember 2024-01-01 2024-09-30 0001027838 tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember 2024-01-01 2024-09-30 0001027838 tcmd:VeteransAdministrationMember 2024-07-01 2024-09-30 0001027838 tcmd:PrivateInsurersMember 2024-07-01 2024-09-30 0001027838 tcmd:MedicareMember 2024-07-01 2024-09-30 0001027838 tcmd:DurableMedicalEquipmentDistributorsMember 2024-07-01 2024-09-30 0001027838 tcmd:VeteransAdministrationMember 2024-01-01 2024-09-30 0001027838 tcmd:PrivateInsurersMember 2024-01-01 2024-09-30 0001027838 tcmd:MedicareMember 2024-01-01 2024-09-30 0001027838 tcmd:DurableMedicalEquipmentDistributorsMember 2024-01-01 2024-09-30 0001027838 tcmd:VeteransAdministrationMember 2023-07-01 2023-09-30 0001027838 tcmd:PrivateInsurersMember 2023-07-01 2023-09-30 0001027838 tcmd:MedicareMember 2023-07-01 2023-09-30 0001027838 tcmd:DurableMedicalEquipmentDistributorsMember 2023-07-01 2023-09-30 0001027838 tcmd:VeteransAdministrationMember 2023-01-01 2023-09-30 0001027838 tcmd:PrivateInsurersMember 2023-01-01 2023-09-30 0001027838 tcmd:MedicareMember 2023-01-01 2023-09-30 0001027838 tcmd:DurableMedicalEquipmentDistributorsMember 2023-01-

01 2023-09-30 0001027838 tcmd:TermLoanMember 2023-08-01 2023-08-01 0001027838 tcmd:FollowOnPublicOfferingMember 2023-02-27 2023-02-27 0001027838 2023-11-28 2023-11-28 0001027838 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001027838 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001027838 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001027838 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001027838 2024-09-04 2024-09-04 0001027838 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember 2023-08-01 2023-08-01 0001027838 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember 2023-08-01 2023-08-01 0001027838 us-gaap:RevolvingCreditFacilityMember 2021-09-08 0001027838 srt:MinimumMember us-gaap:EquipmentMember 2024-09-30 0001027838 srt:MinimumMember us-gaap:BuildingMember 2024-09-30 0001027838 srt:MaximumMember us-gaap:EquipmentMember 2024-09-30 0001027838 srt:MaximumMember us-gaap:BuildingMember 2024-09-30 0001027838 srt:MinimumMember 2024-09-30 0001027838 us-gaap:EquipmentMember 2024-01-01 2024-09-30 0001027838 us-gaap:TradeNamesMember 2024-09-30 0001027838 us-gaap:PatentsMember 2024-09-30 0001027838 us-gaap:TradeNamesMember 2023-12-31 0001027838 us-gaap:PatentsMember 2023-12-31 0001027838 tcmd:AfflovestPMember 2021-09-30 0001027838 us-gaap:PatentsMember 2024-09-30 0001027838 us-gaap:DevelopedTechnologyRightsMember 2024-09-30 0001027838 us-gaap:CustomerRelationshipsMember 2024-09-30 0001027838 us-gaap:CustomerContractsMember 2024-09-30 0001027838 tcmd:DefensiveIntangibleAssetsMember 2024-09-30 0001027838 us-gaap:PatentsMember 2023-12-31 0001027838 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0001027838 us-gaap:CustomerRelationshipsMember 2023-12-31 0001027838 us-gaap:CustomerContractsMember 2023-12-31 0001027838 tcmd:DefensiveIntangibleAssetsMember 2023-12-31 0001027838 us-gaap:EmployeeStockOptionMember 2024-09-30 0001027838 tcmd:TimeBasedRestrictedStockUnitsRsusMember tcmd:EquityIncentivePlan2016Member 2024-09-30 0001027838 tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember tcmd:EquityIncentivePlan2016Member 2024-09-30 0001027838 tcmd:DefinedContribution401kRetirementPlanMember 2024-07-01 2024-09-30 0001027838 tcmd:DefinedContribution401kRetirementPlanMember 2024-01-01 2024-09-30 0001027838 tcmd:DefinedContribution401kRetirementPlanMember 2023-07-01 2023-09-30 0001027838 tcmd:DefinedContribution401kRetirementPlanMember 2023-01-01 2023-09-30 0001027838 us-gaap:RevolvingCreditFacilityMember 2023-12-21 2023-12-21 0001027838 tcmd:TermLoanMember 2024-01-01 2024-09-30 0001027838 tcmd:TermLoanMember 2021-09-08 0001027838 tcmd:TermLoanMember 2024-09-30 0001027838 us-gaap:RevolvingCreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-01 2024-09-30 0001027838 us-gaap:RevolvingCreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrMember 2023-08-01 2023-08-01 0001027838 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrMember 2023-06-21 2023-06-

21 0001027838 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2023-06-21 2023-06-21 0001027838 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrMember 2023-06-21 2023-06-21 0001027838 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2023-06-21 2023-06-21 0001027838 us-gaap:RevolvingCreditFacilityMember us-gaap:FederalFundsEffectiveSwapRateMember 2023-06-21 2023-06-21 0001027838 us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2023-06-21 2023-06-21 0001027838 us-gaap:SecuredOvernightFinancingRateSofrMember 2023-06-21 2023-06-21 0001027838 2023-06-21 2023-06-21 0001027838 us-gaap:ProductMember 2024-07-01 2024-09-30 0001027838 tcmd:RentalProductServiceMember 2024-07-01 2024-09-30 0001027838 us-gaap:ProductMember 2024-01-01 2024-09-30 0001027838 tcmd:RentalProductServiceMember 2024-01-01 2024-09-30 0001027838 us-gaap:ProductMember 2023-07-01 2023-09-30 0001027838 tcmd:RentalProductServiceMember 2023-07-01 2023-09-30 0001027838 us-gaap:ProductMember 2023-01-01 2023-09-30 0001027838 tcmd:RentalProductServiceMember 2023-01-01 2023-09-30 0001027838 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember tcmd:VendorOneMember 2024-07-01 2024-09-30 0001027838 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember tcmd:VendorOneMember 2024-01-01 2024-09-30 0001027838 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember tcmd:VendorOneMember 2023-07-01 2023-09-30 0001027838 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember tcmd:VendorOneMember 2023-01-01 2023-09-30 0001027838 us-gaap:EmployeeStockMember 2024-09-30 0001027838 us-gaap:EmployeeStockMember 2024-01-01 0001027838 us-gaap:EmployeeStockMember 2016-04-27 0001027838 2023-09-30 0001027838 2022-12-31 0001027838 us-gaap:FairValueInputsLevel3Member 2023-09-30 0001027838 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001027838 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-09-30 0001027838 tcmd:CorporateHeadQuarterSecondLeaseMember 2018-12-31 0001027838 tcmd:CorporateHeadQuarterInitialLeaseMember 2018-10-31 0001027838 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001027838 us-gaap:PerformanceSharesMember 2024-07-01 2024-09-30 0001027838 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001027838 tcmd:EmployeeStockPurchasePlanMember 2024-07-01 2024-09-30 0001027838 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001027838 us-gaap:PerformanceSharesMember 2024-01-01 2024-09-30 0001027838 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001027838 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001027838 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001027838 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001027838 us-gaap:PerformanceSharesMember 2023-01-01 2023-09-30 0001027838 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001027838 tcmd:TimeBasedRestrictedStockUnitsRsusMember

tcmd:EquityIncentivePlan2016Member 2024-07-01 2024-09-30 0001027838 tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember tcmd:EquityIncentivePlan2016Member 2024-07-01 2024-09-30 0001027838 us-gaap:SellingAndMarketingExpenseMember 2024-07-01 2024-09-30 0001027838 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001027838 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001027838 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001027838 us-gaap:EmployeeStockMember 2024-07-01 2024-09-30 0001027838 us-gaap:CostOfSalesMember 2024-07-01 2024-09-30 0001027838 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-09-30 0001027838 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001027838 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001027838 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001027838 us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0001027838 tcmd:TimeBasedRestrictedStockUnitsRsusMember tcmd:EquityIncentivePlan2016Member 2023-07-01 2023-09-30 0001027838 tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember tcmd:EquityIncentivePlan2016Member 2023-07-01 2023-09-30 0001027838 us-gaap:SellingAndMarketingExpenseMember 2023-07-01 2023-09-30 0001027838 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001027838 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001027838 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001027838 us-gaap:EmployeeStockMember 2023-07-01 2023-09-30 0001027838 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0001027838 tcmd:TimeBasedRestrictedStockUnitsRsusMember tcmd:EquityIncentivePlan2016Member 2023-01-01 2023-09-30 0001027838 tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember tcmd:EquityIncentivePlan2016Member 2023-01-01 2023-09-30 0001027838 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-09-30 0001027838 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001027838 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001027838 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001027838 us-gaap:EmployeeStockMember 2023-01-01 2023-09-30 0001027838 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0001027838 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001027838 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001027838 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001027838 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001027838 srt:MinimumMember tcmd:TwoThousandTwentyFourPsuMember tcmd:EquityIncentivePlan2016Member 2024-01-01 2024-09-30 0001027838 srt:MinimumMember tcmd:TwoThousandTwentyFivePsuMember

tcmd:EquityIncentivePlan2016Member 2024-01-01 2024-09-30 0001027838 srt:MinimumMember tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember tcmd:EquityIncentivePlan2016Member 2024-01-01 2024-09-30 0001027838 srt:MaximumMember tcmd:TwoThousandTwentyFourPsuMember tcmd:EquityIncentivePlan2016Member 2024-01-01 2024-09-30 0001027838 srt:MaximumMember tcmd:TwoThousandTwentyFivePsuMember tcmd:EquityIncentivePlan2016Member 2024-01-01 2024-09-30 0001027838 srt:MaximumMember tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember tcmd:EquityIncentivePlan2016Member 2024-01-01 2024-09-30 0001027838 tcmd:TwoThousandTwentyThreePsuMember tcmd:EquityIncentivePlan2016Member 2024-01-01 2024-09-30 0001027838 tcmd:TimeBasedRestrictedStockUnitsRsusMember tcmd:EquityIncentivePlan2016Member 2024-01-01 2024-09-30 0001027838 tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember tcmd:EquityIncentivePlan2016Member 2024-01-01 2024-09-30 0001027838 tcmd:EquityIncentivePlan2016Member 2024-09-30 0001027838 srt:MinimumMember 2024-01-01 2024-09-30 0001027838 srt:MaximumMember 2024-01-01 2024-09-30 0001027838 tcmd:LymphedemaProductsMember 2024-07-01 2024-09-30 0001027838 tcmd:AirwayClearanceProductsMember 2024-07-01 2024-09-30 0001027838 tcmd:LymphedemaProductsMember 2024-01-01 2024-09-30 0001027838 tcmd:AirwayClearanceProductsMember 2024-01-01 2024-09-30 0001027838 tcmd:LymphedemaProductsMember 2023-07-01 2023-09-30 0001027838 tcmd:AirwayClearanceProductsMember 2023-07-01 2023-09-30 0001027838 tcmd:LymphedemaProductsMember 2023-01-01 2023-09-30 0001027838 tcmd:AirwayClearanceProductsMember 2023-01-01 2023-09-30 0001027838 tcmd:VendorOneMember 2024-09-30 0001027838 tcmd:VendorOneMember 2023-09-30 0001027838 tcmd:WeaverLawsuitMember 2024-05-24 0001027838 2021-09-08 2021-09-08 0001027838 us-gaap:IPOMember 2016-08-02 2016-08-02 0001027838 us-gaap:EmployeeStockMember 2024-01-01 2024-09-30 0001027838 tcmd:TermLoanMember 2022-02-22 2022-02-22 0001027838 2021-09-08 0001027838 2023-05-25 2023-05-25 0001027838 2023-07-01 2023-09-30 0001027838 2023-01-01 2023-09-30 0001027838 tcmd:CorporateHeadQuarterThirdLeaseMember 2019-12-31 0001027838 tcmd:CorporateHeadQuarterSecondLeaseMember 2019-12-31 0001027838 2024-09-30 0001027838 2023-12-31 0001027838 us-gaap:RevolvingCreditFacilityMember us-gaap:SubsequentEventMember 2024-11-01 0001027838 us-gaap:SubsequentEventMember 2024-10-30 0001027838 2024-07-01 2024-09-30 0001027838 2024-10-31 0001027838 2024-01-01 2024-09-30 shares iso4217:USD utr:sqft pure tcmd:item iso4217:USD shares 23997089 P1Y P3Y P7Y 23600584 0 0 http://fasb.org/us-gaap/2024#OperatingLeaseRightOfUseAsset http://fasb.org/us-gaap/2024#OperatingLeaseRightOfUseAsset http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent

http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent 0001027838 --12-31 2024 Q3 false P3M 0.3333 0.3333 P1Y 0.3333 0.3333 0.3333 P1Y10M24D 10-Q true 2024-09-30 false 001-37799 Tactile Systems Technology, Inc. DE 3701 Wayzata Blvd, Suite 300 41-1801204 Minneapolis MN 55416 612 355-5100 Common Stock, Par Value $0.001 Per Share TCMD NASDAQ Yes Yes Accelerated Filer false false false 23997089 82146000 61033000 39970000 43173000 13953000 14195000 21176000 22527000 5127000 4366000 162372000 145294000 5878000 6195000 17553000 19128000 43708000 46724000 31063000 31063000 3628000 10936000 19719000 19378000 3803000 2720000 125352000 136144000 287724000 281438000 7290000 6659000 2956000 2956000 13086000 16789000 7088000 5904000 611000 1467000 2883000 2807000 3240000 4475000 37154000 41057000 23959000 26176000 1448000 1681000 495000 446000 16767000 18436000 42669000 46739000 79823000 87796000 0.001 0.001 50000000 50000000 0 0 0.001 0.001 300000000 300000000 23997089 23600584 24000 24000 181739000 174724000 26138000 18894000 207901000 193642000 287724000 281438000 63168000 58866000 180742000 171459000 9925000 10720000 26657000 25312000 73093000 69586000 207399000 196771000 15603000 17016000 46810000 48523000 2703000 3211000 8270000 9122000 18306000 20227000 55080000 57645000 47565000 41850000 133932000 122936000 7222000 7509000 18387000 16190000 54787000 49359000 152319000 139126000 26838000 26030000 82803000 80538000 2417000 1964000 6794000 6030000 18118000 16449000 51158000 46874000 633000 -3073000 1898000 -557000 48006000 41370000 142653000 132885000 6781000 7989000 9666000 6241000 452000 -404000 832000 -2235000 7233000 7585000 10498000 4006000 2078000 -14714000 3254000 -16307000 5155000 22299000 7244000 20313000 0.21 0.95 0.30 0.89 0.21 0.94 0.30 0.88 23985364 23483269 23842049 22714574 24254176 23848729 24070084 22987667 23966748 24000 179669000 20983000 200676000 2070000 2070000 30341 5155000 5155000 23997089 24000 181739000 26138000 207901000 23600584 24000 174724000 18894000 193642000 5969000 5969000 288598 2000 2000 107907 1044000 1044000 7244000 7244000 23997089 24000 181739000 26138000 207901000 23458302 23000 170347000 -11607000 158763000 1766000 1766000 39255 2000 2000 22299000 22299000 23497557 23000 172115000 10692000 182830000 20252677 20000 131001000 -9621000 121400000 5597000 5597000 249064 13000 13000 2875000 3000 34622000 34625000 120816 882000 882000 20313000 20313000 23497557 23000 172115000 10692000 182830000 7244000 20313000 5079000 4916000 -341000 -20717000 5969000 5597000 -308000 -3000 2475000 -3203000 -10947000 -242000 -2527000 -1351000 374000 807000 99000 1844000 369000 18000 -292000 -7308000 -8425000 582000 -3622000 -3703000 -2316000 -251000 -5545000 24322000 17503000 1932000 1424000 12000 85000 117000 -2005000 -1541000 8250000 5000000 2250000 2250000 8250000 125000 2000 13000 1044000 882000 34625000 -1204000 28145000 21113000 44107000 61033000 21929000 82146000 66036000 1612000 2810000 4428000 3006000 49000 40000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-

family:'Arial','Helvetica','sans-serif';font-weight:bold;">Note 1. Nature of Business and Operations Tactile Systems Technology, Inc. (“we,” “us,” “our,” and the “Company”) manufactures and distributes medical devices for the treatment of patients with underserved chronic diseases at home. We provide our Flexitouch® Plus and Entre™ Plus systems, which help control symptoms of lymphedema, a chronic progressive medical condition, through our direct sales force for use in the home following receipt of prescriptions from vascular, wound and lymphedema clinics throughout the United States. On September 8, 2021, we acquired the assets of the AffloVest airway clearance business (“AffloVest Acquisition”). AffloVest is a portable, wearable vest that treats patients with chronic respiratory conditions. We sell this device through home medical equipment and durable medical equipment (“DME”) providers throughout the United States. We were originally incorporated in Minnesota under the name Tactile Systems Technology, Inc. on January 30, 1995. During 2006, we established a merger corporation and subsequently, on July 21, 2006, merged with and into this merger corporation, resulting in our reincorporation as a Delaware corporation. The resulting corporation assumed the name Tactile Systems Technology, Inc. In September 2013, we began doing business as “Tactile Medical”. On August 2, 2016, we closed the initial public offering of our common stock, which resulted in the sale of 4,120,000 shares of our common stock at a public offering price of $10.00 per share. We received net proceeds from the initial public offering of approximately $35.4 million, after deducting underwriting discounts and approximately $2.9 million of transaction expenses. On February 27, 2023, we closed on a public offering of 2,875,000<span style="font-

family:'Arial','Helvetica','sans-serif';"> shares of our common stock at a public offering price of $13.00 per share. We received net proceeds from this offering of $34.6 million after deducting underwriting discounts, commissions, and offering expenses. Our business is affected by seasonality. In the first quarter of each year, when most patients have started a new insurance year and have not yet met their annual out-of-pocket payment obligations, we experience substantially reduced demand for our products. We typically experience higher revenue in the third and fourth quarters of the year when patients have met their annual insurance deductibles, thereby reducing their out-of-pocket costs for our products, and because patients desire to exhaust their flexible spending accounts at year end. This seasonality applies only to purchases and rentals of our products by patients covered by commercial insurance and is not relevant to Medicare, Medicaid or the Veterans Administration, as those payers either do not have plans that have declining deductibles over the course of the plan year and/or do not have plans that include patient deductibles for purchases or rentals of our products. 4120000 10.00 35400000 2900000 2875000 13.00 34600000 Note 2. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. The results for the nine months ended September 30, 2024, are not necessarily indicative of results to be expected for the year ending December 31, 2024, or for any other interim period or for any future year. The condensed consolidated interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023. <span style="font-

family:'Arial','Helvetica','sans-serif';font-style:italic;font-weight:bold;">Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Tactile Systems Technology, Inc. and its wholly owned subsidiary, Swelling Solutions, Inc. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and to disclose contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. The results for the nine months ended September 30, 2024, are not necessarily indicative of results to be expected for the year ending December 31, 2024, or for any other interim period or for any future year. The condensed consolidated interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023. Principles of Consolidation <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements include the accounts of Tactile Systems Technology, Inc. and its wholly owned subsidiary, Swelling Solutions, Inc. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and to disclose contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Note 3. Summary of Significant Accounting Policies Significant Accounting Policies There were no material changes in our significant accounting policies during the nine months ended September 30, 2024. See Note 3 – “Summary of Significant Accounting Policies” to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023, for information regarding our significant accounting policies. Accounting Pronouncement Not Yet Adopted In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures” which requires entities to enhance disclosures around segment reporting. The guidance is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its consolidated financial statements and related disclosures. <span style="font-

family:'Arial','Helvetica','sans-serif';">In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” which requires entities to enhance disclosures around income taxes. The guidance is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its consolidated financial statements and related disclosures. Accounting Pronouncement Not Yet Adopted In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures” which requires entities to enhance disclosures around segment reporting. The guidance is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” which requires entities to enhance disclosures around income taxes. The guidance is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its consolidated financial statements and related disclosures. Note 4. Inventories Inventories consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.42%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0.05pt 0pt

0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:40.42%;background:#cceeff;margin:0pt;padding:0pt;"> Finished goods </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 7,022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:25.34%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';"> 7,979</p></td></tr><tr>
<td style="vertical-align:bottom;width:40.42%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';">Component parts and work-in-
process</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt
0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-
serif';visibility:hidden;"></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span
style="font-family:'Arial','Helvetica','sans-serif';"> </p></td><td
style="vertical-align:bottom;white-space:nowrap;width:25.36%;border-
bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-
align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';"> 14,154</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt
0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-
serif';visibility:hidden;"></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span
style="font-family:'Arial','Helvetica','sans-serif';"> </p></td><td
style="vertical-align:bottom;white-space:nowrap;width:25.34%;border-
bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-
align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';"> 14,548</p></td></tr><tr>
<td style="vertical-
align:bottom;width:40.42%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';">Total inventories</p></td>
<td style="vertical-align:bottom;white-
space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';visibility:hidden;"></p></td>
<td style="vertical-align:bottom;white-
space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span
style="font-family:'Arial','Helvetica','sans-serif';">$</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:25.36%;background:#cceeff;border-bottom:3px double
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">21,176 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:25.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 22,527 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.36%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:40.42%;background:#cceeff;margin:0pt;padding:0pt;">

Finished goods </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 7,022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:25.34%;background:#cceeff;margin:0pt;padding:0pt;"> 7,979 </td></tr><tr><td style="vertical-align:bottom;width:40.42%;margin:0pt;padding:0pt;"> Component parts and work-in-process </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,154 </td><td

style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,548 </td></tr><tr><td style="vertical-align:bottom;width:40.42%;background:#cceeff;margin:0pt;padding:0pt;"> Total inventories </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 21,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:25.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 22,527 </td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-

indent:36pt;background:#ffffff;margin:0pt;"> 7022000 7979000 14154000 14548000 21176000 22527000 Note 5. Goodwill and Intangible Assets Goodwill In the third quarter of fiscal 2021, we completed the AffloVest Acquisition. The purchase price of the AffloVest product line exceeded the net acquisition-date estimated fair value amounts of the identifiable assets acquired and the liabilities assumed by $31.1 million, which was assigned to goodwill. Intangible Assets Our patents and other intangible assets are summarized as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';font-

size:8pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"> Gross </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> Amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"> Carrying </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"> Accumulated </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"> Net </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">Period </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amount </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amount </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Definite-lived intangible assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> Patents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"> 12 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"> 310 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';"> 838 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Defensive intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> 1 year </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 1,125 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 1,029 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';visibility:hidden;"> </td>
<td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> 96 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> Customer accounts </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"> 125 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"> 125 </td><td

style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Customer relationships </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> 10 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 31,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';visibility:hidden;"> </td>
<td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 7,299 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td>
<td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> 23,701 </td></tr><tr>
<td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> Developed technology </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td>
<td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"> 8 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 13,000 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,618 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,382 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Subtotal </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td>

<td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 46,398 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 12,381 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> 34,017 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> Unamortized intangible assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Tradenames </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td>

<td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 9,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> 9,500 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';">Patents pending </td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;">
</td>
<td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;">
</td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;">
</td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 191 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;">
</td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;">
</td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">

* </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 191 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Total intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 56,089</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,381 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> <span style="font-family:'Arial','Helvetica','sans-*

serif';visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 43,708 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-

word;position:relative;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-

align:center;margin:0.05pt 0pt 0.05pt 0pt;">Gross </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> Amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"> Carrying </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"> Accumulated </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"> Net </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Period </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amount </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">Amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amount </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Definite-lived intangible assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:center;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> Patents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"> 12 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,018 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 248</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;background:#cceeff;margin:0pt;padding:0pt;"> 770 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Defensive intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> 1 year </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 1,125 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 920 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> 205 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> Customer accounts </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"> 125 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"> 125 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Customer relationships </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> 11 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 31,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 5,511 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> 25,489 </td></tr><tr>

<td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> Developed technology </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"> 9 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 13,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,731 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,269 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Subtotal </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 46,268 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 9,535 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> 36,733 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> Unamortized intangible assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Tradenames </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 9,500 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> 9,500 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> Patents pending </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <span

style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 491 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 491 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Total intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 56,259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,535 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 46,724 </td></tr></table> Amortization expense was $0.9 million for each of the three months ended September 30, 2024

and 2023, and $2.8 million and $2.9 million for the nine months ended September 30, 2024 and 2023, respectively, of which $0.3 million in each of the three months ended September 30, 2024 and 2023, and $0.9 million in each of the nine months ended September 30, 2024 and 2023, were recorded in cost of sales revenue. Future amortization expenses are expected as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-

space:nowrap;width:4.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.05%;background:#cceeff;margin:0pt;padding:0pt;"> 2024 (October 1 - December 31) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"> 951 </td></tr><tr><td style="vertical-align:bottom;width:71.05%;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';"> 3,714</p></td></tr><tr>
<td style="vertical-
align:bottom;width:71.05%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';">2026</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';visibility:hidden;"></p></td>
<td style="vertical-align:bottom;white-
space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';"> </p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';"> 3,650</p></td></tr><tr>
<td style="vertical-align:bottom;width:71.05%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';">2027</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt
0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-
serif';visibility:hidden;"></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';"> </p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-
align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';"> 3,641</p></td></tr><tr>
<td style="vertical-
align:bottom;width:71.05%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';">2028</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';visibility:hidden;"></p></td>
<td style="vertical-align:bottom;white-
space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;">

 </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"> 3,638 </td></tr><tr><td style="vertical-align:bottom;width:71.05%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 18,423 </td></tr><tr><td style="vertical-align:bottom;width:71.05%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 34,017 </td></tr></table> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:14pt 0pt 0pt

0pt;">In the third quarter of 2024, we performed our annual goodwill impairment test utilizing both the qualitative and quantitative approach described in FASB ASU No. 2021-03, “Intangibles—Goodwill and Other (Topic 350) – Accounting Alternative for Evaluating Triggering Events.” Based on the testing using the qualitative approach, it was determined that it was not more likely than not that the fair value of the reporting unit was less than the carrying value. As a result, it was not deemed necessary to proceed to the quantitative test and no impairment was recognized. 31100000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-

word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> <p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"> <b style="font-

family:'Arial','Helvetica','sans-serif';font-weight:bold;">Gross </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> Amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"> Carrying </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"> Accumulated </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"> Net </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Period </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amount </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">Amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amount </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Definite-lived intangible assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:center;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> Patents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"> 12 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,148 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;background:#cceeff;margin:0pt;padding:0pt;"> 838 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Defensive intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> 1 year </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 1,125 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 1,029 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> 96 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> Customer accounts </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"> 125 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"> 125 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Customer relationships </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> 10 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 31,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 7,299 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> 23,701 </td></tr><tr>

<td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> Developed technology </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"> 8 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 13,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,618 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,382 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Subtotal </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 46,398 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 12,381 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> 34,017 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> Unamortized intangible assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Tradenames </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 9,500 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> 9,500 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> Patents pending </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <span

style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 191 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 191 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Total intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 56,089</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,381 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 43,708 </td></tr></table> <table style="border-

*collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> *

* </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-*

family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"> Gross </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-

space:nowrap;width:15.73%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> Amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"> Carrying </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"> Accumulated </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"> Net </td></tr><tr><td style="vertical-align:bottom;white-

space:nowrap;width:30.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Period </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amount </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amount </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Definite-lived intangible assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:center;margin:0.05pt 0pt 0.05pt 0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> Patents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"> 12 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"> 248 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;background:#cceeff;margin:0pt;padding:0pt;"> 770 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Defensive intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> 1 year </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 1,125 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 920 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> 205 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> Customer accounts </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"> 125 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';visibility:hidden;"> </td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;">
 </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;">
 125 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;">
</td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;">
 </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;background:#cceeff;margin:0pt;padding:0pt;">
 — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Customer relationships </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;">
</td>
<td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> 11 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;">
</td>
<td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 31,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 5,511 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> 25,489 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> Developed technology </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"> 9 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td>

<td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 13,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,731 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,269 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Subtotal </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 46,268 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 9,535 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> 36,733 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> Unamortized intangible assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;">

</td>
<td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;">
</td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;">
</td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;">
</td>
<td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;">
</td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;">
</td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;">
</td>
<td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;">
</td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;">
</td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;">
</td>
<td style="vertical-align:bottom;white-space:nowrap;width:13.84%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0.05pt 0pt 0.05pt 0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;margin:0pt;padding:0pt;"> Tradenames </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> 9,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"> 9,500 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.91%;background:#cceeff;margin:0pt;padding:0pt;"> Patents pending </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 491 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt

*0.05pt 0pt;"> —
</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';visibility:hidden;"></p></td>
<td style="vertical-align:bottom;white-
space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span
style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">
</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:13.84%;background:#cceeff;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt
0.05pt 0pt;">
491</p></td></tr><tr><td style="vertical-align:bottom;white-
space:nowrap;width:30.91%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt
0.05pt 6pt;">Total
intangible assets</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-
align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';visibility:hidden;"></p></td>
<td style="vertical-align:bottom;white-
space:nowrap;width:16.6%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-
align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';visibility:hidden;"></p></td>
<td style="vertical-align:bottom;white-
space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt
0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-
serif';visibility:hidden;"></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td
style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-
bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-
align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';"> 56,259</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt
0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-
serif';visibility:hidden;"></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New*

Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 9,535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 46,724 </td></tr></table> P12Y 1148000 310000 838000 P1Y 1125000 1029000 96000 125000 125000 P10Y 31000000 7299000 23701000 P8Y 13000000 3618000 9382000 46398000 12381000 34017000 9500000 9500000 191000 191000 56089000 12381000 43708000 P12Y 1018000 248000 770000 P1Y 1125000 920000 205000 125000 125000 P11Y 31000000 5511000 25489000 P9Y 13000000 2731000 10269000 46268000 9535000 36733000 9500000 9500000 491000 491000 56259000 9535000 46724000 900000 900000 2800000 2900000 300000 300000 900000 900000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.05%;background:#cceeff;margin:0pt;padding:0pt;"> 2024 (October 1 - December 31) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"> 951 </td></tr><tr><td style="vertical-align:bottom;width:71.05%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"> 3,714 </td></tr><tr><td style="vertical-align:bottom;width:71.05%;background:#cceeff;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"> 3,650 </td></tr><tr><td style="vertical-align:bottom;width:71.05%;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:19.78%;margin:0pt;padding:0pt;"> 3,641 </td></tr><tr><td style="vertical-align:bottom;width:71.05%;background:#cceeff;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"> 3,638 </td></tr><tr><td style="vertical-align:bottom;width:71.05%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 18,423 </td></tr><tr><td style="vertical-align:bottom;width:71.05%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';visibility:hidden;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 34,017 </td></tr></table> 951000 3714000 3650000 3641000 3638000 18423000 34017000 0 Note 6. Accrued Expenses Accrued expenses consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:normal;width:34.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:34.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At September 30, 2024 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"> Warranty </td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"> 1,991 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"> 2,357 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:34.62%;margin:0pt;padding:0pt;"> Legal and consulting </td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;margin:0pt;padding:0pt;"> 921 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;margin:0pt;padding:0pt;"> 611 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"> In-transit inventory </td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:normal;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"> 1,565 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"> 401 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:34.62%;margin:0pt;padding:0pt;"> Travel </td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;margin:0pt;padding:0pt;"> 1,000 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;margin:0pt;padding:0pt;"> 1,038 </td></tr><tr><td style="vertical-align:bottom;white-

space:normal;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"> Clinical studies </td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"> 339 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"> 363 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:34.62%;margin:0pt;padding:0pt;"> Sales and use tax </td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;margin:0pt;padding:0pt;"> 168 </td><td

style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;margin:0pt;padding:0pt;"> 183 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,104 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 951 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:34.62%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:27.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,088</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,904 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:normal;width:34.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:34.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At September 30, 2024 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"> Warranty </td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';"> 1,991 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"> 2,357 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:34.62%;margin:0pt;padding:0pt;"> Legal and consulting </td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;margin:0pt;padding:0pt;"> 921 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;margin:0pt;padding:0pt;"> 611 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"> In-transit inventory </td><td style="vertical-align:bottom;white-

space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"> 1,565 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"> 401 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:34.62%;margin:0pt;padding:0pt;"> Travel </td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;margin:0pt;padding:0pt;"> 1,000 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

*space:normal;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;margin:0pt;padding:0pt;"> 1,038 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"> Clinical studies </td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"> 339 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"> 363 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:34.62%;margin:0pt;padding:0pt;"> Sales and use tax </td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"> *

* </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;margin:0pt;padding:0pt;"> 168 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;margin:0pt;padding:0pt;"> 183 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,104 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;background:#cceeff;border-bottom:1px solid*

#000000;margin:0pt;padding:0pt;"> 951 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:34.62%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:27.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,088</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:27.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,904 </td></tr></table> . 1991000 2357000 921000 611000 1565000 401000 1000000 1038000 339000 363000 168000 183000 1104000 951000 7088000 5904000 Note 7. Warranty Reserves The activity in the warranty reserve during and as of the end of the reporting periods presented was as follows: . <table style="border-

*collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;margin:0pt;padding:0pt;"> *

</td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="5"

style="vertical-align:bottom;white-space:normal;width:31.15%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:31.48%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:31.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:31.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:33.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <b

style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">2024 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:14.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:14.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:14.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:33.21%;background:#cceeff;margin:0pt;padding:0pt;"> Beginning balance </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> 3,692 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-family:'Arial','Helvetica','sans-

serif';visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,828</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> 4,038 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"> 4,212 </td></tr><tr><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"> Warranty provision </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:normal;width:12.74%;margin:0pt;padding:0pt;"> 629 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;margin:0pt;padding:0pt;"> 1,228 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;margin:0pt;padding:0pt;"> 2,371 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;margin:0pt;padding:0pt;"> 3,128 </td></tr><tr><td style="vertical-align:bottom;width:33.21%;background:#cceeff;margin:0pt;padding:0pt;"> Processed warranty claims </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (882) </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,403) </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,970) </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

*Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,687) </td></tr><tr><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"> Ending balance </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,439</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,653 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,439 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> *

</td><td style="vertical-align:bottom;white-space:normal;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,653 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:33.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"> Accrued warranty reserve, current </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,991</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-

space:normal;width:12.75%;margin:0pt;padding:0pt;"> 1,872 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,991</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;margin:0pt;padding:0pt;"> 1,872 </td></tr><tr><td style="vertical-align:bottom;width:33.21%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued warranty reserve, non-current </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,448 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;">

* </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,781 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,448 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,781 </td></tr><tr><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"> Total accrued warranty reserve </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New*

Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,439</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:normal;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,653 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,439</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,653 </td></tr></table> <span style="font-

family:'Arial','Helvetica','sans-serif';font-size:1pt;font-weight:bold;visibility:hidden;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-

word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">
</p>
</td><td style="vertical-align:bottom;white-
space:normal;width:2.29%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-
word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">
</p>
</td><td style="vertical-align:bottom;white-
space:normal;width:1.84%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-
word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">
</p>
</td><td style="vertical-align:bottom;white-
space:normal;width:12.74%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-
word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">
</p>
</td><td style="vertical-align:bottom;white-
space:normal;width:2.29%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-
word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">
</p>
</td><td style="vertical-align:bottom;white-
space:normal;width:1.84%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-
word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">
</p>
</td><td style="vertical-align:bottom;white-
space:normal;width:12.75%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-
word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">
</p>
</td></tr><tr><td style="vertical-
align:bottom;width:33.21%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">
<span style="font-family:'Arial','Helvetica','sans-serif';font-
size:11pt;visibility:hidden;"></p></td><td style="vertical-

*align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:31.15%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:31.48%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:31.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:31.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:33.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> *

</td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:14.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:14.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:14.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:33.21%;background:#cceeff;margin:0pt;padding:0pt;"> Beginning balance </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> 3,692 </td><td

style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,828</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> 4,038 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"> 4,212 </td></tr><tr><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"> Warranty provision </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:normal;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;margin:0pt;padding:0pt;"> 629 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;margin:0pt;padding:0pt;"> 1,228 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;margin:0pt;padding:0pt;"> 2,371 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;margin:0pt;padding:0pt;"> 3,128 </td></tr><tr><td style="vertical-align:bottom;width:33.21%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-

*family:'Arial','Helvetica','sans-serif';">Processed warranty claims </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (882) </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,403) </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,970) </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> *

 </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,687) </td></tr><tr><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"> Ending balance </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,439</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,653 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';"> 3,439 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,653 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:33.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"> Accrued warranty reserve, current </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;margin:0pt;padding:0pt;"> 1,991 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:normal;width:1.67%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,872</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;margin:0pt;padding:0pt;"> 1,991 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;margin:0pt;padding:0pt;"> 1,872 </td></tr><tr><td style="vertical-align:bottom;width:33.21%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued warranty reserve, non-current </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,448 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,781 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,448 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,781 </td></tr><tr><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"> Total accrued warranty reserve </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,439</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,653 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,439</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0pt 3pt 0pt 0pt;"> 3,653 </td></tr></table> 3692000 3828000 4038000 4212000 629000 1228000 2371000 3128000 882000 1403000 2970000 3687000 3439000 3653000 3439000 3653000 1991000 1872000 1991000 1872000 1448000 1781000 1448000 1781000 3439000 3653000 3439000 3653000 Note 8. Credit Agreement On April 30, 2021, we entered into an Amended and Restated Credit Agreement (the “Restated Credit Agreement”) with the lenders from time to time party thereto, and Wells Fargo Bank, National Association, as Administrative Agent. The Restated Credit Agreement amended and restated in its entirety our prior credit agreement. On September 8, 2021, we entered into a First Amendment Agreement (the “Amendment”), which amended the Restated Credit Agreement (as amended by the Amendment, the “Credit Agreement”) with the lenders from time to time party thereto and Wells Fargo Bank, National Association, as administrative agent. The Amendment, among other things, added a $30.0 million incremental term loan to the $25.0 million revolving credit facility provided by the Restated Credit Agreement. The term loan is reflected on our condensed consolidated financial statements as a note payable. The Credit Agreement provides that, subject to satisfaction of certain conditions, we may increase the amount of the revolving loans available under the Credit Agreement and/or add one or more term loan facilities in an amount not to exceed $25.0 million in the aggregate, such that the total aggregate principal amount of loans available under the Credit Agreement (including under the revolving credit facility) does not exceed $80.0 million. <span style="font-

family:'Arial','Helvetica','sans-serif';">On September 8, 2021, in connection with the closing of the AffloVest Acquisition, we borrowed the $30.0 million term loan and utilized that borrowing, together with a draw of $25.0 million under the revolving credit facility and cash on hand, to fund the purchase price. On February 22, 2022, we entered into a Second Amendment Agreement (the "Second Amendment"), which further amended the Credit Agreement. The Second Amendment modified the maximum leverage ratio, the minimum fixed charge coverage ratio and the minimum consolidated EBITDA covenants under the Credit Agreement, and added a minimum liquidity covenant, through the quarter ended June 30, 2023. The Second Amendment also increased the applicable margin for LIBOR rate loans under the Credit Agreement during the period commencing on the date of the Second Amendment and ending on the last day of the fiscal quarter ending June 30, 2023. Pursuant to the Second Amendment, we made a mandatory principal prepayment of the term loan of $3.0 million on February 22, 2022. On June 21, 2023, we entered into a Third Amendment Agreement (the "Third Amendment") that replaced the interest rate benchmark under the Credit Agreement from LIBOR to the term Secured Overnight Financing Rate ("SOFR"). All tenors of term SOFR are subject to a credit spread adjustment of 0.10% ("Adjusted Term SOFR"). Following the Third Amendment, the term loan and amounts drawn under the revolving credit facility bear interest, at our option, at a rate equal to (a) the highest of (i) the prime rate, (ii) the federal funds rate plus <span style="font-

family:'Arial','Helvetica','sans-serif';">0.50% and (iii) Adjusted Term SOFR for a one-month tenor plus 1% (the “Base Rate”) plus an applicable margin or (b) Adjusted Term SOFR for an interest period of one, three or six months, at our option, plus the applicable margin. The applicable margin is 0.75% to 2.25% on loans bearing interest at the Base Rate and 1.75% to 3.25% on loans bearing interest at Adjusted Term SOFR, in each case depending on our consolidated total leverage ratio; except that, pursuant to the Second Amendment and the Third Amendment, during the period commencing on February 22, 2022 and ending on the last day of the fiscal quarter ending June 30, 2023, the applicable margin for LIBOR rate loans and Adjusted Term SOFR loans, as applicable, was 3.50%. On August 1, 2023, we entered into a Fourth Amendment Agreement (the “Fourth Amendment”), which further amended the Credit Agreement. The Fourth Amendment, among other things, decreased the commitment fees payable under the revolving credit facility under the Credit Agreement such that the undrawn portions of the revolving credit facility are subject to an unused line fee at a rate per annum from 0.125% to 0.200%, depending on our consolidated leverage ratio, and eliminated the language providing that the applicable margin for Adjusted Term SOFR loans was 3.50%, such that the interest rates are in effect as set forth in the above paragraph. The Fourth Amendment also eliminated the liquidity financial covenant and modified the remaining financial covenants to reflect the termination of the temporary covenant relief period that was in place until June 30, 2023 pursuant to the Second Amendment, such that the financial covenants now include a maximum consolidated total leverage ratio covenant, a minimum consolidated EBITDA covenant and a minimum fixed

charge coverage ratio covenant. In addition, the Fourth Amendment provided for an additional term loan in the amount of $8.25 million, which we used for a paydown of the revolving credit facility. The Fourth Amendment also extended the maturity date of the term loans and revolving credit facility under the Credit Agreement from September 8, 2024, to August 1, 2026. On November 1, 2024, we entered into a Fifth Amendment Agreement (the “Fifth Amendment”), which further amended the Credit Agreement. The Fifth Amendment permits the Company to make payments to repurchase shares of its common stock, as long as the Company is not in default before and after giving effect to such repurchases, and as long as such repurchases do not exceed $30.0 million. On December 21, 2023, we made a payment of $16.8 million to repay in full the outstanding balance on the revolving credit facility. As of September 30, 2024, we had outstanding borrowings of $27.0 million under the Credit Agreement, comprised entirely of the term loan. At September 30, 2024, all outstanding borrowings were subject to interest at a rate calculated at Adjusted Term SOFR plus an applicable margin, for an interest rate of <span

style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">7.10%. The principal of the term loan is required to be repaid inquarterly installments of$750,000. Maturities of the term loan for the next three years as of September 30, 2024, were as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-

align:center;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amount </td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"> 2024 (October 1 - December 31) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;margin:0pt;padding:0pt;"> 750 </td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"> 3,000 </td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-

space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 23,250 </td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"> 27,000 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"> Less: Deferred financing fees </td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt

0.05pt 0pt;"> (85) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.78%;margin:0pt;padding:0pt;"> Net Note Payable </td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"> 26,915 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"> Less: Current portion of note payable </td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,956) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.78%;margin:0pt;padding:0pt;"> Non-current portion of note payable </td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

*Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 23,959 </td></tr></table> Our obligations under the Credit Agreement are secured by a security interest in substantially all of our and our subsidiary's assets and are also guaranteed by our subsidiary. As of September 30, 2024, the Credit Agreement contained a number of restrictions and covenants, including that we maintain compliance with a maximum consolidated total leverage ratio, a minimum fixed charge coverage ratio and a minimum consolidated EBITDA covenant. As of September 30, 2024, we were in compliance with all covenants under the Credit Agreement. 30000000.0 25000000.0 25000000.0 80000000.0 30000000.0 25000000.0 3000000.0 0.0010 0.0050 0.01 0.0075 0.0225 0.0175 0.0325 0.0350 0.00125 0.00200 0.0350 8250000 30000000.0 16800000 27000000.0 0.0710 quarterly 750000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"> *

</td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amount </td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"> 2024 (October 1 - December 31) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;margin:0pt;padding:0pt;"> 750 </td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"> 3,000 </td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 23,250 </td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"> 27,000 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';">Less: Deferred financing fees </td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (85) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.78%;margin:0pt;padding:0pt;"> Net Note Payable </td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"> 26,915 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"> Less: Current portion of note payable </td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> (2,956) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.78%;margin:0pt;padding:0pt;"> Non-current portion of note payable </td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 23,959 </td></tr></table> 750000 3000000 23250000 27000000 85000 26915000 2956000 23959000 Note 9. Commitments and Contingencies Lease Obligations We lease property and equipment under operating leases, typically with terms greater than 12 months, and determine if an arrangement contains a lease at inception. In general, an arrangement contains a lease if there is an identified asset and we have the right to direct the use of and obtain substantially all of the economic benefit from the use of the identified asset. We record an operating lease liability at the present value of lease payments over the lease term on the commencement date. The related right of use (“ROU”) operating lease asset reflects rental escalation clauses, as well as renewal options and/or termination options. The exercise of lease renewal and/or termination options are at our discretion and are included in the determination of the lease term and lease payment obligations when it is deemed reasonably certain that the option will be exercised. When available, we use the rate implicit in the lease to discount lease payments to present value; however, certain leases do not provide a readily determinable implicit rate. Therefore, we must

estimate our incremental borrowing rate to discount the lease payments based on information available at lease commencement. We classify our leases as buildings, vehicles or computer and office equipment and do not separate lease and non-lease components of contracts for any of the aforementioned classifications. In accordance with applicable guidance, we do not record leases with terms that are less than one year on the Condensed Consolidated Balance Sheets. None of our lease agreements contain material restrictive covenants or residual value guarantees. Buildings We lease certain office and warehouse space at various locations in the United States where we provide services. These leases are typically greater than one year with fixed, escalating rents over the noncancelable terms and, therefore, ROU operating lease assets and operating lease liabilities are recorded on the Condensed Consolidated Balance Sheets, with rent expense recognized on a straight-line basis over the term of the lease. The remaining lease terms vary from approximately one to seven years as of September 30, 2024. We entered into a lease (“initial lease”) in October 2018, for approximately 80,000 square feet of office space for our new corporate headquarters in Minneapolis, Minnesota. In December 2018, we amended the initial lease to add approximately 29,000 square feet of additional office space, which is accounted for as a separate lease (“second lease”) in accordance with ASU No. 2016-02, “Leases” (Topic 842) (“ASC 842”). In December 2019, we further amended the lease which extended the expiration date of the initial lease, extended the expiration date of and added approximately 4,000 square feet to the second lease, as

well as added approximately 37,000 square feet of additional office space, accounted for as a separate lease (“third lease”) in accordance with ASC 842. The portion of the space covered under the initial lease was placed in service in September 2019. The portion of the space covered under the second lease commenced in September 2020. Finally, the portion of the space covered under the third lease commenced in September 2021. The three portions were recognized as an operating lease and included in the ROU operating lease assets and operating lease liabilities on the Condensed Consolidated Balance Sheets. Computer and Office Equipment We also have operating lease agreements for certain computer and office equipment. The remaining lease terms as of September 30, 2024, ranged from less than one year to approximately four years with fixed monthly payments that are included in the ROU operating lease assets and operating lease liabilities. The leases provide an option to purchase the related equipment at fair market value at the end of the lease. The leases will automatically renew as a month-to-month rental at the end of the lease if the equipment is not purchased or returned. Lease Position, Undiscounted Cash Flow and Supplemental Information The table below presents information related to our ROU operating lease assets and operating lease liabilities that we have recorded: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;background:#cceeff;margin:0pt;padding:0pt;"> Right of use operating lease assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17,553</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,128 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;margin:0pt;padding:0pt;"> Current </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;margin:0pt;padding:0pt;"> 2,807 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-

*family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-current </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,767 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 18,436 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 19,650 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> *

* </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 21,243 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;margin:0pt;padding:0pt;"> Operating leases: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;">*

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted average remaining lease term </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#cceeff;margin:0pt;padding:0pt;"> 6.0 years </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;background:#cceeff;margin:0pt;padding:0pt;"> 6.7 years </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;margin:0pt;padding:0pt;"> Weighted average discount rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"> 4.4% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;margin:0pt;padding:0pt;"> 4.3% </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:44.37%;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:21.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:20.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;margin:0pt;padding:0pt;"> Supplemental cash flow information for our operating leases: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:19.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:18.88%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;background:#cceeff;margin:0pt;padding:0pt;"> Cash paid for operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;">

$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,642</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;background:#cceeff;margin:0pt;padding:0pt;"> 2,579 </td></tr><tr><td style="vertical-align:bottom;width:53.84%;margin:0pt;padding:0pt;"> Non-cash right of use assets obtained in exchange for new operating lease obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';"> 132 </td></tr></table> The table below reconciles the undiscounted cash flows for the periods presented to the operating lease liabilities recorded on the Condensed Consolidated Balance Sheet for the periods presented: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:normal;width:64.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:28%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-family:'Arial','Helvetica','sans-

serif';">2024 (October 1 - December 31) </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:28%;background:#cceeff;margin:0pt;padding:0pt;"> 924 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:28%;margin:0pt;padding:0pt;"> 3,734 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;background:#cceeff;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:28%;background:#cceeff;margin:0pt;padding:0pt;"> 3,807 </td></tr><tr>

<td style="vertical-align:bottom;white-space:normal;width:64.85%;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:28%;margin:0pt;padding:0pt;"> 3,309 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;background:#cceeff;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:28%;background:#cceeff;margin:0pt;padding:0pt;"> 3,275 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0pt 3pt 0pt 0pt;"> 7,008 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;background:#cceeff;margin:0pt;padding:0pt;"> Total minimum lease payments </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:28%;background:#cceeff;margin:0pt;padding:0pt;"> 22,057 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;margin:0pt;padding:0pt;"> Less: Amount of lease payments representing interest </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,407) </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;background:#cceeff;margin:0pt;padding:0pt;"> Present value of future minimum lease payments </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-

align:bottom;white-space:normal;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:28%;background:#cceeff;margin:0pt;padding:0pt;"> 19,650 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;margin:0pt;padding:0pt;"> Less: Current obligations under operating lease liabilities </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,883) </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;background:#cceeff;margin:0pt;padding:0pt;"> Non-current obligations under operating lease liabilities </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 16,767 </td></tr></table> <span style="font-

family:'Arial','Helvetica','sans-serif';visibility:hidden;"> Operating lease costs were $0.9 million for each of the three months ended September 30, 2024 and 2023. Operating lease costs were $2.6 million and $2.7 million for the nine months ended September 30, 2024 and 2023, respectively. Major Vendors We had purchases from one vendor that accounted for 22% of our total purchases for the three months ended September 30, 2024, and purchases from one vendor that accounted for 20% of our total purchases for the nine months ended September 30, 2024. We had purchases from one vendor that accounted for 29% of our total purchases for the three months ended September 30, 2023, and purchases from one vendor that accounted for 26% of our total purchases for the nine months ended September 30, 2023. Purchase Commitments <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-

indent:36pt;background:#ffffff;margin:0pt;">We issued purchase orders prior to September 30, 2024, totaling $24.8 million for goods that we expect to receive within the next year. Retirement Plan We maintain a 401(k) retirement plan for our employees in which eligible employees can contribute a percentage of their pre-tax compensation. We recorded an expense related to our discretionary contributions to the 401(k) plan of $0.6 million and $0.4 million for the three months ended September 30, 2024 and 2023, respectively, and $1.7 million and $1.1 million for the nine months ended September 30, 2024 and 2023, respectively. Legal Proceedings From time to time, we are subject to various claims and legal proceedings arising in the ordinary course of business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. On May 24, 2022, a stockholder derivative lawsuit was filed in the United States District Court for the District of Minnesota, purportedly on behalf of the Company against certain of our present and former officers and directors and the Company (as a nominal defendant), captioned Jack Weaver v. Moen, et al., File No. 0:22-cv-01403-NEB-BRT (the “Weaver Lawsuit”). The Weaver Lawsuit generally arises out of the same subject matter as a previously settled

securities class action captioned Brian Mart v. Tactile Sys. Tech., Inc., et al., File No. 0:20-cv-02074-NEB-BRT (D. Minn.) (the "Mart Lawsuit"), which alleged, inter alia, that we and eight of our former officers and directors made materially false or misleading statements about our business, operational and compliance policies. The Weaver Lawsuit alleges the following claims under the Exchange Act and common law: (1) that the director defendants made materially false or misleading public statements in proxy statements in violation of Section 14(a) of the Exchange Act; (2) that the director defendants' stock and option awards should be rescinded under Section 29(b) of the Exchange Act; (3) that the officer defendants' employment contract compensation should be rescinded under Section 29(b) of the Exchange Act; (4) that certain officer defendants are liable for contribution arising out of any liability incurred in the Mart Lawsuit, under Sections 10(b) and 21D of the Exchange Act; (5) that the individual defendants breached their fiduciary duties; and (6) that the individual defendants were unjustly enriched. The Weaver Lawsuit seeks unspecified damages. In August 2022, the matter was transferred to the United States District Court for the District of Delaware by order granting the Parties Stipulation to Transfer. On February 10, 2023, we filed a motion to dismiss the action. The plaintiff filed an Amended Complaint on March 3, 2023. On March 31, 2023, we filed a motion to dismiss the Amended Complaint. On July 31, 2023, the plaintiff filed a Joint Notice of Preliminary Settlement indicating that the parties had reached a non-binding settlement-in-principal on most of the material terms that would resolve all claims between the parties and requested that the Court temporarily stay all deadlines, hearings, and conferences while the parties continued to finalize settlement. On June 6, 2024, the parties entered into a Stipulation of Settlement in the Weaver Lawsuit. On June 7, 2024, the plaintiff filed an unopposed motion for preliminary approval of the settlement. On June 27, 2024, the Court entered an order granting the motion for preliminary approval of the settlement. The final settlement hearing occurred on August 28, 2024, and on September 4, 2024, the Court entered its order approving the settlement, including the agreed upon attorneys' fees and expense awards to plaintiffs' counsel and service awards to the shareholder plaintiffs. Pursuant to the settlement, we are adopting, implementing, and maintaining certain corporate governance reforms. The attorneys' fees and expense award of approximately $0.5 million was covered by insurance and has been paid. The settlement does not constitute an admission of liability or wrongdoing by us or any of our current or former directors or officers. This matter is now concluded. On October 25, 2024, the

United States District Court, District of Massachusetts (Boston) unsealed two qui tam complaints against us. The first complaint is captioned United States ex. rel. Benjaman Scarborough vs. Tactile Systems Technology, Inc., Case No. 1:21-cv-10813-IT, and was filed under seal on May 17, 2021, on behalf of the United States by a former employee (the "Scarborough Complaint"). The Scarborough Complaint alleges that we submitted false claims and made false statements in connection with the Medicare programs, in violation of the Federal False Claims Act. The second complaint is captioned United States ex. rel. Jackie Gorham, an individual, and Dustin Gast, an individual, vs. Tactile Systems Technology, Inc. Case No. 1:21-cv-11809-IT, and was filed under seal on September 1, 2021, on behalf of the United States by two former employees (the "Gorham Complaint"). The Gorham Complaint alleges that we submitted false claims and made false statements in connection with the Medicare, Medicare Advantage plans, Medicaid and other government payers, in violation of the Federal False Claims Act and submitted false claims resulting from kickbacks in violation of the Federal False Claims Act and the Federal Anti-Kickback Statute. Both complaints seek damages, statutory penalties, attorneys' fees, and costs. P12M P7Y 80000 29000 4000 37000 P1Y P4Y true <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:19.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> At December 31, 2023 </td></tr><tr><td style="vertical-

align:bottom;white-space:nowrap;width:53.84%;background:#cceeff;margin:0pt;padding:0pt;"> Right of use operating lease assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17,553</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 19,128 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"> <span style="font-family:'Arial','Helvetica','sans-

serif';visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;margin:0pt;padding:0pt;"> <span style="-sec-ix-

hidden:Hidden_KOOT9wE1pUOd1SvpreoXUw;">Current </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;margin:0pt;padding:0pt;"> 2,807 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;background:#cceeff;margin:0pt;padding:0pt;"> Non-current </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,767 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 18,436 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,650</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 21,243 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;margin:0pt;padding:0pt;"> Operating leases: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> <span style="font-family:'Arial','Helvetica','sans-

serif';visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted average remaining lease term </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#cceeff;margin:0pt;padding:0pt;"> 6.0 years </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;background:#cceeff;margin:0pt;padding:0pt;"> 6.7 years </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;margin:0pt;padding:0pt;"> Weighted average discount rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"> 4.4% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;margin:0pt;padding:0pt;"> 4.3% </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-

*align:bottom;white-space:nowrap;width:18.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:44.37%;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:21.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:20.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;margin:0pt;padding:0pt;"> Supplemental cash flow information for our operating leases: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> *

</td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:19.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:18.88%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.84%;background:#cceeff;margin:0pt;padding:0pt;"> Cash paid for operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,642</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;background:#cceeff;margin:0pt;padding:0pt;">

 2,579 </td></tr><tr><td style="vertical-align:bottom;width:53.84%;margin:0pt;padding:0pt;"> Non-cash right of use assets obtained in exchange for new operating lease obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.88%;margin:0pt;padding:0pt;"> 132 </td></tr></table> 17553000 19128000 2883000 2807000 16767000 18436000 19650000 21243000 P6Y P6Y8M12D 0.044 0.043 2642000 2579000 386000 132000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:normal;width:64.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:normal;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:28%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;background:#cceeff;margin:0pt;padding:0pt;"> 2024 (October 1 - December 31) </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:28%;background:#cceeff;margin:0pt;padding:0pt;"> 924 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-

space:normal;width:4.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:28%;margin:0pt;padding:0pt;"> 3,734 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;background:#cceeff;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:28%;background:#cceeff;margin:0pt;padding:0pt;"> 3,807 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:28%;margin:0pt;padding:0pt;"> 3,309 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-family:'Arial','Helvetica','sans-

serif';">2028 </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:28%;background:#cceeff;margin:0pt;padding:0pt;"> 3,275 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,008 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;background:#cceeff;margin:0pt;padding:0pt;"> Total minimum lease payments </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:28%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';"> 22,057 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;margin:0pt;padding:0pt;"> Less: Amount of lease payments representing interest </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,407) </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;background:#cceeff;margin:0pt;padding:0pt;"> Present value of future minimum lease payments </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:28%;background:#cceeff;margin:0pt;padding:0pt;"> 19,650 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;margin:0pt;padding:0pt;"> Less: Current obligations under operating lease liabilities </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,883) </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:64.85%;background:#cceeff;margin:0pt;padding:0pt;"> Non-current obligations under operating lease liabilities </td><td style="vertical-align:bottom;white-space:normal;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 16,767 </td></tr></table> 924000 3734000 3807000 3309000 3275000 7008000 22057000 2407000 19650000 2883000 16767000 900000 900000 2600000 2700000 1 0.22 1 0.20 1 0.29 1 0.26 24800000 600000 400000 1700000 1100000 8 500000 Note 10. Stockholders' Equity Stock-Based Compensation Our 2016 Equity Incentive Plan (the “2016 Plan”) authorizes us to grant stock options, stock appreciation rights, restricted stock, stock units and other stock-based awards to employees, non-employee directors and certain consultants and advisors. There were up to 4,800,000 shares of our common stock initially reserved for issuance pursuant to the 2016 Plan. The 2016 Plan provides that the number of

shares reserved and available for issuance under the 2016 Plan will automatically increase annually on January 1 of each calendar year, commencing in 2017 and ending on and including January 1, 2026, by an amount equal to the lesser of: (a) 5% of the number of common shares of stock outstanding as of December 31 of the immediately preceding calendar year, or (b) 2,500,000 shares; provided, however, that our Board of Directors may determine that any annual increase be a lesser number. In addition, all awards granted under our 2007 Omnibus Stock Plan and our 2003 Stock Option Plan that were outstanding when the 2016 Plan became effective and that are forfeited, expired, cancelled, settled for cash or otherwise not issued, will become available for issuance under the 2016 Plan. Pursuant to the automatic increase feature of the 2016 Plan, 1,180,019 shares were added as available for issuance thereunder on January 1, 2024. Our Board of Directors exercised its prerogative to forego the automatic increase on January 1, 2023. As of September 30, 2024, 6,462,956 shares were available for future grant pursuant to the 2016 Plan. Upon adoption and approval of the 2016 Plan, all of our previous equity incentive compensation plans were terminated. However, existing awards under those plans continue to vest in accordance with the original vesting schedules and will expire at the end of their original terms. We recorded stock-based compensation expense of $2.1 million and $1.8 million for the three months ended September 30, 2024 and 2023, respectively, and $6.0 million and $5.6 million for the nine months ended September 30, 2024 and 2023, respectively. This expense was allocated as follows: <table style="border-

*collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.28%;margin:0pt;padding:0pt;"> *

</td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.22%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';font-

size:8pt;font-weight:bold;visibility:hidden;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:22.48%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:22.57%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:50.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:22.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:22.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:50.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-

align:bottom;white-space:normal;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:50.8%;background:#cceeff;margin:0pt;padding:0pt;"> Cost of revenue </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"> 100 </td><td

style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 116</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"> 286 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> 340 </td></tr><tr><td style="vertical-align:bottom;width:50.8%;margin:0pt;padding:0pt;"> Sales and marketing expenses </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"> 595 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.28%;margin:0pt;padding:0pt;"> 634 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.26%;margin:0pt;padding:0pt;"> 1,939 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.22%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2,196 </td></tr><tr><td style="vertical-align:bottom;width:50.8%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development expenses </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"> 42 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"> 5 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 123 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> 98 </td></tr><tr><td style="vertical-align:bottom;width:50.8%;margin:0pt;padding:0pt;"> Reimbursement, general and administrative expenses </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,333 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,011 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,621 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,963 </td></tr><tr><td style="vertical-align:bottom;width:50.8%;background:#cceeff;margin:0pt;padding:0pt;"> Total stock-based compensation expense </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,070 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td>

<td style="vertical-align:bottom;white-space:normal;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:8.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">1,766</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,969 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,597 </td></tr></table> Stock Options <span

style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Stock options issued to participants other than non-employees typically vest over three or four years and typically have a contractual term of seven or ten years. Stock-based compensation expense included in the Condensed Consolidated Statements of Operations for stock options was $0.0 million and $0.2 million for the three months ended September 30, 2024 and 2023, respectively, and $0.2 million and $0.8 million for the nine months ended September 30, 2024 and 2023, respectively. At September 30, 2024, there was approximately $42,100 of total unrecognized pre-tax stock option expense under our equity compensation plans, which is expected to be recognized on a straight-line basis over a weighted-average period of 1.0 years. Our stock option activity for the nine months ended September 30, 2024, was as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.08757782%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';font-

size:8pt;font-weight:bold;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"> <b style="font-

family:'Arial','Helvetica','sans-serif';font-weight:bold;">Remaining </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"> Intrinsic </td></tr><tr><td style="vertical-align:bottom;width:39.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands except options and per share data) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Per Share ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Contractual Life </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value ⁽²⁾ </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;background:#cceeff;margin:0pt;padding:0pt;"> Balance at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 429,960 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"> 40.74 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';">3.8 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 223</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1,153)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> 1.35 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">(24,142)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"> 43.45 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td>

<td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;margin:0pt;padding:0pt;"> Balance at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 404,665 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> 40.69 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"> 3.1 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> 218 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td>

<td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;margin:0pt;padding:0pt;"> Options exercisable at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> 385,514 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 42.11 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"> 3.0 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> 116 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(1)</td><td style="padding:0pt 0pt 6pt 0pt;">The exercise price of each option granted during the period shown was equal to the market price of the underlying stock on the date of grant.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">(2)</td><td style="padding:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options exercised

represents the difference between the exercise price of the option and the closing stock price of our common stock on the date of exercise. The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.</td></tr></table> Options exercisable of 400,484 as of September 30, 2023, had a weighted-average exercise price of $43.45 per share. Time-Based Restricted Stock Units We have granted time-based restricted stock units to certain participants under the 2016 Plan that are stock-settled with common shares. Time-based restricted stock units granted under the 2016 Plan vest over one to three years. Stock-based compensation expense included in the Condensed Consolidated Statements of Operations for time-based restricted stock units was $1.5 million and $1.2 million for the three months ended September 30, 2024 and 2023, respectively, and $4.4 million and $3.8 million for the nine months ended September 30, 2024 and 2023, respectively. At September 30, 2024, there was approximately $7.7 million of total unrecognized pre-tax compensation expense related to outstanding time-based restricted stock units that is expected to be recognized over a weighted-average period of <span style="-sec-ix-

hidden:Hidden_9xa4GKXhnEu4Pzqp8sDaBw;">1.9 years. Our time-based restricted stock unit activity for the nine months ended September 30, 2024, was as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:normal;width:46.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-

word;position:relative;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.25%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:16.27%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.25%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:46.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:16.27%;margin:0pt;padding:0pt;"> Average Grant </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:16.25%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:46.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"> Units </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:16.27%;margin:0pt;padding:0pt;"> Date Fair Value </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:16.25%;margin:0pt;padding:0pt;"> Intrinsic </td></tr><tr><td style="vertical-align:bottom;width:46.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands except unit and per unit data) </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:16.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <b style="font-

family:'Arial','Helvetica','sans-serif';font-weight:bold;">Per Unit </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value⁽¹⁾ </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:46.74%;margin:0pt;padding:0pt;"> Balance at December 31, 2023 </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"> 589,142 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 16.35</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-

space:normal;width:14.25%;margin:0pt;padding:0pt;"> 8,425 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"> 539,496 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"> 13.82 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:46.74%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Vested </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"> (254,490) </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"> 17.44 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.25%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"> Cancelled </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;background:#cceeff;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> (113,724) </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"> 14.70 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:46.74%;margin:0pt;padding:0pt;"> Balance at September 30, 2024 </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 760,424 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> <span style="font-family:'Arial','Helvetica','sans-

serif';visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 14.44</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:14.25%;margin:0pt;padding:0pt;"> 11,110 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(1)</td><td style="padding:0pt 0pt 6pt 0pt;">The aggregate intrinsic value of restricted stock units outstanding was based on our closing stock price on the last trading day of the period. </td></tr></table> Performance-Based Restricted Stock Units We have granted performance-based restricted stock units (“PSUs”) to certain participants under the 2016 Plan. These PSUs have both performance-based and time-based vesting features. The PSUs granted in 2023 have three separate performance

periods, and one-third of each grant will be earned if and to the extent performance goals based on revenue change and adjusted EBITDA margin are achieved in each of 2023 and 2024 (ranging from 25% to 175% of target), and one-third will be earned if and to the extent performance goals based on revenue change and adjusted EBITDA change are achieved in 2025 (ranging from 25% to 175% of target). The PSUs granted in 2024 have three separate performance periods, and one-third of each grant will be earned if and to the extent performance goals based on revenue change and adjusted EBITDA margin are achieved in 2024 (ranging from 25% to 175% of target), one-third will be earned if and to the extent performance goals based on revenue change and adjusted EBITDA change are achieved in 2025 (ranging from 25% to 175% of target), and <span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-

weight:normal;">one-third will be earned if and to the extent performance goals to be established are achieved in 2026. All earned and vested PSUs will be settled in shares of common stock. Stock-based compensation expense recognized for PSUs was $0.4 million and $0.3 million for the three months ended September 30, 2024 and 2023, respectively, and $1.0 million and $0.6 million for the nine months ended September 30, 2024 and 2023, respectively. At September 30, 2024, there was approximately $2.0 million of total unrecognized pre-tax compensation expense related to outstanding PSUs that is expected to be recognized over a weighted average period of 2.2 years. Our PSU activity for the nine months ended September 30, 2024, was as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:normal;width:44.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:15.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:15.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:17.1%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:44.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:15.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:17.1%;margin:0pt;padding:0pt;"> Average Grant </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:17.04%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:44.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.95%;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:normal;width:15.08%;margin:0pt;padding:0pt;"> PSUs </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:17.1%;margin:0pt;padding:0pt;"> Date Fair Value </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:17.04%;margin:0pt;padding:0pt;"> Intrinsic </td></tr><tr><td style="vertical-align:bottom;width:44.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands except unit and per unit data) </td><td style="vertical-align:bottom;white-space:normal;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:17.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Per Unit </td><td style="vertical-align:bottom;white-

space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:17.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value⁽¹⁾ </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:44.22%;background:#cceeff;margin:0pt;padding:0pt;"> Balance at December 31, 2023 </td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:15.08%;background:#cceeff;margin:0pt;padding:0pt;"> 198,232 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 18.93</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td

style="vertical-align:bottom;white-space:normal;width:14.93%;background:#cceeff;margin:0pt;padding:0pt;"> 2,785 </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:44.22%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:normal;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:15.08%;margin:0pt;padding:0pt;"> 223,762 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:15%;margin:0pt;padding:0pt;"> 13.76 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:14.93%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:44.22%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td

style="vertical-align:bottom;white-space:normal;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:15.08%;background:#cceeff;margin:0pt;padding:0pt;"> (44,162) </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:15%;background:#cceeff;margin:0pt;padding:0pt;"> 27.31 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:44.22%;margin:0pt;padding:0pt;"> Cancelled </td><td style="vertical-align:bottom;white-space:normal;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (104,913) </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:15%;margin:0pt;padding:0pt;"> 14.14 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:44.22%;background:#cceeff;margin:0pt;padding:0pt;"> Balance at September 30, 2024 </td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:15.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 272,919 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td>

<td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 15.19</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:14.93%;background:#cceeff;margin:0pt;padding:0pt;"> 3,987 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">(1)</td><td style="padding:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of PSUs outstanding was based on our closing stock price on the last trading day of the period.</td></tr></table> Employee Stock Purchase Plan Our employee stock purchase plan (“ESPP”), which was approved by our Board of Directors on April 27, 2016, and by our stockholders on June 20, 2016, allows participating employees to purchase shares of our common stock at a discount through payroll

deductions. The ESPP is available to all of our employees and employees of participating subsidiaries. Participating employees may purchase common stock, on a voluntary after-tax basis, at a price equal to 85% of the lower of the closing market price per share of our common stock on the first or last trading day of each stock purchase period. The ESPP provides for six-month purchase periods, beginning on May 16 and November 16 of each calendar year. A total of 1,600,000 shares of common stock was initially reserved for issuance under the ESPP. This share reserve will automatically be supplemented each January 1, commencing in 2017 and ending on and including January 1, 2026, by an amount equal to the least of (a) 1% of the shares of our common stock outstanding on the immediately preceding December 31, (b) 500,000 shares or (c) such lesser amount as our Board of Directors may determine. Pursuant to the automatic increase feature of the ESPP, 236,003 shares were added as available for issuance thereunder on January 1, 2024. Our Board of Directors exercised its prerogative to forego the automatic increase on January 1, 2023. As of September 30, 2024, 1,497,964 shares were available for future issuance under the ESPP. We recognized stock-based compensation expense associated with the ESPP of $0.2 million and $0.1 million for the three months ended September 30, 2024 and 2023, respectively, and $0.4 million for each of the nine months ended September 30, 2024 and 2023. 4800000 0.05 2500000 1180019 6462956 2100000 1800000 6000000.0 5600000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.8%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.22%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:22.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:center;margin:0.05pt 0pt 0.05pt 0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:22.57%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:50.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:22.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:22.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:50.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <b style="font-family:'Arial','Helvetica','sans-serif';font-

weight:bold;">2024 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:50.8%;background:#cceeff;margin:0pt;padding:0pt;"> Cost of revenue </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"> 100 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';visibility:hidden;"> </td>
<td style="vertical-align:bottom;white-space:normal;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;">
* $ </td><td*
style="vertical-align:bottom;white-space:normal;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;">
* 116 </td><td*
style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;">
* </td>*
<td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;">
* $ </td><td*
style="vertical-align:bottom;white-space:normal;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;">
* 286 </td><td*
style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;">
* </td>*
<td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;">
* $ </td><td*
style="vertical-align:bottom;white-space:normal;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;">
* 340 </td></tr><tr><td*
style="vertical-align:bottom;width:50.8%;margin:0pt;padding:0pt;"><p
*style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Sales and marketing expenses </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.82%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"> 595 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.28%;margin:0pt;padding:0pt;"> 634 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.26%;margin:0pt;padding:0pt;"> 1,939 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.22%;margin:0pt;padding:0pt;"> 2,196 </td></tr><tr><td style="vertical-

align:bottom;width:50.8%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development expenses </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"> 42 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"> 5 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"> 123 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> 98 </td></tr><tr><td style="vertical-align:bottom;width:50.8%;margin:0pt;padding:0pt;"> Reimbursement, general and administrative expenses </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,333 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,011 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.89%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,621 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,963 </td></tr><tr><td style="vertical-align:bottom;width:50.8%;background:#cceeff;margin:0pt;padding:0pt;"> Total stock-based compensation expense </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,070 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> <span

*style="font-family:'Arial','Helvetica','sans-serif';">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">1,766</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,969 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,597 </td></tr></table> 100000 116000 286000 340000 595000 634000 1939000 2196000 42000 5000 123000 98000 1333000 1011000 3621000 2963000 2070000 1766000 5969000 5597000 P4Y P10Y 0.0 200000 200000 800000 42100000 P1Y <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.08757782%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;margin:0pt;padding:0pt;"> *

* </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div*

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">Weighted- </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:13.6%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"> Remaining </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"> Intrinsic </td></tr><tr><td style="vertical-align:bottom;width:39.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands except options and per share data) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Per Share ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Contractual Life </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value ⁽²⁾ </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;background:#cceeff;margin:0pt;padding:0pt;"> Balance at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 429,960 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"> 40.74 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"> 3.8 years </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 223</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1,153)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> 1.35 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">(24,142)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"> 43.45 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;margin:0pt;padding:0pt;"> Balance at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 404,665 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> 40.69 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;">

3.1 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> 218 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.56%;margin:0pt;padding:0pt;"> Options exercisable at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> 385,514 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> 42.11 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"> 3.0 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> 116 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(1)</td><td style="padding:0pt 0pt 6pt 0pt;">The exercise price of each option granted during the period shown was equal to the market price of the underlying stock on the date of grant.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">(2)</td><td style="padding:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options exercised represents the difference between the exercise price of the option and the closing stock price of our common stock on the date of exercise. The aggregate intrinsic value of options outstanding represents the difference

*between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.</td></tr></table> 429960 40.74 P3Y9M18D 223000 1153 1.35 14000 24142 43.45 404665 40.69 P3Y1M6D 218000 385514 42.11 P3Y 116000 400484 43.45 P3Y 1500000 1200000 4400000 3800000 7700000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:normal;width:46.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"> *

</td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.25%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:16.27%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.25%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:46.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:16.27%;margin:0pt;padding:0pt;"> Average Grant </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:16.25%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:46.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">Units </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:16.27%;margin:0pt;padding:0pt;"> Date Fair Value </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:16.25%;margin:0pt;padding:0pt;"> Intrinsic </td></tr><tr><td style="vertical-align:bottom;width:46.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands except unit and per unit data) </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:16.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Per Unit </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt

0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value⁽¹⁾ </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:46.74%;margin:0pt;padding:0pt;"> Balance at December 31, 2023 </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"> 589,142 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 16.35</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:14.25%;margin:0pt;padding:0pt;"> 8,425 </td></tr><tr>

<td style="vertical-align:bottom;white-space:normal;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"> 539,496 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"> 13.82 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:46.74%;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"> (254,490) </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"> 17.44 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.25%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"> Cancelled </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (113,724) </td><td style="vertical-align:bottom;white-

space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"> 14.70 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:46.74%;margin:0pt;padding:0pt;"> Balance at September 30, 2024 </td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 760,424 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';">$</p></td><td style="vertical-align:bottom;white-space:normal;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 14.44</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:14.25%;margin:0pt;padding:0pt;"> 11,110 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(1)</td><td style="padding:0pt 0pt 6pt 0pt;">The aggregate intrinsic value of restricted stock units outstanding was based on our closing stock price on the last trading day of the period. </td></tr></table> 589142 16.35 8425000 539496 13.82 254490 17.44 113724 14.70 760424 14.44 11110000 3 0.25 1.75 0.25 1.75 3 0.25 1.75 0.25 1.75 400000 300000 1000000.0 600000 2000000.0 P2Y2M12D <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:normal;width:44.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

*space:normal;width:15.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:15.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:17.1%;margin:0pt;padding:0pt;"> Weighted- *

</td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:44.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:15.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:17.1%;margin:0pt;padding:0pt;"> Average Grant </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:17.04%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:44.22%;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:normal;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:15.08%;margin:0pt;padding:0pt;"> PSUs </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:17.1%;margin:0pt;padding:0pt;"> Date Fair Value </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:17.04%;margin:0pt;padding:0pt;"> Intrinsic </td></tr><tr><td style="vertical-align:bottom;width:44.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands except unit and per unit data) </td><td style="vertical-align:bottom;white-space:normal;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:17.1%;border-

bottom:1px solid #000000;margin:0pt;padding:0pt;"> Per Unit </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:17.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value⁽¹⁾ </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:44.22%;background:#cceeff;margin:0pt;padding:0pt;"> Balance at December 31, 2023 </td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:15.08%;background:#cceeff;margin:0pt;padding:0pt;"> 198,232 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:15%;background:#cceeff;margin:0pt;padding:0pt;"> 18.93 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td>

<td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:14.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2,785</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:44.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:normal;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:normal;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 223,762</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:15%;margin:0pt;padding:0pt;"> 13.76 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:14.93%;margin:0pt;padding:0pt;"> . </td>

</tr><tr><td style="vertical-align:bottom;white-space:normal;width:44.22%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:15.08%;background:#cceeff;margin:0pt;padding:0pt;"> (44,162) </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:15%;background:#cceeff;margin:0pt;padding:0pt;"> 27.31 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:44.22%;margin:0pt;padding:0pt;"> Cancelled </td><td style="vertical-align:bottom;white-space:normal;width:1.95%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:normal;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (104,913) </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:15%;margin:0pt;padding:0pt;"> 14.14 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:14.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:44.22%;background:#cceeff;margin:0pt;padding:0pt;"> Balance at September 30, 2024 </td><td style="vertical-align:bottom;white-space:normal;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:15.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">

272,919 </td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 15.19</p></td><td style="vertical-align:bottom;white-space:normal;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:14.93%;background:#cceeff;margin:0pt;padding:0pt;"> 3,987 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">(1)</td><td style="padding:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of PSUs outstanding was based on our closing stock price on the last trading day of the period.</td></tr></table> 198232 18.93 2785000 223762 13.76 44162 27.31 104913 14.14 272919 15.19 3987000 0.85 P6M 1600000 0.01 500000 236003 1497964 200000 100000 400000 400000 <p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> Note 11. Revenue We derive our revenue from the sale and rental of our products to our customers in the United States. The following table presents our revenue, inclusive of sales and rental revenue, disaggregated by product line: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> <p style="font-

*family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> *

* </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.98%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.36%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td colspan="5"*

style="vertical-align:bottom;white-space:nowrap;width:29.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:36.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:36.53%;background:#cceeff;margin:0pt;padding:0pt;">

Revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> Lymphedema products </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 65,282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> 62,506 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

*size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 182,278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> 172,257 </td></tr><tr><td style="vertical-align:bottom;width:36.53%;background:#cceeff;margin:0pt;padding:0pt;"> Airway clearance products </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,811 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> *

* </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,080 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 25,121 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 24,514 </td></tr><tr><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-*

align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 73,093 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 69,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 207,399 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 196,771 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> Percentage of total revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.53%;background:#cceeff;margin:0pt;padding:0pt;"> Lymphedema products </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"> 89% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;">

90% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 88% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> 88% </td></tr><tr><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> Airway clearance products </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11%

* </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12% </td></tr><tr><td style="vertical-align:bottom;width:36.53%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-*

family:'Arial','Helvetica','sans-serif';visibility:hidden;"> </td>
<td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 100% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td>
<td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 100% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td>
<td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 100% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td>
<td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 100% </td></tr></table> Our revenue by channel, inclusive of sales and rental revenue, for the three and nine months ended September 30, 2024 and 2023, are summarized in the following table: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:10.66%;margin:0pt;padding:0pt;"> <p style="font-

*family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:10.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> *

</td><td style="vertical-align:bottom;white-space:normal;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:36.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:3.31%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:27.98%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:29.36%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:3.31%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:27.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:center;margin:0.05pt 0pt 0.05pt 0pt;">September 30, </td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:29.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:36.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:normal;width:3.31%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td colspan="2"

style="vertical-align:bottom;white-space:normal;width:13.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:36.53%;background:#cceeff;margin:0pt;padding:0pt;"> Private insurers and other payers </td><td style="vertical-align:bottom;white-space:normal;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 47,564</p></td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"> 39,376 </td><td style="vertical-align:bottom;white-space:normal;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-

space:normal;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 122,907 </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> 101,300 </td></tr><tr><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> Veterans Administration </td><td style="vertical-align:bottom;white-space:normal;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:10.66%;margin:0pt;padding:0pt;"> 8,442 </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:10.66%;margin:0pt;padding:0pt;"> 7,259 </td><td

style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.36%;margin:0pt;padding:0pt;"> 23,339 </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.34%;margin:0pt;padding:0pt;"> 20,203 </td></tr><tr><td style="vertical-align:bottom;width:36.53%;background:#cceeff;margin:0pt;padding:0pt;"> Medicare </td><td style="vertical-align:bottom;white-space:normal;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"> 9,276 </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"> 15,871 </td><td style="vertical-align:bottom;white-space:normal;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 36,032 </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> 50,754 </td></tr><tr><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> Durable medical equipment distributors </td><td style="vertical-align:bottom;white-space:normal;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-

*align:bottom;white-space:normal;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,811 </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,080 </td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 25,121 </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> *

24,514 </td></tr><tr><td style="vertical-align:bottom;width:36.53%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:normal;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">73,093</p></td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 69,586 </td><td style="vertical-align:bottom;white-space:normal;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:11.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 207,399 </td><td style="vertical-align:bottom;white-

space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:11.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 196,771 </td></tr></table> Our rental revenue is derived from rent-to-purchase arrangements that typically range from three to ten months. As title transfers to the patient, with whom we have the contract, upon the termination of the lease term and because collectability is probable, under ASC 842, these are recognized as sales-type leases. Each rental agreement contains two components, the controller and related garments, both of which are interdependent and recognized as one lease component. The revenue and associated cost of revenue of sales-type leases are recognized on the lease commencement date and a net investment in leases is recorded on the Condensed Consolidated Balance Sheets. We bill the patients' insurance payers monthly over the duration of the rental term. We record the net investment in leases and recognize revenue upon commencement of the lease in the amount of the expected consideration to be received through the monthly payments. Similar to our sales revenue, the transaction price is impacted by multiple factors, including the terms and conditions contracted by third-party payers. As the rental contract resides with the patients, we have elected the portfolio approach, at the payer level, to determine the expected consideration, which considers the impact of early terminations. While the contract is with the patient, in certain circumstances, the third-

party payer elects an initial rental period with an option to extend. We assess the likelihood of extending the lease at the onset of the lease to determine if the option is reasonably certain to be exercised. As the lease is short-term in nature, we anticipate collection of substantially all of the net investment within the first year of the lease agreement. Completion of these payments represents the fair market value of the equipment, and as such, interest income is not applicable. Rental revenue for the three and nine months ended September 30, 2024 and 2023, was primarily from private insurers. Sales-type lease revenue and the associated cost of revenue for the three and nine months ended September 30, 2024 and 2023, was: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:29.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> <p style="font-

*family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> *

</td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';font-

weight:bold;visibility:hidden;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.98%;background:#cceeff;margin:0pt;padding:0pt;"> Sales-type lease revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.18%;background:#cceeff;margin:0pt;padding:0pt;"> 9,925 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td>

<td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 10,720</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"> 26,657 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"> 25,312 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.98%;margin:0pt;padding:0pt;"> Cost of sales-type lease revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,703 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,211 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,270 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,122 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.98%;background:#cceeff;margin:0pt;padding:0pt;">

Gross profit </td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">7,222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,509 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,387 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 16,190 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.98%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.36%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:36.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <b style="font-

*family:'Arial','Helvetica','sans-serif';font-weight:bold;">2023 </td></tr><tr><td style="vertical-align:bottom;width:36.53%;background:#cceeff;margin:0pt;padding:0pt;"> Revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> *

* </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> Lymphedema products </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 65,282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> 62,506 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> <span style="font-family:'Arial','Helvetica','sans-*

serif';visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 182,278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> 172,257 </td></tr><tr><td style="vertical-align:bottom;width:36.53%;background:#cceeff;margin:0pt;padding:0pt;"> Airway clearance products </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,811 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,080 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 25,121 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 24,514 </td></tr><tr><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td

style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 73,093 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 69,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 207,399 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 196,771 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.53%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-

*family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">
</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">
</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">
</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">
</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">
</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">
</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">
</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">
</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">
</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">
</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-
family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">*

* </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> *
* </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> *
* </td></tr><tr><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> Percentage of total revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> *
* </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> *
* </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> *
* </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> *
* </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> *
* </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-*

align:center;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.53%;background:#cceeff;margin:0pt;padding:0pt;"> Lymphedema products </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"> 89% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"> 90% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 88% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> 88% </td></tr><tr><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> Airway clearance products </td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> 11% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12% </td></tr><tr><td style="vertical-align:bottom;width:36.53%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-

space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 100% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 100% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 100% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double

#000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 100% </td></tr></table> 65282000 62506000 182278000 172257000 7811000 7080000 25121000 24514000 73093000 69586000 207399000 196771000 0.89 0.90 0.88 0.88 0.11 0.10 0.12 0.12 1 1 1 1 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:10.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-

word;position:relative;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:10.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;margin:0pt;padding:0pt;"> <p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:36.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:3.31%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:27.98%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:29.36%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:3.31%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:27.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt

0.05pt 0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:29.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:36.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:normal;width:3.31%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td>

</tr><tr><td style="vertical-align:bottom;width:36.53%;background:#cceeff;margin:0pt;padding:0pt;"> Private insurers and other payers </td><td style="vertical-align:bottom;white-space:normal;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 47,564</p></td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"> 39,376 </td><td style="vertical-align:bottom;white-space:normal;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 122,907 </td><td style="vertical-align:bottom;white-

space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> 101,300 </td></tr><tr><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> Veterans Administration </td><td style="vertical-align:bottom;white-space:normal;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:10.66%;margin:0pt;padding:0pt;"> 8,442 </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:10.66%;margin:0pt;padding:0pt;"> 7,259 </td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:normal;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.36%;margin:0pt;padding:0pt;"> 23,339 </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.34%;margin:0pt;padding:0pt;"> 20,203 </td></tr><tr><td style="vertical-align:bottom;width:36.53%;background:#cceeff;margin:0pt;padding:0pt;"> Medicare </td><td style="vertical-align:bottom;white-space:normal;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"> 9,276 </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"> 15,871 </td><td style="vertical-align:bottom;white-space:normal;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 36,032 </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> 50,754 </td></tr><tr><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"> Durable medical equipment distributors </td><td style="vertical-align:bottom;white-space:normal;width:3.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:normal;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,811 </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,080 </td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 25,121 </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 24,514 </td></tr><tr><td style="vertical-align:bottom;width:36.53%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td

style="vertical-align:bottom;white-space:normal;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">73,093</p></td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:normal;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 69,586 </td><td style="vertical-align:bottom;white-space:normal;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:11.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 207,399 </td><td style="vertical-align:bottom;white-space:normal;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:normal;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:normal;width:11.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 196,771 </td></tr></table> 47564000 39376000 122907000 101300000 8442000 7259000 23339000 20203000 9276000 15871000 36032000 50754000 7811000 7080000 25121000 24514000 73093000 69586000 207399000 196771000 P10M <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:29.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:13.7%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td colspan="2"

style="vertical-align:bottom;white-space:nowrap;width:15.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.98%;background:#cceeff;margin:0pt;padding:0pt;"> Sales-type lease revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.18%;background:#cceeff;margin:0pt;padding:0pt;"> 9,925 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 10,720</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"> 26,657 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"> 25,312 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.98%;margin:0pt;padding:0pt;"> Cost of sales-type lease revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,703 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,211 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,270 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,122 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Gross profit </td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">7,222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,509 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,387 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 16,190 </td></tr></table> 9925000 10720000 26657000 25312000 2703000 3211000 8270000 9122000 7222000 7509000 18387000 16190000 Note 12. Income Taxes We record our interim provision for income taxes by applying our estimated annual effective tax rate to our year-to-date pre-tax income (loss) and adjusting for discrete tax items recorded in the period. Deferred income taxes result from temporary differences between the reporting of amounts for financial statement purposes and income tax purposes. These differences relate primarily to different methods used for income tax reporting purposes, including for depreciation and amortization, warranty and vacation accruals, and deductions related to allowances for doubtful accounts receivable and inventory reserves. Our provision for income taxes includes current federal and state income tax expense, as well as deferred federal and state income tax expense. The effective tax rate for the three months ended September 30, 2024, was an expense of 28.7%, compared to a benefit of 194.0% for the three months ended September 30, 2023. The primary driver of the change in our effective tax rate was attributable to the fact that we did not have a full valuation allowance on our deferred tax assets for the current year period, while the prior year period released a valuation allowance to recognize the full value of its deferred tax assets. We recorded income tax expense of $2.1<span style="font-family:'Arial','Helvetica','sans-

serif';"> million and an income tax benefit of $14.7 million for the three months ended September 30, 2024 and 2023, respectively. The effective tax rate for the nine months ended September 30, 2024, was an expense of 31.0%, compared to a benefit of 407.1% for the nine months ended September 30, 2023. The primary driver of the change in our effective tax rate was attributable to the fact that we did not have a full valuation allowance on our deferred tax assets for the current year period, while the prior year period released a valuation allowance to recognize the full value of its deferred tax assets. We recorded an income tax expense of $3.3 million and an income tax benefit of $16.3 million for the nine months ended September 30, 2024 and 2023, respectively. We recognize the financial statement benefit of a tax position only after determining that the relevant tax authority is more-likely-than-not to sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the condensed consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company currently is not under examination in any jurisdictions. 0.287 -1.940 2100000 -14700000 0.310 -4.071 3300000 -16300000 Note 13. Net Income Per Share The following table sets forth the computation of our basic and diluted net income per share:

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:40.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;">

</td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.62%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.62%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:40.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:40.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands, except share and per share data) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-

space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:middle;width:40.62%;background:#cceeff;margin:0pt;padding:0pt;"> Net income </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,155 </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,244 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 20,313 </td></tr><tr><td style="vertical-align:bottom;width:40.62%;margin:0pt;padding:0pt;"> Weighted-average shares outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">

* </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"> 23,985,364 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"> 23,483,269 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"> 23,842,049 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"> 22,714,574 </td></tr><tr><td style="vertical-align:bottom;width:40.62%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average shares used to compute diluted net income per*

*share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 24,254,176 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 23,848,729 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 24,070,084 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> *

* </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 22,987,667 </td></tr><tr><td style="vertical-align:bottom;width:40.62%;margin:0pt;padding:0pt;"> Net income per share - Basic </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.21 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.95 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.30 </td><td*

style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.89 </p></td></tr><tr><td style="vertical-align:bottom;width:40.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income per share - Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.21 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.94 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-family:'Arial','Helvetica','sans-

*serif';visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.88 </td></tr></table> The following common stock equivalents were excluded from the computation of diluted net income per share for the periods presented because including them would have been anti-dilutive: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.91%;margin:0pt;padding:0pt;"> *

</td><td style="vertical-align:bottom;white-space:normal;width:11.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:3.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-

align:bottom;width:38.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.91%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:27.52%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:27.66%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:38.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.91%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:27.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:27.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:38.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-

weight:bold;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:normal;width:3.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:38.32%;background:#cceeff;margin:0pt;padding:0pt;"> Restricted stock units </td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 361,130 </td><td

style="vertical-align:bottom;white-space:normal;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 74,972 </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 520,171 </td><td style="vertical-align:bottom;white-space:normal;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 190,071 </td></tr><tr><td style="vertical-align:bottom;width:38.32%;margin:0pt;padding:0pt;"> Common stock options </td><td style="vertical-align:bottom;white-space:normal;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;margin:0pt;padding:0pt;"> 370,040 </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';"> 430,521 </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;margin:0pt;padding:0pt;"> 370,040 </td><td style="vertical-align:bottom;white-space:normal;width:3.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"> 430,521 </td></tr><tr><td style="vertical-align:bottom;width:38.32%;background:#cceeff;margin:0pt;padding:0pt;"> Performance stock units </td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 63,103 </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;">

 142,351 </td><td style="vertical-align:bottom;white-space:normal;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 17,392 </td></tr><tr><td style="vertical-align:bottom;width:38.32%;margin:0pt;padding:0pt;"> Employee stock purchase plan </td><td style="vertical-align:bottom;white-space:normal;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 79,295 </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:normal;width:3.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:38.32%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 873,568 </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 505,493 </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,032,562 </td><td style="vertical-align:bottom;white-space:normal;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 637,984 </td></tr></table> . <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:40.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"> <p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.62%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.62%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:40.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:40.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands, except share and per share data) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:middle;width:40.62%;background:#cceeff;margin:0pt;padding:0pt;"> Net income </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,155 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;">

* </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,244 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 20,313 </td></tr><tr><td style="vertical-align:bottom;width:40.62%;margin:0pt;padding:0pt;"> Weighted-average shares outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-*

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"> 23,985,364 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"> 23,483,269 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"> 23,842,049 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"> 22,714,574 </td></tr><tr><td style="vertical-align:bottom;width:40.62%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average shares used to compute diluted net income per share </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 24,254,176 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 23,848,729 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 24,070,084 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 22,987,667 </td></tr><tr><td style="vertical-align:bottom;width:40.62%;margin:0pt;padding:0pt;"> Net income per share - Basic </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.21 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.95 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.30 </td><td style="vertical-align:bottom;white-

*space:nowrap;width:2.29%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.89 </p></td></tr><tr><td style="vertical-align:bottom;width:40.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income per share - Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.21 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.94 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-*

*align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.88 </td></tr></table> 5155000 22299000 7244000 20313000 23985364 23483269 23842049 22714574 24254176 23848729 24070084 22987667 0.21 0.95 0.30 0.89 0.21 0.94 0.30 0.88 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;margin:0pt;padding:0pt;"> *

</td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:3.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.91%;margin:0pt;padding:0pt;"> </td><td colspan="3"

style="vertical-align:bottom;white-space:normal;width:27.52%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:27.66%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:38.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.91%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:27.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:27.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:38.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <b

style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">2024 </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:normal;width:3.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:38.32%;background:#cceeff;margin:0pt;padding:0pt;"> Restricted stock units </td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 361,130 </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0pt 3pt 0pt 0pt;"> 74,972 </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 520,171 </td><td style="vertical-align:bottom;white-space:normal;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 190,071 </td></tr><tr><td style="vertical-align:bottom;width:38.32%;margin:0pt;padding:0pt;"> Common stock options </td><td style="vertical-align:bottom;white-space:normal;width:2.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;margin:0pt;padding:0pt;"> 370,040 </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;margin:0pt;padding:0pt;"> 430,521 </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0pt 3pt 0pt 0pt;"> 370,040 </td><td style="vertical-align:bottom;white-space:normal;width:3.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"> 430,521 </td></tr><tr><td style="vertical-align:bottom;width:38.32%;background:#cceeff;margin:0pt;padding:0pt;"> Performance stock units </td><td style="vertical-align:bottom;white-space:normal;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 63,103 </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 142,351 </td><td style="vertical-align:bottom;white-space:normal;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-

align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 17,392 </td></tr><tr><td style="vertical-align:bottom;width:38.32%;margin:0pt;padding:0pt;"> Employee stock purchase plan </td><td style="vertical-align:bottom;white-space:normal;width:2.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 79,295 </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:normal;width:3.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:38.32%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-

space:normal;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 873,568 </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 505,493 </td><td style="vertical-align:bottom;white-space:normal;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,032,562 </td><td style="vertical-align:bottom;white-space:normal;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 637,984 </td></tr></table> 361130 74972 520171 190071 370040 430521 370040 430521 63103 142351 17392 79295 873568 505493 1032562 637984 Note 14. Fair Value Measurements We determine the fair value of our

***assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We use a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1). The next highest priority is based on quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in non-active markets or other observable inputs (Level 2). The lowest priority is given to unobservable inputs (Level 3). As of September 30, 2024, our obligations under the AffloVest Acquisition earn-out arrangements had been paid in full. Prior to the determination of the actual amount of the earn-out, the earn-out liability was valued by employing a Monte Carlo Simulation model in a risk-neutral framework, which is a Level 3 input. The underlying simulated variable included recognized revenue. The recognized revenue volatility estimate was based on a study of historical asset volatility for a set of comparable public companies. The model included other assumptions including the market price of risk, which was calculated as the weighted average cost of capital less the long-term risk-free rate. The earn-out liability was adjusted to fair value at each reporting date until the end of the earn-out period, which was September 30, 2023. Changes in fair value were included in intangible asset amortization and earn-out expenses in our Condensed Consolidated Statements of Operations. <p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-**

align:justify;text-indent:36pt;margin:0pt;"> Changes in the earn-out liability measured at fair value using Level 3 inputs were as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-

space:nowrap;width:3.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"> Earn-out liability at December 31, 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"> 13,050 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"> Payment on earn-out </td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"> (5,000) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-

family:'Arial','Helvetica','sans-serif';">Fair value adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,475) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"> Earn-out liability at September 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,575 </td></tr></table> On May 25, 2023, the Company paid $5.0 million, plus an imputed interest payment of $250,000, relating to the initial earn-out. Subsequent to September 30, 2023, it was determined that the calculated amount of the second earn-out payment was $5.6 million, which was paid by the Company on November 28, 2023. <table style="border-

collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> </td></tr></table> The carrying amounts of financial instruments such as cash equivalents, accounts receivable, other assets, accounts payable, accrued expenses and other liabilities approximate their related fair values due to the short-term maturities of these items. Non-financial assets, such as equipment and leasehold improvements, and intangible assets are subject to non-recurring fair value measurements if they are deemed impaired. <p style="font-family:'Times New

Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (In thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Earn-out liability at December 31, 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"> 13,050 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"> Payment on earn-out </td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"> (5,000) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"> Fair value adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:23.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,475) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"> Earn-out liability at September 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,575 </td></tr></table> 13050000 5000000 -2475000 5575000 5000000.0 250000 5600000 Note 15. Subsequent Event On October 30, 2024, our Board of Directors authorized a program to repurchase up to $30.0 million of common stock. Under the program, purchases may be made from time to time in the open market, in privately negotiated purchases, or both. The timing and number of shares to be purchased will be based on the price of the Company's common stock, general business and market conditions and other investment considerations and factors. The share repurchase program expires on October 31, 2026. The program does not obligate the Company to repurchase any specific number of shares and may be suspended or discontinued at any time without prior notice. 30000000.0 false false false false